


&OLQLFDO6WXG\3URWRFRO


$5DQGRPL]HG'RXEOH%OLQG3 ODFHER&RQWUROOHG6WXG\RI7(9 
'HXWHWUDEHQD]LQHIRUWKH7UHD WPHQWRI'\VNLQHVLDLQ&HUHEUDO 3DOV\LQ&KLOGUHQ
DQG$GROHVFHQWV


6WXG\1XPEHU79&16


1&7


3URWRFROZLWK$PHQGPHQW$SSURYDO'DWH0DUFK
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1 
Clinical Study Protocol Amendment 05
Study Number TV50717 -CNS -30080
A Randomized, Double -Blind, Placebo- Controlled Study of TEV -50717 (Deutetrabenazine) 
for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Short title: Reduction of Childhood and Adolescent Abnormal Involuntary Movements in 
Patients with Dyskinetic Cerebral Palsy in Children and Adolescents (RECLAIM -DCP)
Lay person title: A Study to Tes t if TEV -50717 is Effective in Relieving Abnormal 
Involuntary Movements in Cerebral Palsy
Phase 3
IND Number: 139700; NDA Number: NA; EudraCT Number: 2018-003742-17
EMA Decision Number of Pediatric Investigation Plan: Not Applicable
Article 45 or 46 of 1901/2006 does not apply
Protocol Approval Date: 27 September 2018
Protocol Amendment 0 5Approval Date: 24March 2022
Sponsor
Teva Branded Pharmaceutical
Products R&D, Inc.
145 Brandywine Parkway
West Chester, Pennsylvania 19380
United States of America
Information regarding clinical laboratories and other departments and institutions is 
found in Appendix A
COVID -19 pandemic -related operational updates are provided in Appendix M.
This clini cal study will be conducted in accordance with current Good Clinical Practice (GCP) as directed 
by the provisions of the International Council for Harmonisation (ICH); United States (US) Code of 
Federal Regulations (CFR) and European Union (EU) Directives and Regulations (as applicable in the 
region of the study); national country legislation; and the sponsorâ€™s standard operating procedures 
(SOPs).
Confidentiality Statement
This document contains confidential and proprietary information (including confident ial commercial 
information pursuant to 21CFRÂ§20.61) and is a confidential communication of Teva Branded 
Pharmaceutical Products R&D and/or its affiliates. The recipient agrees that no information contained 
herein may be published or disclosed without writt en approval from the sponsor.
Â© 2022 Teva Branded Pharmaceutical Products R&D, Inc. All rights reserved.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
2AMENDMENT HISTORY
The protocol for Stud y TV50717 -CNS -30080 (original protocol dated 27 September 2018) has 
been amended and reissued as follows:
Amendm ent 05 24March 2022
63patients enrolled to date
Administrative L etter 07 05 May  2021
Amendment 04 09 March 2021
46 patients enrolled to date
Amendment 03 08 June 2020
30 patients enrolled to date
Amendment 02 17 October 2019
0 patients randomized/enrolled to date
Letter of Clarification 06 05 August 2019
Letter of Clarification 05 16January 2019
Amendment 01 20December 2018
0patients randomized/enrolled to date
Letter of Clarification 04 05December 2018
Letter of Clarification 03 22 November 2018
Letter of Clarification 02 16November 2018
Letter of Clarification 01 17October 2018
The Summary  of Changes to the Protocol includes the corresponding reason/justification for 
each change and is provided in Section 16.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
3INVESTIGATOR AGREEME NT
Original Protocol Dated 27September 2018
Amendment 05 Dated: 24March 2022
IND Number: 139700; NDA Number: NA; EudraCT Number: 2018-003742-17
EMA Decision Number of Pediatric Investigation Plan: Not Applicable
Article 45 or 46 of 1901/2006 does not apply
A Randomized, Double -Blind, Placebo- Controlled Study of TEV -50717 (Deutetrabenazine) 
for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Principal Investigator: 
Title:
Address of Investigational Center:
Tel:
I have read the protocol with amendment 05 and agree that it contains all necessary  details for 
carrying out this study . I am qualified by  education, experience, and training to conduct this 
clinical research stud y. The signature below constitutes agreement with this protocol and 
attachments and p rovides assurance that this study will be conducted according to all stipulations 
of the protocol, including all statements regarding confidentiality , and according to national or 
local legal and regulatory requirements and applicable regulations and guide lines.
I will make available the protocol and all information on the investigational medicinal product 
(IMP) that were furnished to me by  the sponsor to all phy sicians and other study  personnel 
reporting to me who participate in this study  and will discuss this material with them to ensure 
that they  are fully  informed regarding the IMP and the conduct of the study . I agree to keep 
records on all patient information, I MP shipment and return forms, and all other information 
collected during the study , in acco rdance with national and local Good Clinical Practice (GCP) 
regulations as well as all other national and international laws and regulations. 
Principal Investigator Signature Date
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
4SPONSOR PROTOCOL APP ROVAL
Sponsorâ€™s Authorized 
Representative
 Signature Date
Executed signatu re pages a re maintained within t he Trial Master File.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
5COORDINATING INVESTIGATOR AGREEMENT
Original Protocol Dated 27September 2018
Amendment 05 Dated: 24March 2022
IND Number: 139700; NDA Number: NA; EudraCT Number: 2018-003742-17
EMA Decision Number of Pediatric Investigation Plan: Not Applicable
Article 45 or 46 of 1901/2006 does not apply
A Randomized, Double -Blind, Placebo- Controlled Study of TEV -50717 (Deutetrabenaz ine) 
for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
I have read the protocol with amendment 05 and agree that it contains all necessary  details for 
carrying out this study . I am qualified by  education, experience, and trainin g to conduct this 
clinical research stud y. The signature below constitutes agreement with this protocol and 
attachments and provides assurance that this study will be conducted according to all stipulations 
of the protocol, including all statements regarding confidentiality , and according to national and 
local legal and regulatory requirements and applicable regulations and guidelines.
I will make available the protocol and all information on the investigational medicinal product 
(IMP) that were furnished t
o me by  the sponsor to all phy sicians and other study  personnel 
reporting to me who participate in this study  and will discuss this material with them to ensure 
that they  are fully  informed regarding the IMP and the conduct of the study . I agree to keep 
records on patient information, I MPs shipment and return forms, and other information collected 
during the stud y, in accordance with m y responsibilities under the function of the coordinating 
investigator and in accordance with national and local Good Clinic al Practice (GCP) regulations 
as well as all other national and international laws and regulations. In addition, I  will assume the 
responsibility  of the coordinating investigator according to a separate contract.
Coordinating Investigator:  
Title:
Address of Investigational Center:Vanderbilt Universit y Medical Center
Department of Neurology
1161 21st Avenue South
A-0118 MCN
Nashville, TN 37232 -2551
Tel:
Coordinating Investigator Signature Date
Executed signatu re pages a re maintained within t he Investigat or Site Fil e and Trial Master File.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
6COORDINATING INVESTIGATOR AGREEMENT
Original Protocol Dated 27September 2018
Amendment 05 Dated: 24March 2022
IND Number: 139700; NDA Number: NA; EudraCT Number: 2018-003742-17
EMA Decision Number of Pediatric Investigation Plan: Not Applicable
Article 45 or 46 of 1901/2006 does not apply
A Randomized, Double -Blind, Placebo- Controlled Study of TEV -50717 (Deutetrabenazine) 
for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
I have read the protocol with amendment 05 and agree that it contains all necessary  details for 
carrying out this study . I am qualified by  educati on, experience, and training to conduct this 
clinical research stud y. The signature below constitutes agreement with this protocol and 
attachments and provides assurance that this study will be conducted according to all stipulations 
of the protocol, inclu ding all statements regarding confidentiality , and according to national and 
local legal and regulatory requirements and applicable regulations and guidelines.
I will make available the protocol and all information on the investigational medicinal product 
(IMP) that were furnished to me by  the sponsor to all phy sicians and other study  personnel 
reporting to me who participate in this study  and will discuss this material with them to ensure 
that they  are fully  informed regarding the IMP and the conduct of th e stud y. I agree to keep 
records on patient information, I MPs shipment and return forms, and other information collected 
during the stud y, in accordance with m y responsibilities under the function of the coordinating 
investigator and in accordance with nat ional and local Good Clinical Practice (GCP) regulations 
as well as all other national and international laws and regulations. In addition, I  will assume the 
responsibility  of the coordinating investigator according to a separate contract.
Coordinating Inv
estigator:
Title: at Childrenâ€™s of 
Alabama Hospital
Address of Investigational Center: 1600 7th Ave. S.
CHB Suite 314
Birmingham, AL 35233
Tel:
Coordinating Investigator Signature Date
Executed signatu re pages a re maintained within t he Investigat or Site Fil e and Trial Master File.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
7CLINICAL STUDY PROTOCOL SYNOPSIS
Study TV50717- CNS -30080
Title of Study: A Randomized, Double -Blind, Placebo -Controlled Study  of TEV -50717 
(Deutetrabenazine) for the Treatment of Dy skinesia in Cerebral Palsy  in Children and 
Adolescents
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc., 145 Brand ywine Parkway , West 
Chester, Pennsy lvania 19380, United States of America
Investigational New Drug (IND) Number: 139700
New Drug Application (NDA) Number: Not applicable
EudraCT Number: 2018 -003742-17
Name of Active Ingredient: Deutetrabenazine
EMA Decision Number of Pediatric Investigation Plan: Does not appl y
Name of Test Investigational Medicinal Product (IMP): TEV -50717 (previously  SD-809)
EudraVigilance code for the IMP, if applicable: SUB179485
Type of Study: Efficacy  and safet y stud y (Phase 3)
Indication: Dyskinesia in cerebral pals y (DCP)
Is this study conducted to investigate the New Use of an approved, marketed product? Yes
Number of Investigational Centers Planned: The study  is planned to be conducted in 
approximately  60investigational centers. 
Regions Planned: North America, Asia, and Europe
Planned Study Period: Fourth quarter of 2018 to fourth quarter of 2022
Number of Patients Planned (total): Approximately  65 patients are planned to be randomized 
to TEV -50717 versus placebo in a 2:1 ratio (approximately  43in the TEV -50717 group; 
approximately  22in the plac ebo group) stratified by age at baseline (6 to <12 y ears; 12 through 
18years, inclusive) and region (United States [US]; non -US). 
Study Population: Male and female patients, 6 through 18 years of age (inclusive ) at baseline , 
diagnosed with DCP.
Primary a nd Secondary Objectives and Endpoints: The primary  and secondary  study  
objectives and measures/endpoints are the following:
Objectives Measures/Endpoints
The primary objective of the 
study  is to evaluate the efficacy  
of TEV -50717 to reduce the 
severit y of d yskinetic 
involuntary  movements 
associated with CP.The primary  efficacy  endpoint is the change from baseline to 
week 15 in the MD -CRS part II total score (movement 
disorder severity , centrally  read) (TEV -50717 versus placebo).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
8Objectives Measures/Endpoints
A secondary objective is to 
evaluate the specific efficacy  
parameters of TEV -50717 
beyond the measure of the 
primary  objective.The key  secondary  efficacy  endpoints (TEV -50717 versus 
placebo) are the following: 
ï‚·MD-CRS part I  total score (general assessment, 
centrall y read) change from baseline to week 15
ï‚·CaGI -I Scale (global, caregiver rated) at week 15
ï‚·CGI-I Scale (global, physician rated) at week 15
ï‚·UHDRS -TMC (centrally  read)
ï‚·UHDRS -TMD (centrall y read )
Other efficacy  measures and endpoints (TEV- 50717 versus 
placebo) include the following:
ï‚·MD-CRS part I  total score ( general assessment, 
physician rated)
ï‚·MD-CRS part II total score ( general assessment, 
physician rated)
ï‚·MD-CRS Global I ndex (calculated from MD -CRS 
parts I and II total scores)
ï‚·UHDRS -TMS ( physician rated)
ï‚·UHDRS -TMC ( physician rated)
ï‚·UHDRS -TMD ( physician rated)
ï‚·PEDI -CAT (ADL, caregiver completed, content -
balanced ver sion)
ï‚·The CP module of the PedsQL  (QoL, 
patient/caregiver)
ï‚·PGI-I Scale (global, patient/caregiver)
ï‚·CGI-S Scale (global, ph ysician rated)
ï‚·CaGI -I response, defined as patients who are 
described b y the caregiver as â€œMuch Improvedâ€ or 
â€œVer y Much Improvedâ€ in the CaGI -I score
ï‚·CGI-I response, defined as patients who are 
described as â€œMuch Improvedâ€ or â€œVery  Much 
Improvedâ€ in the CGI- I score
ï‚·CGI-S response, defined as patients who have a 
reduction of â‰¥1 point in the CGI -S score
ï‚·PGI-I response, defined as patients who are 
described as â€œMuch Improvedâ€ or â€œSomewhat 
Improvedâ€ in the PGI- I score 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
9Objectives Measures/Endpoints
A secondary objective of the 
study  is to evaluate the safet y 
and tolerability  of TEV -50717.The safet y variables include adverse events (and the number of 
patients who withdraw from the study  due to adverse events), 
vital signs, laboratory  tests (hematology , chemistry , and 
urinaly sis), ECG measurements, CBCL , ESRS, ESS , and the 
childrenâ€™s C -SSRS.
ADL=activities of daily living; CaGI -I=Caregiver Global Impression of Impr ovement; CBCL=Child Behavior 
Checklist (for ages 6 -18); CGI-I=Clinical Global Impression of Improvement; CGI -S=Clinical Global Impression of 
Severity; CP=cerebral palsy; C -SSRS=Columbia- Suicide Severity Rating Scale; ECG=electrocardiogram; 
ESRS=Extrapyrami dal Symptom Rating Scale (subscales I and II) ; ESS=Epw orth Sleepiness Scale (for children and 
adolescents); MD-CRS=Movement Disorder -Childhood Rating Scale; PEDI -CAT=Pediatric Evaluation Disability 
Inventory -Computer Adapted Test; PedsQL=Pediatric Quality of Life Inventory; PGI -I=Patient Global Impression 
of Improvement; QoL=quality of life; UHDRS -TMC=Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal 
Chorea; UHDRS -TMD=Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Dystonia; 
UHDRS -TMS=Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score.
Exploratory Objective and Endpoint: The exploratory  study  objective and endpoint are the 
following:
Objective Endpoint
  
 
General Study Design:
This is a Phase 3, 21- week, multicenter, randomized, double -blind, placebo -controlled, parallel 
group stud y to evaluate the efficacy and safet y of TE V-50717 administered as oral tablets at a 
starting dose of 6 mg once daily  in patients (age 6 through 18 y ears) with DCP with predominant 
choreiform movement disorder, who have had CP sy mptoms, of a non- progressive nature, since 
infancy  (â‰¤2 years of age). â€œPredominantâ€ in this instance indicates that the choreiform movement 
disorder is the main cause of impairment or distress. 
The study  will consist of a screening period (up to 31 days) and a double -blind treatment period 
including a titration period (7 we eks) and a maintenance period (8 weeks), followed by  a 
washout period of 1 week, and a follow -up telephone contact 1 week after the washout period. 
Throughout the stud y, patients will interact regularly with investigational center personnel, in -
clinic and by telephone (with non -recording live video), for the evaluation of safet y/tolerability , 
dyskinesia severit y, and behavioral status (in -clinic only ). 
For the purposes of this protocol, a caregiver is defined as an adult who is familiar with the 
patient and is responsible for dail y care, enabling that person to effectivel y complete the protocol 
requirements. The caregiver accompanies the patient to the v isits and provides input to the 
relevant scales as required by  the protocol. 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
10For patients who are minors, the caregiver is t ypically a parent or a legall y accepted 
representative. In some countries, an adult (such as grandparent or nurse) can be appointed by 
the parent or legall y accepted representative (as per local regulations and laws) and would take 
over this responsibility  as a caregiver. The parent or legally  accepted representative only  has to 
sign the parent/legall y accepted representative informed consent form (ICF) and not the 
caregiver ICF.
For adult patients, a caregiver must be appointed by  the patient; this can be the parent, a legall y 
accepted representative, or other adult, as appropriate and according to local laws and 
regulations.
For pati ents who are minors, certain responsibilities in the protocol can only  be completed by  the 
parent/legall y accepted representative, ie, informed consent, withdrawal of consent, requests for 
discontinuation of the I MP, or withdrawal from the study  for any  reason. To further clarify , the 
caregiver is not allowed to make decisions on the childâ€™s health or where â€œparent/legall y 
accepted representativeâ€ is specificall y indicated in the protocol.
At the baseline visit (day 1), patients will be randomly  assigned to 1 of 2 treatment groups with 
TEV -50717 IMP or placebo IMP in a 2:1 ratio stratified by  age at baseline (6 to <12 y ears; 
12through 18 years, inclusive) and region (US; non- US). IMP will be titrated during the 
double -blind treatment period starting with 6 mg of TEV -50717 or matching placebo IMP in the 
morning of day  2. Patients in the highest bod y weight group ( â‰¥40 kg/88 lbs) will start an evening 
administration from day  3 and for the remainder of the first week. TEV -50717 daily  doses of 
12mg and higher wi ll be administered as 2 divided equal doses, approximately  8 to 10 hours 
apart during the day . The number of matching placebo IMP tablets will be increased accordingl y. 
Dose increases may  not occur more frequentl y than every 5 days, except for patients 
â‰¥40kg/88 lbs. For patients â‰¥40kg/88 lbs, the first dose increase should be performed in an 
interval less than 5 day s, only  once, on day  3. During the titration period, the dose of IMP will be 
adjusted according to the titrations scheme to identify  a dose level that optimally  reduces 
dyskinesia (as determined by  the investigator, as indicated b y a reduction in the Clinical Global 
Impression of Improvement [CGI -I]) and is well tolerated. If a patient experiences a â€œclinicall y 
significantâ€ adverse event attributable to the I MP, the investigator will first determine if a dose 
reduction (to the previous dose level) or suspension is necessary and possible. After titration, 
patients will remain at their optimal dose for the length of the maintenance period.
Screen ing period (up to 31 days): After written informed consent/assent, as appropriate, is 
obtained, patients who are stable from a medical and psy chiatric standpoint will undergo a 
screening evaluation, including medical history ; phy sical and neurological examination; 
laboratory  testing; 12 -lead electrocardiogram (ECG); along with Movement Disorder -Childhood 
Rating Scale (MD -CRS) part II (ph ysician rated, with video recording, centrally  read with video 
review, centrall y read b y Enrollment Adjudication Board [EAB]) to assess severit y of 
dyskinesia; Clinical Global I mpression of Severity (CGI -S) to assess clinical impression of DCP
severit y, comorbid CP symptoms, and behavioral status; childrenâ€™s Columbia -Suicide Severit y 
Rating Scale (C -SSRS); assessment of drug- induced parkinsonism according to the 
Extrapy ramidal S ymptom Rating Scale (subscales I  and II; ESRS); assessment of change in 
behavior according to the Child Behavior Checklist (for ages 6 -18) ( CBCL) questionnaire; and 
assessment of sedation according to t
he Epworth Sleepiness Scale (for children and adolescents)
(ESS) questionnaire . Screening may  be conducted over 2 separate visits at the discretion of the 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
11investigator. The diagnosis of CP and DCP will be established based on clinical features as 
described in the inclusion/exclusion criteria. The EAB will also confirm, based on video 
recordings, that choreiform is clinically  the predominant movement disorder of the patientâ€™s 
DCP. EAB assessment results will be available to the investigator prior to baseline and 
randomization. The MD- CRS part II will be administered b y the investigational center ph ysician 
and video review, for central -blinded reading. In this study, the MD -CRS part II will be scored 
only based on chorea.
Titration period (7 weeks) : Patients w ho remain eligible for participation in the study  will be 
randomized at the baseline visit (day  1) and instructed to take the first dose of blinded IMP the 
following morning with food (eg, a snack) and should not be taken on an empty  stomach. The 
titration scheme and maximum dose will be determined by  body  weight and cy tochrome P450 
2D6 (CYP2D6) impairment status at baseline. Patients will be classified as CYP2D6 impaired if 
they are receiving a strong CYP2D6 inhibitor or are a CYP2D6 poor metabolizer. At the baseline 
visit, a telephone for non -recording live video will be provided to the patient and caregiver. 
Patients and their caregiver will interact weekl y with the investigator/staff, either by telephone 
contact (with non -recording live video) or clinic visit from week 1 through week 7 of the titration 
period, in order to evaluate safet y/tolerabilit y and establish a dose of IMP that optimally  reduces 
the severit y of d yskinetic involuntary  movements (clinically  meaningful reduction in dy skinesia, 
as indica ted b y a reduction in the CGI- I) and is well tolerated. Safet y/tolerability  in-clinic 
evaluations during titration include assessment of vital signs, monitoring for adverse events and 
concomitant medications, 12 -lead ECGs, identify ingsubjects at risk for suicide according to the 
C-SSRS questionnaire, assessment of drug -induced parkinsonism according to the ESRS 
(subscales I and II), assessment of change in behavior according to the CBCL questionnaire, and 
assessment of sedation according to the ESS questio nnaire . If a patient experiences a â€œclinically  
significantâ€ adverse event attributable to the I MP, the investigator will first determine if a dose 
reduction (to the previous dose level) or suspension is necessary and possible. At the end of the 
titration p eriod, the patientâ€™s dose will be established for the maintenance period. All IMP 
adjustments are made only after a remote or in -clinic visit; if the dose is escalated, the dose 
escalation will occur with the next morningâ€™s dose.
In-person (in- clinic) stud y visits will be scheduled at weeks 3 and 7, and telephone contacts (with 
non-
recording live video) will be scheduled for weeks 1, 2, 4, 5, and 6 in order to assess 
dyskinesia and adverse events. The telephone contacts to the patient will be supported by  live 
video stream, without recording, to provide visual confirmation to the investigator of the verbal 
information provided b y the patient or caregiver. The dose of the IMP should be increased on a 
weekl y basis to reach a clinically  meaningful reduction in dy skinesia, as indicated by  a reduction 
in the CGI -I. The IMP dose should not be increased further if either of the following occurs:
ï‚·the patient experiences a protocol- defined â€œclinically  significantâ€ adverse event 
(defined as an adverse event that is rel ated to IMP and is either moderate or severe in 
intensity  or meets the criteria for a serious adverse event), OR
ï‚·the maximum allowable dose is reached based on the patientâ€™s weight and CYP2D6 
impairment status at baseline.
Dose adjustments can be made up t o and including the week 7 in
-clinic visit. If an optimal dose 
is reached before the week 7 in- clinic visit, the dose of IMP should not be increased further, but 
the patient should continue on that dose for the remainder of the titration period and through out 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
12the maintenance period. If a patient experiences a â€œclinically significantâ€ adverse event 
attributable to the IMP, the investigator will first determine if a dose reduction (to the previous 
dose level) or suspension is necessary  and possible. If the de termination that a patient requires a 
dose reduction or suspension is made during a telephone contact, an unscheduled clinic visit 
should be conducted as soon as practicable thereafter. 
Maintenance period (8 weeks) : Patients will continue to receive their maintenance dose over the 
next 8 weeks, although a 1 -time dose reduction (to the previous dose level for the remainder of 
the study ) for adverse events is allowed. Patients will return to the clinic at weeks 9, 12, and 
15for assessments of efficacy  and safety . 
Washout period and follow -up:All patients will discontinue IMP at the week 15 visit and will 
return 1 week later for the end -of-study  visit. Patients who complete the study  may  be eligible to 
begin participation in the open- label safet y extension Study  TV50717- CNS -30081 at that time . 
At the week 16 visit, patients may  choose to enter Study  TV50717- CNS -30081 (on that day ) or 
up to 1 week later (2 weeks from the week 15 visit). Patients who complete treatment but choose 
not to participate in the open- label safet y extension Study  TV50717- CNS -30081 any  time before 
week 17 of Stud y TV50717 -CNS -30080 will be contacted for a safet y evaluation call occurring 
2weeks after their last dose of IMP. Additional details for patients to enter Study  TV50717-
CNS -30081 are provided in the TV50717 -CNS -30081 protocol.
When approximately  50 patients have completed the study  (including follow -up), an independent 
Data Monitoring Committee (iDMC) will perform an unblinded non -binding interim analy sis 
(IA)for futility  based on centrall y read MD-
CRS part II total score. 
An iDMC charter will be developed for the IA, and the procedures to ensure the integrity  of the 
study  will be provided in the charter.
At the time of informed consent, the parent/legally accepted representative will be counseled 
that, once randomized to treatment, patients are to remain in the study  and complete all study  
procedures unless the choice is made to withdraw consent. Patients who withdraw from the stud y 
before completing the 15 -week tre atment period should have an earl y termination (ET) visit as 
soon as possible after the last dose of IMP. All patients who discontinue early  will have a 
follow -up telephone contact for safet y evaluation 2 weeks after ET; evaluations will be as 
described fo r week 17. 
Patients who screen fail or terminate earl y from the study due to emergency circumstances (such 
as coronavirus disease 2019 [ COVI D-19]) may  be allowed to re-screen/re -enter (respectivel y) 
the study  at a later date, depending on the circumstance s. Each case should be referred to the 
medical monitor and approved in advance.
There is a separate protocol for the open- label safety  extension Study  TV50717- CNS -30081.
Brief Summary of Study Design for the Trial Registry(s):
CP refers to a group of neuro logical disorders that appear in infancy  or early  childhood and 
permanentl y affect body movement and muscle coordination. CP is caused by damage to or 
abnormalities inside the developing brain that disrupt the brainâ€™s abilit y to control movement and 
mainta in posture and balance. The signs of CP usually  appear in the earl y months of life, 
although specific diagnosis may  be delay ed until the age of 2 years or older. TEV -50717 
(deutetrabenazine, also known as SD-809) has already  provided evidence for safe and effective 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
13use in 2 other hyperkinetic movement disorders, namely chorea in Huntingtonâ€™s disease (HD) 
and tardive d yskinesia (TD). Currentl y, there is no approved treatment available for DCP. The 
available treatment options address some of the manifestation s of DCP. The study  population 
will include pediatric and adolescent patients (6 through 18 years of age) with DCP with 
predominant choreiform movement disorder, who have had non -progressive CP sy mptoms since 
infancy  (â‰¤2 years of age). Diagnosis of DCP is based on the Surveillance of Cerebral Palsy in 
Europe criteria. 
This is a Phase 3 study  that will evaluate the efficacy and safet y of TEV -50717 administered as 
oral tablets at a starting dose of 6 mg once daily  in patients (age 6 through 18 y ears, inclusi ve) 
with DCP with predominant choreiform movement disorder. The stud y will be conducted in 
multiple centers and will use 2 parallel treatment groups (ie, TEV -50717 and placebo) in which 
patients will be randomized in a 2:1 ratio.
Method of Randomization an d Blinding: 
Patients will be randomly  assigned to receive treatment with TEV -50717 or matching placebo in 
a 2:1 ratio using Randomization and Trial Supply Management (RTSM). Patients will be 
stratified by  age at baseline (6 to <12 years; 12 through 18 years, inclusive) and region (US; 
non-US). Patients and investigators will remain blinded to treatment assignment during the 
study . In addition, the sponsorâ€™s clinical personnel and all vendors (with the exception of the 
sponsorâ€™s clinical supply  chain staff and RTSM vendor) will be blinded to the IMP identity  until 
the database has been locked for anal ysis and the treatment assignments are revealed. 
The iDMC will perform an unblinded non- binding IA for futility  and will monitor safety  
throughout the stud y based on unblinded data . An iDMC charter will be developed for the IA, 
and the procedures to ensure the integrit y of the study will be provided in the charter.
Investigational Medicinal Products: Dose, Pharmaceutical Form, Route of Administration, 
and Admini stration Rate:
The IMPs are defined as the test IMP and placebo IMP. There is no reference IMP in this study .
Test I MP will be administered as oral tablets at a starting dose of 6 mg once daily with food 
(eg, 
a snack) and should not be taken on an empty  stomach. Titration schemes based on body  weight 
at baseline are shown in Table 1. The maximum daily  dose is determined by  body  weight at 
baseline and CYP2D6 impairment status ( Table 2). Patients will be classified as CYP2D6 
impaired if they  are receiving a strong CYP2D6 inhibitor or are a CYP2D6 poor metabolizer. 
Although dose adjustments can be made up to and including the week 7 in-clinic visit, if the 
optimal dose is reached before then, the dose of IMP should not be increased an y further, but the 
patient should continue taking that dose for the re
mainder of the titration period and throughout 
the maintenance period. If a patient experiences a â€œclinically significantâ€ adverse event that is 
attributed to the I MP, the investigator will first determine if a dose reduction (to the previous 
dose level) or suspension is necessary  and possible. At the end of the titration period, the 
patientâ€™s dose will be established for the maintenance period. If a patient experiences an adverse 
event during the maintenance period and the investigator believes a dose redu ction is warranted, 
the dose may  be reduced once for the remainder of the maintenance period.
TEV -
50717 tablets (test IMP) are available in the following dose strengths: 6, 9, 12, 15, and 
18 mg, all of which are identical in size, shape, and color (white). Test IMP will be supplied in 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1420-count tablets per dose strength per bottle assembling 6, 12, 18, 24, 30, 36, 42, and 48 mg dose 
kit combinations. 
The placebo IMP tablets and packaging will match those for TEV -50717.  
All IMP adjustments are made only  after a remote or in -
clinic visit; if the dose is escalated, the 
dose escalation will occur with the next morningâ€™s dose.
IMP will be administered as follows:
ï‚·IMP should be swallowed whole. If the IMP is crushed or split, it should not be 
ingested; it should be replaced with a new tablet. The tablets will be taken with food 
(eg, a snack) and should n ot be taken on an empty stomach. Patients may  be offered 
the optional use of a Medi+StrawÂ®, which is a commerciall y available straw that can 
assist patients to overcome their swallowing difficulties.
ï‚·Dosing will be based on body  weight at the baseline visit and CYP2D6 impairment 
status, as shown in Table 1and Table 2, respectively .
ï‚·If there is onl y a single dose of IMP per day, the dose should be taken in the morning. 
However, patients experiencing somnolence while taking the 6 -mg dose in the 
morning may  switch to taking it as an evening dose for the r est of the day s up to 
day14.
ï‚·The starting dose of 6 mg will be administered in the morning on day  2 and for the 
remainder of the first week. Patients in the highest body  weight group ( â‰¥40 kg/88 lbs) 
will start an evening administration from day 3 and for the remainder of the first 
week. TEV -50717 dail y doses of 12 mg and higher will be administered as 2 divided 
equal doses, approximately  8 to 10 hours apart during the day . A minimum of 6 hours 
should elapse between doses. If a patient misses a dose, and it is within 6 hours of the 
next dose, the missed dose should be skipped. 
ï‚·Dose increases may  not occur more frequentl y than every 5 days, except for patients 
â‰¥40 kg/88 lbs. For patients â‰¥40 kg/88 lbs, the first dose increase should be performed 
in an interval less than 5 day s, onl y once, on day 3.
ï‚·During the week 3 visit, the investigator or designee will make sure the patient 
receives the last treatment kit back so the patient can take the evening dose to 
complete the week 3 dosing for that day . Refer to the pharmacy  manual for further 
details.
ï‚·For an y dose adjustment, the investigator or designee should confirm that patients 
have the bottle that contains the appropriate tablet strength and quantity to complete 
the recommended dail y regimen.
ï‚·At an in- clinic visit, a dose reduction, if required, should be made to the previously  
tolerated dose level. If more than 1 dose reduction is required for an adverse 
event, the medical monitor should be notified .
ï‚·During the titration period, the dose of IMP should be adjusted according to Table 1
to identify  a dose level that optimally  reduces d yskinesia (as determined by  the 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
15investigator, as indicated by  a reduct ion in the CGI -I) and is well tolerated. Dose 
adjustments should ONLY take place after telephone or in -clinic visit.
Table 1: Maximum Daily Dose of IMP During the Titration Period by Week and 
Weight Category at Basel ine
Daily dosea,b
Study time period12 kg to <17 kg
(26 lbs to <37 lbs)17 kg to <30 kg
(37 lbs to <66 lbs)30 kg to <40 kg
(66 lbs to <88 lbs)â‰¥40 kg
(â‰¥88lbs)
Day 2 (first dose in morning ) 6 mg 6 mg 6 mg 6 mg
Week 1 6 mg 6 mg 6 mg 12 mgc
Week 2 6 mg 12 mg 12 mg 18 mg
Week 3 12 mgd18 mgd18 mgd24 mg
Week 4 12 mgd18 mgd24 mgd30 mg
Week 5 18 mgd24 mgd30 mgd36 mgd
Week 6 18 mgd24 mgd36 mgd42 mgd
Week 7 24 mgd30 mgd42 mgd48 mgd
aAll IMP adjustments are made only after a remote or in-clinic visit; if the dose is escalated, the dose escalation will 
occur w ith the next morningâ€™s dose. Dose adjustments should ONLY take place after telephone or in -clinic visit.
bDose increases may not occur more frequently than every 5 days, except for patients â‰¥40 kg/88 lbs. For patients 
â‰¥40 kg/88 lbs, the first dose increase should be performed in an interval less than 5 days, only once, on day 3. 
Refer to Table 3for the exact visit windows at each weekly titration visit.
cPatients in this weight category will receive the 6 -mg once -daily  dose in the morning on day 2, follow ed by  
twice-daily administration of 6 mg starting on day 3.
dFor those taking strong CYP2D6 inhibitors, such as paroxetine, fluoxetine, and bupropion, or those who are poor 
CYP2D6 metabolizers, the m aximum daily dose for patients â‰¥40 kg is 36 mg/day, that for 30 to <40 kg is 
24mg/day, that for 17 to <30 kg is 18 mg/day, and that for 12 to <17 kg is 12 mg/day (see Table 2).
CYP2D6=cytochrome P450 2D6; IMP=investigational medicinal product.
Table 2: Maximum Daily Dose of IMP by CYP2D6 Impairment Status
Weight category Maximum daily dose in the absence of 
CYP2D6 impairmentMaximum daily dose in the presence of 
CYP2D6 impairment
12 kg to <17 kg
(26 lbs to <37 lbs)24 mg 12 mg
17 kg to <30 kg
(37 lbs to <66 lbs)30 mg 18 mg
30 kg to <40 kg
(66 lbs to <88 lbs)42 mg 24 mg
â‰¥40 kg
(â‰¥88 lbs)48 mg 36 mg
CYP2D6=cytochrome P450 2D6; IMP=investigational medicinal product.
Note: Patients will be classified as CYP2D6 impaired if they are receiving a strong CYP2D6 inhibitor or are a 
CYP2D6 poor metabolizer. Strong CYP2D6 inhibitors include paroxetine, fluoxetine, and bupropion.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
16Test IMP: TEV -50717 (deutetrabenazine, also known as SD -809)
Reference IMP: None
Placebo IMP: Placebo tablets match TEV -50717 (deutetrabenazine, also known as SD -809)
Duration of Patient Participation and Maximal Exposure to IMP:
This study  will consist of up to a 31- day screening period, a 15- week double -blind treatment 
period (a 7- week titration period followed by an 8 -week maintenance period), and a 2 -week 
follow -up period. Patients are expected to participate in this study  for its entire duration.
Study Duration: Fourth quarter of 2018 to fourth quarter of 2022
End of Study: End of study  is defined as the last visit of the last patient.
Plans for Treatment or Care After the Patient Has Ended Participation in the Study:
Patients who complete the study  may  be eligible to begin participation in the open- label safet y 
extension Study  TV50717- CNS -30081 at the end of t he washout period. Patients who complete 
treatment, but choose not to participate in the open -label safety  extension 
Study TV50717- CNS -30081 any  time before week 17 of Study  TV50717- CNS -30080 will be 
contacted for a safet y evaluation call occurring 2 weeks after their last dose of IMP.
Inclusion Criteria: Patients may  be included in the study  only if they meet all of the following 
criteria: 
1.Patient is 6 through 18 years of age (inclusive) at baseline. 
2. Patient weighs at least 26 pounds (12 kg) at baseline.
3.Patient has had CP sy mptoms since infancy  (â‰¤2 years), and CP is judged by the 
investigator to be of a non-
progressive nature ( Monbaliu et al 2017 , 
Wimalasundera et al 2016 ). 
4.Patient has a diagnosis of DCP according to the Surveillance of Cerebral Palsy  in Europe 
criteria ( Cans 2000 ).
5.Patient has an MD -CRS part II total score of â‰¥10 at the baseline visit, based on 
investigator scoring of chorea. 
6.Patientâ€™s sympt oms are causing functional problems determined by  a CGI -S score of 4 or 
greater based on investigator scoring.
7.Choreiform is the predominant (ie, the main cause of impairment or distress) movement 
disorder as assessed at screening.
8.Patient is able to swallow study  medication whole.
9.Patient and caregiver are willing to adhere to the medication regimen and to comply  with 
all study  procedures.
10.Patient is in good general health, as indicated b y medical and ps ychiatric history , as well 
as phy sical and neurological examination.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1711. In the investigatorâ€™s opinion, the patient and /orcaregiver has the ability  to understand the 
nature of the stud y and its procedures, and the patient is expected to complete the study 
as designed.
12.For a patient who is a minor, the pare nt(s)/legall y accepted representative(s) provide 
written informed consent, and the patient provides assent (in accordance with local 
regulations). Adult patients provide their own written informed consent (in accordance 
with local regulations) and the lega lly acceptable representative will sign, if needed.
In this study, eligible patients are patients with dyskinetic cerebral pals y who may have 
some degree of mental, motor, and/or communication (eg, speech, writing, etc) 
limitations or disabilities. The pat ient may  not be able to read the assent/consent form. 
Some patients may  only be able to provide a limited assent/consent (for instance, by  
verbalizations or gestures). The investigator will determine the suitability  of enrolling 
such patients in this study and will follow the local regulation to obtain the relevant 
consent/assent.
13. Caregivers provide written informed consent after being assigned the role by an adult 
patient, or if this role is delegated b y the parent/ legall y accepted representative of a 
patient who is a minor.
14.Females who are postmenarchal or â‰¥12 y ears of age may  be included onl y if they  have a 
negative beta -human chorionic gonadotropin test at baseline or are sterile. Definitions of 
sterile, premenarchal, and postmenarchal are given in Appendix F. 
15.Females who are postmenarchal or â‰¥12 y ears of age whose male partners are potentially  
fertile (ie, no vasectom y) must use highly  effective birth control methods for the duration 
of the study  (ie, starting at screening) and for 30 days after the last dose of IMP. Further 
details are included in Appendix F.
Exclusion Criteria: Patients will be excluded from participating in this study  if they  meet any  of 
the following criteria:
1. a. Patient has a predominant movement disorder other than d yskinesia.
b. Patientâ€™s predominant motor sy mptoms are dystonic.
c. Patientâ€™s predominant motor sy mptoms are spastic.
d. Patient has another movement disorder that could impair the motor assessment in the 
MD-CRS part II.
e. Patient has choreiform movement disorder that has not been consistent throughout the 
life of the patient.
2.Patient has clinically  significant depression at screening or baseline. 
ï€­Note : Patients receiving antidepressant therap y may be enrolled if on a stable dose 
for at least 6 weeks before screening and anticipated to remain stable (dose and 
frequency ) within the study  duration.
3.Patient has a history  of suicidal intent or related behaviors based on medical or 
psychiatric history  or the C -SSRS within 2 y ears of screening:
ï€­Previous intent to act on suicidal ideation with a specific plan, irres pective of 
level of ambivalence, at the time of suicidal thought
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
18ï€­Previous suicidal preparatory acts or behavior
4.Patient has a history  of a previous actual, interrupted, or aborted suicide attempt based on 
medical or ps ychiatric history or the C -SSRS.
5.Patient has a first- degree relative who has completed suicide.
6.Patient has received an y of the following concomitant medications within the specified 
exclusionary  windows of screening:
ï€­Within 30 day s: tetrabenazine, deutetrabenazine, or valbenazine
ï€­Within 21 day s: reserpine 
ï€­Within 14 day s: levodopa, dopamine agonists, and monoamine oxidase inhibitors
7. Patient has received treatment with stem cells, deep brain stimulation, transmagnetic 
stimulation, or transcranial direct current stimulation for treat ment of abnormal 
movements or CP within 6 months of the screening visit, or the patient is not in a stable 
clinical condition. 
8. Patient has recent surgical procedure or is anticipated to have a surgical procedure during 
the study  that, in the opinion of the investigator, makes the patient unsuitable for the 
study .
9.Patient has a severe mental disability  or an unstable or serious medical illness (eg, 
epilepsy ) at screening or baseline that, in the opinion of the investigator, could jeopardize 
or would comprom ise the patientâ€™s ability  to participate in this study .
10.Patient has a QT interval corrected for heart rate using Fridericiaâ€™s formula value 
>450 msec on 12-lead ECG at screening. 
11.Patients with a history  of torsade de pointes, congenital long QT s yndrome, 
bradyarrh ythmias, other cardiac arrhy thmias, or uncompensated heart failure.
12.Patient has evidence of diminished hepatic function, as indicated b y the following:
ï€­Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5Ã— the 
upper limit of the normal range (ULN) at screening
ï€­Alkaline phosphatase (ALP) or total bilirubin >2Ã— ULN at screening
ï€­Note : Patients with Gilbertâ€™s sy ndrome are eligible to participate if approved by  
the medical monitor. 
ï€­Note: Patients with abnormalities in 2 or more of th e following clinical laboratory  
parameters must be approved for enrollment by  the medical monitor: AST, AL T, 
ALP, and total bilirubin. 
13.Patient has evidence of clinically  significant renal impairment, indicated by a serum 
creatinine >1.5 Ã— ULN at screening. 
14.Patient has a known allergy  to an y of the components of the I MP.
15.Patient has participated in an investigational drug or device study  and received 
IMP/intervention within 30 day s or 5 drug half -lives of screening, whichever is longer.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1916.Patient is pregnant or breastfeeding.
17.Patient has a history  of or acknowledges alcohol or other substance abuse in the 
12months before screening.
18.Patient has a positive urine drug screen test result (with exception of medications listed in 
Table 10of Appendix H). Any  request to include a patient with a positive urine drug 
screen test result should be discussed with, and approved b y, the medical monitor. Refer 
to Section 7.5.2.2 (urine drug screen) for more details.
Statistical Considerations
Primary and Secondary Estimands:
The primary  estimand is the difference in means between TEV -50717 and placebo in the target 
p
atient population for the change from baseline to week 15 in centrall y read MD -CRS part II 
total score, regardless of whether or not dose reduction, suspension, or discontinuation occurred, 
and regardless of treatment-
related adverse events. 
The secondary estimands are the differences in means between TEV- 50717 and placebo in the 
target patient population for (1) change from baseline to week 15 in centrally  read MD -CRS 
partI total score ,(2) Caregiver Global Impression of I mprovement (CaGI -I) at week 15, (3) 
CGI-I at week 15, (4) change from baseline to week 15 in centrall yread UHDRS -TMC, and (5) 
change from baseline to week 15 in centrall yread UHDRS -TMD, regardless of whether or not 
dose reduction, suspension, or discontinuation occurred, and regardless of treatment -related 
adverse events.
The primary  estimand assesses the effectiveness in the reduction of choreiform movements in 
patients with DCP with predominant choreiform movement disorder, evaluated b y the central 
reviewers, 
focusing on the causal ef fects attributable to the I MP. The secondary  estimands assess 
the effectiveness on patientsâ€™ ability  to perform daily  functions, the improvement in dy skinesia 
evaluated b y the caregiver and the investigator , and the reduction in chorea and dy stonia 
evaluat ed by the central reviewers, all with a focus on the causal effects attributable to the I MP.
The patient population for this study  is patients with DCP with predominant choreiform 
movement disorder and severit y of DCP represented by MD -CRS part II total sc ore of â‰¥10 and 
CGI-S â‰¥4 at baseline. This population is expected to have the sensitivity  to demonstrate 
clinically  meaningful improvement following treatment with TEV -50717. Due to practical 
reasons, it is not possible to obtain a central reading of MD -CRS part II items at the time of the 
baseline visit prior to randomization ; therefore, i nclusion of a subject into the study  is based on 
investigator scoring of MD -CRS part II items at baseline. 
Analysis of Primary Endpoint:
The primary  endpoint is the chang e from baseline to week 15 in centrally  read MD -CRS part II 
total score (TEV -50717 versus placebo). The MD- CRS part II total score is obtained by  
summing the total raw scores of MD -CRS part II items (0 to 28). 
The modified intent -to treat (mITT) anal ysis set (all randomized patients with at least 
1post-baseline centrall y read MD -CRS part II assessment) will be used for the primary  analy sis.
The primary  anal ysis will be a mixed -model, repeated -measures with the change in MD- CRS 
part II total score as the dependent variable. The model will include fixed effects for treatment 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
20group, week (3 levels: weeks 9, 12, and 15), and treatment group by  week interaction. The 
baseline MD -CRS part II total score, age group at baseline (2 levels: 6 to <12 years; 12 through 
18 years, inclusive ), and region (US; non- US)will be included as covariates. The unstructured 
covariance model will be used.
Missing data 
will be classified as missing at random (MAR) and missing not at random 
(MNAR). Earl y terminations related to tolerabilit y, treatment -related adverse even ts, or lack of 
efficacy  will be classified as MNAR. Intermittent missing data, earl y terminations for patients 
who are lost to follow -up, and earl y terminations due to COVID -19 will be classified as MAR. 
For all other cases and for cases classified as above, classification as MAR/MNAR will be 
done/revisited in a blinded manner on a case -by-case basis prior to the IA and prior to database 
lock for final anal ysis. The MAR/MNAR multiple imputation method will be applied in the 
primary  anal ysis, where MNAR data will be imputed using the jump- to-reference method, and 
MAR data will be imputed based on the randomized treatment group. The resulting complete, 
imputed datasets will each be anal yzed using the analy sis model described above, and the 
resulting statistics combined using methodology  presented b y Rubin (1987) and Little and Rubin 
(2002) .
The difference in least squares (LS) mean of the change in MD-CRS part II total score from 
baseline to week 15 (TEV -50717 versus placebo) will be compared using a 1- sided test for 
superiority  at a nominal significan ce level of Î±=0.025. 
The L S mean and standard error for the treatment groups, the L S mean difference, 2- sided 95% 
confidence interval, and p- value for the comparison (TEV -50717 versus placebo) at week 15 will 
be presented.
Sample Size Rationale:
The initi al sample size estimation of approximately 185 patients randomized to TEV -50717 
versus placebo in a 2:1 ratio (approximately  124 in the TEV -50717 group; approximately  61 in 
the placebo group) is the sample size required to obtain a statistically  significant result in the 
primary  anal ysis based on a 1 -sided test for mean difference at a significance level of Î±=0.025 
with a power of approximately  90%, assuming a mean difference of 1.8 and a standard deviation 
(SD) of 3.5 in each treatment group. 
At the time of writing Amendment 05, the initially planned sample size has been reduced to 
approximately  65patients randomized to TEV -50717 versus placebo in a 2:1 ratio 
(approximately  43in the TEV -50717 group; approximately  22in the placebo group).
The initial assumptions regarding the mean difference and SD are based on the change from 
baseline to month 6 in patients treated with trihexyphenid yl reported b y Battini et al (2014) , 
assuming an effect size of 55% for TEV -50717 versus plac ebo. The effect size of 55% was 
assumed based on the observed effect sizes of TEV -50717 in the pivotal studies in HD and TD. 
In the current study , these assumptions correspond to a mean difference of 2.0 in MD -CRS 
partII total score and an SD of 3.5 in each treatment group.
The rate of MNAR data for the primary  anal ysis is expected to be 10%. MNAR data will be 
imputed in a conservative manner as if they  were obtained from patients in the placebo treatment 
group, regardless of the treatment group. As a resu lt, the mean difference is expected to be 
reduced from 2.0 to 1.8 in the primary  analy sis. The impact of the missing data imputation on the 
SD is negligible.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
21Sensitivity Analysis:
To assess the robustness of the primary  efficacy  analy sis, sensitivity  anal yses will include the 
following:
Sensitivity  analy ses for assumptions of missing data mechanism:
ï‚·tipping point (MNAR)
ï‚·MAR multiple imputation 
Sensitivity  analy sis for the statistical model:
ï‚·analysis of covariance (ANCOVA)
ï‚·primary  model, including only the following covariates: treatment group, week, and 
treatment group b y week interaction
Other:
ï‚·primary  model repeated for the intent -to-treat (ITT) anal ysis set
ï‚·primary  model repeated for the set of patients in the mITT anal ysis set that received 
at leas t 1 dose of IMP
ï‚·primary  model repeated for the set of patients that complete the study  without any  
major protocol deviations that may  impact efficacy  (per-protocol anal ysis)
ï‚·ANCOVA models for MD -CRS part II total score change from baseline to week 9 
and to week 12
Key Secondary Endpoints and Analysis: 
The key  secondary  endpoints are the following:
1.Change from baseline to week 15 in centrall y read MD -CRS part I  total score 
(TEV -50717 versus placebo) 
2.CaGI -I at week 15 (TEV -50717 versus placebo)
3.CGI-I at wee k 15 (TEV -50717 versus placebo)
4.Change from baseline to week 15 in centrall yread UHDRS -TMC ( TEV -5
0717 versus 
placebo)
5.Change from baseline to week 15 in centrally read UHDRS -TMD ( TEV -50717 
versus placebo)
Each key  secondary  endpoint will be analy zed in the same fashion as the primary  endpoint, with 
the exception that the baseline value of the given endpoint will be included as the covariate. 
Other Efficacy Measures/Endpoints: 
Other efficacy  measures and e ndpoints (TEV-50717 versus placebo) include the following:
ï‚·MD-CRS part I  total score ( general assessment, physician rated)
ï‚·MD-CRS part II total score ( general assessment, phy sician rated)
ï‚·MD-CRS Global I ndex (calculated from MD -CRS parts I  and II total sco res)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
22ï‚·UHDRS -TMS (phy sician rated)
ï‚·UHDRS -TMC ( physician rated)
ï‚·UHDRS -TMD ( physician rated)
ï‚·Pediatric Evaluation Disability  Inventory -Computer Adapted Test (PEDI -CAT) 
(activities of dail y living, caregiver completed, content -balanced version)
ï‚·The CP module of the Pediatric Quality  of Life Inventory  (PedsQL) (quality  of life, 
patient/caregiver)
ï‚·Patient Global I mpression of Improvement Scale ([PGI -I] global, patient/caregiver)
ï‚·Clinical Global I mpression of Severit y ([CGI -S], global, phy sician rated)
ï‚·CaGI -I respo nse, defined as patients who are described by  the caregiver as â€œMuch 
Improvedâ€ or â€œVery  Much I mprovedâ€ in the CaGI -I score
ï‚·CGI-I response, defined as patients who are described as â€œMuch Improvedâ€ or â€œVery  
Much I mprovedâ€ in the CGI -I score
ï‚·CGI-S response, defined as patients who have a reduction of â‰¥1 point in the CGI -S 
score
ï‚·PGI-I response, defined as patients who are described as â€œMuch Improvedâ€ or 
â€œSomewhat Improvedâ€ in the PGI -I score
Analy sis methods will be provided in the statistical analy sis plan.
Multiple Comparisons and Multiplicity:
The primary  efficacy  endpoint will be tested at the 1- sided significance level of Î±=0.025. 
If the primary  endpoint is statistically  significant (p- value â‰¤0.025), the 5 key secondary  
hypotheses will be tested using a hierarchical approach at the 1 -sided significance level of 
Î±=0.025, in the following order: (1) MD- CRS part I total score, (2) CaGI -I, (3) CGI -I, (4) 
UHDRS -TMC centrall yread, and (5) UHDRS -TMD centrall yread. 
 
 
 
 
No multiplicity  control will be applied to the sensitivity anal ysisor other endpoints.
Planned Interim Analysis:
When approximately  50 patients have completed the study  (including follow -up), an iDMC will 
perform an unblinded non -binding IA for futility  based on centrall y read MD -CRS part II total 
score.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
23Safety Analyses: 
Safety  anal yses will be performed on the safety  analy sis set.
All adverse events will be coded using the Medical Dictionary  for Regulatory  Activities. Each 
patient will be counted only  once in each preferred term or s ystem organ class cat egory  for the 
analyses of safet y. Summaries will be presented for all adverse events (overall and by severit y), 
adverse events determined by  the investigator to be related to test IMP (ie, reasonable 
possibility ) (defined as related or with missing relatio nship) (overall and b y severit y), serious 
adverse events, and adverse events causing withdrawal from the stud y. Summaries will be 
presented b y treatment group and for all patients. Patient listings of serious adverse events and 
adverse events leading to withdrawal will be presented.
Changes in laboratory , ECG, and vital signs measurements data will be summarized 
descriptivel y. ECG and vital signs values will be compared with predefined criteria to identify 
potentially  clinicall y significant values or change s, and such values will be listed.
The use of concomitant medications will be summarized by  therapeutic class using descriptive 
statistics.
The frequency  and severity  of suicidal ideation or behavior according to the childrenâ€™s 
Columbia -Suicide Severity  Rating Scale (C -SSRS) questionnaire will be presented by  visit and 
by treatment group. A shift table for childrenâ€™s C- SSRS categories at baseline, compared to the 
worst (highest) category  during the treatment period, will be presented. 
Assessment of drug -induced parkinsonism according to the ESRS (subscales I  and II), 
assessment of change in behavior according to the CBCL  questionnaire, and assessment of 
sedation according to the ESS questionnaire will be summarized descriptively .
For continuous variables, descriptive statistics will be provided for actual values and changes 
from baseline to each time point. For categorical variables, patient counts and percentages will 
be provided. Descriptive summaries of serious adverse events, patient withdrawals due to 
adverse events, and potentially  clinicall y significant abnormal values (clinical laboratory or vital 
signs) based on predefined criteria will be provided as well.
If any patient dies during the study, a listing of deaths will be provided, and all relevant 
information will be discussed in the patient narrative included in the clinical study  report.
Tolerability Analysis:
If more than 15% of the patients withdraw from the study  before the end of the treatment period, 
the number of day s until study  discontinua tion will be anal yzed using Kaplan- Meier 
methodology  using the ITT anal ysis set.
Pharmacokinetic/Pharmacodynamic Analysis:
 
 
 
 
 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
24 
 
Biomarker Analysis: Not applicable
Immunog enicity Analysis: Not applicable
Ancillary Studies Analysis: Not applicable

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
25TABLE OF CONTENTS
TITLE PAGE ...................................................................................................................................1
AMENDMENT HI STORY .............................................................................................................2
INVESTIGATOR AGR EEMENT ...................................................................................................3
SPONSOR PROTOCOL APP ROVAL ...........................................................................................4
COORDINATING INVESTI GATOR AGREEMENT ...................................................................5
COORDINATING INVESTI GATOR AGREEMENT ...................................................................6
CLINICAL STUDY PROTO COL SYNOPSI S...............................................................................7
LIST OF ABBREVIATION S
................................................................
........................................33
1. INTRODUCTION AND BAC KGROUND INFORMATI ON..................................36
1.1. Introduction ................................................................ ................................ ................. 36
1.1.1. Background for TEV -50717 .......................................................................................36
1.1.2. Experience with Tetrabenazine in the Treatment of Dyskinesia in Cerebral 
Palsy  and Other Hy perkinetic Movement Disorders in Children and 
Adolescents ................................................................
.................................................37
1.2. Findings from Nonclinical and Clinical Studies .........................................................38
1.2.1. Nonclinical Studies................................
.....................................................................38
1.2.1.1. Nonclinical Pharmacology..........................................................................................38
1.2.1.2. Nonclinical Pharmacokinetics and Drug Metabolism ................................................38
1.2.1.3. Toxicology ................................
..................................................................................39
1.2.2. Clinica l Studies ...........................................................................................................39
1.2.2.1. Clinical Pharmacology  Studies ...................................................................................40
1.2.2.2. Clinical Safety  and Efficacy  Studies ..........................................................................40
1.2.2.3. Pharmacometric Anal ysis of TEV -50717 Active Metabolites to Support 
Dose Selection and Pharmacokinetic Characterization in a Pediatric 
Population ...................................................................................................................41
1.3. Known and Potential Benefits and Risks to Patients................................ .................. 41
1.3.1. Known and Potential Benefits and Risks of the Test I nvestigational 
Medicinal Product(s) ..................................................................................................41
1.3.1.1. Benefits of TEV -50717................................ ................................ ............................... 41
1.3.1.2. Potential Risks of TEV -50717....................................................................................41
1.3.2. Overall Benefit and Risk Assessment for This Study ................................................42
2. STUDY OBJECTIVES AND ENDPOINTS................................ .............................. 43
2.1. Primary  and Secondary  Study  Objectives and Endpoints ................................ .......... 43
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
262.1.1. Justification of Primary  Endpoint ...............................................................................44
2.1.2. Primary  and Secondary  Estimands .............................................................................45
2.2. Exploratory  Objectives and Endpoints .......................................................................46
3. STUDY DESIGN .......................................................................................................47
3.1. General Study  Design and Study  Schematic Diagram ...............................................47
3.2. Planned Number of Patients and Regions ..................................................................52
3.3. Justification for Study  Design and Selection of Population .......................................52
3.4. Stopping Rules for the Study ......................................................................................52
3.5. Schedule of Study  Procedures and Assessments ........................................................53
4. SELECTION AND WITHDR AWAL  OF PATIENTS ..............................................59
4.1. Patient I nclusion Criteria ............................................................................................59
4.2. Patient Exclusion Criteria ................................
...........................................................60
4.3. Withdrawal Criteria and Procedures for the Patient...................................................62
4.4. Replacement of Patients ................................
.............................................................64
4.5. Rescreening .................................................................................................................64
4.6. Screening Failure ........................................................................................................64
5. TREATMENTS ..........................................................................................................65
5.1. Investigational Medicinal Products Used in the Study ...............................................65
5.1.1. Test I nvestigational Medicinal Product ......................................................................65
5.1.1.1. Starting Dose and Dose Levels ...................................................................................65
5.1.1.2. Dose Modification and Dose Stratification ................................................................65
5.1.2. Placebo Investigational Medicinal Product ................................
................................68
5.2. Preparation, Handling, Labeling, Storage, and Accountability  for 
Investigational Medicinal Products ............................................................................70
5.2.1. Storage and Security ................................ ................................ ................................ ...70
5.2.2. Labeling ................................ ................................ ................................ ...................... 70
5.2.3. Accountability ................................ ................................ ................................ ............. 70
5.3. Justifi cation for Investigational Medicinal Products ..................................................71
5.3.1. Justification for Dose of Test I nvestigational Medicinal Product ..............................71
5.3.2. Justification for Use of Placebo Investigational Medicinal Product ..........................71
5.4. Treatment after the End of the Study ..........................................................................71
5.5. Restrictions .................................................................................................................72
5.6. Prior and Concomitant Medication .............................................................................72
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
275.7. Procedures for Monitoring Patient Compliance .........................................................73
5.8. Temporary  Discontinuation of Investigational Medicinal Product ............................73
5.9. Randomization and Blinding ......................................................................................74
5.10. Maintenance of Randomization and Blinding ............................................................75
5.10.1. Maintenance of Randomization ................................
..................................................75
5.10.2. Blinding and Unblinding ................................
............................................................75
5.10.3. Independent Data Monitoring Committee ..................................................................75
5.11. Total Blood Volume ...................................................................................................76
6. ASSESSMENT OF EFFICACY ................................................................................77
6.1. Primary  Efficacy  Measure ................................
..........................................................77
6.2. Key Secondary  Efficacy  Measures .............................................................................78
6.2.1. Movement Disorder -Childhood Rating Scale Part I Total Score ...............................78
6.2.2. Caregiver Global Impression of I mprovement Scale .................................................79
6.2.3. Clinical Global I mpression of I mprovement Scale ....................................................79
6.2.4. Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Chorea .........................80
6.2.5. Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Dy stonia .......................80
6.3. Other Efficacy  Measures ................................
............................................................80
6.3.1. Movement Disorder -Childhood Rating Scale Part I and Part II Total Scores ............80
6.3.2. Movement Disorder -Childhood Rating Scale Global I ndex ......................................80
6.3.3. Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score ................................81
6.3.4. Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Chorea .........................81
6.3.5. Unified Huntingtonâ€™ s Disease Rating Scale -Total Maximal Dy stonia .......................81
6.3.6. Pediatric Evaluation Disability  Inventory -Computer Adapted Test (Activities 
of Daily  Living, Caregiver Completed, Content- Balanced Version) .........................81
6.3.7. Pediatric Quality  of Life Inventory , Cerebral Palsy  Module ......................................81
6.3.8. Patient Global I mpression of I mprovement Scale ......................................................82
6.3.9. Clinical Global I mpression of Severity ................................ ................................ ......82
7. ASSESSMENT OF SAFETY .....................................................................................84
7.1. Adverse Events ................................ ................................ ................................ ........... 84
7.1.1. Definition of an Adverse Event ..................................................................................84
7.1.2. Recording and Reporting of Adverse Events .............................................................85
7.1.3. Severity  of an Adverse Event .....................................................................................86
7.1.4. Relationship of an Adverse Event to the Investigational Medicinal Product .............86
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
287.1.5. Serious Adverse Events ..............................................................................................86
7.1.5.1. Definition of a Serious Adverse Event .......................................................................87
7.1.5.2. Expectedness ...............................................................................................................87
7.1.5.3. Reporting a Serious Adverse Event ............................................................................88
7.1.6. Protocol -Defined Adverse Events of Special Interest ................................................90
7.1.7. Protocol Deviations Because of an Adverse Event ....................................................90
7.2. Safety  Rating Scales ...................................................................................................90
7.2.1. Childrenâ€™s Columbia -Suicide Severit y Rating Scale ..................................................90
7.2.2. Child Behavior Checklist (for Ages 6-
18)..................................................................90
7.2.3. Extrapy ramidal S ymptom Rating Scale ......................................................................91
7.2.4. Epworth Sleepiness Scale (for Children and Adolescents) ........................................91
7.3. Pregnancy ................................
...................................................................................92
7.4. Medication Er ror and Special Situations Related to the I nvestigational 
Medicinal Products .....................................................................................................93
7.5. Clinical L aboratory  Tests ...........................................................................................93
7.5.1. Serum Chemistry , Hematology , and Urinal ysis.........................................................94
7.5.2. Other Clinical Laboratory  Tests .................................................................................95
7.5.2.1. Beta-Human Chorionic Gonadotropin Tests ..............................................................95
7.5.2.2. Urine Drug Screen ................................
......................................................................95
7.6. Physical Examination .................................................................................................95
7.7. Vit al Signs ................................................................
..................................................96
7.8. Electrocardiograph y................................................................
....................................96
7.9. Assessment of Suicidality...........................................................................................97
7.10. Assessment of Depression ..........................................................................................98
7.11. Neurological Examinations ................................
........................................................99
7.12. Concomitant Medication or Treatment .......................................................................99
7.13. Methods and Time Points of Assessing, Recording, and Anal yzing Safety  
Data ................................................................
...........................................................100
8. ASSESSMENT OF PHARMA COKINETICS/ PHARMACO DYNAMICS 
AND PHARMACOGENETI CS...............................................................................101
8.1. Pharmacokinetic Assessment ....................................................................................101
8.2. Assessment of Exploratory Biomarkers ...................................................................102
8.3. Pharmacogenetics ................................
.....................................................................102
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
298.3.1. CYP2D6 Genoty ping/Pharmacogenetics..................................................................102
9. STATI STICS ............................................................................................................103
9.1. Sample Size and Power Considerations ................................
...................................103
9.2. Analy sis Sets .............................................................................................................103
9.2.1. Intent -to-Treat Anal ysis Set ......................................................................................103
9.2.2. Modified Intent -to-Treat Analy sis Set ......................................................................104
9.2.3. Safety  Anal ysis Set ...................................................................................................104
9.2.4. Per- Protocol Anal ysis Set ................................
.........................................................104
9.3. Data Handling Conventions ......................................................................................104
9.3.1. Handling Withdrawals and Missing Data................................
.................................104
9.4. Study  Population .......................................................................................................105
9.4.1. Pat ient Disposition ................................................................
....................................105
9.4.2. Demographic and Baseline Characteristics ..............................................................105
9.5. Efficacy  Anal ysis................................
......................................................................105
9.5.1. Primary  Estimand .....................................................................................................105
9.5.2. P rimary  Endpoint ................................................................
......................................106
9.5.2.1. Primary  Efficacy  Anal ysis........................................................................................106
9.5.2.2. Sensitivity  Anal ysis..................................................................................................106
9.5.2.3. Minimal Clinically  Important Difference and Minimal Clinically  Important 
Change ......................................................................................................................107
9.5.3. Secondary  Estimands ................................................................................................107
9.5.4. Key Secondary  Endpoints .........................................................................................108
9.5.4.1. Secondary  Efficacy  Analy sis....................................................................................108
9.5.5. Other Efficacy  Endpoints .........................................................................................108
9.5.5.1. Other Efficacy  Anal ysis............................................................................................109
9.6. Multiple Comparisons and Multiplicity ....................................................................109
9.7. Planned Interim Anal ysis..........................................................................................110
9.8. Safety  Endpoints and Analy sis.................................................................................110
9.9. Tolerability  Anal ysis................................................................................................111
9.10. Pharmacokinetic/Pharmacody namic Anal ysis..........................................................111
9.11. Reporting Deviations from the Statistical Plan ........................................................111
10. QUALITY CONTROL AND QUALITY ASSURANCE .......................................112
11. COMPLIANCE STATEMENT ................................................................................113
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
3012. DATA MANAGEMENT AND RECORD KEEPING ............................................114
13. FINANCING AND INSURA NCE ...........................................................................115
14. PUBLICATION POLICY ........................................................................................116
15. REFERENCES .........................................................................................................117
16. SUMMARY OF CHANGES TO PROTOCOL .......................................................120
16.1. Amendment 05 Dated 24 March 2022 ......................................................................120
16.2. Administrative L etter 07 Dated 05 May  2021
..........................................................142
16.3. Amendment 04 Dated 09 March 2021 ......................................................................145
16.4. Amendment 03 Dated 08 June 2020 ................................
.........................................174
16.5. Amendment 02 Dated 17 October 2019 ...................................................................177
16.6. Letter of Clarification 06 Dated 05 August 2019 .....................................................195
16.7. Letter of Clarification 05 Dated 16 January  2019 ....................................................196
16.8. Amendment 01 Dated 20 December 2018 ................................................................198
16.9.
Letter of Clarification 04 Dated 05 December 2018 ................................................217
16.10.
Letter of Clarification 03 Dated 22 November 2018................................................220
16.11. Letter of Clarification 02 Dated 16 Novem ber 2018 ................................................222
16.12. Letter of Clarification 01 Dated 17 October 2018 ....................................................225
APPENDIX A. CLINICAL LABORATORI ES AND OTHER DEPARTME NTS AND 
INST ITUTIONS ................................
.......................................................................227
APPENDIX B.INDEPENDENT DATA MON ITORING COMM ITTEE ..............................229
APPENDIX C.STUDY PROCEDURES AND ASSESSMENTS BY VISIT .........................230
APPENDIX D. QUALITY CONTROL AND QUALITY ASSURANCE ..............................237
APPENDIX E.ETHI CS............................................................................................................239
APPENDIX F.BIRTH CONTROL METHOD S AND PREGNANCY TEST ING.................241
APPENDIX G. LOST TO FOLLOW -UP.................................................................................242
APPENDIX H. LIST OF ALLOWED AND PROHIBITED MEDICATIO NS.......................243
APPENDIX I.TOTAL BLOOD VOLUME .............................................................................245
APPENDIX J.PRODUCT COMPLAINTS
.............................................................................246
APPENDIX K. DATA MANAGEMENT AND RECORD KEEPING ................................ ...248
APPENDIX L.PUBLICATION POLICY................................................................................251
APPENDIX M. MANAGEMENT OF STUDY ACTIVITIES DURI NG CO VID-19.............252
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
31LIST OF TABLES
Table 1: Maximum Daily  Dose of I MP During the Titration Period by  Week and 
Weight Category  at Baseline ................................................................ ...................... 15
Table 2: Maximum Daily  Dose of I MP by  CYP2D6 Impairment Status .................................15
Table 3: Study  Procedures and Assessments ............................................................................54
Table 4: Maximum Daily  Dose of I MP During the Titration Period by  Week and 
Weight Category  at Baseline ......................................................................................67
Table 5: Maximum Daily  Dose of I MP by  CYP2D6 Impairment Status .................................68
Table 6: Investigational Medicinal Products Used in the Study ...............................................69
Table 7: The Relationship of an Adverse Event to the IMP .....................................................86
Table 8: Clinical L aboratory  Tests ...........................................................................................94
Table 9: Blood Sampling Scenarios ................................
........................................................101
Table 10: Allowed Medications ................................................................................................243
Table 11: Prohibited QTc-
Prolonging Drugs............................................................................244
Table 12: Total Blood Volumes ................................................................................................245
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
32LIST OF FIGURES
Figure 1: Overall Study  Schematic Diagram .............................................................................51
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
33LIST OF ABBREVIATION S
Abbreviation Term
ADL activities of daily living
AIMS Abnorm al Involuntary Movements Scale
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
BoNT botulinum neurotoxin
CDMS clinical data management system
CFR Code of Federal Regulations
CaGI -I Caregiver Global Impression of Improvement
CBCL Child Behavior Checklist (for ages 6 -18)
CGI-I Clinical Global Impression of Improvement
CGI-S Clinical Global Impression of Severity
ClinRO clinician -reported outcome
COVID -19 coronavirus disease 2019
CP cerebral palsy
CRF case report form
CRO contract research organization
CSR clinical study report
C-SSRS Columbia -Suicide Severity Rating Scale
CYP cytochrome P450
CYP2D6 cytochrome P450 2D6
DCP dyskinesia in cerebral palsy
EAB Enrollment Adjudication Board
ECG electrocardiogram
ESRS Extrapyramidal Symptom Rating Scale (subscales I and II)
ESS Epworth Sleepiness Scale (for children and adolescents)
ET early termination
EOS end of study
EU European Union
GCP Good Clinical Practice
GMP Good Manufacturing Practice
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
34Abbreviation Term
GPSP Global Patient Safety and Pharmacovigilance
Î²-HCG beta-human chorionic gonadotropin
HD Huntingtonâ€™s disease
IA interim analysis
IB Investigatorâ€™s Brochure
ICF informed consent form
iDMC independent Data Monitoring Committee
IEC Independent Ethics Committee
IMP investigational medicinal product
IND Investigational New Drug
IRB Institutional Review Board
ITT Intent -to-treat
LS least squares
LSO local safety officer
MAOI monoamine oxidase inhibitor
MAR missing at random
MD-CRS Movement Disorder -Childhood Rating Scale
mITT modified intent -to-treat
MMRM mixed -effects model repeat measurement 
MNAR missing not at random
n number
NDA New  Drug Application
PEDI- CAT Pediatric Evaluation Disability Inventory -Com puter Adapted Test
PedsQL Pediatric Quality of Life Inventory
PGI-I Patient Global Impression of Improvement
PGx pharmacogenetics
PND postnatal day
PP per-protocol
QoL quality of life
QTc QT corrected for heart rate
QTcF QT interval corrected for heart rate using Fridericiaâ€™s formula
RSI reference safety information
RTSM Randomization and Trial Supply Management
SAP statistical analysis plan
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
35Abbreviation Term
SD standard deviation
SOP standard operating procedure
SUSAR suspected unexpected serious adverse reaction
TD tardive dyskinesia
TS Tourette syndrome
UHDRS -TMC Unified Huntingtonâ€™s Disease Rating Scale- Total Maximal Chorea
UHDRS -TMD Unified Huntingtonâ€™s Disease Rating Scale- Total Maximal Dystonia
UHDRS -TMS Unified Huntingtonâ€™s Disease Rating Scale- Total Motor Score
ULN upper limit of the normal range
US United States
USA United States of America
VMAT2 vesicular monoamine transporter type 2
Î±-HTBZ alpha -dihydrotetrabenazine
Î²-HTBZ beta-dihydrotetrabenazine
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
361. INTRODUCTION AND BAC KGROUND INFORMATION
1.1. Introduction
Cerebral palsy  (CP) denotes a non -progressive disturbance of brain function that usually  occurs 
in the developing fetal or infant brain (age â‰¤2 years) ( Rosenbaum et al 2007 ). It is the most 
common and costly  form of chronic motor disability  in children, with a prevalence of 2 to 4 per 
1,000 live births in the United States (US), and the condition is more common in boy s than in 
girls ( Maenner et al 2016 , Monbaliu et al 2017 , CDC , Prevalence of Cerebral Palsy ). Although 
there have been no general studies of life expectancy  in people with CP, most children affected 
by CP live between 30 and 70 y ears, depending on the severit y of the condition. I n general, a 
child with a mild case of CP usually  lives longer than a child with mobility  and intellectual 
limitations ( Cerebral Palsy Life Expectancy  2018). In the US, there are about 764,000 children 
and adults with CP, including about 500,000 children under the age of 18 years (Prevalence of 
Cerebral Pals y).
Prematurity  is the most common cause of CP, but other causes include stroke, hy poxic ischemic 
injury , infection, brain malformation, and genetic abnor malities ( CDC Causes and Risk Factors 
of Cerebral Palsy  2018; NINDS Cerebral Pals y: Hope Through Research 2019 ). Complications 
of CP may  include ey e movement abnormalities, communica tion problems, swallowing 
difficulty , poor weight gain, social isolation, hip dy splasia and dislocation, scoliosis, osteopenia 
and fractures, and pain. A variet y of movement disorders are associated with CP, including 
spasticity , dyskinesia (d ystonia, chor ea, athetosis, and even ballismus), and ataxia. Many  patients 
with CP present with mixed ty pes of movement disorders ( Monbaliu et al 2017 , CDC ). 
Dyskinesia is considered to result from an insult of non- progressive nature in the basal ganglia of 
the brain. Dy skinesia in cerebral pals y (DCP) is a form of CP characterized by abnormal 
involuntary  movements of the dy stonic and choreiform ty pes in approximately  6% to 15% of 
patients with CP. 
DCP is a ra re disease, and based on the above prevalence numbers of CP in the 
US,one could assume that approximately  30,000 to 75,000 children <18 years of age and 16,000 
to 40,000 adults have DCP ( Monbaliu et al 2017 ).
There are curren tly no approved treatments for DCP, which is a serious disease with an unmet 
medical need. Current treatment options (off -label use) to treat d ystonia and chorea include 
tetrabenazine, dopaminergic, or gamma- aminobuty ric acidergic interventions, but these show 
high variability  in response ( Monbaliu et al 2017 ). Botulinum neurotoxin A is also in clinical use 
for the treatment of spasticity  and d ystonia and is considered modestl y effective in selected 
patients, but it does not me et the full treatment need. Currentl y, there are very  few agents with 
novel mechanisms of action in development for movement disorders in CP. 
The purpose of the study  is to determine whether TEV -50717 is effective in the treatment of 
dyskinetic involuntar y movements associated with CP.
1.1.1. Background for TEV -
50717
TEV -50717 (deutetrabenazine, also known as SD- 809) was initially  developed to provide 
patients and prescribers with an effective treatment for chorea in Huntingtonâ€™s disease (HD) with 
an improved pha rmacokinetic and tolerabilit y profile compared with tetrabenazine. TEV -50717 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
37is a vesicular monoamine transporter t ype 2 (VMAT2) inhibitor structurally related to 
tetrabenazine, with 2 trideuteromethox y groups instead of the 2 methox y groups attached to th e 
positions 9 and 10 of tetrabenazine. This deuterium placement does not change the target 
pharmacology , but it attenuates metabolism through cy tochrome P450 2D6 (CYP2D6). Thus, 
this deuterium placement in TEV-50717 increases the half- life of the active me tabolites relative 
to those of tetrabenazine, enabling reduced dosing frequency  and plasma fluctuation and thus 
potentially  improving safety  and tolerability .
TEV -50717 is a VMAT2 inhibitor with the chemical name (RR,SS) -1,3,4,6,7,11b -hexahy dro-
9,10- di(met hoxy -d3)- 3-(2-methy lprop yl)-2H- benzo[a]quinolizin -2-one. IMP tablets are available 
in the following dose strengths: 6, 9, 12, 15, and 18 mg, all of which are identical in size, shape, 
and color (white). The investigational medicinal product (IMP) will be s upplied in 20 -count 
tablets per dose strength per bottle.
TEV -50717 was approved for the treatment of chorea associated with HD and for the treatment 
of tardive d yskinesia (TD) in adults on 03 April 2017 and 30 August 2017, respectivel y. For 
details, see also the US Prescribing Information ( AUSTEDO USPI  2017 ).
1.1.2. Experience with Tetrabenazine in the Treatment of Dyskinesia in Cerebral Palsy 
and Other Hyperkinetic Movement Disorders in Children and Adolescents
Tetrabenazine is ano ther VMAT2 inhibitor that presy napticall y depletes monoamines, such as 
dopamine, serotonin, norepinephrine, and histamine, from nerve terminals ( Kaur et al 2016 ). 
Although widel y known among ph ysicians treating DCP, there is l imited and rather anecdotal 
literature on the potential efficacy  of tetrabenazine on the treatment of h yperkinetic movement 
disorders in patients with CP of pediatric age. 
Tetrabenazine has been studied in a pediatric population with a variet y of hyperkinetic 
movement disorders. Jain et al (2006) reviewed the outcomes of 31 children at Columbia 
University  Medical Center who were treated with tetrabenazine. Eighteen of these children had 
chorea, of which half had additional mov ement disorders, 10 had tics, and 3 had dy stonia. The 
average duration of sy mptoms before treatment was 4 y ears, and the age of children in the study  
ranged from 22 months to 18 y ears, with a mean age of 11Â±4.9 y ears. The primary  causes of the 
abnormal mov ements in these pediatric patients were CP in 2 patients; primary  generalized 
dystonia in 2 patients; various brain injuries (intraventricular hemorrhage with developmental 
delay or post -hypoxic injury ), genetic abnormalities with brain lesions (arterioven ous 
malformations with developmental delay  and neurofibromatosis ty pe I), metabolic disorders 
(propionic acidemia, Lesch -Nyhan s yndrome, and L eighâ€™s sy ndrome), immune mediated 
(Sydenhamâ€™s chorea), medication effects (tardive dy stonia or withdrawal -emergent syndrome), 
and unknown etiology in 5 patients. Doses of tetrabenazine ranged from 25 mg dail y 
(0.9mg/kg/day ) to 350 mg dail y (10 mg/kg/day), and the average dose was 107 mg dail y 
(3.7mg/kg/day ). Twenty- four of these pediatric patients with hy perkinetic movement disorders 
had improved s ymptoms (14 out of 18 with chorea, 8 out of 10 with tics, and 2 out of 3 with 
dystonia). Adverse events and tolerability  findings were present in 19 (61%) patients who had at 
least 1 side effect (sedation, 35%; behavioral c hanges, 19%; depression, 10%; nausea, 3%; and 
parkinsonism, 3%), and the treatment was stopped in 17 (55%) patients. 
Although not related to CP, in another study , Vuong et al (2004) evaluated the safet y and 
efficacy  of tetrabenazine as a potential treatment for hy perkinetic movement disorders in 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
3810patients with chorea, 12 patients with dy stonia, and 53 patients with tics. I n this study , the 
doses ranged from 6.25 to 150 mg/day . The patients with chorea had approximately  90% 
improvement at the second visit, and those with dystonia had approximately 50% improvement 
at the second visit. Adverse events included dose -dependent nausea, vomiting, drowsiness, and 
depression.
1.2. Findings from Nonclinical and Clinical Studies
Brief summari es of nonclinical pharmacology , pharmacokinetics, and toxicology  studies and 
clinical studies are provided in the following sections. More detailed information is provided in 
the Investigatorâ€™s Brochure (IB).
1.2.1. Nonclinical Studies
The key  nonclinical study  findings are provided below, with details available in the IB.
1.2.1.1. Nonclinical Pharmacology
TEV -50717 is a selectively  deuterium -substituted VMAT2 inhibitor structurally  related to 
tetrabenazine. The biologically active metabolites formed from TEV -50717 
(alpha -dihydrotetrabenazine [Î± -HTBZ] and beta- dihydrotetrabenazine [Î²- HTBZ]) are potent 
inhibitors of VMAT2 binding, with inhibition constant values of 3.8 and 22 nM, respectivel y, 
that are similar to previously  reported values of their corresponding non- deuterat ed forms 
(Scherman et al 1988 ). Off -target binding occurs at a similar extent with deuterated and 
non-deuterated Î± -HTBZ and Î² -HTBZ. TEV -50717 and tetrabenazine in male rats at doses 
resulting in similar sy stemic exposure to th e test articles (Î± -HTBZ and Î² -HTBZ) produced 
similar, expected, exaggerated central nervous sy stem pharmacological effects. I n particular, the 
adverse event of catalepsy, a known response in rats to drugs that reduce central nervous s ystem 
dopamine concent rations ( Fuenmay or and Vogt 1979), was similar in magnitude after 
TEV -50717 and tetrabenazine administration.
1.2.1.2. Nonclinical Pharmacokinetics and Drug Metabolism
In human liver S9, the metabolite profile of TEV -50717 overlapped w ith that of tetrabenazine. In 
a clinical comparative human [14C]-absorption, distribution, metabolism, and excretion and 
mass -balance study , the approximately  22 metabolites of TEV -50717 were also metabolites of 
tetrabenazine. Thus, previous clinical exper ience with tetrabenazine provides predictive 
information about the safety  of TEV -50717 and its metabolites. 
Tetrabenazine, Î± -HTBZ, and Î²
-HTBZ and, b y extension, their deuterated forms, do not inhibit or 
induce cy tochrome P450 (CYP) isoenzy mes at clinicall y relevant concentrations ( Xenazine 
Prescribing Information 2015 ). M1, a minor metabolite that may  circulate in greater 
concentrations as a metabolite of TEV -50717 as compared to tetrabenazine, is neither an 
inhibitor of major CYP isozy mes or transporters nor an inducer of CYP isozy mes. M4, a major 
metabolite of tetrabenazine and TEV -50717, is neither an inhibitor of major CYP isozy mes or 
transporters nor an inducer of CYP isozy mes.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
391.2.1.3. Toxicology
General and Reproductive Adult Tox icology : Oral administration of TEV -50717 in rats reduced 
body  weight gain, increased mammary  hyperplasia, and produced estrous cy cle changes, all of 
which occurred with tetrabenazine at doses that produced similar s ystemic exposures to test 
articles and m etabolites. Mammary  and estrus effects are likely  consequences of reduced central 
dopamine and subsequent increased prolactin, consistent with information in the XenazineÂ®
(tetrabenazine) label. Oral administration of TEV-50717 in pregnant rats did not produce test 
article -related embry ofetal toxicities, even at doses that led to reduced body weight gain in dams. 
Oral administration of metabolite M1 to pregnant rats from gestational days 6 to 17 produced no 
test article -related maternal or fetal toxicities.
Genetic Toxicology : TEV -50717 and its Î± -HTBZ and Î² -HTBZ metabolites were negative in in 
vitro studies for mutagenicity  (bacterial reverse mutation or the Ames test) and for chromosomal 
structural aberrations in human peripheral blood ly mphocy tes. Oral dos es of TEV -50717 were 
negative for inducing micronuclei in the bone marrow of treated mice.
Juvenile Toxicology : The effects of TEV -50717 on juvenile development was assessed in male 
and female rats with oral dosing from weaning (postnatal day  [PND] 21) to PND 71, similar to 
human dosing from y ear 2 through earl y adolescence and overlapping with TEV -50717 oral 
dosing in a general adult toxicology  study . The effects of M1 was assessed in male and female 
juvenile rats from PND 25 to PND 70 with a recovery  phas e and postdosing reproductive 
assessment.
TEV -50717 produced no test article -related effects on learning and memory  functions, on 
histopathology  assessments, on reproductive capacity  (male and female fertility  and estrus 
cyclicity ), or on intrauterine surv ival of embry os from matings during recovery  from test article 
administration. Adversely  reduced body  weight gain and adverse clinical observation of tremors 
and in- cage h yperactivity were all noted in previous studies with adult rats; these effects have n ot 
predicted adult clinical intolerance to TEV -50717. The highest dose level of M1 (50 mg/kg/day ) 
produced no test article -related toxicities (clinical observations, changes in body  weight gain, 
clinical pathology , histopathology , ophthalmology, and perfor mance in learning and memory  
tests).
1.2.2. Clinical Studies
The clinical development plan for TEV -50717 to date includes the following:
ï‚·Fourteen completed Phase 1 studies in healthy  adult volunteers
ï‚·One completed Phase 3 pivotal study  for the treatment of chorea associated with HD
ï‚·One completed Phase 3 long -term safety  study  in patients with HD
ï‚·Two completed pivotal Phase 2/3 and Phase 3 studies in patients with TD
ï‚·One completed Phase 3 long -term safety  study  in patients with TD
ï‚·One completed Phase 1b study  in pa tients with Tourette s yndrome (TS)
ï‚·Two completed pivotal studies in patients with TS
ï‚·One terminated Phase 3 long -term safety  study  in patients with TS
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
40Further details may  be found in the IB.
1.2.2.1. Clinical Pharmacology Studies
Fourteen Phase 1 clinical pharmacol ogy studies were conducted in healthy  adult volunteers. In 
addition, sparse pharmacokinetic sampling was included in the Phase 3 studies in patients with 
HD and TD where the population pharmacokinetic anal yses including these data have been 
performed to ex tensively evaluate both the pharmacokinetics and pharmacokinetic -
pharmacod ynamic relationship of TEV- 50717. A summary  of the clinical pharmacology  findings 
is provided in the IB.
Pharmacometric anal yses of the active metabolites of TEV- 50717 based on the P hase 1 clinical 
pharmacology  studies in healthy  adult volunteers were performed to support dose selection and 
pharmacokinetic characterization in a pediatric population. Subsequently , a further 
pharmacometric anal ysis of active metabolites following admini stration of TEV -50717 to 
adolescent patients with TS with tics (Study  SD-809-C-17) was completed. The results of these 
analyses are described in Section 1.2.2.3.
1.2.2.2. Clinical Safety and Efficacy Studies
The safet y profile of TEV -50717 has been characterized to date in healthy  volunteers, as well as 
in adult patients with chorea associated with HD and TD (as detailed in the IB ) and in children 
and adolesce nts with TS .Study  SD-809-C- 17 also evaluated the safet y of TEV -50717 in 
adolescent patients with TS. Results of the safety  anal yses indicate that treatment with 
TEV -50717 at doses up to 36 mg dail y given in 2 divided doses is generally safe and well 
tolerated for up to 8 weeks in patients with TS. No serious treatment -emergent adverse events or 
severe treatment -emergent adverse events occurred in this study . The most frequentl y observed 
treatment -emergent adverse events during the entire treatment period were fatigue and headache, 
each reported in 4/23 (17.4%) patients, followed by irritabilit y, which was reported in 3/23 
(13.0%) patients. 
Studies TV50717 -CNS -30046 and TV50717- CNS -30060 evaluated children and adolescent 
patients with tics associated with T S. Neither study met the primary  efficacy  endpoint. In both 
studies, TEV- 50717 was generall y safe and well tolerated. No deaths occurred in either stud y. 
One patient had 2 serious adverse events. There were no trends in changes from baseline in 
serum labor atory , vital signs, ECG, and phy sical and neurological parameters. There was no 
evidence of a new safety  signal in pediatric patients with TS treated with TEV -50717 in 
comparison to the known safet y profile of this drug in adult patients with HD or TD.
Theopen -label, long -term Study  TV50717- CNS -30047 evaluated children and adolescent 
patients with tics associated with TS. Treatment with TEV- 50717 through 54 weeks resulted in 
improvement of tics. The safety profile observed in pediatric patients with TS rec eiving 
long-term treatment with TEV -50717 was generally  comparable to the known safet y profile of 
this drug in adult patients with HD or TD, with the exception of the adverse event of weight gain.
There were no clinicall y meaningful trends in mean changes from baseline for any  clinical 
laboratory  variable or any  other observations related to safet y.
This is the first study  to assess the safet y and efficacy  of TEV -50717 in patients with DCP.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
411.2.2.3. Pharmacometric Analysis of TEV -50717 Active Metabolites to Support Dose 
Selection and Pharmacokinetic Characterization in a Pediatric Population
Population pharmacokinetic modeling of the TEV -50717 active metabolites ï¡-HTBZ and 
Î²-HTBZ has been performed throughout the clinical development program. Based on sequential 
pharmacokinetic sampling data obtained in healthy  volunteers in the Phase 1 program, a 
structural population pharmacokinetic model was developed to guide dose selection for HD 
patients with chorea (Study SD-809- CLN-076) and subsequently  optimized to better describe the 
absorption/bioconversion profile of ï¡-HTBZ and Î² -HTBZ (Study SD-
809-CLN-077). 
Employ ing the structural model defined in Study SD-809- CLN-077, sequential and sparse 
pharmacokinetic sampling data obtained from Study  SD-809-C- 17 were combined with the 
Phase 1 data emplo yed in Study SD-809- CLN-077 to estimate the total ( Î±+Î²)-HTBZ exposure in 
adolescent patients (age 12 through 18 years) with TS and to simulate exposure in adolescent and 
pediatric patients (age 6 through 11 years) with and without con comitant CYP2D6 impairment 
(genetic or because of concomitant use of a strong CYP2D6 inhibitor) across a range of doses 
(Appendix H). Population model parameters were re -estimated for the combined Phase 1 and 
adolescent data obtained from patients in Study  SD-809-C-17. The model was used to simulate 
total ( Î±+Î²)-HTBZ exposures across a range of body  weights corresponding to a pediatric and 
adolescent population according to the Centers for Disease Control growth charts. 
This analy sis indicated that exposure to total ( ï¡+Î²)-HTBZ is influenced b y body  weight, and a 
reduction in dose for pediatric and adolescent patients weighing <40 kg is necessary  in or der to 
provide comparable exposure to doses up to 48 mg/day  in adults, a level previously  
demonstrated to be safe and well tolerated in treated patients with chorea associated with HD. 
This analy sis provides the basis for the dosing recommendations in Sec tion5.1.
1.3. Known and Potential Benefits and Risks to Patients
1.3.1. Known and Potential Benefits and Risks of the Test Investigational Medicinal 
Product(s)
Additional information regarding benefits and risks to patients may  be found in the current IB 
and in the US prescribing information for AUSTEDOÂ®(deutetrabenazine).
1.3.1.1. Benefits of TEV -50717
Although the efficacy  of TEV -50717 in patients with DCP has not y etbeen established, 
TEV -50717 has alread y provided evidence for safe and effective use in 2 hy perkinetic movement 
disorders, namel y chorea in HD and TD.
1.3.1.2. Potential Risks of TEV -50717
The following information is based on clinical trial experience with TEV -50717 and the US 
prescribing information for Xenazine (tetrabenazine) 
and Austedo (deutetrabenazine) :
ï‚·TEV -50717 is contraindicated in patients with HD who are activel y suicidal or in 
patients with untreated or inadequatel y treated depression.
ï‚·TEV -50717 is contraindicated in patients with impaired hepatic function.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
42ï‚·TEV -50717 is contraindicated in patients taking monoamine oxidase inhibitors 
(MAOIs). TEV -50717 should not be used in combination with a MAOI or within a 
minimum of 14 day s of discontinuing therap y with a MAOI.
ï‚·TEV -50717 is contraindicated in patients taking reserpine. At least 21 days should 
elapse after stopping reserpine before starting TEV -50717.
ï‚·TEV -50717 is contraindicated in patients taking tetrabenazine or valbenazine. At 
least 30 day s should elapse after stopping tetrabenazine or valbenazine before starting 
TEV -50717.
Additional information regarding each potential issue may  be found in the current IB.
1.3.2. Overall Benefit and Risk Assessment for This Study
There are currently  no approved treatm ents for DCP, which is a serious disease with an unmet 
medical need. Also, there is a significant need to identify  effective treatments for DCP. The 
results from studies in other study populations, such as patients with TS or HD, demonstrated no 
signal on safet y scales, vital signs, laboratory parameters, or 12 -lead electrocardiograms (ECGs). 
The rates for TEV -50717 and placebo were similar for overall adverse events, neurologic and 
psychiatric adverse events, as well as dose reduction or dose suspension for adverse events (see 
the IB for details).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
432. STUDY OBJECTIVES AND ENDPOINTS
2.1. Primary and Secondary Study Objectives and Endpoints
The primary  and secondary  study  objectives and endpoints are the following:
Objectives Measures/Endpoints
The primary objective of the 
study  is to evaluate the efficacy  
of TEV -50717 to reduce the 
severit y of d yskinetic 
involuntary  movements 
associated with CP.The primary  efficacy  endpoint is the change from baseline to 
week 15 in the MD -CRS part II total score (movement 
disorder severity , centrally  read) (TEV -50717 versus placebo).
A secondary objective is to 
evaluate the specific efficacy  
parameters of TEV -50717 
beyond the measure of the 
primary  objective.The key  secondary  efficacy  endpoints (TEV -50717 versus 
placebo) are the f ollowing:
ï‚·MD-CRS part I  total score (general assessment, 
centrall y read) change from baseline to week 15
ï‚·CaGI -I Scale (global, caregiver rated) at week 15
ï‚·CGI-I Scale (global, physician rated) at week 15
ï‚·UHDRS -TMC (centrally  read)
ï‚·UHDRS -TMD (centrall y read )
Other efficacy  measures and endpoints (TEV- 50717 versus 
placebo) include the following:
ï‚·MD-CRS part I  total score ( general assessment, 
physician rated)
ï‚·MD-CRS part II total score ( general assessment, 
physician rated)
ï‚·MD-CRS Global I ndex (calculated from MD-CRS 
parts I and II total scores)
ï‚·UHDRS -TMS ( physician rated)
ï‚·UHDRS -TMC ( physician rated)
ï‚·UHDRS -TMD ( physician rated)
ï‚·PEDI -CAT (ADL, caregiver completed, 
content -balanced version)
ï‚·The CP module of the PedsQL  (QoL, 
patient/caregiver)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
44Objectives Measures/Endpoints
ï‚·PGI-I Scale (global, patient/caregiver)
ï‚·CGI-S Scale (global, ph ysician rated)
ï‚·CaGI -I response, defined as patients who are 
described b y the caregiver as â€œMuch Improvedâ€ or 
â€œVer y Much Improvedâ€ in the CaGI -I score
ï‚·CGI-I response, defined as patients who are 
described as â€œMuch Improvedâ€ or â€œVery  Much 
Improvedâ€ in the CGI- I score
ï‚·CGI-S response, defined as patients who have a 
reduction of â‰¥1 point in the CGI -S score
ï‚·PGI-I response, defined as patients who are 
described as â€œMuch Improvedâ€ or â€œSomewhat 
Improvedâ€ in the PGI- I score
A secondary objective of the 
study  is to evaluate the safet y 
and tolerability  of TEV -50717.The safet y variables include adverse events (and the number of 
patients who withdraw from the study  due to adverse events), 
vital signs, laboratory  tests (hematolog y, chemistry, and 
urinaly sis), ECG measurements, CBCL , ESRS, ESS, and the 
childrenâ€™s C -SSRS.
ADL=activities of daily living; CaGI -I=Caregiver Global Impression of Improvement; CBCL=Child Behavior 
Checklist (for ages 6 -18); CGI-I=Clinical Global Impression of Improvement; CGI -S=Clinical Global Impression of 
Severity; CP=cerebral palsy; C -SSRS=Columbia- Suicide Severity Rating Scale; ECG=electrocardiogram; 
ESRS=Extrapyramidal Symptom Rating Scale (subscales I and II) ; ESS=Epw orth Sleepiness Scale (for childre n and 
adolescents); MD-CRS=Movement Disorder -Childhood Rating Scale; PEDI -CAT=Pediatric Evaluation Disability 
Inventory -Computer Adapted Test; PedsQL=Pediatric Quality of Life Inventory; PGI -I=Patient Global Impression 
of Improvement; QoL=quality of life; UHDRS -TMC=Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal 
Chorea; UHDRS -TMD=Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Dystonia; 
UHDRS -TMS=Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score.
2.1.1. Justification of Primary Endpoint
The rationale to use a movement disorder scale as the primary  endpoint to evaluate patients with 
DCP is based on a few key drivers. In prior studies, the motor scales measured and demonstrated 
a treatment benefit of TEV- 50717 in patients with abnormal movem ents (eg, chorea and 
dyskinesia) associated with HD (Unified Huntingtonâ€™s Disease Rating Scale [UHDRS] -Total 
Maximal Chorea [TMC]) and TD (Abnormal Involuntary  Movements Scale [AI MS]) ( Austedo 
Prescriber Information ). Moreover , the use of motor scales as a primary  outcome measure has 
been sufficient for TEV -50717 to gain regulatory  approval to treat patients with abnormal 
movements. Conversel y, the functional and global scales did not consistently show a treatment 
benefit of TE V-50717 in patients with abnormal movements. 
The Movement Disorder -Childhood Rating Scale (MD -CRS) part II is similar to UHDRS- TMC 
and AIMS in assessing the severit y of abnormal h yperkinetic movement disorders in the 7 bod y 
regions using a 0 to 4 scale. N either MD -CRS part II nor AIMS differentiates whether the 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
45dyskinesia is dy stonic or choreiform . Experts in the field support the choice of MD -CRS part II 
to assess the severit y of movement disorders in children with DCP.
The MD -CRS has 2 parts: part I for general assessment of the functioning and impact of CP on 
the activities of the patient, and part II for a specific motor assessment of the severit y of the 
movement disorder. 
MD-CRS part II evaluates the severit y of the movement disorder in 7 body regions, all areas in 
which dy skinesia can be seen in patients with CP. The MD -CRS part II does not differentiate 
whether the d yskinesia is of the dy stonic or choreiform phenot ype, and the worst dyskinesia in 
any of the regions observed during the assessment session will be taken as the score for each 
affected bod y region. The MD -CRS part II was developed and validated in the CP population for 
children and adolescents aged 4 to 18 years ( Battini et a l 2008 ). In addition, the scale was shown 
to be suitable for detecting a treatment effect after an intervention with trihexy phenid yl, a drug 
used to treat d yskinesia in children with CP ( Battini et al 2014 ).
The MD -CRS was developed based on centralized readings of the video recordings of the patient 
assessments. The use of blinded centralized readings and ratings of videos of patients with 
movement disorders in clinical trials may  decrease the inter -site and intra -site variabi lity of data. 
This clinical trial will use centralized ratings of the videos to reduce data variability .
2.1.2. Primary and Secondary Estimands
The primary  estimand is the difference in means between TEV -50717 and placebo in the target 
patient population for the change from baseline to week 15 in centrall y read MD -CRS part II 
total score, regardless of whether or not dose reduction, suspension, or discontinuation occurred, 
and regardless of treatment-related adverse events. 
The secondary  estimands are the differences in means between TEV- 50717 and placebo in the 
target patient population for (1) change from baseline to week 15 in centrally  read MD -CRS 
partI total score ,(2) Caregiver Global Impression of I mprovement (CaGI -I) at week 15,
(3)Clinical Global Impression of I mprovement (CGI -I) at week 15, (4) change from baseline to 
week 15 in centrall yread UHDRS -TMC, and (5) change from baseline to week 15 in centrally
read UHDRS -TMD, regardless of whether or not dose reduction, suspension, or discontinuation 
occurred, and regardless of treatment- related adverse events.
The primary  estimand assesses the effectiveness in the reduction of choreiform mo vements in 
patients with DCP with predominant choreiform movement disorder, as evaluated by  the central 
reviewers, focusing on the causal effects attributable to the I MP. The secondary  estimands assess 
the effectiveness on patientsâ€™ ability  to perform dail y functions, the improvement in dyskinesia 
evaluated b y the caregiver and the investigator, and the reduction in chorea and dy stonia 
evaluated b y central reviewers, all with a focus on the causal effects attributable to the IMP.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
462.2. Exploratory Objectives and Endpoints
The exploratory  study  objective and endpoint of this study  are the following:
Objective Endpoint
  
 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
473. STUDY  DESIGN
3.1. General Study Design and Study Schematic Diagram
This is a Phase 3, 21- week, multicenter, randomized, double -blind, placebo -controlled, parallel 
group stud y to evaluate the efficacy and safet y of TEV- 50717 administered as oral tablets at a 
starting dose of 6 mg once daily  in patients (age 6 through 18 years, inclusive) with DCP with 
predominant choreiform movement disorder, who have had CP sy mptoms, of a non -progressive 
nature, since infancy  (â‰¤2 years of age). â€œPredominantâ€ in this instance indicates that the 
choreiform moveme nt disorder is the main cause of impairment or distress.
The study  will consist of a screening period (up to 31 days) and a double -blind treatment period 
including a titration period (7 weeks) and a maintenance period (8 weeks), followed by  a 
washout peri od of 1 week, and a follow-up telephone contact 1 week after the washout period. 
Throughout the stud y, patients will interact regularly with investigational center personnel, 
in-clinic and b y telephone (with non -recording live video), for the evaluation of
safet y/tolerability , dyskinesia severit y, and behavioral status (in -clinic onl y). Every effort should 
be made to utilize the same investigator to perform assessments on a patient throughout the 
duration of the study during these interactions. Under circum stances that require or encourage 
involvement of the patientâ€™s caregiver when administering assessments, every  effort should be 
made to involve the same caregiver of a patient throughout the duration of the study . Standard of 
care for treatment of CP shoul d continue throughout the study, with some possible restrictions.
Standard of care could include any possible rehabilitation service(s), such as phy siotherapy , 
occupational therap y, or sensory  integration of the patient, should remain constant throughout t he 
course of the stud y.
For the purposes of this protocol, a caregiver is defined as an adult who is familiar with the 
patient and is responsible for dail y care, enabling that person to effectivel y complete the protocol 
requirements. The caregiver accompan ies the patient to the visits and provides input to the 
relevant scales as required by  the protocol. 
For patients who are minors, the caregiver is t ypically a parent or a legall y accepted 
representative. In some countries, an adult (such as grandparent or nurse) can be appointed b y 
the parent or legall y accepted representative (as per local regulations and laws) and would take 
over this responsibility  as a caregiver. The parent or legally  accepted representative only  has to 
sign the parent/legall y accepted representative informed consent form (ICF) and not the 
caregiver ICF.
For adult patients, a caregiver must be appointed by  the patient; this can be the parent, a legall y 
accepted representative, or other adult, as appropriate and according to local laws a nd 
regulations.
For patients who are minors, certain responsibilities in the protocol can only  be completed by  the 
parent/legall y accepted representative, ie, informed consent, withdrawal of consent, requests for 
discontinuation of the I MP, or withdrawal f rom the study  for any  reason. To further clarify , the 
caregiver is not allowed to make decisions on the childâ€™s health or where â€œparent/legall y 
accepted representativeâ€ is specificall y indicated in the protocol.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
48At the baseline visit (day 1), patients will be randomly  assigned to 1 of 2 treatment groups with 
TEV -50717 IMP or placebo IMP in a 2:1 ratio stratified by  age at baseline (6 to <12 y ears; 
12through 18 years, inclusive) and region (US; non- US). IMP will be titrated during the 
double -blind treatment period starting with 6 mg of TEV -50717 or matching placebo IMP in the 
morning of day  2. Patients in the highest bod y weight group ( â‰¥40 kg/88 lbs) will start an evening 
administration from day  3 and for the remainder of the first week. TEV -50717 daily  dose s of 
12mg and higher will be administered as 2 divided equal doses, approximately  8 to 10 hours 
apart during the day . The number of matching placebo IMP tablets will be increased accordingl y. 
Dose increases may  not occur more frequentl y than every 5 days, except for patients 
â‰¥40kg/88 lbs. For patients â‰¥40 kg/88 lbs, the first dose increase should be performed in an 
interval less than 5 day s, only  once, on day  3. During the titration period, the dose of IMP will be 
adjusted according to the titrations sche me (details are given in Section 5) to identify  a dose level 
that optimally  reduces dyskinesia (as determined by  the investigator, as indicated by  areduction 
in the clinician -reported outcome [ClinRO] of the assessment of the CGI -I) and is well tolerated. 
If a patient experiences a â€œclinically significantâ€ adverse event attributable to the I MP, the 
investigator will first determine if a dose reductio n (to the previous dose level) or suspension is 
necessary  and possible (Section 5.8). After titration, patients will remain at their optimal dose f or 
the length of the maintenance period. 
Screening period (up to 31 days): After written informed consent/assent, as appropriate, is 
obtained, patients who are stable from a medical and psy chiatric standpoint will undergo a 
screening evaluation, including medical history ; phy sical and neurological examination; 
laboratory  testing; 12 -lead ECG; along with MD -CRS part II (ph ysician rated, with video 
recording, centrall y read with video review, centrally read b y the Enrollment Adjudication Board 
[EAB]) to asse ss severit y of dyskinesia; Clinical Global I mpression of Severity  (CGI -S) to assess 
global clinical impression of DCP severity , comorbid CP sy mptoms, and behavioral status; 
childrenâ€™s Columbia- Suicide Severit y Rating Scale (C -SSRS); assessment of drug- induced 
parkinsonism according to the Extrapy ramidal S ymptom Rating Scale (subscales I and II; 
ESRS); assessment of change in behavior according to the Child Behavior Checklist (for ages 
6-18) (CBCL) questionnaire; and assessment of sedation according to the E pworth Sleepiness 
Scale (for children and adolescents) (ESS) questionnaire. Screening may  be conducted over 
2 separate visits at the discretion of the investigator. The diagnosis of CP and DCP will be 
established based on clinical features as described in the inclusion/exclusion criteria. The EAB 
will also confirm, based on video recordings, that choreiform is clinically  the predominant 
movement disorder of the patientâ€™s DCP. EAB assessment results will be available to the 
investigator prior to baseline and randomization. The MD- CRS part II will be administered by  
the investigational center phy sician and video review for central -blinded reading. In this stud y, 
the MD -CRS part II will be scored onl
y based on chorea.
Titration period (7 weeks) : Patients who re main eligible for participation in the study  will be 
randomized at the baseline visit (day  1) and instructed to take the first dose of blinded IMP the 
following morning with food ( eg, a snack) and should not be taken on an empty  stomach. The 
titration sche me and maximum dose will be determined by  body  weight and CYP2D6 
impairment status at baseline, as shown in Table 4and Table 5. Patients will be classified as 
CYP2D6 impaired if they are receiving a strong CYP2D6 inhibitor or are a CYP2D6 poor 
metabolizer. At the baseline visit, a telephone for non- recording live video will be provided to 
the patient and caregiver. Patients and their caregiver will interact weekl y with the 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
49investigator/staff, either by  telephone contact (with non -recording live video) or clinic visit from 
week 1 through week 7 of the t itration period, in order to evaluate safet y/tolerability  and 
establish a dose of IMP that optimally  reduces the severit y of d yskinetic involuntary  movements 
(clinically  meaningful reduction in dy skinesia, as indicated by  a reduction in the CGI -I) and is 
well tolerated. Safet y/tolerability  in-clinic evaluations during titration include assessment of vital 
signs, monitoring for adverse events and concomitant medications, 12 -lead ECGs, identify ing 
subjects at risk for suicide according to the C -SSRS questionnaire, assessment of drug- induced 
parkinsonism according to the ESRS (subscales I and II), assessment of change in behavior 
according to the CBCL  questionnaire, and assessment of sedation according to the ESS 
questionnaire. If a patient experiences a â€œclini cally significantâ€ adverse event attributable to the 
IMP, the investigator will first determine if a dose reduction (to the previous dose level) or 
suspension is necessary  and possible. At the end of the titration period, the patientâ€™s dose will be 
establi shed for the maintenance period. All IMP adjustments are made only  after a remote or in -
clinic visit; if the dose is escalated, the dose escalation will occur with the next morningâ€™s dose.
In-person (in- clinic) study  visits will be scheduled for weeks 3 and 7, and telephone contacts 
(with non-recording live video) will be scheduled for weeks 1, 2, 4, 5, and 6 in order to assess 
dyskinesia and adverse events. The telephone contacts to the patient will be supported by  live 
video stream, without recording, to provide visual confirmation to the investigator of the verbal 
information provided b y the patient or caregiver. The dose of the IMP should be increased on a 
weekl y basis to reach a clinically  meaningful reduction in dy skinesia, as indicated by  a reduction 
in the CGI -I. The IMP dose should not be increased further if either of the following events 
occurs:
ï‚·the patient experiences a protocol- defined â€œclinically  significantâ€ adverse event 
(defined as an adverse event that is related to IMP and is either moderat e or severe in 
intensity  or meets the criteria for a serious adverse event), OR
ï‚·the maximum allowable dose is reached based on the patientâ€™s weight and CYP2D6 
impairment status at baseline.
Dose adjustments can be made up to and including the week 7 in -clinic visit. If an optimal dose 
is reached before the week 7 in -clinic visit, the dose of IMP should not be increased further, but 
the patient should continue on that dose for the remainder of the titration period and throughout 
the maintenance period. If a patient experiences a â€œclinically  significantâ€ adverse event 
attributable to the IMP, the investigator will first determine if a dose reduction (to the previous 
dose level) or suspension is necessary  and possible. If the determination that a patient requir es a 
dose reduction or suspension is made during a telephone contact, an unscheduled clinic visit 
should be conducted as soon as practicable thereafter.
Maintenance period (8 weeks) : Patients will continue to receive their maintenance dose over the 
next 8 weeks, although a 1-time dose reduction (to the previous dose level for the remainder of 
the study ) for adverse events is allowed. Patients will return to the clinic at weeks 9, 12, and 
15for assessments of efficacy  and safety . 
Washout period and follow -up:All patients will discontinue IMP at the week 15 visit and will 
return 1 week later for the end -of-study  (EOS) visit. Patients who complete the study  may  be 
eligible to begin participation in the open -label safety  extension Study  TV50717- CNS -30081 at 
that time. At the week 16 visit, patients may  choose to enter Study  TV50717 -CNS -30081 (on 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
50that day ) or up to 1 week later (2 weeks from the week 15 visit). Patients who complete 
treatment but choose not to participate in the open -label safety  extension Stud y 
TV50717- CNS -30081 any  time before week 17 of Study  TV50717- CNS -30080 will be 
contacted for a safet y evaluation call occurring 2 weeks after their last dose of IMP. Additional 
details for patients to enter Study  TV50717 -CNS -30081 are provided in the TV507 17-CNS -
30081 protocol.
When approximately  50 patients have completed the study  (including follow -up), an independent 
Data Monitoring Committee (iDMC) will perform an unblinded non -binding interim analy sis 
(IA) for futility  based on centrall y read MD- CRS pa rt II total score. 
An iDMC charter will be developed for the IA, and the procedures to ensure the integrity  of the 
study  will be provided in the charter.
At the time of informed consent, the parent/legally accepted representative will be counseled 
that, once randomized to treatment, patients are to remain in the study  and complete all study  
procedures unless the choice is made to withdraw consent. Patients who withdraw from the stud y 
before completing the 15 -week treatment period should have an earl y termi nation (ET) visit as 
soon as possible after the last dose of IMP. All patients who discontinue early  will have a 
follow -up telephone contact for safet y evaluation 2 weeks after ET; evaluations will be as 
described for week 17.
Patients who screen fail or t erminate earl y from the study due to emergency circumstances (such 
as coronavirus disease 2019 [COVI D
-19]) may  be allowed to re- screen/re -enter (respectivel y) 
the study  at a later date, depending on the circumstances. Each case should be referred to the 
medical monitor and approved in advance.
There is a separate protocol for the open
-label safety  extension Study  TV50717- CNS -30081.
The end of stud y is defined as last visit of the last patient.
The study  schematic diagram is presented in Figure 1.
For coronavirus disease 2019 (COVID -19) updates, refer to Appendix M.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
51Figure 1:Overall Study Schematic Diagram
ScreeningTitration Period
Investigator, in consultation with the patient and caregiver, will 
determine if a dose increase is warranted to achieve optimal dyskinesia 
reductionMaintenance TherapyWas h 
outFollow Up
â‰¥ 40 kg
30 < 40 kg
6 (6)
mg12 (12) 
mg18 (18) 
mg24 (24) 
mg30 (24) 
mg36 (24) 
mg42 (24) 
mgStable maintenance dose 
42 (24) mg/day
17 < 30 kg
6 (6)
mg12 (12) 
mg18 (18) 
mg24 (18) 
mg30 (18) 
mgStable maintenanc e dose 
30 (18) mg/day6 (6) 
mg12 (12) 
mg24 (24) 
mg30 (30) 
mg36 (36) 
mg42 (36) 
mg48 (36) 
mgStable maintenanc e dose 
48 (36) mg/day 18 (18) 
mg
12 < 17 kg6 (6)
mg12 (12) 
mg18 (12) 
mg24 (12) 
mgStable maintenance dose 
24 (12) mg/dayIn-clinic visit
Telephone callTelephone call with 
non recorde d video
Video recording
Option of 
participation in 
long -term safety 
studyUp to 31 
daysWeek 
15/ ETend-of-
study visit
Week 
1Week 
3Week 
16
Baseline
Day 
1
Week 
12
Week 
7
Week  
9Week 
2Day 
2Week 
4Week 
5Week 
17Week 
6Day
3Week 
15
1 
week
AE=adverse event; CGI=Clinical Global Impression; CYP2D6=cytochrome P450 2D6; ET=early termination; max=maximum.
Note: If a patient is CYP2D6 -impaired, the dose administered is indicated in parentheses. The dose of the IMP should be increased on a w eekly basis until any of 
the following events occur: clinically meaningful reduction in dyskinesia (ie, CGI -I) as determ ined by the investigator, clinically significant AE, or the maximum 
allow able dose is reached after remote or in -clinic visits .
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
523.2. Planned Number of Patients and Regions
Approximately  65patients are planned to be randomized to TEV -50717 versus placebo in a 
2:1ratio (approximately  43in the TEV -50717 group; approximately  22in the placebo group) 
stratified by  age at baseline (6 to <12 years; 12 through 18 years) and region (US; non- US). 
Details on sample size are given in Section 9.1
.
This study  is planned to be conducted in approximately  60 investigational centers in North 
America, Asia, and Europe. 
3.3. Justification for Study Design and Selection of Population
Currently , there is no approved treatment available for DCP. The available treatment options 
address some of the manif estations of DCP, which is hy perkinetic motor impairment due to a 
non-progressive disturbance of brain function that occurred in the developing fetal or infant 
brain, generall y before the age of 2 years, and will therefore have a major debilitating impact 
on 
the ability  of the child with CP to further develop motor skills. Therefore, the study  population 
will include pediatric and adolescent patients (6 through 18 years of age) with DCP with 
predominant choreiform movement disorder, who have had non -progres sive CP sy mptoms since 
infancy  (â‰¤2years of age). Diagnosis of DCP is based on the Surveillance of Cerebral Palsy  in 
Europe criteria ( Cans 2000 ).
Consequently , the placebo -controlled, double -blind study  design (TEV -50717 versu
s placebo in 
a 2:1 ratio) was chosen for this Phase 3 study  to determine whether treatment with study  
medication results in a statistically  significant effect on dy skinetic involuntary  movements of 
patients with DCP.
3.4. Stopping Rules for the Study
When approximately  50 patients have completed the study  (including follow -up), an iDMC will 
perform an unblinded non -binding IA for futility  based on the primary  endpoint, the centrall y 
read MD -CRS part II total score. Based on the results of the IA, the study  may  be stopped for 
futility .
During the conduct of the study , serious adverse events will be reviewed ( Section 7.1.5), as they  
are reported from the investigational centers to identify  safet y concerns.
The study  may  be terminated by  the sponsor for any  reason at any  time. For example, the 
sponsor should ter minate the study  in the event of the following:
ï‚·new toxicological or pharmacological findings or safet y issues invalidate the earlier 
positive benefit -risk assessment
ï‚·discontinuation of the development of the IMP
If the stud y will be stopped, the patients who are terminated earl y will be followed according to 
Withdrawal Criteria and Procedures for the Patient (Section 4.3
).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
533.5. Schedule of Study Procedure s and Assessments
Study  procedures and assessments with their time points are presented in Table 3. Detailed 
descriptions of each method of procedures a nd assessments are provided in Section 6(efficacy  
assessments), Section 7(safet y assessments), and Section 8(pharmacokinetic and other 
assessments). Study  procedures and assessments by visit are listed in Appendix C.
For COVID -19 updates, refer to 
Appendix M.
Placebo- Controlled Study â€“Dyskinesia in Cereb ral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
54Table 3: Study Procedures and Assessments
Screening BLaTitration Maintenance Follow -up U
Study weekb-31 days Day 1 1
(Day 
7)2
(Day 
14)3
(Day 
21)4
(Day 
28)5
(Day 
35)6
(Day 
42)7
(Day 
49)9
(Day 
63)12
(Day 
84)15c/
ETd
(Day 
105)16/EOS 
(7 days 
from  
week 15 
visit)17e
(14 days 
from  
week 15 
visit)
Visit window (days) 0 +1 -1 and 
+3 Â±3 days from  day 1/baseline and â‰¥5 days from  last dose 
changeÂ±2 days from  
week 15 visit
In-clinic visit XfX X X X X X X X
Telephone contactgX X X X X X Xh
Evaluate/adjust IMPiXjXjXjXjXjXjXjX
Informed consent/assentkX
Eligibility criteria X X
Medical history and psychiatric 
historyX
Dem ographics X
Vital signs and weightlX XmX X X X XmX X
Physical examination X X X Xh
Neurological examination X X X Xh
Height X X
12-lead ECGnX X X X XoXh
XpXq
Chemistry/hematology/urinalysis X X XrXh
Urine drug screen X X X X X Xh
CYP2D6 genotypesX
Î²-HCG testtX X X X X X X Xh

Placebo- Controlled Study â€“Dyskinesia in Cereb ral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
55Screening BLaTitration Maintenance Follow -up U
Study weekb-31 days Day 1 1
(Day 
7)2
(Day 
14)3
(Day 
21)4
(Day 
28)5
(Day 
35)6
(Day 
42)7
(Day 
49)9
(Day 
63)12
(Day 
84)15c/
ETd
(Day 
105)16/EOS 
(7 days 
from  
week 15 
visit)17e
(14 days 
from  
week 15 
visit)
Visit window (days) 0 +1 -1 and 
+3 Â±3 days from  day 1/baseline and â‰¥5 days from  last dose 
changeÂ±2 days from  
week 15 visit
Randomization X
MD-CRS part I (physician rated, 
with video recording)uX X X X X Xh
MD-CRS part I (centrally read, 
with video review )uX X X X X Xh
MD-CRS part II (physician rated, 
with video recording)u X XX X X X Xh
MD-CRS part II (centrally read, 
with video review )uX
(EAB)XX X X X Xh
CaGI -IvX X X X X X Xh
CGI-I (global, physician rated)wX X X X X X X X X X X Xh
CGI-S (global, physician rated) X X X X X X X X Xh
PEDI- CAT (ADL, caregiver 
completed, content -balanced 
version)X X Xh
PedsQL (QoL, patient/caregiver) X X Xh
PGI- I (global, patient/caregiver)vX X X X X X Xh
UHDRS -TMC (centrally read) X X X X Xh
UHDRS -TMD (centrally read) X X X X Xh
UHDRS -TMS (physician rated) X X X X Xh
Placebo- Controlled Study â€“Dyskinesia in Cereb ral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
56Screening BLaTitration Maintenance Follow -up U
Study weekb-31 days Day 1 1
(Day 
7)2
(Day 
14)3
(Day 
21)4
(Day 
28)5
(Day 
35)6
(Day 
42)7
(Day 
49)9
(Day 
63)12
(Day 
84)15c/
ETd
(Day 
105)16/EOS 
(7 days 
from  
week 15 
visit)17e
(14 days 
from  
week 15 
visit)
Visit window (days) 0 +1 -1 and 
+3 Â±3 days from  day 1/baseline and â‰¥5 days from  last dose 
changeÂ±2 days from  
week 15 visit
Childrenâ€™s C -SSRS (Baseline/ 
Screening)xX
Childrenâ€™s C -SSRS (Since Last 
Visit)xX X X X X X X Xh
ESRS subscales I and II X X X X X X X X Xh
CBCLyX X X X X X X X Xh
ESS X X X X X X X X Xh
Dispense IMP XzXzXaaXaaXaaXh
Collect IMP X X X X X Xh
Assess IMP accountability/ 
compliance/supplybbXccXccXddXccXccXccX X X X Xh
Assess adverse events X X X X X X X X X X X X X X
Concomitant medications X XeeXeeXeeXeeXeeXeeXeeXeeXeeXeeXeeXeeXeeXee
Contact RTSM X X X X X X
aThe BL visit will occur (day 1), and the first dose of the IMP w ill be taken the next morning (day 2).
bAssessment is to occur at the end of study week, unless stated otherw ise.
cThe date and time of the last dose of study medication before the week 15 visit should be reported to the investigator/staff by the patient or ca regiver. The 
investigational center will document the date and time of the sample collection.
dFor patients who withdraw prematurely, an ET visit should be conducted as soon as possible after th e last dose of IMP. All patients who discontinue early will 
have a follow -up telephone contact for safety evaluation 2 weeks after ET visit; evaluations will be as described for w eek 17.
eThis v isit is a telephone contact for safety evaluation, required only for patients who will not roll over into the open -label safety extension study for 
TV50717 -CNS -30081.
fThe screening visit may be conducted over 2 separate visits at the discretion of the investigator.
Placebo- Controlled Study â€“Dyskinesia in Cereb ral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
57gTelephone contacts at weeks 1, 2, 4, 5, and 6 w ill be conducted w ith non -recording live video. Telephone contact at w eek17 is a phone contact only (ie, no 
live video streaming).
hAssessment to be completed at investigatorâ€™s discretion.
iDose increases may not occur more frequently than every 5 days, except for patients â‰¥40 kg/88 lbs. For patients â‰¥40 kg/88 lbs, the first dose increase should
be performed in an interval less than 5 days, only once, on day 3.  
jDose adjustment will be made by the investigator after telephone contact with the patient and caregiver or in -clinic visit to evaluate dyskinesia reduction and 
adverse events. If the dose is escalated, the dose escalation will occur with the next morningâ€™s dose.
k
lWeigh t must be measured with shoes and outerwear off. Before pulse and BP are measured, the patient must be in a supine or semi -erect/seated position and 
resting for at least 3 minutes (the same position and arm or leg should be used each time vital signs are m easured for a given patient).
mOrthostatic BP and pulse will be measured after the patient is in a standing position for at least 3 minutes (for patients wh o are able to stand); for patients who 
find standing difficult or do not allow  for a reliable BP and pulse measurement, alternative methods to collect orthostatic BP and pulse should be discussed 
with the medical monitor .
nAll ECGs will be performed after at least 5 minutes rest in a supine or semi -supine position.
oPerform ECG if there was a signif icant abnormality at the ET visit.
p
 
 
 
q 
 
rPatients with clinically significant laboratory abnormalities at w eek 15 w ill have those laboratory evaluations repeated at t he week 16 visit.
sThe patientâ€™s CYP2D6 genotype results will be provided to the RTSM, w hich drives each patientâ€™s dose regimen, and the patientâ€™s CYP2D6 genotype will 
remain blinded during the conduct of the study.
tFor females who are postmenarchal or aged â‰¥12 years of childbearing potential. Serum test will be administered at screening a nd week 15, whereas a urine 
test will be administered at baseline and all other in -clinic visits where this test is administered.
uMD-CRS parts I and II assessments are done locally at the investigational center, by the investigator, and video recorded. An EAB will confirm, at the 
screening visit, that choreiform movement disorder is the predominant dyskinetic movement disorder and that DCP severity repr esented by an MD -CRS part 
II score is â‰¥10. The EAB w ill inform the local rater if their assessment is different than the local raterâ€™s assessment; however, it is the investigator who 
determines the subjectâ€™s eligibility. All the subsequent MD -CRS ratings will be performed by the investigator and video recorded and then centrally read, in a 
blinded manner.
vCaGI-I and PGI -I are to be completed before all other investigator -rated scales during visits where CaGI -I and PGI -I are collected.
wDuring telephone contact, the CGI -I scale can only be done if non -recording video is available, allow ing the investigator t o complete the required assessment.
xThe childrenâ€™s C -SSRS questionnaire will be presented to patients who have reached â‰¥12 years of age at screening or 11 years of age at screening but will 
turn 12 years of age during the study. Children 13 years of age and under must be interviewed in conjunction with the caregiver. For children over 13 years of 
age, parent/legally accepted representative involvement is strongly encouraged. Questions should be direc ted to the child, but the parent/legally accepted 
representative should be encouraged to add relevant information. 
yA full CBCL assessment (Competence Scale [Parts I to VII] and a Syndrome Scale [behavioral items]) w ill be performed at scree ning and week 15/ET. The 
Syndrome Scale part of the CBCL assessment only will be performed at baseline and weeks 3, 7, 9, 12, and 16/EOS.

Placebo- Controlled Study â€“Dyskinesia in Cereb ral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
58zIMP w ill be dispensed in the clinic. At the baseline visit, patients will receive IMP kits of increasing doses sufficient for 3 weeks. At the week 3 visit, 
4additional kits of increasing doses w ill be dispensed to cover the following 4 weeks until the end of the titration period at week 7. These supplies will allow  
the patient to maintain their titration scheme between clinic visit s by way of remote caregiver/patient telephone contacts. Dose adjustments can be made up to 
and including the week 7 in -clinic visit. If an optimal dose is reached before then, the dose of IMP should not be increased any further, but the patient should 
continue on that same dose for the remainder of the titration period and throughout maintenance dosing. The investigational cent er will determine titration (ie, 
starting the next dose) for the patient by telephone. See Table 4for baseline w eight -based dosing titration. For any dose adjustment, the investigator or 
designee should confirm that patients have the bottle that contains the appropriate tablet str ength and quantity to complete the recommended daily regimen.
aaPatients will receive doses for 3 w eeks (Â±3 days) of maintenance treatment.
bbStudy drug accountability will be assessed during in -clinic visits only. A check for compliance with TEV -50717 intake will be performed during each 
in-clinic visit and telephone contact after TEV -50717 has been dispensed.
ccThe study staff needs to discuss the drug status during the telephone contacts to ensure that the patients have adequate tabl ets, inform the p atients if they 
should titrate, and remind them to bring used and unused IMP bottles to the next in -clinic visit.
ddDuring the week 3 visit, the investigator or designee will make sure the patient receives the last treatment kit back so the patient can ta ke the evening dose to 
complete the week 3 dosing for that day. Refer to the pharmacy manual for further details.
eeCaregivers and patients will be instructed during the course of the study to notify the investigator if any new medication is prescribed/administered (other than 
TEV -50717) or if there is any change in current medications, including over -the-counter medications. Any new and/or any change in current medications 
should be review ed with the investigator.
Î²-HCG=beta human chorionic g onadotropin; ADL=activities of daily living; BL=baseline visit; BP=blood pressure; CaGI -I=Caregiver Global Impression of 
Improvement; CBCL=Child Behavior Checklist (for ages 6 -18); CGI-I=Clinical Global Impression of Improvement; CGI -S=Clinical Global Impr ession of 
Severity; C-SSRS=Columbia -Suicide Severity Rating Scale; CYP2D6=cytochrome P450 2D6; DCP=dyskinesia in cerebral palsy; EAB=Enrollment 
Adjudication Board; ECG=electrocardiogram; EOS=end of study visit; ESRS=Extrapyramidal Symptom Rating Scale (subscales I and II) ; ESS =Epw orth 
Sleepiness Scale (for children and adolescents); ET=early termination visit; ; IMP=investigational medicinal product; 
MD-CRS=Movement Disorder -Childhood Rating Scale; PEDI -CAT=Pediatric Evaluation Dis ability Inventory -Com puter Adapted Test; PedsQL=Pediatric 
Quality of Life Inventory; PGI -I=Patient Global Impression of Improvement; ; QoL=quality of life; RTSM=Randomization and Trial 
Supply Management; U=unscheduled visit; UHDRS- TMC=U nified Huntingtonâ€™s Disease Rating Scale- Total Maximal Chorea; UHDRS -TMD=Unified 
Huntingtonâ€™s Disease Rating Scale- Total Maximal Dystonia; UHDRS -TMS=Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
594. SELECTION AND WITHDR AWA L OF PATIENTS
Prospective waivers (exceptions) from study  inclusion and exclusion criteria to allow patients to 
be randomized/enrolled are n ot granted b y Teva ( Appendix D).
Standard of care for treatment of CP should continue throughout the study , with some possible 
restrictions related to concomitant medication, for example, as outlined in Section 5.5. Standard 
of care could include an y possible rehabilitation service(s), such as p hysiotherapy , occupational 
therap y, or sensory  integration of the patient, which should remain constant throughout the 
course of the stud y.
4.1. Patient Inclusion Criteria
Patients may  be randomized/enrolled in this study  only  if they  meet all of the following criteria:
1.Patient is 6 through 18 years of age (inclusive) at baseline. 
2. Patient weighs at least 26 pounds (12 kg) at baseline.
3.Patient has had CP sy mptoms since infancy  (â‰¤2 years), and CP is judged by the 
investigator to be of a non-progressive nature ( Monbaliu et al 2017 , 
Wimalasundera et al 2016 ).
4.Patient has a diagnosis of DCP according to the Surveillance of Cerebral Palsy  in Europe 
criteria ( Cans 2000 ).
5.Patient has an MD -CRS part II total score of â‰¥10 at the baseline visit, based on 
investigator scoring of chorea.
6.Patientâ€™s sy mptoms are causing functional problems determined by  a CGI -S score of 4 or 
greater based on investigator scoring.
7.Choreiform is the predomin ant(ie, the main cause of impairment or distress) movement 
disorder as assessed at screening.
8.Patient is able to swallow study  medication whole.
9.Patient and caregiver are willing to adhere to the medication regimen and to comply  with 
all study  procedures.
10.Patient is in good general health, as indicated b y medical and ps ychiatric history , as well 
as phy sical and neurological examination.
11. In the investigatorâ€™s opinion, the patient and /orcaregiver has the ability  to understand the 
nature of the stud y and its procedures, and the patient is expected to complete the study 
as designed.
12.For a patient who is a minor, the parent(s)/legall y accepted representative(s) provide 
written informed consent, and the p atient provides assent (in accordance with local 
regulations). Adult patients provide their own written informed consent (in accordance 
with local regulations) and the legally  acceptable representative will sign, if needed .
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
60In this stud y, eligible patients are patients with dy skinetic CP who may  have some degree 
of mental, motor, and/or communication (eg, speech, writing, etc) limitations or 
disabilities. The patient may  not be able to read the assent/consent form. Some patients 
may only be able to provide a limited assent/consent (for instance, b y verbalizations or 
gestures). The investigator will determine the suitability  of enrolling such patients in this 
study  and will follow the local regulation to obtain the relevant assent/consent. 
13.Caregivers provide written informed consent after being assigned the role by  an adult 
patient, or if this role is delegated b y the parent/legall y accepted representative of a 
patient who is a minor.
14.Females who are postmenarchal or â‰¥12 y ears of age may  be included onl y if they have a 
negative beta -human chorionic gonadotropin (Î² -HCG) test at baseline or are sterile. 
Definitions of sterile, premenarchal, and postmenarchal are given in Appendix F. 
15.Females who are postmenarchal or â‰¥12 y ears of age whose male partners are potentially  
fertile (ie, no vasectom y) must use highly  effective birth control methods for the duration 
of the study  (ie, starting at screening) and for 30 day s after the last dose of IMP. Further 
details are included in Appendix F.
4.2. Patient Exclusion Criteria
Patients will not be randomized/enrolled in this study  if they  meet any  of the following criteria:
1.a. Patient has a predominant movement disorder other than d yskinesia.
b. Patientâ€™s predominant motor sy mptoms are d ystonic.
c. Patientâ€™s predominant motor sy mptoms are spastic.
d. Patient has anothe r other movement disorder that could impair the motor assessment in 
the MD -CRS part II.
e. Patient has choreiform movement disorder that has not been consistent throughout the 
life of the patient.
2.Patient has clinically  significant depression at screening or baseline. 
ï€­Note : Patients receiving antidepressant therap y may be enrolled if on a stable dose 
for at least 6 weeks before screening and anticipated to remain stable (dose and 
frequency ) within the study  duration.
3.Patient has a history of suicidal intent or related behaviors based on medical or 
psychiatric history  or the C -SSRS within 2 y ears of screening:
ï€­Previous intent to act on suicidal ideation with a specific plan, irrespective of 
level of ambivalence, at the time of suicidal thought
ï€­Previous suici dal preparatory  acts or behavior
4.Patient has a history  of a previous actual, interrupted, or aborted suicide attempt based on 
medical or ps ychiatric history or the C -SSRS.
5.Patient has a first- degree relative who has completed suicide.
6.Patient has received any of the following concomitant medications within the specified 
exclusionary  windows of screening:
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
61ï€­Within 30 day s: tetrabenazine, deutetrabenazine, or valbenazine
ï€­Within 21 day s: reserpine
ï€­Within 14 day s: levodopa, dopamine agonists, and MAOIs
7.Patient ha s received treatment with stem cells, deep brain stimulation, transmagnetic 
stimulation, or transcranial direct current stimulation for treatment of abnormal 
movements or CP within 6 months of the screening visit, or the patient is not in a stable 
clinical condition. 
8. Patient has recent surgical procedure or is anticipated to have a surgical procedure during 
the study  that, in the opinion of the investigator, makes the patient unsuitable for the 
study .
9.Patient has a severe mental disability  or an unstable or serious medical illness (eg, 
epilepsy ) at screening or baseline that, in the opinion of the investigator, could jeopardize 
or would compromise the patientâ€™s ability  to participate in this study .
10.Patient has a QT interval corrected for heart rate using Fr idericiaâ€™s formula (QTcF) value 
>450 msec on 12-lead ECG at screening. 
11.Patients with a history  of torsade de pointes, congenital long QT s yndrome, 
bradyarrh ythmias, other cardiac arrhy thmias, or uncompensated heart failure.
12.Patient has evidence of diminis hed hepatic function, as indicated b y the following:
ï€­Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 Ã— the 
upper limit of the normal range (ULN) at screening
ï€­Alkaline phosphatase (ALP) or total bilirubin >2 Ã— ULN at screening
ï€­Note : Patients with Gilbertâ€™s sy ndrome are eligible to participate if approved by  
the medical monitor. 
ï€­Note : Patients with abnormalities in 2 or more of the following clinical laboratory  
parameters must be approved for enrollment by  the medical monitor: AST, ALT, 
ALP, and total bilirubin. 
13.Patient has evidence of clinically  significant renal impairment , indicated b y a serum 
creatinine >1.5 Ã— ULN at screening. 
14.Patient has a known allergy  to an y of the components of the I MP.
15.Patient has participated in an inves tigational drug or device study  and received 
IMP/intervention within 30 day s or 5 drug half -lives of screening, whichever is longer.
16.Patient is pregnant or breastfeeding.
17.Patient has a history  of or acknowledges alcohol or other substance abuse in the 
12 m onths before screening.
18. Patient has a positive urine drug screen test result (with exception of medications listed in 
Table 10of Appendix H). Any  request to include a patient with a positive urine drug 
screen test result should be discussed with, and approved by , the medical m onitor . 
Refer 
to Section 7.5.2.2 (urine drug screen) for more details.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
624.3. Withdrawal Criteria and Procedures for the Patient
Patients are expected to p articipate in this study  for its entire duration and perform the scheduled 
visits and procedures. 
During the titration period, an optimal dose should be sought for each patient. Throughout the 
maintenance period, patients will continue to receive the opti mal dose determined during 
titration. I f a patient experiences a â€œclinically significantâ€ adverse event attributable to the I MP, 
the investigator will first determine if a dose reduction (to the previous dose level) or suspension 
is necessary  and possible (Section 5.8). Each patient is free to withdraw from the study  or 
discontinue from IMP at any  time, without prejudice to their continued care, but e very effort 
should be made to determine the reason for discontinuation. 
Every  effort should be made to ensure that patients comply  with study  visits and procedures, as 
detailed in the protocol. Patients must be withdrawn from the study  if an y of the follo wing events 
occur:
1.Patient or parent(s)/legally acceptable representative withdraws consent or requests 
discontinuation from the IMP or withdrawal from the study  for any  reason.
2.Patient develops an illness that would interfere with his/her continued partic ipation.
3.Patient is noncompliant with the study  procedures and assessments or administration of 
IMPs in the opinion of the investigator.
4. Patient takes prohibited concomitant medications as defined in this protocol 
(see Appendix H).
5.Patient engages in 
alcohol or other substance abuse.
6.A female patient has a confirmation of pregnancy  during the study  from a positive 
pregnancy  test.
7. The sponsor requests withdrawal of the patient.
8. Patient experiences an adverse event or other medical condition that indicates to the 
investigator that continued participation is not in the best interest of the patient.
9.The patient experiences a serious adverse event or pregnancy , or in cases when the 
investigator deems it necessary  to unblind the patientâ€™s IMP assignment to make 
treatment decisions.
10. Patient has evidence of diminished hepatic function based on the following liver function 
laboratory  test results:
a.AST or ALT >2.5 Ã— ULN
b.ALP or total bilirubin >2 Ã— ULN
11.Patient develops Neuroleptic Malignant S yndrome (NMS)
12.If a post -baseline QTcF value >500 msec or change from screening >60 msec is found, 
the investigator should repeat the ECG assessment twice more and compare the average 
of these 3 post-screening QTcF values to the pre -treatment QTcF values at screening. The 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
63IMP must be stopped for any  confirmed post -baseline QTcF average value >500 msec or 
average increase from screening >60 msec. 
13. In patients who experience signs of suicidal idea tion or behavior (Section 7.9), t he 
investigator should consult with the medical monitor to determine whether the patient 
should continue in the study .
In addition, a patient may  be withdrawn from the study  as described in Sections 3.4,3.5, 
and 5.10 and Appendix C.
Because the statistical analy sis of the primary  endpoint of this study  includes the assessment of 
randomness of missing data (Section 9.5.2.1), the most accurate as possible determination of the 
reason for ET is very  important. Investigators should make every  effort to obtain accurate 
information on patients in the case of withdrawal from the study  or disco ntinuation from I MP. 
Results of any  evaluations and observations, together with a narrative describing the reason(s) 
for withdrawal from the study  or discontinuation from I MP, must be recorded in the source 
documents. The case report form (CRF) must docume nt the primary  reason for withdrawal from 
the study  or discontinuation from IMP.
See Appendix Gfor information regarding how the study  will define and address lost to 
follow -up patients to help limit the amount and impact of missing data.
If the reason for withdrawal from the stud y or discontinuation from IMP is an adverse event 
and/or clinicall y significant abnormal laboratory test result, monitori ng will be continued as 
applicable (eg, until the event has resolved or stabilized, until the patient is referred to the care of 
a health care professional, or until a determination of a cause unrelated to the IMP or study 
procedure is made). If a patient is withdrawn wholly  or in part because of an adverse event, the 
specific event or test result (including repeated test results, as applicable) must be recorded both 
on the source documentation and in the adverse events page and termination page of the CRF.
The patient will be monitored at the discretion of the investigator (eg, until the event has 
resolved or stabilized, until the patient is referred to the care of a health care professional, or 
until a determination of a cause unrelated to the IMP or study procedure is made). The 
investigator must inform the clinical project ph ysician/clinical leader as soon as possible of any  
patients who are being considered for withdrawal due to adverse event(s). Additional reports 
must be provided when requested.
If a p atient is withdrawn from the study  for multiple reasons that also include adverse events, the 
relevant page of the CRF should indicate that the withdrawal was related to an adverse event. An 
exception to this requirement will be the occurrence of an advers e event that, in the opinion of 
the investigator, is not severe enough to warrant discontinuation but that requires the use of a 
prohibited medication, thereb y requiring discontinuation of the patient. In such a case, the reason 
for discontinuation would b e â€œneed to take a prohibited medicationâ€ and not the adverse event.
All assessments should be performed according to the protocol on the last day  the patient takes 
IMP, or as soon as possible thereafter.
For COVID -
19 updates, refer to Appendix M.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
644.4. Replacement of Patients
A patient who is enrolled but does not complete the treatment period will not be replaced.
4.5. Rescreening
A patient who is screened but no t enrolled (eg, because inclusion and exclusion criteria were not 
met or enrollment did not occur within the specified time) may  be considered for rescreening 
1 time if there is a change in the patientâ€™s medical background or other relevant change. (Note: 
the medical monitor should approve rescreening after review of the enabling reasons.)
Patients may  have individual parameters retested at the discretion of both the investigator and the 
sponsor .
If the patient is rescreened, an informed consent form ( ICF) will need to be re -signed.
For COVID -19 updates, refer to Appendix M.
4.6. Screening Failure
Screening failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomized in the study . Minimal information includes, but is not limited 
to, demograph y, screening failure details, eligibility criteria, and an y serious adverse events.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
655. TREA TMENTS
5.1. Investigational Medicinal Products Used in the Study
IMP is defined as the test I MPs and matching placebo IMPs to the respective test I MPs. There is 
no reference IMP in this study .
5.1.1. Test Investigational Medicinal Product
Test IMP (TEV -50717 [deutetrabenazin e, previously  SD-809]) will be administered as oral 
tablets with food (eg, a snack) and should not be taken on an empty  stomach. The IMP is coated 
with a white poly mer coating to aid in swallowing. TEV -50717 tablets have been manufactured 
according to curr ent Good Manufacturing Practice (GMP) regulations. TEV -50717 tablets will 
be supplied as 6 -, 9-, 12- , 15-, and 18- mg tablets by  bottle and labeled according to applicable 
regulatory  guidelines. Each bottle pack (20 -count tablets per dose strength per bottl e) will 
contain a sufficient supply of drug until the next specified visit/telephone contact, plus overage 
to account for potential delay s in study  visits.
Additional details may be found in 
Table 6,the IB for TEV -50717, and the Prescribing 
Information for TEV- 50717.
5.1.1.1. Starting Dose and Dose Levels
Test I MP will be administered as oral tablets at a starting dose of 6 mg once daily with food 
(eg, 
a snack) a nd should not be taken on an empty  stomach. Titration schemes based on body  weight 
at baseline are shown in Table 4. The maximum daily  dose is determin ed by  body  weight at 
baseline and CYP2D6 impairment status (see Table 5). Patients will be classified as CYP2D6 
impaired if they  are receiving a strong CYP2D6 inhibitor or are a CYP2D6 poor metabolizer. 
Dose adjustments can be made up to and including the week 7 in-clinic visit. If an optimal dose 
is reached before the week 7 in-
clinic visit, the dose of IMP should not be increased further, but 
the patie nt should continue on that dose for the remainder of the titration period and throughout 
the maintenance period. If a patient experiences a â€œclinically significantâ€ adverse event that is 
attributed to the I MP, the investigator will first determine if a dos e reduction (to the previous 
dose level) or suspension is necessary and possible. At the end of the titration period, the 
patientâ€™s dose will be established for the maintenance period. If a patient experiences an adverse 
event during the maintenance period and the investigator believes a dose reduction is warranted, 
the dose may  be reduced once for the remainder of the maintenance period.
TEV -50717 tablets (test IMP) are available in the following dose strengths: 6, 9, 12, 15, and 
18mg, all of which are identical in size, shape, and color (white). Test IMP will be supplied in 
20-count tablets per dose strength per bottle assembling 6, 12, 18, 24, 30, 36, 42, and 48 mg dose 
kit combinations. The placebo IMP tablets and packaging will match those for TEV -50717.
5.1.1.2. Dose Modification and Dose Stratification
All IMP adjustments are made only  after a remote or in -
clinic visit; if the dose is escalated, the 
dose escalation will occur with the next morningâ€™s dose.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
66IMP will be administered as follows:
ï‚·IMP should be swallowed whole. If the I MP is crushed or split, it should not be 
ingested; it should be replaced with a new tablet. The tablets will be taken with food 
(eg, a snack) and should not be taken on an empty stomach. Patients may  be offered 
the optional use of a Medi+StrawÂ®, which is a commerciall y available straw that can 
assist patients to overcome their swallowing difficulties.
ï‚·Dosing will be based on body  weight at the baseline visit and CYP2D6 impairment 
status, as shown in Table 4and Table 5, respectively .
ï‚·If there is onl y a single dose of IMP per day, the dose should be taken in the morning. 
However, patients experiencing somnolence while taking the 6 -mg dose in the 
morning may  switch to taking it as an evening dose for the rest of the day s up to 
day14.
ï‚·The starting dose of 6 mg will be administered i n the morning on day  2 and for the 
remainder of the first week. Patients in the highest body  weight group ( â‰¥40 kg/88 lbs) 
will start an evening administration from day 3 and for the remainder of the first 
week. TEV -50717 dail y doses of 12 mg and higher will be administered as 2 divided 
equal doses, approximately  8 to 10 hours apart during the day . A minimum of 6 hours 
should elapse between doses. If a patient misses a dose, and it is within 6 hours of the 
next dose, the missed dose should be skipped. 
ï‚·Dose increases may  not occur more frequentl y than every 5 days, except for patients 
â‰¥40 kg/88 lbs. For patients â‰¥40 kg/88 lbs, the first dose increase should be performed 
in an interval less than 5 day s, onl y once, on day 3.
ï‚·During the week 3 visit, the investigator or designee will make sure the patient 
receives the last treatment kit back so the patient can take the evening dose to 
complete the week 3 dosing for that day . Refer to the pharmacy  manual for further 
details.
ï‚·For an y dose adjustment, the investigat or or designee should confirm that patients 
have the bottle that contains the appropriate tablet strength and quantity to complete 
the recommended dail y regimen.
ï‚·At an in-clinic visit, a dose reduction, if required, should be made to the previously  
tolerat ed dose level. If more than 1 dose reduction is required for an adverse 
event, the medical monitor should be notified .
ï‚·During the titration period, the dose of IMP should be adjusted according to Table 4
to identify  a dose level that optimally  reduces d yskinesia (as determined by  the 
investigator, as indicated by  a reduction in the CGI -I) and is well tolerated. Dose 
adjustments should ONLY take place after telephone or in- clinic visit.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
67Table 4: Maximum Daily Dose of IMP During the Titration Period by Week and 
Weight Category at Baseline
Study time periodDaily dosea,b
12 kg to <17 kg
(26 lbs to <37 lbs)17 kg to <30kg
(37 lbs to <66 lbs)30 kg to <40 kg
(66 lbs to <88 lbs)â‰¥40 kg
(â‰¥88lbs)
Day 2 (first dose in morning ) 6 mg 6 mg 6 mg 6 mg
Week 1 6 mg 6 mg 6 mg 12 mgc
Week 2 6 mg 12 mg 12 mg 18 mg
Week 3 12 mgd18 mgd18 mgd24 mg
Week 4 12 mgd18 mgd24 mgd30 mg
Week 5 18 mgd24 mgd30 mgd36 mgd
Week 6 18 mgd24 mgd36 mgd42 mgd
Week 7 24 mgd30 mgd42 mgd48 mgd
aAll IMP adjustments are made only after a remote or in -clinic visit; if the dose is escalated, the dose escalation will 
occur w ith the next morningâ€™s dose. Dose adjustments should ONLY take place after telephone or in -clinic visit.
bDose increases may not occur more frequently than every 5 days, except for patients â‰¥40 kg/88 lbs. For patients 
â‰¥40 kg/88 lbs, the first dose increase should be performed in an interval less than 5 days, only once, on day 3. 
Refer to Table 3for the exact visit windows at each weekly titration visit.
cPatie nts in this weight category will receive the 6 -mg once -daily  dose in the morning on day 2, follow ed by  
twice-daily administration of 6 mg starting on day 3.
dFor those taking strong CYP2D6 inhibitors, such as paroxetine, fluoxetine, and bupropion, or thos e who are poor 
CYP2D6 metabolizers, the m aximum daily dose for patients â‰¥40 kg is 36 mg/day, that for 30 to <40 kg is 
24mg/day, that for 17 to <30 kg is 18 mg/day, and that for 12 to <17 kg is 12 mg/day (see Table 5).
CYP2D6=cytochrome P450 2D6; IMP=investigational medicinal product.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
68Table 5: Maximum Daily Dose of IMP by CYP2D6 Impairment Status
Weight category Max imum daily dose in the absence of 
CYP2D6 impairmentMaximum daily dose in the presence of 
CYP2D6 impairment
12 kg to <17 kg
(26 lbs to <37 lbs)24 mg 12 mg
17 kg to <30 kg
(37 lbs to <66 lbs)30 mg 18 mg
30 kg to <40 kg
(66 lbs to <88 lbs)42 mg 24 mg
â‰¥40 kg
(â‰¥88 lbs)48 mg 36 mg
CYP2D6=cytochrome P450 2D6; IMP=investigational medicinal product.
Note: Patients will be classified as CYP2D6 impaired if they are receiving a strong CYP2D6 inhibitor or are a 
CYP2D6 poor metabolizer. Strong CYP2D6 inhibitors include paroxetine, fluoxetine, and bupropion.
5.1.2. Placebo Investigational Medicinal Product
Placebo tablets match TEV- 50717 tablets. Additional details may  be found in Table 6.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
69Table 6: Investigational Medicinal Products Used in the Study
IMP Nam e TEV -50717 Test IMP Placebo IMP
Company -assigned number TEV -50717 (SD -809, AUSTEDOÂ®, 
deutetrabenazine)Not applicable
Form ulation Modified release solid oral dosage form (tablet with 
film coating)Modified release solid oral dosage form (tablet with 
film coating)
Unit dose strength(s)/Dosage level(s) TEV -50717 tablets are available in the following 
dose strengths: 6, 9, 12, 15, and 18 mg, all of which 
are identical in size, shape, and colo r (white). Test 
IMP w ill be supplied in 20 -count tablets per dose 
strength per bottle.Not applicable
Route of administration Oral Oral
Packaging Test IMP w ill be provided in bottles. Placebo IMP w ill be provided in bottles.
Manufacturer Norw ich Pharm aceuticals Inc., New  York, United 
States
(Referenced as NPI or Norwich)
6826 State Highway 12
Norw ich, NY 13815
Anesta LLC
4745 Wiley Post Way 
Salt Lake City, UT 84116Norw ich Pharmaceuticals Inc., New  York, United 
States
(Referenced as NPI or Norwi ch)
6826 State Highway 12
Norw ich, NY 13815
Anesta LLC
4745 Wiley Post Way 
Salt Lake City, UT 84116
Storage conditionsaStored at controlled room temperature, 20Â°C -25Â°C 
(68Â°F -77Â°F)Stored at controlled room temperature, 20Â°C -25Â°C 
(68Â°F -77Â°F)
aFor additional information related to the IMP storage condition, refer to Section 11 of the Pharmacy Manual.
IMP=investigational medicinal product.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
705.2. Preparation, Handling, Labeling, Storage, and Accountability for 
Investigational Medicinal Products
5.2.1. Storage and Security
The investigator or designee must confirm that appropriate temperature conditions have been 
maintained for all IMPs received and an y discrepancies are reported and resolved before use of 
the IMPs.
The IMPs (TEV -50717 and placebo IMP) must be stored at a controlled room temperature, 20ÂºC 
to 25ÂºC (68ÂºF to 77ÂºF), in a securel y locked, substantially constructed cab inet or enclosure with 
access limited to authorized staff. For additional information related to the IMP storage 
condition, refer to Section 11 of the Pharmacy  Manual.
5.2.2. Labeling
Supplies of I MPs will be labeled according to the current International Council for 
Harmonisation guidelines on Good Clinical Practice (GCP) and GMP and will include any  
locally  required statements. I f necessary , labels will be translated into the local language.
5.2.3. Accountability
Each IMP shipment will include a packing slip listing th e contents of the shipment and any  
applicable forms.
The investigator is responsible for ensuring that deliveries of IMPs and other study  materials 
from the sponsor are correctly received, recorded, handled, and stored safely  and properl y in 
accordance wit h the Code of Federal Regulations (CFR) or national and local regulations, and 
used in accordance with this protocol.
Only  patients enrolled in the study  may  receive IMPs, and only  authorized staff at the 
investigational center may suppl y or administer IMP s. All I MPs must be stored in a secure, 
environmentally  controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions or appropriate instructions with access limited to the investigator and 
authorized staff at the investigational center.
The investigator (or designee) will instruct the patient to store the IMP according to the 
instructions on the label, if applicable, or will give instructions in an appropriate form.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for IMP accountability , reconciliation, and record maintenance (ie, receipt, 
reconciliation, and final disposition records).
A record of IMP accountability  (ie, IMP and other study  materials received, used, retained, 
returned, or destro yed) must be prepared and signed by  the principal investigator or designee, 
with an account given for any  discrepancies. Any  used (partiall y used or empty ) bottles and 
unused kits/bottles that are not destro yed at the sit e are returned to the sponsor or designee, as 
agreed with the sponsor (including expired and damaged kits). 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
715.3. Justification for Investigational Medicinal Products
5.3.1. Justification for Dose of Test Investigational Medicinal Product
Based on the feedback from th e external experts, the optimal dose of tetrabenazine in the 
treatment of DCP in a pediatric population is individualized and not related to any  specific dose 
per bod y weight. Also, the 2 published studies ( Jain et al 2006 , Vuong et al 2004) on the use of 
tetrabenazine in the treatment of hy perkinetic movement disorders (including DCP) (see 
Section 1.1.2) introduce a wide range of doses of tetrabenazine that were found to be effective. 
As variability  in optimal dose of tetrabenazine might be due to its highly  variable metabolism of 
the active ( ï¡+Î²)-HTBZ, it is also conceivable that the patient s with hy perkinetic movement 
disorders would require an individually  optimized dose. Therefore, this uses a flexible dose 
design, where maximal dose is limited based on body  weight and CYP2D6 impairment status. 
Based on modeling and simulations of the expo sure (area under the plasma concentration -time 
curve) and maximum observed concentration in adults and adolescents, it is possible to design 
dosing regimens in alternative body  weight categories depending on their CYP2D6 impairment 
status, which would give comparable exposure and maximum observed concentration across the 
range of strata. This approach is analogous to what has also been adopted in the ongoing 
TV50717- CNS -30046 Phase 2/3 and TV50717 -CNS -30060 Phase 3 studies of TEV -50717 in 
TS.
5.3.2. Justification for Use of Placebo Investigational Medicinal Product
A standard placebo -controlled, double -blind study design (TEV- 50717 versus placebo in a 
2:1ratio) was chosen to determine whether TEV -50717 treatment results in a statistically  
significant effect on the motor sy stem of patients with CP. As CP is not a progressive 
neurological disorder, and available treatments are for s ymptomatic control, the use of placebo is 
justified in a short- term study  where safet y is carefully monitored. Moreover, a placebo contro l is 
ideal for characterizing the efficacy  and safet y of an experimental agent in a new stud y 
population.
5.4. Treatment after the End of the Study
All patients will discontinue IMP at the week 15 visit and will return 1 week later for the EOS 
visit.  
Patients 
will not receive the evening 
IMP dose on this day . 
Patients who complete the study  may  be eligible to begin participation in the open- label safet y 
extension Study  TV50717- CNS -30081. At the week 16 visit, patients may  choose to enter Study  
TV50717- CNS -
30081 (on that day ) or up to 1 week later (2 weeks from the week 15 visit). 
Patients who complete treatment but choose not to participate in the open -label safet y extension 
Study TV50717- CNS -30081 before week 17 of Study  TV50717 -CNS -30080 will be contacted 
fora safet y evaluation call occurring 2 weeks after their last dose of IMP. Additional details for 
patients to enter Study  TV50717- CNS -30081 are provided in the TV50717 -CNS -30081 protocol. 
Note: Patients can also roll over to the extension study  within 2 to 4 weeks after the week 15 visit 
but will be required to complete additional scales and tests as part of Stud yTV50717
-CNS -30081. 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
725.5. Restrictions
Medications prohibited before and/or during the study  are described in Section 5.6. 
While patients receiving a strong CYP2D6 inhibitor (such as paroxetine, fluoxetine, or 
bupropion) at baseline may  be enrolled into this study , the removal of strong CYP2D6 inhibitors 
during treatment is discouraged, as this would have an effect on exposure to active circulating 
drug. If the removal of a strong CYP2D6 inhibitor is required from a clinical perspective, the 
medical monitor should be contacted so that an appropriat e change in IMP dosing can be made. 
The addition of a strong CYP2D6 inhibitor is prohibited during the stud y.
Restrictions in regard to sexual activity  and required laboratory  values are provided in the 
inclusion and exclusion criteria. 
As with other VMAT2 inhibitors (tetrabenazine and reserpine), patients should be advised that 
the concomitant use of alcohol or other sedating drugs with TEV -50717 may  have additive 
effects and cause or worsen somnolence. 
Patients should be advised not to drive a car or op erate dangerous machinery  until they  
understand how TEV -50717 affects them.
Use of non
-approved drugs (per protocol) is prohibited from the time of signing of the ICF and 
throughout stud y participation.
Patients may  not donate blood from the time of signing of the informed consent, while taking the 
IMP, and for 14 day s after the last dose.
5.6. Prior and Concomitant Medication
Any prior or concomitant medication a patient has had within 3 months prior to baseline and up 
to the end of study , including follow-up, will be recorded on the CRF. Generic or trade name, 
indication, dose, and start and end dates of the administered medication will be recorded. The 
sponsor will encode all medication according to the World Health Organization drug dictionary .
At each clinic visit after the screening visit, the investigator will ask patients and/or caregiver 
whether the patient has taken an y medications (other than IMP), including over -the-counter 
medications, vitamins, or herbal or nutritional supplements, since the pr evious visit. Caregivers 
and patients will be instructed during the course of the study  to notify  the investigator if any  new 
medication is prescribed /administered (other than TEV -50717) or if there is any  change in 
current medications, including over -the-counter medications. An y prescribed new and/or an y 
change in current medication should be reviewed with the investigator. Indication, dosage, and 
start and end dates should be entered on the CRF. 
The medical monitor must be contacted if a patient is receiving (or has to begin or stop receiving 
during the stud y) a medication that is associated with QT prolongation or that is a known strong 
CYP inhibitor. Allowed strong CYP inhibitors at baseline are shown in Appendix H, Table 10. 
The addition of a strong CYP inhibitor is prohibited during the study .
Prohibited medications that are associated with QT prolongation are listed in Appendix H, 
Table 11. 
Concomitant medication will be monitored throughout the study . 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
735.7. Procedures for Monitoring Patient Compliance
The investigator will be responsible for monitoring patient compliance until completion of the 
IMP administration according to the protocol or discontinuation from I MP. A check of 
compliance with IMP intake will be performed during each in -clinic visit after the used IMP has 
been returned, and IMP accountability  records will be completed. At week 3, I MP administration 
compliance can be calculated only  for weeks 1 and 2, as the last kit at week 3 is returned to the 
patient so that the patient can complete the week 3 dosing for that evening.
If the investigato r or the sponsor determines that the patient is not in compliance with the study  
protocol, the investigator and the sponsor should determine whether the patient should be 
withdrawn from the study. Based on pill counts at in- clinic visits, poor compliance w ith study  
drug intake (ie, <80%) or overdose (ie, >105%) is to be recorded as an important deviation and 
expeditiously  reported to the medical monitor.
Patients are expected to participate in this study  for its entire duration. Exposure to IMP will be 
assessed as required (Section 5.1).
5.8. Temporary Discontinuation of Investigational Medicinal Product
Refer to Table 3for data to be collected at the time of IMP discontinuation and follow -up and for 
any further evaluations that need to be completed.
If a patient experiences a â€œclinically significantâ€ ad verse event that is attributed to I MP, the 
investigator will first determine if a dose reduction (to the previous dose level) or suspension is 
necessary  and possible. Dose adjustments should be made based on all available information, 
including the patient
â€™s and parentâ€™s/caregiverâ€™s reports of adverse events and motor function 
improvement, the clinical assessment of safety  and efficacy  by the investigator, and information 
from rating scales. If more than 1 dose reduction is required for an adverse event, th e 
medical monitor should be notified. Suspension of IMP treatment for up to 1 week, if 
warranted, is allowed. If the patient restarts IMP within 7 day s of suspension, the full dose of 
IMP may  be resumed without titration at the same dose level or 1 dose lo wer (last tolerated 
dose). Suspension of IMP treatment for adverse events must be reviewed with the medical 
monitor before IMP treatment is restarted. Suspensions for more than 7 days must be reviewed 
by the medical monitor before therap y is restarted, and also to determine if there is adequate time 
for patients to be reinstated and complete stud y evaluations. The reason for a dose reduction or 
suspension must be clearly  documented in the related adverse event form.
Dose reduction or suspension is allowed once during the titration period and once during the 
maintenance period. Patients who restart IMP treatment will remain at the current dose 
throughout that period with no further dose changes and will, otherwise, follow the visit schedule 
as outlined in the protocol. I f a dose reduction occurs before a scheduled clinic visit, the clinic 
visit will be postponed so that efficacy  evaluations can be performed at least 7 days after the 
change. 
If a dose suspension occurs before a scheduled clinic visit, an unscheduled visit should be 
scheduled as soon as possible so that efficacy  evaluations can be performed at least 7 days after 
the change. 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
74If the determination that a patient requires a dose reduction or suspension is made during a 
telephone contact, an unscheduled clinic visit should be conducted as soon as practicable 
thereafter.
If a patientâ€™s serum potassium or magnesium level falls below the lower limit of normal, I MP 
should be suspended. Since TEV -50717 does not have any  known effect on potassium and 
magnesium levels, the reference to potassium and magnesium is in the context of other factors 
related to an y current underly ing condition, such as severe diarrhea or intake of drugs that lower
serum potassium and magnesium. The investigator will be responsible to manage the patientâ€™s 
condition per the siteâ€™s standard of care and assess continuation of treatment. The medical 
monitor should be contacted to discuss the suspension and possible resu mption of the IMP . IMP 
treatment may  only be restarted once serum potassium and/or magnesium levels have 
normalized.
Patients who restart IMP treatment will follow the visit schedule as outlined in Table 3. Patients 
who withdraw from the study  will proceed as described in Section 4.3.
5.9. Randomizatio n and Blinding
This is a double -blind study . Patients will be randomized to either TEV -50717 or matching 
placebo in a 2:1 ratio using Randomization and Trial Supply  Management (RTSM). Patients will 
be stratified b y age at baseline (6 to <12 years; 12 through 18 years, inclusive) and region (US; 
non-US). Patients and investigators will remain blinded to treatment assignment during the 
study . In addition, the sponsorâ€™s clinical personnel and all vendors (with the exception of the 
sponsorâ€™s clinical supply  chain staff and RTSM vendor) will be blinded to the IMP identity  until 
the database has been locked for anal ysis and the treatment assignments are revealed.
The iDMC will perform an unblinded non- binding IA for futility  and will monitor safety  
throughout the study  based on unblinded data. An iDMC charter will be developed for the 
interim analy ses, and the procedures to ensure the integrit y of the stud y will be provided in the 
charter (see Section 5.10.3 for more details).
In the event of an emergency
, it will be possible to determine to which treatment group and dose 
the patient has been allocated b y accessing the RTSM sy stem. All investigat ional centers will be 
provided with details of how to access the s ystem for code breaking at the start of the study . The 
medical monitor or equivalent should be notified following unblinding. Any  unblinding of the 
IMP performed b y the investigator must be recorded in the source documents.
Patients re- entering the study  will be manually  assigned to their initial treatment group b y the 
RTSM unblinded vendor. Blinding will be maintained for the patient, investigator, and sponsor 
as described above; the only  information that will be available is that the patient was assigned to 
the same treatment group previously . 
The randomization list will be assigned to the relevant treatment groups through a qualified 
service provider (eg, via an RTSM sy stem). The generatio n of the randomization list and 
management of the RTSM sy stem will be done by  a qualified service provider under the 
oversight of the responsible function at Teva.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
755.10. Maintenance of Randomization and Blinding
5.10.1. Maintenance of Randomization
Patient randomization codes will be maintained in a secure location at the service provider 
contracted to generate the codes. At the time of analy sis (after the end of study  or at the IA), after 
receiving unblinding request from a Teva statistician, the service provider will p rovide the 
unblinded I MP assignment according to the processes defined in the relevant standard operating 
procedure. For the IA and iDMC closed sessions, the codes will be provided to an independent 
statistician who will perform the IA.
5.10.2. Blinding and Unblin ding
For information about personnel who may  be aware of IMP assignments, see Section 5.9. These 
individuals will not be involved in conduct of an y study  procedures or assessment of any  adverse 
events .
In case of a serious adverse event, pregnancy , or in cases when knowledge of th e IMP 
assignment is needed to make treatment decisions, the investigator may  unblind the patientâ€™s 
IMP assignment as deemed necessary , mainl y in emergency situations, through specialized 
access in the RTSM sy stem. Breaking of the treatment code may  alway s be performed by  the 
investigator without prior approval b y the sponsor; however, the sponsor should be notified that 
the code was broken, but the patient treatment assignment should not be revealed to the sponsor.
When a blind is broken, the patient will b e withdrawn from the stud y, and the event will be 
recorded on the CRF. The circumstances leading to the breaking of the code should be fully  
documented in the investigatorâ€™s study files and in the patientâ€™s source documentation. 
Assignment of IMP should no t be recorded in an y study  documents or source document.
In blinded studies, for an adverse event defined as a suspected unexpected serious adverse 
reaction (SUSAR) (ie, reasonable possibility ; see Section 7.1.4), Global Patient Safety  and 
Pharmacovigilance (GPSP) may  independentl y request that the blind code be broken (on a 
case-by-case basis) to comply  with regulatory  requirements. The report will 
be provided in an 
unblinded manner for regulatory  submission. If this occurs, blinding will be maintained for the 
investigator and for other personnel involved in the conduct of the stud y and anal ysis and 
reporting of the data.
5.10.3. Independent Data Monitoring Committee
There will be an iDMC in this study . 
When approximately  50 patients have completed the study  (including follow -up), the iDMC will 
perform an unblinded non -binding IA for futility  based on centrall y read MD -CRS part II total 
score.
Details on how the iDMC chairperson will communicate with the sponsor in regard to issues 
resulting from the conduct and clinical aspects of the study  are described in the iDMC charter. 
The iDMC charter will be developed for the IA, and the procedures to ensure the inte grity of the 
study  will be provided in the charter. The sponsor will work closely  with the iDMC to provide 
the necessary  safet y and efficacy data for review. In addition, results of the IA will be 
communicated to the sponsor as outlined in the iDMC charter .
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
76Details are given in Appendix B.
5.11. Total Blood Volume
The total blood volume to be collected for each patient in this study  is approximately  40mL (at 
maximum), as detailed in Appendix I.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
776. ASSESSMENT OF  EFFICA CY
Efficacy  in this study  will be evaluated using MD -CRS part I  total score, MD -CRS pa rt II total 
score, CaGI -I, CGI -I, CGI -S, PEDI -CAT, UHDRS -TMS, UHDRS-TMC, UHDRS- TMD, and 
PGI-I. It is recommended that the same order of administration/completion of the scales be kept 
per patient throughout the study , as best as possible (refer to the Stud y TV50717 -CNS -30080 
RECL AIM-DCP: Order of scales administration/completion document). At all relevant visits 
where collected, PGI-I and CaGI- I are to be completed before all other investigator- rated scales.
The investigator should review all scales and que stionnaires in a timely  manner for any  potential 
reporting of adverse events and document this review accordingl y. At each study  visit, as 
applicable, the investigator should compare the current scores to the baseline scores.
For COVID -19 updates, refer to Appendix M.
6.1. Primary Efficacy Measure
The primary  efficacy  measure is centrall y read MD -CRS part II total score, which is part of the 
MD-CRS for the a ge group 4 to 18 y ears. MD -CRS part II was shown to be suitable for detecting 
a treatment effect after an intervention with trihexyphenid yl, a drug used to treat dy skinesia in 
children with CP ( Battini et al 2014 ).
The MD -CRS was developed as a child -oriented instrument aimed to describe various ty pes of 
movement disorders (d ystonia, chorea, athetosis, ballismus, and hy pokinetic -rigid) and to 
compare changes during natural history  and/or pharmacological treatments or to monitor
interventions ( Battini et al 2008 andBattini et al 2014 ). MD -CRS reliability  (eg, inter -and 
intra-rater reliability) has been evaluated when used by clinicians and professionals of 
rehabilitation after a 1 -day training on its scoring ( Sgandurra et al 2018 ). The version â€œMD -CRS 
4-
18â€ has been designed to evaluate various movement disorders in children and adolescents, 
aged 4 to 18 years, and their influen ce on dail y living activities or motor function in different 
body  regions at rest and during specific tasks ( Battini et al 2008 ). 
The MD -CRS has 2 parts: part I for general assessment of the functioning and impact of CP on 
the activities of the patient and part II for a specific motor assessment of severity  of the 
movement disorder. MD -CRS part II evaluates the severit y of the movement disorder in a scale 
of 0 to 4 in 7 body  regions, all areas in which d yskinesia can be seen in patients with CP. I n 
rating the movement disorder of the bod y part, 0 refers to absence of a movement disorder and 
4refers to a situation where movement disorder is present during all of the tasks for the region 
examined and/or involves 3 or more of the other regions, making completion impossible. The 
7body  regions are (i) eye and periorbital region, (ii) face, (iii) tongue and perioral region, (iv) 
neck, (v) trunk, (vi) upper limb, and (vii) lower limb. The MD -CRS part II does not differentiate 
whether the d yskinesia is of the dy stonic or choreiform phenot ype, and the worst dyskinesia in 
any of the regions observed during the assessment session will be taken as the score for each 
affected bod y region. The minimum score is 0 (absent) and the maximum scor e is 28 
(marked/prolonged).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
78The MD -CRS part II will be administered by  the investigational center ph ysician, or other 
appropriatel y trained study  team member, and video -recorded at screening, baseline, week 9, 
week 12, week 15/ET, and week 16/EOS visits.
The MD -CRS has been updated to version 2 with changes to the scoring language. This version 
should be used when available. However, a patient will complete all study  visits using the same 
version.
Assessment of MD -CRS part II items will be based solely  on c horea in this study  and performed 
as follows: 
ï‚·Local assessment (all time points): the investigational center ph ysician will 
administer the MD -CRS part II and complete the assessment of item scores. Note: the 
physicians will receive training on MD -CRS scor ing prior to the study .
ï‚·EAB review (screening): EAB will review the MD -CRS part II at the screening visit 
to confirm that dy skinesia severit y is aligned with the protocol criteria for inclusion 
into the study . The review will include determination of the p redominant dy skinesia 
type and scoring of MD -CRS part II items. The EAB will inform the site prior to the 
baseline visit if there are any  discrepancies between the local and central assessments, 
and offer to discuss with the investigator. Ultimately , it is the investigator who 
determines the patientâ€™s eligibility . EAB assessment of screening MD- CRS part II 
total score will not be included in the statistical analy sis.
ï‚·Central reading (baseline, week 9, week 12, week 15/ET, and week 16/EOS): Video 
review of M D-CRS part II will be assessed periodically  in a blinded manner (ie, visit, 
investigator site rating, and other study -related information) by  a central review 
board. Central reading results performed b y the central raters, who are also the EAB 
members, wil l not be disclosed to the investigational site. Central reading details will 
be provided in a separate charter.
The primary  efficacy  endpoint is the change from baseline to week 15 in the MD-CRS part II 
total score (TEV -50717 versus placebo) , assessed by  central reading.
6.2. Key Secondary Efficacy Measures
6.2.1. Movement Disorder -Childhood Rating Scale Part I Total Score
The MD -CRS part I evaluates impact of DCP on the activities of the patient and provides a 
general assessment of the movement disorder of motor function (7 items), oral/verbal function 
(3items), self-care (3 items), and attention/alertness (2 items) on a scale of 0 (present) to 
4(absent) ( Battini et al 2008 , Battini et al 2014 ). The min imum score is 0 and the maximum 
score is 60.
The MD -CRS part I will be administered at baseline, week 9, week 12, week 15/ET, and 
week 16/EOS visits. The MD -CRS partI will be administered by  the investigational center 
physician and video recorded for cent ral blinded review. The protocol refers to MD -CRS as a 
physician -rated scale, but in certain instances, based on the experience of the rater, certain 
non-physicians may  be approved to rate the MD
-CRS.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
796.2.2. Caregiver Global Impression of Improvement Scale
The Ca GI-I is single item questionnaire to assess the caregiverâ€™s impression of improvement in 
dyskinesia s ymptoms after initiating therapy . The scale is a caregiver- reported outcome that aims 
to evaluate all aspects of patientsâ€™ health and determine if there ha s been an overall improvement 
or not in dy skinesia s ymptoms. The CaGI -I is to be completed before all other investigator- rated 
scales during visits where CaGI -I is collected ( Table 3). The caregiver has to select the 
1response from the response options that gives the most accurate description of change in 
dyskinesia s ymptoms of the patient they  care for from the beginning of the study : 
1=very  much improved (since the initiation of treatment);
2=much improved;
3=minimally  improved;
4=no change from baseline (s ymptoms remain essentially  unchanged);
5=minimally  worse;
6=much worse;
7=very  much worse (since the initiation of treatment). 
The CaGI -I is a dministered at week 3, week 7, week 9, week 12, week 15/ET, and week 16/EOS 
visits. 
6.2.3. Clinical Global Impression of Improvement Scale
Each time the patient is seen during the treatment period (ie, at each in -clinic visit or during 
telephone contacts with non-
recording live video), the investigator compares the patientâ€™s 
improvement in overall dy skinesia sy mptoms to the 1- week period just prior to the baseline visit 
(Busner and Targum 2007). The CGI -
S score obtained at the baseli ne visit (see Section 6.3.9) 
serves as a good basis for making this assessment. The CGI -I is a ClinRO that uses a 7 -point 
Likert scale that allows the clinician to compare the patientâ€™s condition at the visit to the baseline 
condition as follows (with anchor points for choosing the most appropriate improvement level):
1=very  much improved since the initiation of treatment (nearl y all better; good level of 
functioning; minimal symptoms; represents a very  substantial change);
2=much improved (notably  better with significant reduction of s ymptoms; increase in the 
level of functioning but some sy mptoms remain);
3=minimally  improved (slightly  better with l ittle or no clinically  meaningful reduction of 
symptoms; represents very  little change in basic clinical status, level of care, or functional 
capacity ); 
4=no change from baseline (s ymptoms remain essentially  unchanged);
5=minimally  worse (slightly  worse b ut may  not be clinically  meaningful; may  represent very  
little change in basic clinical status or functional capacit y); 
6=much worse (clinicall y significant increase in symptoms and diminished functioning); 
7=very  much worse since the initiation of treat ment (severe exacerbation of sy mptoms and 
loss of functioning).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
80The CGI -I administered at the in -clinic visits (week 3, week 7, week 9, week 12, week 15/ET, 
and week 16/EOS) will be included in the analy sis of the key  secondary  endpoint. Patients will 
alsobe assessed for CGI -I during telephone contacts (with non- recording live video) at week 1, 
week 2, week 4, week 5, and week 6.
6.2.4. Unified Huntingtonâ€™s Disease Rating Scale- Total Maximal Chorea
The UHDRS -TMC is part of the UHDRS -
TMS assessment and assesses th e severit y of chorea in 
the face, mouth, trunk, and the 4 extremities. The minimum score is 0 (absent) and the maximum 
score is 28 (marked/prolonged) ( Huntington Study  Group 1996 ).
A central reading of the UHDRS- TMC will be performed at baseline and at weeks 9, 12, 15/ET, 
and 16/EOS visits. The central rating will be done for all patients, based on the videos collected 
for the central rating of MD -CRS. Video review will be assessed periodically  in a blinded 
manner (eg, visit and investigator site rating) by a central review board. Central reading results 
performed b y the central raters will not be disclosed to the investigational site. Central reading 
details will be provided in a separate charter .
6.2.5. Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Dystonia
The UHDRS -Total Maximal Dy stonia (TMD) is part of the UHDRS -TMS assessment and 
assesses the severit y of dystonia in the trunk and the 4 extremities. The minimum score 
is0 (absent) and the maximum score is 20 (marked/pr olonged) ( Huntington Study  Group 1996). 
When rating d ystonia (question #11), buccal- oral-lingual and facial dy stonia (blepharospasm, 
jaw opening and closing) should be included in the assessment of the truncal region. 
Acentral reading of the UHDRS -TMD will be performed at baseline and at weeks 9, 12, 15/ET, 
and 16/EOS visits. The central rating will be done for all patients, based on the videos collected 
for the central rating of MD -CRS. Video review will be assessed pe riodically  in a blinded 
manner (eg, visit and investigator site rating) b y a central review board. Central reading results 
performed b y the central raters will not be disclosed to the investigational site. Central reading 
details will be provided in a sepa rate charter.
6.3. Other Efficacy Measures
6.3.1. Movement Disorder -Childhood Rating Scale Part I and Part II Total Scores
The MD -CRS part I and part II total score s will be evaluated b y the investigator at baseline, 
week 9, week 12, week 15/ET, and week 16/EOS visits .See Section 6.1and Section 6.2.1 for 
description of these rating scales.  
6.3.2. Movement Disorder -Childhood Rating Scale Global Index
The MD -CRS Global I ndex is a global measure of the MD -CRS that consolidates the 
information from parts I and II using the method of weighted means of the 2 normalized indexes 
obtained from each part ( Battini et al 2008 ). The minimum score is 0 and the maximum score 
is1.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
816.3.3. Unified Huntingtonâ€™s Disease Rating Scale- Total Mo tor Score
The UHDRS comprises a broad assessment of features associated with HD. I t is a research tool 
that has been developed to provide a uniform assessment of the clinical features and course of 
HD. The Total Motor Score assessment of the UHDRS (UHDRS-T MS) comprises 15 items and 
assesses ey e movements, speech, alternating hand movements, dy stonia, chorea, and gait. The 
UHDRS -TMS is calculated as the sum of the 31 motor assessments; each of which range 
between 0 to 4. The minimum score is 0 (absent) and t he maximum score is 124 (worst) 
(Huntington Study  Group 1996 ).
The protocol refers to UHDRS -TMS as a phy sician -rated scale, but in certain instances, based on 
the experience of the rater, certain non- physicians may  be approved to rate the UHDRS -TMS.
The UHDRS -TMS is administered at baseline, week 9, week 12, and week 15/ET visits, and will 
be rated b y the investigator.
6.3.4. Unified Huntingtonâ€™s Disease Rating Scale- Total Maximal Chorea
The UHDRS -TMC is administered at baseline, week 9, week 12, and week 15/ET visits, and will 
be rated b y the investigator.
6.3.5. Unified Huntingtonâ€™s Disease Rating Scale- Total Maximal Dystonia
The UHDRS -TMD is administered at baseline, week 9, week 12, and week 15/ET visits, and will 
be rated b y the investig ator.
6.3.6. Pediatric Evaluation Disability Inventory- Computer Adapted Test (Activities of 
Daily Living, Caregiver Completed, Content -Balanced Version)
The Pediatric Evaluation of Disability  Inventory  Computer Adaptive Test (PEDI -CAT) is a 
clinical assessment fo r children and y outh. The PEDI -CAT comprises a comprehensive item 
bank of 276 functional activities acquired throughout infancy , childhood, and y oung adulthood. 
This study  will use only  the caregiver report. The PEDI -CAT is recommended for use with 
childre n approaching 1 year of age and adults up to 21 years of age.
The PEDI -CAT (activities of daily  living [ADL ], caregiver completed, content -balanced version) 
measures function in 4 domains: (1) Daily  Activities; (2) Mobility ; (3) Social/Cognitive, and (4) 
Responsibility . Each domain is self -contained and can be used separatel y or with other domains. 
This study  will use only  the content -balanced version of the Dail y Activities domain ( Dumas and 
Fragala -Pinkham 2012). The content -balanced version presents a balance of items from each of 
the Daily  Activities domainâ€™s content areas (Getting Dressed, Keeping Clean, Home Tasks, and 
Eating & Mealtime). A total of approximately  30 items are administered (total number of items 
administered is dependent upon the responses and decision tree path).
The PEDI -CAT (ADL, caregiver completed, content -balanced version) is administered at 
baseline and at week 15/ET visits. 
6.3.7. Pediatric Quality of Life Inventory, Cerebral Palsy Module
The Pediatric Qua lity of Life Inventory  (PedsQLâ„¢) is a health- related quality -of-life instrument 
that consists of a well -validated generic core measure and some condition and disease-specific 
modules ( Varni et al 2006 ). The 35- item PedsQL 3.0 CP module encompasses 7 scales: (1) Dail y 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
82Activities (9 items); (2) School Activities (4 items); (3) Movement and Balance (5 items); 
(4)Pain and Hurt (4 items); (5) Fatigue (4 items); (6) Eating Activities (5 items); and (7) Speech 
and Communication (4 it ems).
The scales comprise parallel child self -report and parent prox y-report formats. For children ages 
6 and 7 y ears and 8 to 12 y ears, a child self -report and a parent proxy  report are completed. The 
parent prox y report assesses parentsâ€™ perceptions of t heir childâ€™s health- related quality  of life 
(QoL). For children ages 13 to 18 y ears, no parent proxy  report is required. The instructions ask 
how much of a problem each item has been during the past 1 month. A 5- point response scale is 
utilized across chil d self -report and parent prox y report as follows:
0=never a problem; 
1=almost never a problem;
2=sometimes a problem; 
3=often a problem; 
4=almost alway s a problem.
The PedsQL is administered at baseline and at week 15/ET visits. I nput from the caregiver is 
permitted.
6.3.8. Patient Global Impression of Improvement Scale
The Patient Global Impression of I mprovement (PGI -I) is single item questionnaire to assess the 
patientâ€™s impression of improvement in dy skinesia sy mptoms after initiating therapy . The scale 
is a patient -reported outcome that aims to evaluate all aspects of patientsâ€™ health and determine if 
there has been an overall improvement or not in dyskinesia sy mptoms. The PGI -I is to be 
completed before all other investigator -rated scales during visits whe re PGI -I is collected 
(Table 3). The patient has to select the 1 response from the visual response options (â€œemojisâ€) 
that gives the most accurate description of his/her state of health and overall status: 
1=much improved (since the initiation of treatment);
2=somewhat improved;
3=no change;
4=somewhat worse;
5=much worse (since the initiation of treatment). 
The PGI -I is administered at week 3, week 7, week 9, week 12, week 15/ET, and week 16/EOS 
visits. I nput from the caregiver is permitted.
6.3.9. Clinical Global Impression of Severity
Theinvestigator uses all available information and total clinical experience with this particular 
population to assess dy skinesia severit y over the past 1- week period prior to the CGI -S 
assessment on the patient ( Busner and Targ um 2007 ). The CGI -S uses a 7- point L ikert scale to 
assess dy skinesia severity  as follows (with anchor points for choosing the most appropriate 
severit y level caused b y DCP):
1=normal (not at all ill, symptoms of disorder not present past 7 day s);
2=borderl ine (subtle or suspected pathology );
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
833=mild (clearl y established sy mptoms with minimal, if any , distress or difficulty  in social 
and/or occupational function);
4=moderate (overt s ymptoms causing noticeable, but modest, functional impairment or 
distress; sy mptom level may  warrant medication);
5=marked (intrusive sy mptoms that distinctly  impair social/occupational function or cause 
intrusive levels of distress);
6=severe (disruptive s ymptoms, behavior and function are frequentl y influenced b y 
symptoms, may  require assistance from others);
7=extreme (s ymptoms drastically  interferes in many  life functions; may  be hospitalized).
The CGI -S is administered at screening, baseline, week 3, week 7, week 9, week 12, week 
15/ET, and week 16/EOS visits. I nput from the ca regiver is permitted. 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
847. ASSESSMENT OF  SAFETY
In this stud y, safety will be assessed b y qualified study  personnel and will include the evaluation 
of adverse events (and the number of patients who withdraw from the stud y due to adverse 
events), vital signs, l aboratory  tests (hematology, chemistry , and urinal ysis), ECG measurements, 
CBCL , ESRS, ESS, and the childrenâ€™s C -SSRS . The investigator should review all scales and 
questionnaires in a timely manner for any potential reporting of adverse events and documen t 
this review accordingl y.
For COVID -19 updates, refer to 
Appendix M.
7.1. Adverse Events
7.1.1. Definition of an Adverse Event
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and that does not necessarily  have to have a causal relationship with this 
treatment.
An adverse event can, therefore, be an y unfavorable and unintended ph ysical sign, s ymptom, or 
laboratory  parameter that develops or worsens in severit y during the course of thisstudy , or 
significant worsening of the disease under study  or of any  concurrent disease, whether or not 
considered related to TEV -50717. A new condition or the wor sening of a pre -existing condition 
will be considered an adverse event. Stable chronic conditions (such as arthritis) that are present 
before stud y entry  and do not worsen during thisstudy  will not be considered adverse events.
Accordingl y, an adverse eve nt can include an y of the following:
ï‚·intercurrent illnesses
ï‚·physical injuries
ï‚·events possibly  related to concomitant medication
ï‚·significant worsening (change in nature, severit y, or frequency) of the disease under 
study  or other pre- existing conditions
(Note: A condition recorded as pre -existing that is intermittently  symptomatic [eg, 
headache] and that occurs during this study  should be recorded as an adverse event.)
ï‚·drug interactions
ï‚·events occurring during diagnostic procedures or during an y washout phas e of this
study
ï‚·laboratory  or diagnostic test abnormalities that result in the withdrawal of the patient 
from the study , are associated with clinical signs and sy mptoms or a serious adverse 
event, require medical treatment or further diagnostic work-up, or are considered b y 
the investigator to be clinically  significant
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
85(Note: Abnormal laboratory  or diagnostic test results at the screening visit that 
preclude a patient from entering the stud y or receiving stud y treatment are not 
considered adverse events.)
7.1.2. Recording and Reporting of Adverse Events
For recording of adverse events, the study  period is defined for each patient as the time period 
from signature of the ICF to the end of the follow -up period. The follow -up period of recording 
of adverse events is d efined as 2 weeks after the last dose of IMP or up to baseline/day  1 in the 
open -label extension Study TV50717 -CNS -30081 (whichever comes first) or 2 weeks after the 
ET visit for patients who terminate early  from the study .
All adverse events that occur du ring the defined study  period must be recorded both on the 
source documentation and the CRF, regardless of the severit y of the event or judged relationship 
to the I MP. For serious adverse events, the serious adverse event form must be completed, and 
the se rious adverse event must be reported immediately  (Section 7.1.5.3.1). The investigator 
does not need to activel y monitor patients for adverse events after the defined periods.
At each contact with the patient, the investiga tor or designee must question the patient and/or 
parent(s)/ caregiver (as applicable) about adverse events by  asking an open- ended question such 
as â€œHave you had an y unusual symptoms or medical problems since the last visit? I f yes, please 
describe.â€ All re ported or observed signs and s ymptoms will be recorded individually , except 
when considered manifestations of a medical condition or disease state. A precise diagnosis will 
be recorded whenever possible. When such a diagnosis is made, all related signs, s ymptoms, and 
any test findings will be recorded collectivel y as a single diagnosis on the CRF and, if it is a 
serious adverse event, on the serious adverse event form.
The clinical course of each adverse event will be monitored at suitable intervals until r esolved, 
stabilized, or returned to baseline; until the patient is referred for continued care to a health care 
professional; or until a determination of a cause unrelated to the IMP or study  procedure is made. 
Adverse events of patients rolling over to th e open -label extension Study
 TV50717- CNS -30081 
will continue to be monitored as part of the open -label extension study . 
To enable the assessment of the potential relationship of an adverse event and plasma 
concentration of IMP and metabolites, blood sampl es will be collected based on the scenarios 
described in Table 9. 
The onset and end dates, duration (in case of adverse event duration of less than 24hours), action 
taken regarding IMP, treatment administered, and outcome for each adverse event must be 
recorded both on the source documentation and the CRF.
The relationship of each adverse event to IMP and study  procedures and the severit y and 
serious ness of each adverse event, as judged by the investigator, must be recorded as described 
below.
Further details are given in the Safety  Monitoring Plan.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
867.1.3. Severity of an Adverse Event
The severit y of each adverse event must be recorded as one of the followin g:
Mild: No limitation of usual activities
Moderate: Some limitation of usual activities
Severe: Inability  to carry  out usual activities
7.1.4. Relationship of an Adverse Event to the Investigational Medicinal Product
The relationship of an adverse event to the IMP is characterized in Table 7as follows :
Table 7: The Relationshi p of an Adverse Event to the IMP
Term Definition Clarification
No reasonable 
possibility
(not related)This category applies to adverse 
events that, after careful 
consideration, are clearly due to 
extraneous causes (disease, 
environment, etc) or to advers e 
events that, after careful medical 
consideration at the time they are 
evaluated, are judged to be unrelated 
to the IMP.The relationship of an adverse event may be considered 
â€œno reasonable possibilityâ€ if it is clearly due to 
extraneous causes or if at least 2 of the following apply:
1.It does not follow  a reasonable temporal sequence 
from the administration of the IMP.
2.It could readily have been produced by the patientâ€™s 
clinical state, environmental or toxic factors, or other 
modes of therapy administere d to the patient.
3.It does not follow  a known pattern of response to the 
IMP.
4.It does not reappear or w orsen when the IMP is 
re-administered.
Reasonable 
possibility
(related)This category applies to adverse 
events for which, after careful 
medical consideration at the time 
they are evaluated, a connection with 
the administration of IMP cannot be 
ruled out with certainty.The relationship of an adverse event may be considered 
â€œreasonable possibilityâ€ if at least 2 of the following 
apply:
1.It follows a reasonable temporal sequence from 
administration of the IMP.
2.It cannot be reasonably explained by the known 
characteristics of the patientâ€™s clinical state, 
environmental or toxic factors, or other modes of 
therapy administered to the patient.
3.It disap pears or decreases on cessation or reduction in 
dose. There are important exceptions when an 
adverse event does not disappear after 
discontinuation of the IMP, yet an IMP relationship 
clearly exists.
4.It follows a known pattern of response to the IMP.
IMP=investigational medicinal product.
7.1.5. Serious Adverse Events
For recording of serious adverse events, the stud y period is defined for each patient as that time 
period from signature of the I CF to the end of the follow -up period as defined in Section 7.1.2 . 
Serious adverse events occurring in a patient after the end of the follow -up period should be 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
87reported to the sponsor if the investigator becomes aware of them, following the procedures 
described in Section 7.1.5.3.1 .
7.1.5.1. Definition of a Serious Adverse Event
A serious adverse event is an adverse event occurring at an y dose that results in any  of the 
following outcomes or actions:
ï‚·results in death
ï‚·is life -threatening adverse event (ie, the patient was at risk of death at the time of the 
event); it does not refer to an event that hypothetically might have caused death if it 
were more severe
ï‚·requires inpatient hospitalizati on or prolongation of existing hospitalization, which 
means that hospital inpatient admission or prolongation of hospital stay  were required 
for treatment of an adverse event, or that they occurred as a consequence of the event
Hospitalizations scheduled b efore the patient signed the ICF will not be considered 
serious adverse events, unless there was worsening of the preexisting condition 
during the patientâ€™s participation in this study .
ï‚·results in persistent or significant disability /incapacity  (refers to a substantial 
disruption of oneâ€™s ability to conduct normal life functions)
ï‚·is a congenital anomal y/birth defect
ï‚·an important medical event that may  not result in death, be life -threatening, or require 
hospitalization, but may  jeopardize the patient and ma y require medical intervention 
to prevent one of the outcomes listed in this definition
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm, blood dy scrasias or convulsions that do not result in 
hospita lization, or the development of drug dependency  or drug abuse. Note: Any  
suspected transmission of an infectious agent via a medicinal product is considered an 
important medical event.
All occurrences of possible drug -induced liver injury  that meet Hy â€™s law criteria, defined as all 
of the below, must be reported by the investigator to the sponsor as a serious adverse event:
ï‚·ALT or AST increase of >3Ã— ULN
ï‚·total bilirubin increase of >2Ã— ULN
ï‚·absence of initial findings of cholestasis (ie, no substantial increase of ALP)
An adverse event that does not meet an y of the criteria for seriousness listed above will be 
regarded as a nonserious adverse event.
7.1.5.2. Expectedness
A serious adverse event that is not included in the Adverse Reaction section of the relevant 
reference safet y information (RSI ) by its specificity, severit y, outcome, or frequency is 
considered an unexpected adverse event. The RSI for this study  is the IB.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
88A serious adverse event that is not included in the listing of adverse reactions in the RSI  by its 
specificit y, severity, outcome, or frequency is considered an unexpected adverse event.
The sponsorâ€™s GPSP will determine the expectedness for all serious adverse events.
For the purpose of SUSAR reporting, the version of the IB at the time of occur rence of the 
SUSAR applies.
7.1.5.3. Reporting a Serious Adverse Event
7.1.5.3.1. Investigator Responsibility
To satisfy  regulatory  requirements, a ll serious adverse events that occur during the study , 
regardless of judged relationship to administration of the IMP, must be re ported to the sponsor 
by the investigator. The event must be reported within 24 hours of when the investigator learns 
about it. Completing the serious adverse event form and reporting the event must not be delay ed, 
even if not all the information is available. The investigator does not need to activel y monitor 
patients for adverse events once this study  has ended.
Serious adverse events occurring to a patient after the last administration of I MP of that patient 
has ended should be reported to the sponsor if the investigator becomes aware of them .
The serious adverse event form should be sent to the local safet y officer (LSO) or designee (a 
contract research organization [CRO] in a country without a sponsor L SO) (contact information 
is in the Clinical Study  Personnel Contact Information section); the L SO will forward the report 
to the sponsorâ€™s GPSP.
The following information should be provided to record the event accurately  and completel y:
ï‚·study  number
ï‚·investigator and investigational center identification
ï‚·pa
tient number
ï‚·onset date and detailed description of adverse event
ï‚·investigatorâ€™s assessment of the relationship of the adverse event to the IMP (no 
reasonable possibility , reasonable possibility )
Additional information includes:
ï‚·age and sex of patient
ï‚·date of first dose of IMP
ï‚·date and amount of last administered dose of IMP
ï‚·action taken
ï‚·outcome, if known
ï‚·severit y
ï‚·explanation of assessment of relatedness
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
89ï‚·concomitant medication (including doses, routes of administration, and regimens) and 
treatment of the event
ï‚·pertinent laboratory  or other diagnostic test data
ï‚·medical and ps ychiatric history
ï‚·results of dechallenge/rechallenge, if known
ï‚·for an adverse event resulting in death
ï€­cause of death (whether or not the death was related to I MP)
ï€­autopsy  findings (if available)
Each report of a serious adverse event will be reviewed and evaluated b y the investigator and the 
sponsor to assess the nature of the event and the relationship of the event to the I MP, study  
procedures, and to underlying diseases.
Additional information (follow -up) about an y serious adverse event unavailable at the initial 
reporting should be forwarded b y the investigator within 24 hours of when it becomes known to 
the same address as the initial report.
For all countries, the sponsorâ€™s GPSP wil l distribute the Council for International Organizations 
of Medical Sciences form/Extensible Markup Language file to the LSO/CRO for submission to 
the competent authorities, I ndependent Ethics Committees (I ECs)/Institutional Review Boards 
(IRBs), and investigators, according to regulations. The investigator must ensure that the 
IEC/IRB is also informed of the event, in accordance with national and local regulations.
Blinding will be maintained for all stud y personnel. Therefore, in case of an SUSAR, only the 
LSO/CRO will receive the unblinded report for regulatory submission; the others will receive a 
blinded report.
7.1.5.3.2. Sponsor Responsibility
If a serious unexpected adverse event is believed to be related to the IMP or study  procedures, 
the sponsor will take appropriate steps to notify  all investigators participating in sponsored 
clinical studies of TEV -50717 and the appropriate competent authorities (and I EC/IRB, as 
appropriate).
In addition to notify ing the investigators and competent authorities (and IEC/IRB, as 
appropriate), other action may  be required, including the following:
ï‚·altering existing research by  modify ing the protocol
ï‚·discontinuing or suspending the stud y
ï‚·modify ing the existing consent form and informing all study  participants of new 
findings
ï‚·modify ing listings of expected toxicities to include adverse events newl y identified as 
related to TEV -50717
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
907.1.6. Protocol -Defined Adverse Events of Special Interest
No protocol -defined adverse events of special interest for expedited reporting were identified f or 
this study . Events of drug -induced parkinsonism, changes in behavior, and sleepiness will be 
monitored using standardized scores and presented as part of safet y analysis (see Section 7.2).
7.1.7. Protocol Deviations Because of an Adverse Event
If a patient experiences an adverse event or medical emergency , deviations from the protocol 
may be allowed on a case -by-case basis. To ensure patient safety , afte r the event has stabilized or 
treatment has been administered (or both), the investigator or other physician in attendance must 
contact the ph ysician identified in the Clinical Study  Personnel Contact Information section of 
this protocol as soon as possibl e to discuss the situation. The investigator, in consultation with 
the sponsor, will decide whether the patient should continue to participate in the study  
(Section 4.3).
7.2. Safety Rating Scales
Site-administered safet y scales include the childrenâ€™s C- SSRS (Posner et al 2011) , CBCL, ESRS
(Chouinard and Margolese 2005 ), and ESS ( Janssen et al 2017 ). The investigator should review 
all scales and questionnaires in a timely  manner for any  potential reporting of adverse events and 
document this review accordingl y. At each stud y visit, as applicable, the inv estigator should 
compare the current scores to the baseline scores.
7.2.1. Childrenâ€™s Columbia-Suicide Severity Rating Scale
The childrenâ€™s C -SSRS Baseline/Screening scale assesses past and current suicidal ideation and 
behaviors to determine suicide risk and is administered at screening. The childrenâ€™s C -SSRS 
Since Last Visit scale is administered at baseline, weeks 3, 7, 9, 12, 15/ET, and 16. The 
childrenâ€™s C -SSRS questionnaire will be presented to patients â‰¥12 y ears of age at screening or 
11
years of age at screening but will turn 12 y ears of age during the study . Children 13 years of age 
and under must be interviewed in conju nction with the caregiver as appropriate or defined by  the 
scale. For children over 13 years of age, parent/legally  accepted representative involvement is 
strongl y encouraged. Questions should be directed to the child, but the caregiver parent/legall y 
accepted representative should be encouraged to add relevant information.
The childrenâ€™s C-SSRS is an interview by  trained study  personnel. 
The frequency  and severity  of suicidal ideation or behavior according to the childrenâ€™s C- SSRS 
questionnaire will be pr esented by  visit and by  treatment group. A shift table for childrenâ€™s 
C-SSRS categories at baseline, compared to the worst (highest) category  during the treatment 
period, will be presented. 
7.2.2. Child Behavior Checklist (for Ages 6 -18)
The CBCL assesses behavi oral and emotional status in children ages 6 through 18 years of age as 
reported b y the caregiver ( Achenbach and Ruffle 2000 ; Achenbach 2005). The full CBCL has 
two parts, a Competence Scale (Part s I to VII) and a Sy ndrome Scale (behavioral items).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
91The Competence Scale ( Parts I  to VII) assesses various activities (eg, sports, hobbies, games, 
organizations, clubs, teams, groups, jobs, and chores), interpersonal relationships, and academic 
performanc e. 
The Sy ndrome Scale comprises 113 questions related to problem behaviors. This study  will use a 
recall period of â€œnow or within the last week,â€ representing a modification from the original 
scale, which was â€œnow or within the last 6 monthsâ€. For each it em, the caregiver will circle 0 if 
the item is not true of their child, 1 if the item is somewhat or sometimes true, and 2 if the item is 
very true or often true. 
The CBCL is part of the Achenbach Sy stem of Empirically  Based Assessment that identifies 
syndromes that are behavioral clusters that indicate certain ty pes of behavioral, social, or 
emotional problems ( Achenbach and Rescorla 2004 ). The problem behaviors are scored on the 
following 8 empirically  based s yndromes: anxious/depressed, withdrawn/depressed, somatic 
complaints, social problems, thought problems, attention problems, rule -breaking behavior, and 
aggressive behavior. 
The Competence and Syndrome Scales are displayed on profiles in relation to gender and age -
specific percentiles and T scores based on national normative samples. 
The full CBCL assessment (Competence and S yndrome Scales) will be completed at screening 
and at week 15/ET. Onl y the CBCL  Syndrome scale will be completed at baseline, weeks 3, 7, 9, 
12, and 16/EOS.
7.2.3.
Extrapyramidal Symptom Rating Scale
The ESRS was designed to assess 4 ty pes of drug -induced movement disorders: parkinsonism, 
akathisia, dy stonia, and TD (Chouinard and Margolese 2005 ). In this study , parkinsonism and 
akathisia will be evaluated with subscales I (subjective questionnaire) and II (evaluation for 
parkinsonism/akathisia). The ESRS is administered at screening; baseline; and weeks 3, 7, 9, 12, 
15/ET, and 16/EOS.
The subscale I of the ESRS questionnaire rates subjective parkinsonism/akathisia at periods other 
than the day  of examinations during the last 7 day s. It is scored on a 4 -point scale (0=Absent, 
1=Mild, 2=Moderate, or 3=Severe). The evaluation takes into account the verbal report of the 
patient on: 1)the frequency  and duration of the symptom during the day , 2) the number of day s 
the sy mptom was present during the last week, and 3) the subjective evaluatio n of the intensity  
of the sy mptom by  the patient. 
The subscale II of the ESRS questionnaire for evaluation of parkinsonism and akathisia includes 
17 items with scores ranging from 0 -102 to assess the following: tremor (0â€“ 48), gait and posture 
(0â€“6), postural stability  (0-6), rigidity  (0â€“24), expressive automatic movements (0 â€“6), 
bradykinesia (0 -6), and akathisia (0â€“6).
7.2.4. Epworth Sleepiness Scale (for Children and Adolescents)
The ESS is a self-administered questionnaire composed of 8 questions that provide a measure of 
a patientâ€™s general level of day time sleepiness ( Johns 1991 ). Johns (2015) proposed the ESS as 
the official modified version of the ESS for children and adolescents. In 2017, Janssen et al
published results of their validation anal ysis and concluded that the ESS developed for children 
and adolescents is a reliable and internall y valid measure of day time sleepiness in adolescents 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
9212to 18 y ears of age, but f urther studies are needed to establish the internal validity  of the 
questionnaire for children under 12 years and the external validity  and accuracy  of cut -off points 
for children and adolescents. 
For patients 6 to 12 years of age, the ESS will be complet ed by  the caregiver. For patients 
â‰¥13years of age, the ESS will be completed by  the patient .Input from the caregiver is permitted .
The ESS is administered at screening; baseline; and weeks 3, 7, 9, 12, 15/ET, and 16/EOS. The 
ESS asks respondents to rate, on a 4 -point L ikert scale (0 â€“3), their usual chances of dozing off or 
falling asleep in different situations or activities that most people engage in as part of their daily 
lives. The total ESS score is the sum of 8 item scores and can range between 0 and 24 with the
higher the score indicating a higher level of daytime sleepiness. Most people can complete the 
ESS without assistance in 2 or 3 minutes.
Categories
ï‚·0=would never fall asleep
ï‚·1=slight chance of falling asleep
ï‚·2=moderate chance of falling asleep
ï‚·3=high chance of falling asleep
7.3. Pregnancy
Any female patient becoming pregnant during the study  will discontinue IMP.
All pregnancies of female patients participating in the study  that occur during the study  or within 
14days after the end of study  are to be reported immediately  to the individual identified in the 
Clinical Study  Personnel Contact I nformation section of this protocol, and the investigator must 
provide the sponsor with the completed pregnancy form. The process for reporting a pregnancy  
is the same as that for reporting a serious adverse event but using the pregnancy form 
(Section 7.1.5.3). 
The investigator is not required to report patients who are found to be pregnant between 
screening and baseline, provided no IMP was given. All female patients who become pregnant 
will be monitored for the outcome of the pregnancy (including spontaneous, elective, or 
voluntary  abortion). If the pre gnancy  continues to term, the outcome (health of the infant up to 
8weeks of age), including details of birth and presence or absence of an y birth defect, congenital 
abnormalities, or maternal and newborn complications, will be reported to the sponsor. An y
complication of pregnancy  during the study  and any  complication of pregnancy  that the 
investigator becomes aware of after withdrawal from the study  will be reported as an adverse 
event or serious adverse event, as appropriate.
Note: Female partnersâ€™ pregnancies of male participants are not required to be proactivel y 
monitored.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
93If the pregnancy  in the female patient participating in the study  does not continue to term, oneof 
the following actions will be taken:
ï‚·For a spontaneous abortion, report as a serious adverse event and also complete the 
pregnancy  form .
ï‚·For an elective abortion due to developmental anomalies, report as a serious adverse 
event and also complete the pregnancy  form .
ï‚·For an elective abortion notdue to developmental anomalies, comple te the pregnancy  
form; do not report as an adverse event.
7.4. Medication Error and Special Situations Related to the 
Investigational Medicinal Products
Any administration of IMP that is not in accordance with the study  protocol should be reported 
in the CRF an d in the patientâ€™s source documents as a deviation if the event meets the deviation 
criteria specified in the protocol ( Appendix D), regardless of w hether or not an adverse event 
occurs as a result.
The following are t ypes of medication errors and special situations:
1.Medication error: An y unintentional error in the prescribing, dispensing, or 
administration of a medicinal product while in the control of the healthcare professional, 
patient, or consumer.
2.Overdose: Administration of a quantity  of a medicinal product given per administration 
or cumulatively , which is above the maximum recommended dose according to the 
authorized product information. Clini cal judgment should always be applied. Any dose of 
IMP (whether the test IMP, or placebo IMP), whether taken intentionall y or 
unintentionally , in excess of that prescribed must be immediately  reported to the sponsor.
3.Misuse: Situations where the I MP is intentionally  and inappropriately  used not in 
accordance with the authorized product information.
4.Abuse: Persistent or sporadic, intentional excessive use of IMP, which is accompanied by  
harmful ph ysical or ps ychological effects.
5.Off-label use: Situations whe re an IMP is intentionally  used for a medical purpose not in 
accordance with the authorized product information.
6.Occupational exposure: Exposure to an I MP, as a result of oneâ€™s professional or non -
professional occupation.
7. Breastfeeding: Suspected adverse r eactions that occur in infants following exposure to a 
medicinal product from breast milk.
7.5. Clinical Laboratory Tests
All clinical laboratory  test results outside of the reference range will be judged by  the 
investigator as belonging to one of the following categories:
ï‚·abnormal and not clinically  significant
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
94ï‚·abnormal and clinically  significant
A laboratory  test result that is judged by  the investigator as clinicall y significant will be recorded 
both on the source documentation and the CRF as an adverse event and monitored as described 
in Section 7.1.2. An event may  include a laboratory  or diagnostic test abnormality  (once 
confirmed b y repeated testing) that results in the withdrawal of the patient from the study , the 
temporary  or permanent withdrawal of IMP or medical treatment, or further diagnostic work-up. 
(Note: Abnormal laboratory  or diagnostic test results at the screening visit that preclude a patient 
from entering the stud y or receiving IMP are not considered adverse events.)
Table 8:
Clinical Laboratory Tests
Serum Che mistry Hem atology and Coagulation Urinalysis
Calcium
Phosphate
Sodium
Potassium
Chloride
Creatinine
Glucose
Magnesium
Blood urea nitrogen
Total cholesterol
Triglycerides
Uric acid
Alanine aminotransferase
Aspartate aminotransferase
Lactate dehydrogenase
Alkaline phosphatase
Bicarbonate or carbon dioxide
Protein
Albumin
Bilirubin
Direct bilirubinHem oglobin
Hem atocrit
Erythrocytes
Platelets
Leucocytes
Neutrophils
Lymphocytes
Eosinophils
Monocytes
Basophils
Lymphocytes atypical
Prothrombin International Normalized 
RatioProtein
Glucose
Ketones
Hem oglobin
pH
Specific gravity
Microscopic tests
Bacteria
Erythrocytes
Leucocytes
Crystals
Casts
7.5.1. Serum Chemistry, Hematology, and Urinalysis
Clinical laboratory  tests (serum chemistry , hematology  and coagulation, and urinaly sis) will be 
performed at screening, week 15, and week 16, as detailed in Table 3. Clinical laboratory  tests 
will be performed using the central laboratory .Specific laboratory  tests to be performed are 
provided in Table 8. Laboratory  tests performed at screening may  be repeated to determine 
patient eligibility .
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
957.5.2. Other Clinical Laboratory Tests
7.5.2.1. Beta -Human Chorionic Gonadotropin Tests
Î²-HCG tests in urine will be performed for all female patients aged 12 years or older of 
childbearing potential at baseline and other in- clinic visits as detailed in Table 3. The Î² -HCG 
tests in serum will be performed for all female patients aged 12 y ears or older of childbearing 
potential at screening and week 15 and if clinically  indicated.
For COVID -19 updates, refer to Appendix M.
7.5.2.2. Urine Drug Screen
A urine drug screen will be performed at the time points specified in 
Table 3. A urine drug 
screen performed at screening may  be repeated to determine patient eligibility .
The urine drug screen detects the presence of drugs of abuse. Additionally , the urine drug screen 
will detect the presence of drugs prohibited according to the laboratory  manual. If a given 
parameter cannot be tested using urine, or if the investigator considers that additional testing is 
needed, an alternative matrix (eg, serum) may  be considered acceptable. Such tests may  be 
perform ed locall y. The sponsorâ€™s medical expert must be made aware in advance of, and provide 
approval for, drug screen parameters to which this will apply .
A positive result for an y drugs of abuse or their metabolites or drugs prohibited according to the 
laborat ory manual, without medical explanation, will preclude the patient from 
randomization/enrollment or continued participation in the study . Some of the drugs listed in this 
urine drug screen may  be permitted in certain cases when the particular medication is being used 
under a ph ysicianâ€™s or clinicianâ€™s guidance and in compliance with the physicianâ€™s or clinicianâ€™s 
recommendation for a specific condition (for example, phenobarbital [barbiturates] for seizures, 
stimulant medications [including amphetamine, met hylphenidate, and lisdexamfetamine] for 
attention deficit hy peractivity  disorder, and opiates or oxy codone for pain) and if the dosing has 
been stable for at least 4 weeks before screening and no changes to dose or frequency  are 
anticipated during the cour se of the study. Such cases should be discussed with the medical 
monitor. Patients who either are using these medications or have a positive drug screen for these 
substances or derivatives should be submitted to the medical monitor for consideration of 
participation in this study . Patients with a substance use disorder are excluded from this clinical 
trial. However, if per the investigatorâ€™s judgment, a patient does not meet the criteria for 
substance use disorder, a positive drug screen result for these me dications or derivatives, without 
medical explanation, should be discussed on a case -by-case basis with the medical monitor to 
determine the patientâ€™s eligibility , based on the information available.
For COVID -19 updates, refer to 
Appendix M.
7.6. Physical Examination
Physical examinations, including height and weight, general appearance, skin, head, ey es, ears, 
nose, throat, neck, l ymph nodes, cardiovascula r, respiratory , musculoskeletal, abdominal, and 
extremities will be performed at the time points detailed in Table 3. 
Weight must be measured with shoes and outerwear off.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
96Any new physical examination finding (ie, since the screening visit) that is judged b y the 
investigator as clinicall y significant will be considered an adverse event, recorded on the CRF, 
and monitored as described in Section 7.1.2. 
Investigators should pay  special attention to clinical signs related to previous serious diseases.
7.7. Vital Signs
Vital signs (bl ood pressure [sy stolic/diastolic] , respiratory  rate, bod y temperature, and pulse) will 
be measured at the time points detailed in Table 3. All abnormal vital signs will be judged b y the 
investigator as belonging to one of the following categories:
ï‚·abnormal and not clinically  significant
ï‚·abnormal and clinically  significant
Before blood pressure and pulse are measured, the patient must rest in a supine or 
semi -erect/seated position for at least 3 minutes. (The same position and arm or leg should be 
used each time vital signs are measured for a given patient.) Orthostatic blood pressure and pulse 
will be measured after the patient is in a standing position f or at least 3 minutes (for patients who 
are able to stand). For patients who find standing difficult or do not allow for a reliable blood 
pressure and pulse measurement, alternative methods to collect orthostatic blood pressure and 
pulse should be discusse d with the medical monitor. For an y abnormal vital sign value, the 
measurement should be repeated as soon as possible. Any  vital sign value that is judged by  the 
investigator as clinicall y significant will be recorded both on the source documentation and t he 
CRF as an adverse event and monitored as described in Section 7.1.2.
7.8. Electrocardiography
A 12 -lead ECG will be recorded at the time points detailed in Table 3. All ECGs will be 
performed after at least 5 minutes rest in a supine or semi -supine position. 
The ECG ty pes are defined as follow s:
ï‚·A â€œstandard ECGâ€ is a â€œstandardâ€ 10 -second 12 -lead ECG.
ï‚·A â€œsummary  ECGâ€ is a continuously  recorded ECG of longer than 
30 seconds. For a 
â€œsummary  ECG,â€ the minimal recommended duration is 2 minutes or longer, and the 
preferred duration is 5 minutes (as i t provides the most robust result). If a â€œsummary  
ECGâ€ is less than 2 minutes, data will still be captured and anal yzed to the extent 
possible.
The investigator should review the ECG at screening to determine patient eligibility  
for the stud y and subseque nt ECGs for the patientâ€™s continuation in the study . All 
ECGs should be reviewed by  the investigator for any  clinically  significant findings 
during the visit and before the patient leaves the clinic. A qualified ph ysician at a 
central diagnostic center wil l be interpreting the ECG.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
97All ECG results outside of the reference ranges will be judged by  the investigator as belonging to 
one of the following categories:
ï‚·abnormal and not clinically  significant 
ï‚·abnormal and clinically  significant
Any ECG finding that is judged by  the investigator as clinicall y significant (except at the 
screening visit) will be considered an adverse event, recorded on the source documentation and 
in the CRF, and monitored as described in Section 7.1.2.
The criteria for an abnormal post-baseline QTcF are a value >500 msec or change from 
screening >60 msec . If one of 
these criteria is met, the investigator must further evaluate the 
QTcF as follows: 
ï‚·If a standard ECG is abnormal and meets the above protocol criteria, 
oA 5-minute summary  ECG recording should be performed at the research site ,
and a repeat standard ECG is not required. The site should follow the process to 
have these ECGs read b y Spaulding. 
oIf a5-minute summary  ECG cannot be performed (for instance, if patient is 
evaluated at a facility other than the research site, and the summary  ECG is not 
available), the investigator should obtain 2 repeat standard ECGs and determine 
the average of these 3 post-screening QTcF values. The site should foll
ow the 
process to have these ECGs read b y Spaulding.  
ï‚·The investigator should then compare the post -screening QTcF values to the 
pre-treatment QTcF values at screening. As noted above, the post
-screening QTcF 
values will use either the average QTcF from t he 3 post -screening standard ECGs or 
the QTcF from the summary  ECG. The IMP must be stopped for any  confirmed 
post-baseline QTcF average value >500 msec or average increase from screening 
>60msec.
Note: Abnormal ECG results at week 3 and week 7 or at an unscheduled visit may  result in 
patient withdrawal from the study  as detailed in Section 4.3.
7.9. Assessment of Suicidality
TEV -50717 is considered to be central nervous system -active. In addition, there have been some 
reports of suicidal ideation or behavior as reported in the product label when it has been given to 
some patients with certain conditions. The sponsor considers it important to monitor for such 
events before and during this clinical study .
Some central nervous sy stem -active IMPs may  be associated with an increased risk of suicidal 
ideation or behavior when given to some patients with certain conditions. Although this IMP or 
other similar me
dicinal products in this class have not been shown to be associated with an 
increased risk of suicidal thinking or behavior when given to this study  population, the sponsor 
considers it important to monitor for such events before or during this clinical st udy.
The study  population being administered with TEV -50717 should be monitored appropriatel y 
and observed closel y for suicidal ideation and behavior or an y other unusual changes in 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
98behavior. Consideration should be given to discontinuing TEV -50717 in pati ents who experience 
signs of suicidal ideation or behavior.
Families and caregivers of patients being treated with TEV -50717 should be instructed to 
monitor patients for the emergence of unusual changes in behavior, as well as the emergence of 
suicidal ide ation and behavior, and to report such sy mptoms immediately  to the study  
investigator.
Baseline assessment of suicidal ideation and behavior and treatment -emergent suicidal ideation 
and behavior will be assessed during the study  using the childrenâ€™s C -SSRS described in 
Section 7.2.
Patients with a positive childrenâ€™s C-SSRS suicidal ideation score on either items 1 or 2 must be 
1)discussed with the study  medical monitor, 2) re -evaluated within 2 to 3 day s in a clinic visit, 
and 3) treated according to the investigator's medical judgment. Consultation with a 
child/adolescent ps ychiatrist or licensed child/adolescent mental health provider is advised, 
followed b y close ongoing monitoring.
If patients endorse or report a childrenâ€™s C
-SSRS suicidal ideation score of 3, 4, or 5, the patients 
will be evaluated immediately  by the investigator and referred for ps ychiatric evaluation. The 
medical monitor will be immediately  consulted. If it is determined by  the investigator, the 
medical monitor, and consulting psy chiatrist that exposure to the I MP may  have contributed to a 
change in childrenâ€™s C- SSRS and/or increased depressive s ymptoms, study  medication will b e 
immediately  discontinued and the patient will be terminated from the stud y. In cases where it is 
determined that IMP did not contribute to changes in depression or suicidality , the investigator 
will consult with the medical monitor, consulting psy chiatri st, and/or sponsor to determine 
whether the patient should continue in the study .
If patients report an y suicidal behavior that is an actual attempt as assessed in the childrenâ€™s
C-SSRS, they  will be evaluated immediately  by the investigator, referred for psychiatric 
evaluation, and terminated from the study .
If patients report an y suicidal behavior that is interrupted, aborted, or preparatory as assessed in 
the childrenâ€™s C-SSRS, they  will be evaluated immediately  by the investigator and referred for 
psychiatric evaluation. In cases where it is determined in the psy chiatric evaluation that IMP did 
not contribute to changes in suicidal behavior, the investigator will consult with the medical 
monitor, consulting psy chiatrist, and/or sponsor to determine whether the patient should continue 
in the study .
7.10. Assessment of Depression
Families and caregivers of patients are instructed to monitor the patients for any  changes in or 
new onset of depressive symptoms and unusual changes in mood, cognition, or behavior, and to 
report such s ymptoms immediately  to the investigator. Telephone contacts (with non- recording 
live video) and clinic visits also allow opportunities for the investigator to assess adverse events.
If a relevant change in status is identified, patients will be seen immediately  for an unscheduled 
visit by  the investigator and discussed with the medical monitor. The patient will be referred for 
further ps ychiatric evaluation if there is an y suspicion of experiencing depression. The 
investigator will record t hese s ymptoms as an adverse event of depression. If it is determined by  
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
99the investigator, after consultation with the medical monitor and consulting psy chiatrist, that 
exposure to the I MP may have contributed to the adverse event of depression, study  medication 
will be immediately  discontinued and the patient will be terminated from the study . Follow -up 
with a pediatric ps ychiatrist or licensed child/adolescent mental health provider will be arranged.
In cases where it is determined that I MP did not contrib ute to the adverse event of depression, 
the investigator will consult with the medical monitor and/or sponsor to determine whether the 
patient should continue in the study .
7.11. Neurological Examinations
Neurological examination, including mental status, crania l nerves, motor sy stem (strength, tone, 
and posture), coordination, gait and balance, tendon reflexes, and sensation, will be performed at 
the time points detailed in Table 3. An y neurological examination finding that is judged b y the 
investigator as a potentially  clinically significant change (worsening) compared with the baseline 
value will be considered an adverse event, recorded on the CRF, and monitored as described in 
Section 7.1.2 .
7.12. Concomitant Medication or Treatment
Concomitant therapy or medication usage will be monitored throughout the study according to 
time points detailed in Table 3. Parents/patients will be instructed during the course of the stud y 
to notify  the investigator if any  new medication is prescribed/administered (other than 
TEV -50717) or if there is any change in current medications, including over -the-counter 
medications. Any  new prescribed/administered medication and/or an y change in current 
prescribed/administered medication should be reviewed with the investigator. 
Patients may  be included in this study  if they  are using cannabis or formulations or derivatives of 
cannabis in relatively  stable amounts, for medical purposes (where applicable according to local 
regulation), under the guidance, supervision, or prescription of a clinician and antici pated to 
remain stable (dose and frequency ) within the study  duration . Patients who are either using 
cannabis or its derivatives or formulations or patients who have a positive drug screen for 
cannabis or its derivatives or formulations can be submitted to the medical monitor for 
consideration of participation in this study . Patients with a substance use disorder are excluded 
from this clinical trial. If per the investigatorâ€™s judgment, however, a patient does not meet the 
criteria for substance use disorde r, a positive drug screen for cannabis or its metabolites, without 
medical explanation, will be discussed on a case- by-case basis between the research site, the 
Medical Monitor, and the sponsor to determine the patientâ€™s eligibility , based on the informati on 
available. Patients should be advised that the recreational use of cannabis or its derivatives or 
formulations should be avoided during this study . 
Medications that are allowed, provided that conditions outlined in the table are met, are shown in 
Appen dix H, Table 10. Certain considerations mentioned in the table require the review of the 
medical monitor. Changes to the allowed medications may  be permit ted in the context of this 
study  and should be discussed with the medical monitor. If the wellbeing of the patient and the 
urgency  of the clinical decision do not allow discussion with the medical monitor prior to the 
medication change, the investigator sh ould notify the medical monitor in a timely  manner 
following this decision.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
100The medical monitor must be contacted if a patient is receiving (or has to begin or stop receiving 
during the stud y) a medication that is associated with QT prolongation or that is a known strong 
CYP2D6 inhibitor. Prohibited medications that are associated with QT prolongation are listed in 
Appendix H, Table 11.
7.13. Methods and Time P oints of Assessing, Recording, and Analyzing 
Safety Data
All adverse events will be reviewed on a periodic basis by  the clinical project phy sician/medical 
monitor according to the safet y monitoring plan (eg, scheduled safet y reviews for TEV -50717) 
as preli minary  safety databases become available. I n addition, t he iDMC will perform the 
unblinded IA and take part in safet y monitoring throughout the stud y.
Methods and time points of assessing safety  data are discussed in Section 3.4
. Procedures for 
recording safet y data are discussed in Appendix K, and methods of anal yses are discussed in
Section 9.8.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1018. ASSESSMENT OF  PHARMACOKINETICS/
PHARMACODYNAMICS AND PHARMACOG ENETICS
8.1. Pharmacok inetic Assessment
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Blood Sampling Scenarios
Scenario Action
 
 
  
 
 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1028.2. Assessment of Exploratory Biomarkers
8.3. Pharmacogenetics
8.3.1. CYP2D6 Genotyping/Pharmacogenetics
At the screening visit, a mandatory  blood sam ple (3.0 to 5.0 mL ) will be obtained for anal ysis of 
CYP2D6 genot ype from all patients in the study  at the time point detailed in Table 3. The 
CYP2D6 g enotype results will be provided to the RTSM, which drives each patientâ€™s dose 
regimen, and the patientâ€™s genot ype for CYP2D6 will remain blinded during the conduct of the 
study . 
 
 
 
 
 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1039. STATISTICS
This section describes the statistical anal ysis as foreseen at the time of planning the study . 
Changes, additions, and further details about the analy ses will be described in the statistical 
analysis plan (SAP). After finalization of the SAP, any  additiona l anal yses or changes to 
analyses that may  be required will be fully  disclosed in the CSR.
For COVID -19 updates, refer to Appendix M.
9.1. Sample Size and Power Considerations
The initial sample size estimation of approximately 185 patients randomized to TEV -50717 
versus placebo in a 2:1 ratio (approximately  124 in the TEV -50717 group; approximately  61 in 
the placebo group) is the sample size required to ob tain a statistically  significant result in the 
primary  anal ysis based on a 1 -sided test for mean difference at a significance level of Î±=0.025 
with a power of approximately  90%, assuming a mean difference of 1.8 and a standard deviation 
(SD) of 3.5 in each treatment group. 
At the time of writing Amendment 05, the initially planned sample size has been reduced to 
approximately  65patients randomized to TEV -50717 versus placebo in a 2:1 ratio 
(approximately  43in the TEV -50717 group; approximately  22 in the placebo group).
The initial assumptions regarding the mean difference and SD are based on the change from 
baseline to month 6 in patients treated with trihexyphenid yl reported b y Battini et al (2014) , 
assuming an effect size o f 55% for TEV -50717 versus placebo. The effect size of 55% was 
assumed based on the observed effect sizes of TEV -50717 in the pivotal studies in HD and TD. 
In the current study , these assumptions correspond to a mean difference of 2.0 in MD -CRS 
partII tot al score and an SD of 3.5 in each treatment group.
The rate of missing not at random (MNAR) data for the primary  anal ysis is expected to be 10%. 
MNAR data will be imputed in a conservative manner as if they  were obtained from patients in 
the placebo treatment group, regardless of the actual treatment group. As a result, the mean 
difference is expected to be reduced from 2.0 to 1.8 in the primary  anal ysis. The impact of the 
missing data imputation on the SD is negligible.
9.2. Analysis Sets
9.2.1. Intent -to-Treat Analysis Set
The intent -to-treat (ITT) anal ysis set will include all randomized patients.
In the ITT anal ysis set, treatment will be assigned based on the treatment to which patients were 
randomized, regardless of which treatment they  actually  received.
For patients who discontinue the study  and re -enter it (repeating the stud y from baseline), onl y 
the data from the repeated participation will be included in the ITT anal ysis set.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1049.2.2. Modified Intent -to-Treat Analysis Set
The modified intent -to-treat (mITT) anal ysis set is a subset of the ITT anal ysis set including all 
randomized patients with at least 1 post -baseline centrally  read MD -CRS part II assessment .
In the m ITT analysis set, treatment will be assigned based on the treatment to which patients 
were random ized, regardless of which treatment they actuall y received.
9.2.3. Safety Analysis Set
The safet y analysis set will include all randomized patients who receive at least 1 dose of IMP.
In the safet y analysis set, treatment will be assigned based on the treatment patients actuall y 
received, regardless of the treatment to which they were randomized, unless otherwise specified.
Rules for assignment of treatment in case of mixed actual treatments will be provided in the 
SAP.
Rules for handling safet y data for patients who discontinue the study  and re -enter it will be 
provided in the SAP.
9.2.4. Per-Protocol Analysis Set
The per -protocol (PP) analy sis set is a subset of the mITT anal ysis set including onl y patients 
who meet the following criteria:
ï‚·compliant with study  medicati on (80% to 105%)
ï‚·complete the study  without any  major protocol deviations that may  impact efficacy  
ï‚·centrall y read baseline MD -CRS part II total score of â‰¥10
Rules for excluding patients from the PP analy sis set will be provided in the SAP. Evaluation of 
exclusion from the PP analy sis set will be discussed on a case -by-case basis and documented 
prior to database lock and unblinding of the stud y for final analysis .
9.3. Data Handling Conventions
9.3.1. Handling Withdrawals and Missing Data
For this study  design and population, it is unlikely  that patients who withdraw from IMP will be 
willing to attend the remaining scheduled stud y visits and, in particular, the week 15 visit. 
Therefore, patients will not be required to return to the clinic at week 15 for efficacy  evalua tions, 
and the primary  anal ysis will be based on a multiple imputation method for missing data.
For efficacy  analy sis, missing data will be classified as missing at random (MAR) and MNAR. 
The following cases will be considered as MNAR: 
ï‚·early terminations related to tolerability
ï‚·treatment -related adverse events
ï‚·early terminations related to lack of efficacy  
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
105The following cases will be considered as MAR:
ï‚·intermittent missing data
ï‚·early termination for patients who are lost to follow -up 
ï‚·early terminations due to COVID -19
For all other cases, and for cases classified as above, classification as MAR/MNAR will be 
done/revisited in a blinded manner on a case -by-case basis prior to the IA for futility and prior to 
database lock for final analy sis.
Multiple imputation methods will be used in the primary  and secondary  efficacy  anal yses. See 
Section 9.5for details.
9.4. Study Population
The ITT anal ysis set (Section 9.2) will be used for all study  population summaries, unless 
otherwise specified. Summaries will be presented by  treatment group and for al l patients.
9.4.1. Patient Disposition
Data from patients screened; patients screened but not randomized (and reason not randomized); 
patients who are randomized; patients randomized but not treated; patients re -randomized; 
patients in the I TT, mITT, safet y, and PP anal ysis sets; patients who complete the treatment 
period; patients who complete the EOS visit; and patients who withdraw from the study  will be 
summarized using descriptive statistics. Data from patients who withdraw from the study  will 
also be summari zed by  reason for withdrawal using descriptive statistics.
9.4.2. Demographic and Baseline Characteristics
Patient demographic and baseline characteristics, including medical and psychiatric history , prior 
medications and therapies, and ECG findings, will be examined to assess the comparability  of 
the treatment groups and will be summarized using descriptive statistics. For continuous 
variables, descriptive statistics will be provided. For categorical variables, patient counts and 
percentages will be provided. Cat egories for missing data will be presented if necessary .
9.5. Efficacy Analysis
9.5.1. Primary Estimand
The primary  estimand is the difference in means between TEV -50717 and placebo in the target 
patient population for the change from baseline to week 15 in centrall y read MD -
CRS part II 
total score, regardless of whether or not dose reduction, suspension, or discontinuation occurred, 
and regardless of treatment-related adverse events. 
The primary  estimand assesses the effectiveness in the reduction of choreiform movem ents in 
patients with DCP with predominant choreiform movement disorder, evaluated b y the central 
reviewers, focusing on the causal effects attributable to the I MP.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
106The target patient population for this study  is patients with DCP with predominant choreiform 
movement disorder and severit y of DCP represented by the following:
a.total score of â‰¥10 in centrally  read MD-CRS part II items at baseline, and 
b.CGI-S â‰¥4 at baseline.
This population is expected to have the sensitivity  to demonstrate clinicall y meaningful 
improvement following treatment with TEV -50717.
Due to practical reasons, it is not possible to obtain a central reading of MD -CRS part II items at 
the time of the baseline visit prior to randomization; therefore, inclusion of the subject to the 
study  isbased on investigator scoring of MD -CRS part II items at baseline (Section 9.2.2).
9.5.2. Primary Endpoint
The primary  efficacy  endpoint is the change from baseline to week 15 in the MD -CRS part II 
total score (movement disorder severit y, centrally read) (TEV -50717 versus placebo).
9.5.2.1. Primary Efficacy Analysis
The primary  anal ysis will be a mixed -model, repeated -
measures with the change in MD- CRS 
part II total score as the dependent variable. The model will include fixed effects for treatment 
group, week (3 levels: weeks 9, 12, and 15), and treatment group by  week interaction. The 
baseline MD -CRS part II total score, age group at baseline (2 levels: 6 to < 12 years; 12 through 
18 years, inclusive), and region (US; non- US) will be included as covariates. The unstructured 
covariance model will be used.
Missing data will be classified as MAR and MNAR, as described in Section 9.3.1. The 
MAR/MNAR multiple imputation method will be applied in the primary  anal ysis, where MNAR 
data will be imputed using the jump -to-reference method, and MAR data will be impute d based 
on the randomized treatment group. The resulting complete, imputed datasets will each be 
analyzed using the anal ysis model described above, and the resulting statistics combined using 
methodology  presented by  Rubin (1987) and Little and Rubin (2002) .
The difference in least squares (LS) mean of the change in MD-
CRS part II total score from 
baseline to week 15 (TEV -50717 versus placebo) will be compared using a 1- sided test for 
superiority  at a nominal significance level of Î±=0.025. 
The L S mean and standard error for the treatment groups, the L S mean difference, 2- sided 95% 
confidence interval, and p- value for the comparison (TEV -50717 versus placebo) at week 15 will 
be presented.
9.5.2.2. Sensitivit y Analysis
To assess the robustness of the primary  efficacy  analy sis, sensitivity  anal yses will include the 
following:
Sensitivity  analy ses for assumptions of missing data mechanism:
ï‚·tipping point (MNAR)
ï‚·MAR multiple imputation 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
107Sensitivity  analy sis for th e statistical model:
ï‚·analysis of covariance (ANCOVA)
ï‚·primary  model, including only  the following covariates: treatment group, week, and 
treatment group b y week interaction
Other:
ï‚·primary  model repeated for the ITT anal ysis set
ï‚·primary  model repeated for the set of patients in the mITT anal ysis set that received 
at least 1 dose of IMP 
ï‚·primary  model repeated for the PP analy sis set
ï‚·ANCOVA models for MD -CRS part II total score change from baseline to week 9 
and to week 12
9.5.2.3. Minimal Clinically Important Difference and Minimal Clinically Important 
Change
To support the evaluation of the clinical impact of the change in dy skinesia as assessed by  the 
primary  endpoint, the minimal clinically  important difference (MCID) and the minimal clinically  
important cha nge (MCIC) will be calculated. The MCI D and MCI C anal yses will be performed 
based on 3 global impression of improvement anchors: caregiver (CaGI-I), investigator (CGI- I), 
and patient (PGI -I). 
The MCID and MCIC analy sis will be performed separately  for eac h anchor (CaGI -I, CGI -I, and 
PGI-I) yielding a set of thresholds, each reflecting the perspective of the caregiver, the clinician, 
or the patient, depending on the anchor used.
The MCID and MCIC analy ses will be based on the methods described by  Hauser et al 2014 and 
Hauser et al 2022. Details will be provided in the statistical analy sis plan.
9.5.3. Secondary Estimands
The secondary  estimands are the differences in means between TEV-50717 and placebo in the 
target patient population for (1) change from baseline to week 15 in centrally  read MD -CRS 
partI total score ,(2) CaGI -I at week 15, (3) CGI -I at week 15, (4) change from baseline to 
week 15 in centrall yread UHDRS -TMC, (5) change from baseline to wee k 15 in centrall yread 
UHDRS -TMD, regardless of whether or not dose reduction, suspension, or discontinuation 
occurred, and regardless of treatment- related adverse events.
The secondary  estimands assess the effectiveness on patientsâ€™ ability  to perform dai ly functions, 
the improvement in dy skinesia evaluated b y the caregiver and the investigator, and the reduction 
in chorea and d ystonia evaluated b y the central reviewers, all with a focus on the causal effects 
attributable to the IMP.  
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1089.5.4. Key Secondary Endpoi nts
The key  secondary  endpoints are the following:
1. C hange from baseline to week 15 in centrall y read MD -CRS part I  total score 
(TEV -50717 versus placebo) 
2.CaGI -I at week 15 (TEV -50717 versus placebo)
3.CGI-I at week 15 (TEV -50717 versus placebo)
4. C hange from baseline to week 15 in centrally read UHDRS -TMC (TEV -50717 versus 
placebo)
5. C hange from baseline to week 15 in centrall yread UHDRS -TMD (TEV -50717 versus 
placebo)
9.5.4.1. Secondary Efficacy Analysis
Analy ses of the key  secondary  endpoints will be performed as follo ws: 
1.MD-CRS part I  total score change from baseline to week 15 will be anal yzed using a 
mixed -effects model repeat measurement (MMRM) in the same fashion as the primary 
analysis, with the exception that the baseline value of MD -CRS part I total score will be 
included as the covariate instead of MD -CRS part II total score.
2.CaGI -I at week 15 will be anal yzed using an MMRM model in the same fashion as the 
primary  anal ysis, with the exceptions that the baseline value of CGI -S will be included as 
the covariate i nstead of MD -CRS part II total score and that week will include 5 levels 
(weeks 3, 7, 9, 12, and 15).
3.CGI-I at week 15 will be anal yzed using an MMRM model in the same fashion as the 
primary  anal ysis, with the exceptions that the baseline value of CGI -S will be included as 
the covariate instead of MD- CRS part II total score and that week will include 5 levels 
(weeks 3, 7, 9, 12, and 15). 
4.UHDRS -TMC (centrally  read) change from baseline to week 15 will be analy zed using 
an MMRM model in the same fashion as t he primary  anal ysis, with the exception that the 
baseline value of UHDRS- TMC (centrall y read) will be included as the covariate instead 
of MD -CRS part II total score.
5.UHDRS -TMD(centrall yread) change from baseline to week 15 will be analy zed using 
an MMRM model in the same fashion as the primary  anal ysis, with the exception that the 
baseline value of UHDRS- TMD(centrally read) will be included as the covariate instead 
of MD -CRS part II total score.
In addition, sensitivity  analy ses for the key  secondary  endpoints will be performed in the same 
fashion as the primary  endpoint.
9.5.5. Other Efficacy Endpoints
Other efficacy  endpoints (change from baseline to week 15/proportion at week 15; TEV -50717 
versus placebo) are the following:
ï‚·MD-CRS part I  total score ( general assessment, physician rated)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
109ï‚·MD-CRS part II total score ( general assessment, phy sician rated)
ï‚·MD-CRS Global I ndex (calculated from MD -CRS parts I  and II total scores)
ï‚·UHDRS -TMS ( physician rated)
ï‚·UHDRS -TMC ( physician rated)
ï‚·UHDRS -TMD ( physician rated)
ï‚·PEDI -CAT (ADL, caregiver completed, content -balanced version)
ï‚·The CP module of the PedsQL (QoL, patient/caregiver)
ï‚·PGI-I Scale (global, patient/caregiver)
ï‚·CGI-S Scale (global, ph ysician rated)
ï‚·CaGI -I response, defined as patients who are described by  the caregiver as â€œMuch 
Improvedâ€ or â€œVery  Much I mprovedâ€ in the CaGI -I score
ï‚·CGI-I response, defined as patients who are described as â€œMuch Improvedâ€ or â€œVery  
Much I mprovedâ€ in the CGI -I score
ï‚·CGI-S response, defined as patients who have a reduction of â‰¥1 poin t in the CGI -S 
score
ï‚·PGI-I response, defined as patients who are described as â€œMuch Improvedâ€ or 
â€œSomewhat Improvedâ€ in the PGI -I score
9.5.5.1. Other Efficacy Analysis
Analy sis methods will be provided in the SAP.
9.6. Multiple Comparisons and Multiplicity
The primary  efficacy  endpoint will be tested at the 1- sided significance level of Î±=0.025. 
If the primary  endpoint is statistically  significant (p- value â‰¤0.025), the 
5key secondary  
hypotheses will be tested using a hierarchical approach at the 1 -sided significance l evel of 
Î±=0.025, in the following order: (1) MD- CRS part I total score, (2) CaGI -I, (3) CGI -I, 
(4)UHDRS -TMC (centrally read), and ( 5) UHDRS -TMD(centrall yread) . 
 
 
 
 
No multiplicity  control will be applied to the sensitivity anal ysis or other endpoints.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
1109.7. Planned Interim Analysis
This is the first study  to evaluate the efficacy  of TEV -50717 to reduce the severit y of d yskinetic 
involuntary  movements associated with CP in pediatric patients with DCP. Moreover, limited 
data are available on the effect of active treatment on MD-
CRS part II total score in DCP that 
can support sample si ze calculations. Therefore, anIA for futility is planned.
When approximately  50 patients have completed the study  (including follow -up), an iDMC will 
perform an unblinded non -binding IA for futility  based on centrall y read MD -CRS part II total 
score. 
Therules for futility  recommendation (eg, definition of the promising zone) will be included in 
the iDMC charter and the SAP. The iDMC charter will also provide the wording that will be 
used to communicate the iDMC recommendation. The SAP will be finalized b efore the IA will 
be performed.
9.8. Safety Endpoints and Analysis
Safety  anal yses will be performed on the safety  analy sis set (Section 9.2.3).
Safety  assessments and time points are provided in Table 3.
All adverse events will be coded using the Medical Dictionary  for Regulatory  Activities. Each 
patient will be counted only  once in each preferred term or s ystem organ class category  for the 
analyses of safet y. Summaries will be presented for all adverse events (overall and by severit y), 
adverse events determined by  the investigator to be related to tes t IMP (ie, reasonable possibility ; 
see Section 7.1.4
) (defined as related or with missing relationship) (overall and by  severit y), 
serious adverse events, and adverse events causing withdrawal from the study . Summaries will 
be presented b y treatment group and for all patients. Patient listings of serious adverse events and 
adverse events leading to withdrawal will be presented.
Changes in laboratory , ECG, and vital signs measurements data will be summarized 
descriptivel y. ECG and vital signs values will be compared with predefined criteria to identify  
potentially  clinicall y significant values or changes, and such values will be listed.
The use of concomitant medications will be summarized by  therapeutic class using descriptive 
statistics.
The frequency  and severity  of suicidal ideation or behavior according to the childrenâ€™s C- SSRS 
questionnaire will be presented by  visit and by  treatment group. A shift table for childrenâ€™s C -
SSRS categories at baseline, compared to the worst (h ighest) category  during the treatment 
period, will be presented.
Assessment of drug -induced parkinsonism according to the ESRS (subscales I  and II), 
assessment of change in behavior according to the CBCL  questionnaire, and assessment of 
sedation according to the ESS questionnaire will be summarized descriptively .
For continuous variables, descriptive statistics will be provided for actual values and changes 
from baseline to each time point. For categorical variables, patient counts and percentages will 
be provided. Descriptive summaries of serious adverse events, patient withdrawals due to 
adverse events, and potentially  clinicall y significant abnormal values (clinical laboratory or vital 
signs) based on predefined criteria will be provided as well.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
111If any patient dies during the study , a listing of deaths will be provided, and all relevant 
information will be discussed in the patient narrative included in the CSR.
9.9. Tolerability Analysis
If more than 15% of the patients withdraw from the study  before the end of the treatment period, 
the number of day s until study  discontinuation will be anal yzed using Kaplan- Meier 
methodology  using the ITT anal ysis set.
9.10. Pharmacok inetic/Pharmacodynamic Analysis
 
 
 
 
 
9.11. Reporting Deviations from the Statistical Plan
Deviations from the statistical plan, along with the reasons for the deviations, will be described 
in protocol amendments, the SAP, the CSR, or any combination of these, as appropriate, and in 
accordance with applicable national, local, and regional requirements and regulations.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
11210. QUALITY CONTROL  AND QUALITY  ASSURANCE
Refer to Appendix Dfor information regarding quality  control and quality  assurance. This 
includes information about protocol amendments, deviations, responsibilities of the investigator 
to study  personnel, study monitoring, and audit and inspection.
Refer to Appendix Jfor the definition of a clinical product complaint and investigator 
responsibilities in the management of a clinical product complaint.
For COVID -19 updates, refer to Appendix M.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
11311. COMPLIANCE STATEMENT
This study  will be conducted in full accordance with the I nternational Council for Harmonisation 
Harmonised Tripartite Guideline, Guideline for GCP E6, and any applicable national and local 
laws and regulations (eg, Title 21 Code of Federal Regulations [21CFR] Parts 11, 50, 54, 56, 
312, and 314, Directive 2001/20/EC of the Eu ropean Parliament and of the Council on the 
approximation of the laws, regulation s, and administrative provisions of the Member States 
relating to the implementation of GCP in the conduct of clinical trials on medicinal products for 
human use). An y episode of noncompliance will be documented.
The investigator is responsible for perform ing the clinical study  in accordance with this protocol 
and the applicable guidelines referenced above for collecting, recording, and reporting the data 
accuratel y and properl y. Agreement of the investigator to conduct and administer this clinical 
study  inaccordance with the protocol will be documented in separate clinical study  agreements 
with the sponsor and other forms as required b y national competent authorities in the country  
where each investigational center is located.
The investigator is responsib le for ensuring the privacy , health, and welfare of the patients during 
and after the clinical study  and must ensure that trained personnel are immediatel y available in 
the event of a medical emergency . The investigator and the involved clinical study  pers
onnel 
must be familiar with the background and requirements of the study  and with the properties of 
the IMPs as described in the IB or prescribing information.
The principal investigator at each investigational center has the overall responsibility  for the
conduct and administration of the clinical study  at that investigational center and for contacts 
with study  management, with the I EC/IRB, and with competent authorities.
See Appendix Efor the ethics expectations of informed consent or assent, competent authorities 
and IEC and IRB, confidentiality  regarding study  patients, and requirements for registration of 
the clinical study .
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
11412. DATA MANAGEMENT AND REC ORD KEEPING
See Appendix Kfor information regarding data management and record keeping. This includes 
direct access to source data and documents, d ata collection, data quality  control, and archiving of 
CRFs and source documents.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
11513. FINANCING AND INSURA NCE
A separate clinical stud y agreement, including a study  budget, will be signed between each 
principal investigator and the sponsor (or the CRO designat ed by the sponsor) before the IMP is 
delivered.
The patients in this clinical study  are insured in accordance with applicable legal provisions. The 
policy  coverage is subject to the full policy  terms, conditions, extensions, and exclusions. 
Excluded from t he insurance coverage are, for example, damages to health and worsening of 
previous existing diseases that would have occurred or continued if the patient had not taken part 
in the clinical study .
The policy  of Clinical Trials I nsurance will be provided to the investigational centers b y the 
sponsor.
For covered clinical studies (see 21CFR Part 54), the investigator will provide the sponsor with 
financial information required to complete the Food and Drug Administration 3454 form. Each 
investigator will notify  the sponsor of an y relevant changes during the conduct of the study  and 
for 1 year after the stud y has been completed.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
11614. PUBLICA TION POLICY
See Appendix Lfor information regarding the publication policy .
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
11715. REFERENCES 
Achenbach TM, Ruffle TM. The Child Behavior Checklist and related forms for assessing 
behavioral/emotional problems and competencies. Pediatr Rev 2000;21(8):265 -71.
Achenbach TM, Rescorla Leslie. Practical Applications of the Achenbach Sy stem of Empiricall y 
Based Assessment (ASEBA) for Ages 1.5 to 90+ Years. 2004:64-7. 
http://research.acer.edu.au/research_conferenceITU_2004 /2
Achenbach TM. Advancing assessment of children and adolescents: commentary  on evidence-
based assessment of child and adolescent disorders. J Clin Child Adolesc Psy chol 
2005;34:541 -7.
AUSTEDOÂ®(deutetrabenazine) tablets (US prescribing information). Teva Pharmaceuticals 
USA, I nc; 2021. Available at: https://austedo.com/hd/pi.
Battini R, Casarano M, Sgandurra G, Olivieri I, Di Pietro R, Romeo DM, et al. Responsiveness 
of the MD -Childhood Rating Scale in d yskinetic cerebral pals y patients undergoing 
anticho linergic treatment. Eur J Paediatr Neurol 2014;18(6):698-703.
Battini R, Sgandurra G, Petacchi E, Guzzetta A, Di Pietro R, Giannini MT, et al. Movement 
Disorder -Childhood Rating Scale: reliability  and validity . Pediatr Neurol 2008;39(4):259-65.
Busner J, T argum SD. The Clinical Global I mpressions Scale: Apply ing a Research Tool in 
Clinical Practice. Psy chiatry  (Edgmont) 2007;4(7):28-37.
Cans, C. Surveillance of cerebral pals y in Europe: a collaboration of cerebral palsy surveys and 
registers. Developmental Medicine & Child Neurology  2000;42:816-24.
Center for Disease Control and Prevention (CDC). Data & Statistics for Cerebral Pals y. 
Available at: https://www.cdc.gov/ncbddd/cp/data.html
Center for Disease Control and Prevention (CDC). Causes and Risk Factors of Cerebral Palsy . 
Available at: https://www.cdc.gov/ncbddd/cp/causes.html
Cerebral Pals y Life Expectancy . Available at: https://www.birthinjury guide.org/cerebral-
palsy /life-expectancy /. Accessed 22 May  2018.
Chouinard G, Margolese HC. Manual for the Ext rapyramidal Sy mptom Rating Scale (ESRS). 
Schizophrenia Research 2005;76:247 -65.
Dumas HM, Fragala -Pinkham MA. Concurrent Validity  and Reliability  of the Pediatric 
Evaluation of Disability  Inventory -Computer Adaptive Test Mobility  Domain. Pediatric Phy sical
Therap y 2012;24:171-76.
Fuenmay or LD, Vogt M. The influence of cerebral 5 -hydroxytryptamine on cataleps y induced b y 
brain -amine depleting neuroleptics or by  cholinomimetics. B J Pharmacol 1979;67(2):309-18.
Hauser R A, Barkay  H, Wilhelm A, Wieman M , Savola J-M, Gordon MF. Minimal clinically  
important change in abnormal involuntary  movement scale score in tardive dy skinesia as 
assessed in pivotal trials of deutetrabenazine. Parkinsonism Relat Disord.  2022;97:47-51.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
118Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, et al. Minimal clinically  
important difference in Parkinsonâ€™s disease as assessed in pivotal trials of pramipexole extended 
release. Parkinsons Dis. 2014;2014:467131.
Huntington Study  Group. U nified Huntington's Disease Rating Scale: reliability  and consistency . 
Huntington Study  Group. Mov Disord 1996;11(2):136 -42.
Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy  of pediatric h yperkinetic movement 
disorders. Mov Disord 2006;21(11):1966
-72.
Janssen KC, Phillipson S, Oâ€™Connor J, Johns MW. Validation of the Epworth Sleepiness Scale 
for children and adolescents using Rasch analy sis. Sleep Med 2017;33:30 -5.
Johns MW. A new method for measuring day time sleepiness: the Epworth Sleepiness Scale. 
Sleep 1991;14(5):540 -5.
Johns MW. The assessment of sleepiness in children and adolescents. Sleep Biol Rhy thm 
2015;13(Suppl. 1): 97.
Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Tetrabenazine: Spotlight on Drug 
Review. Annals of Neurosciences 2016;23(3):176-85.
Little RJA, Rubin DB. Statistical Analysis with Missing Data, Second Edition. 2002, New York: 
John Wiley  & Sons.
Maenner MJ, Blumberg SJ, Kogan MD, Christensen D, Yeargin -Allsopp M, Schieve LA. 
Prevalence of cerebral palsy and intellectual disabilit y among children identified in two U.S. 
National Survey s, 2011-2013. Ann Epidemiol. 2016;26(3):222-6.
Monbaliu E, Himmelmann K, L in JP, Ortibus E, BonouvriÃ© L, Fey s H, et al. Clinical 
presentation and management of dy skinetic cerebral palsy . Lancet Neurol 2017;16(9):741-9.
National Institute of Neurological Disorders and Stroke (NINDS). Cerebral Palsy : Hope Through 
Research. Available at: https://www.ninds.nih.gov/Disorders/Patient-Caregiver- Education/Hope -
Through -Research/Cerebral -Palsy -Hope -Through- Resear ch. Accessed 27 February  2020.
Posner K, Brown G, Stanley  B, Brent, D, Yershova K, Oquendo M, et al. The Columbia â€“Suicide 
Severity Rating Scale: initial validity  and internal consistency  findings from three multisite 
studies with adolescents and adults. Am J Psy chiatry  2011;168(12):1266- 77.
Prevalence of Cerebral Palsy . Available at: http://www.cerebralpals y.org/about -cerebral -
palsy /prevalence -and-incidence. Accessed 11 June 2018.
Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A rep ort: the 
definition and classification of cerebral palsy  April 2006. Dev Med Child Neurol 
2007;49(s109):8
-14.
Rubin DB. Multiple I mputation for Nonresponse in Survey s. 1987, New York: John Wiley  & 
Sons.
Scherman D, Gasnier B, Jaudon P, Henry  JP. Hy drophobi city of the tetrabenazine -binding site of 
the chromaffin granule monoamine transporter. Mol Pharmacol 1988;33(1):72 -7.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
119Sgandurra G, Olivieri I, Casarano M, Di Pietro R, Menici V, Velli C, et al. Inter and intra -rater 
reliability  and minimal detectable diff erence of Movement Disorder- Childhood Rating Scale. 
Eur J Phy s Rehabil Med 2018;54(1):48-57.
Varni, JW, Burwinkle, TM, Berrin, SJ, Sherman, SA, Artavia, K, Malcarne, VL, et al. The 
PedsQL â„¢ in pediatric cerebral palsy : Reliability , validity , and sensitivity of the Generic Core 
Scales and Cerebral Palsy  Module. Developmental Medicine and Child Neurology  2006;48:442-
49.
Vuong K, Hunter C, Mejia N, Jankovic J. Safety  and efficacy  of tetrabenazine in childhood 
hyperkinetic movement disorders. Mov Disord 2004;19( Suppl. 9):S422.
Wimalasundera N, Stevenson VL. Cerebral pals y. Pract Neurol 2016;16:184â€“194.
Xenazine: Highlights of Prescribing Information. 2018. Available at: 
https://daily med.nlm.nih.gov/dail ymed/drugInfo.cfm?setid=ac768bab -8afa-4446- bc7f-
caeeffec0cda. Accessed 05 Aug 2019.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
12016. SUMMARY OF CHANGES TO PROTOCOL
16.1. Amendment 05 Dated 24March 2022
The reasons for this amendment are to adjust the sample size and to add new endpoints.
All major changes to the protocol body  are listed below in the table and are reflected in the 
synopsis, as applicable. Minor editorial changes (ty pographical errors, punctuation, etc) have 
been made to the protocol (and protocol s ynopsis, as appropriate).
Table 3(Study  Procedures and Assessments) and Figure 1(Overall Study  Schematic Diagram) 
have been revised to reflect change s described below.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
121Protocol text with changes shown New wording Reason/justification for change
1. INTRODUCTION
There are currently no approved treatments for DCP, which 
is a serious disease with an unmet medical need. Current 
treatment options (off -label use) to treat dystonia and chorea 
include tetrabenazine, dopaminergic, or gamma -
aminobutyric acidergic intervent ions, but these show high 
variability in response (Monbaliu et al 2017). Botulinum 
neurotoxin A is also in clinical use for the treatment of 
spasticity and dystonia and is considered modestly effective 
in selected patients, but it does not meet the full treatment 
need. Naxibimols, a non smoked cannabis derivative, was 
approved to treat spasticity associated w ith multiple 
sclerosis in the United Kingdom in 2010 and is being 
investigated to treat spasticity in CP (ClinicalTrials.gov 
Identifier: [STUDY_ID_REMOVED]). Currently, there are very fe w 
agents with novel mechanisms of action in development for 
movement disorders in CP. Dalfampridine, a small molecule 
potassium channel blocker thought to restore conduction in 
central demyelinated axons, is approved for use in multiple 
sclerosis but has failed to demonstrate functional 
improvement in patients with CP (Bethoux et al 2017).There are currently no approved treatments for DCP, which 
is a serious disease with an unmet medical need. Current 
treatment options (off -label use) to treat dystonia and chorea 
include tetrabenazine, dopaminergic, or gamma -
aminobutyric acidergic interventions, but these show high 
variability in response (Monbaliu et al 2017). Botulinum 
neurotoxin A is also in clinical use for the treatment of 
spasticity and dystonia and is considered modestly effective 
in selected patients, but it does not meet the full treatment 
need. Currently, there are very few agents with novel 
mechanisms of action in development for movement 
disorders in CP. New  inform ation indicates 
Naxibimols and Dalfampridine 
will not be used for DCP and 
therefore not relevant to this 
protocol.
1.1.1. Background for TEV -50717
TEV 50717 IMP tablets are available in the following 
dose strengths: â€¦IMP tablets are available in the following dose strengths: â€¦ Clarification
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
122Protocol text with changes shown New wording Reason/justification for change
1.2.2. Clinical Studies
The clinical development plan for TEV -50717 to date 
includes the following:
â€¢Fourteen Thirteen completed Phase 1 studies in healthy 
adult volunteers
â€¢Two com pleted pivotal Phase 2/3 and Phase 3 studies in 
patients with TD
â€¢One ongoing completed Phase 3 long -term safety study 
in patients with TD
â€¢Two com pleted pivotal studies in patients with TS with 
clinical conduct and analysis concluded and clinical 
study report (CSR) fi nalization pending
â€¢One terminated Phase 3 long -term safety study in 
patients with TS with analysis of results ongoingThe clinical development plan for TEV -50717 to date 
includes the following:
â€¢Fourteen completed Phase 1 studies in healthy adult 
volunt eers
â€¢Two com pleted pivotal Phase 2/3 and Phase 3 studies in 
patients with TD
â€¢One completed Phase 3 long -term safety study in 
patients with TD
â€¢Two com pleted pivotal studies in patients with TS
â€¢One terminated Phase 3 long -term safety study in 
patients with TSUpdated the status of the 
TEV -50717 studies that have been 
conducted/completed since the 
last amendment.
1.2.2.1. Clinical Pharm acology Studies
Fourteen Thirteen Phase 1 clinical pharmacology studies 
were conducted in healthy adult volunteers.Fourteen Phase 1 clinical pharmacology studies were 
conducted in healthy adult volunteers.Updated the status of the 
TEV -50717 studies that have been 
conducted/completed sin ce the 
last amendment.
1.2.2.2. Clinical Safety and Efficacy Studies
The safety profile of TEV -50717 has been characterized to 
date in healthy volunteers, as well as in adult patients with 
chorea associated with HD and TD (as detailed in the IB)
and in children and adolescents with TS .The safety profile of TEV -50717 has been characterized to 
date in healthy volunteers, as well as in adult patients with 
chorea associated with HD and TD (as detailed in the IB ) 
and in children and adolescents with TS.Text updated to include the TS 
studies as part of the safety profile 
for TEV -50717
See new wording column The open -label, long -term Study TV50717 -CNS- 30047 
evaluated children and adolescent patients with tics 
associated with TS. Treatment w ith TEV -50717 through 54 
weeks resulted in improvement of tics. The safety profile 
observed in pediatric patients with TS receiving long -term 
treatment with TEV -50717 w as generally comparable to the 
known safety profile of this drug in adult patients with HD 
or TD, w ith the exception of the adverse event of weight 
gain.Text added for the recently 
completed long -term TS study
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
123Protocol text with changes shown New wording Reason/justification for change
1.3.1.2. Potential Risks of TEV -50717
The follow ing information is based on clinical trial 
experience with TEV -50717 and the US prescribing 
information for Xenazine (tetrabenazine) and Austedo 
(deutetrabenazine) :The follow ing information is based on clinical trial 
experience with TEV -50717 and the US prescribing 
information for Xenazine (tetrabenazine) and Austedo 
(deutetrabenazine):Clarification
See new wording column â€¢TEV -50717 is contraindicated in patients taking 
tetrabenazine or valbenazine. At least 30 days should 
elapse after stopping tetrabenazine or valbenazine before 
starting TEV -50717.Updated per the current 
prescribing info of Austedo
2.1. Prim ary and Secondary Study Objectives and Endpoints
See new wording column â€¢UHDRS -TMC (centrally read)
â€¢UHDRS -TMD (centrally read)New  key secondary endpoint
2.1.2. Prim ary and Secondary Estimands
The secondary estimands are the differences in means 
betw een TEV -50717 and placebo in the target patient 
population for (1) change from baseline to w eek 15 in 
centrally read MD -CRS part I total score; (2) Caregiver 
Global Impression of Improvement (CaGI -I)at week 15;  
(3) Clinical Global Impression of Improvement (CGI -I) at 
week 15; (4) change from baseline to week 15 in centrally -
read UHDRS -TMC; and (5) change from baseline to w eek 
15 in centrally -read UHDRS -TMD , regardless of whether or 
not dose reductio n, suspension, or discontinuation occurred, 
and regardless of treatment -related adverse events.
The primary estimand assesses the effectiveness in the 
reduction of choreiform movements in patients with DCP 
with predominant choreiform movement disorder, as 
evaluated by the central reviewers, focusing on the causal 
effects attributable to the IMP. The secondary estimands 
assess the effectiveness on patientsâ€™ ability to perform daily 
functions, the improvement in dyskinesia evaluated by the 
caregiver and the i nvestigator, and the reduction in chorea 
and dystonia evaluated by central reviewers, allwith a focus 
on the causal effects attributable to the IMP.The secondary estimands are the differences in means 
betw een TEV -50717 and placebo in the target patient 
population for (1) change from baseline to w eek 15 in 
centrally read MD -CRS part I total score ,(2) Caregiver 
Global Impression of Improvement (CaGI -I) at week 15 ,(3) 
Clinical Global Impression of Improvement (CGI -I) at w eek 
15,(4) change from baseline t o week 15 in centrally -read 
UHDRS -TMC ,and (5) change from baseline to w eek 15 in 
centrally -read UHDRS -TMD, regardless of whether or not 
dose reduction, suspension, or discontinuation occurred, and 
regardless of treatment -related adverse events.
The primar y estimand assesses the effectiveness in the 
reduction of choreiform movements in patients with DCP 
with predominant choreiform movement disorder, as 
evaluated by the central reviewers, focusing on the causal 
effects attributable to the IMP. The secondary estimands 
assess the effectiveness on patientsâ€™ ability to perform daily 
functions, the improvement in dyskinesia evaluated by the 
caregiver and the investigator, and the reduction in chorea 
and dystonia evaluated by central reviewers, all with a focus 
on the causal effects attributable to the IMP.Text revised to account for new 
key secondary endpoints
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
124Protocol text with changes shown New wording Reason/justification for change
3.1.General Study Design and Study Schematic Diagram
â€¦ the first dose increase mayshould be performed in an 
interval less than 5 days, only once, on day 3.â€¦ the first dose increase should be performed in an interval 
less than 5 days, only once, on day 3.Revised to match other instances 
in protocol
The follow ing was deleted:
When approximately 90 patients have completed the study 
(including follow up), an iDMC will perform an unblinded 
IA for futility and sample size re estimation based on 
centrally read MD CRS part II total score. Based on the 
results of the IA, the study may be s topped or the sample 
size may be kept as planned (approximately 185 total 
patients) or increased (up to approximately 230 total 
patients) (Section 9.7).Text deleted to account for the 
change in sample size and the 
removal of the second IA for 
sample size reassessment
There is a separate protocol will be issued for the open -label 
safety extension Study TV50717 -CNS -30081, as applicable.There is a separate protocol for the open -label safety 
extension Study TV50717 -CNS -30081.The open -label extension has been 
approved for use.  
Figure 1: Overall Study Schem atic Diagram
See new wording column Figure 1 has been revised as described below :
ï‚·Footnote w as edited to clarify dose increases 
should be performed after remote or in-clinic 
visits .Clarification
3.2. Planned Number of Patients and Regions
Approximately 18565patients are planned to be randomized 
to TEV -50717 versus placebo in a 2:1 ratio (approximately 
12443 in the TEV -50717 group; approximately 6122 in the 
placebo group) stratified by age at baseline (6 to <12 years; 
12 through 18 years) and region (US; non -US). The sample 
size will be re estimated in an interim analysis and may be 
adjusted up to a total of approximately 230 patients.Approximately 65patients are planned to be randomized to 
TEV -50717 versus placebo in a 2:1 ratio (approximately 43
in the TEV -50717 group; approximately 2 2in the placebo 
group) stratified by age at baseline (6 to <12 years; 12 
through 18 years) and region (US; non -US).Text revised to account for the 
change in sample size and the 
removal of the second interim 
analysis
This study is planned to be conducted in approximately 70
60investigational centers in North America, Asia, and 
Europe. The study is expected to start by end of 2018 and 
last until the fourth quarter of 2022.This study is planned to be conducted in approximately 60 
investigational centers in North America, Asia, and Europe. The expected end of the study 
changed to account for current 
pace of enrollment
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
125Protocol text with changes shown New wording Reason/justification for change
3.4. Stopping Rules for the Study
The follow ing was deleted:
When approximately 90 patients have completed the study 
(including follow up), an iDMC will perform an unblinded 
IA for futility and sample size re estimation based on the 
primary endpoint, the centrally read MD CRS part II total 
score. Based on the results of the IA, the study may be 
stopped for futility. For further details, see Section 9.Text revised to account for the 
change in sample size and the 
removal of the second interim 
analysis
Table 3: Study Procedures and Assessments
See new wording columnTable 3 has been revised as described below :
â€¢The time for the follow -up visits 16 and 17 w as clarified .
â€¢The new  endpoints (UHDRS -TMC and UHDRS -TMD ) 
were added .
â€¢For the efficacy endpoints, assessments were added for 
possible unscheduled visits.
â€¢For the telephone contact visits, â€œContact RTSMâ€ w as 
removed.
â€¢The footnotes were revised to make consistent with the 
changes to the table and the body of the protocol .Revised to clarif y and align the 
schedule of events and its 
corresponding footnotes against 
the updates included throughout 
the study design and body of the 
protocol
4.1. Patient Inclusion Criteria
11.In the investigatorâ€™s opinion, the patient and /or
caregiver have hasthe ability to understand the nature of 
the study and its procedures, and the patient is expected 
to complete the study as designed.11.In the investigatorâ€™s opinion, the patient and/or 
caregiver has the ability to understand the nature of the 
study and its procedures, and the patient is expected to 
complete the study as designed.Revised to clarify the caregiverâ€™s 
role in understanding the nature of 
the study.
4.3. Withdrawal Criteria and Procedures for the Patient
See new wording column 13.In patients who experience signs of suicidal ideation or 
behavior (Section 7.9), the investigator should consult 
with the medical monitor to determine whether the 
patient should continue in the study.Added to align with Section 7.9
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
126Protocol text with changes shown New wording Reason/justification for change
Table 4: Maximum Daily Dose of IMP During the Titration Period by Day and Weight Category at Baseline
See new wording column Table 4 has been revised as described below :
â€¢The first column for study visit w as changed from days 
to weeks.
â€¢The footnotes were revised to make con sistent with the 
changes to the table and the body of the protocol .Revised for clarity
5.1.1.2. Dose Modification and Dose Stratification
See new wording column All IMP adjustments are made only after a remote or in -
clinic visit; if the dose is escalated, the dose escalation will 
occur w ith the next morningâ€™s dose.Revised to match similar change 
in Administrative Letter #07
â€¢Dose increases may not occur more frequently than 
every 5 days, except for patients â‰¥40 kg/88 lbs. For 
patients â‰¥40 kg/88 lbs, the first dose increase mayshould
be performed in an interval less than 5 days, only once, 
on day 3.â€¢Dose increases may not occur more frequently than 
every 5 days, except for patients â‰¥40 kg/88 lbs. For 
patients â‰¥40 kg/88 lbs, the first dose increase should be 
performed in an interval less than 5 days, only once, on 
day 3.Revised for clarity
â€¢At an in -clinic visit, a Adose reduction, if required, 
should be made to the previously tolerated dose level. If 
more than 1 dose reduction is required for an adverse 
event, the m edical monitor should be notified.â€¢At an in -clinic visit, a dose reduction, if required, should 
be ma de to the previously tolerated dose level. If more 
than 1 dose reduction is required for an adverse 
event, the m edical monitor should be notified.Revised for clarity
â€¢During the titration period, the dose of IMP should be 
adjusted according to Table 4 t o identify a dose level that 
optimally reduces dyskinesia (as determined by the 
investigator, as indicated by a reduction in the CGI -I) 
and is well tolerated.  Dose adjustments should ONLY 
take place after telephone or in -clinic visit.â€¢During the titrati on period, the dose of IMP should be 
adjusted according to Table 4 to identify a dose level 
that optimally reduces dyskinesia (as determined by the 
investigator, as indicated by a reduction in the CGI -I) 
and is well tolerated. Dose adjustments should ONLY 
take place after telephone or in -clinic visit.Revised for clarity
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
127Protocol text with changes shown New wording Reason/justification for change
Table 4: Maximum Daily Dose of IMP During the Titration Period by Week and Weight Category at Baseline
See new wording column Table 4 has been revised as described below :
â€¢The title w aschanged from â€œby Dayâ€ to â€œby Weekâ€.
â€¢Study day column was changed from â€œStudy dayâ€ to 
â€œStudy time periodâ€, and the time periods w ere changed 
to weeks.
â€¢The footnotes were revised to make consistent with the 
changes to the table and the body of the proto col.Clarification
5.4. Treatm ent after the End of the Study
All patients will discontinue IMP at the week 15 visit and 
will return 1 week later for the EOS visit.  
 
Patients w ill not receive the evening IMP dose 
on this day.
 All patients will discontinue IMP at the w eek 15 visit and 
will return 1 week later for the EOS visit.  
 
atients w ill not receive the evening IMP 
dose on this day.Revised for clarity
Note: Patients can also roll over to the extension study 
within 2 to 4 w eeks after the week 15 visit but will be 
required to complete additional scales and tests as part of 
Study TV50717 -CNS- 30081. Patients will further be 
allow ed to roll over to Study TV50717 CNS 30081 betw een 
4 weeks and up to 6 months from the week 15 visit and will 
be subject to the full screening process. More details are 
presented in the TV50717 CNS 30081 pro tocol.Note: Patients can also roll over to the extension study 
within 2 to 4 w eeks after the week 15 visit but will be 
required to complete additional scales and tests as part of 
Study TV50717 -CNS- 30081.Text deleted to loosening 
restrictions regarding COVID -19
5.7. Procedures for Monitoring Patient Com pliance
See new wording column Based on pill counts at in -clinic visits, poor compliance 
with study drug intake (ie, <80%) or overdose (ie, >105%) 
is to be recorded as an important deviation and 
expeditiou sly reported to the medical monitor.Added to define compliance

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
128Protocol text with changes shown New wording Reason/justification for change
5.9. Randomization and Blinding
In addition, the sponsorâ€™s clinical personnel and all vendors 
(with the exception of the sponsorâ€™s clinical supply chain 
staff and RTSM vendor) w ill be blinded to the IMP identity 
until the database has been locked for analysis and the 
treatment assignments are revealed.In addition, the sponsorâ€™s clinical personnel and all vendors 
(with the exception of the sponsorâ€™s clinical supply chain 
staff and RTSM vendor) w ill be blinded to the IMP identity 
until the database has been locked for analysis and the 
treatment assignments are revealed.Clarification
The iDMC will perform oneanunblinded non -binding IA for 
futility , another unblinded IA for futility and sample size 
reassessment andwill monitor safety throughout the study 
based on unblinded data. The iDMC will perform an unblinded non -binding IA for 
futility and will monitor safety throughout the study based 
on unblinded data. Text revised to account fo r the 
change in sample size and the 
removal of the second interim 
analysis
5.10.3. Independent Data Monitoring Committee
The follow ing was deleted:
When approximately 90 patients have completed the study 
(including follow up), the iDMC will perform an unblinded 
IA for futility and sample size re estimation based on 
centrally read MD CRS part II total score. Based on current 
initial assumptions, the study may be stopped or the sample 
size may be kept as planned (approximately 185 total 
patients) or incre ased (up to approximately 230 total 
patients). The iDMC will also perform regular safety 
monitoring throughout the study.Text deleted to account for the 
change in sample size and the 
removal of the second interim 
analysis
6.2.Key Secondary Efficacy Mea sures
See new wording column 6.2.4. Unified Huntingtonâ€™s Disease Rating Scale- Total 
Maximal ChoreaNew  section added to account for 
the addition of a new key 
secondary endpoint
See new wording column 6.2.5.Unified Huntingtonâ€™s Disease Rating Scale- Total 
Maximal DystoniaNew  section added to account for 
the addition of a ne w key 
secondary endpoint
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
129Protocol text with changes shown New wording Reason/justification for change
6.2.4. Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Chorea
The follow ing text was moved from a later section to this 
new section: 
The UHDRS TMC is part of the UHDRS -TMS assessment 
and assesses the severity of chorea in the face, mouth, trunk, 
and the 4 extremities. The minimum score is 0 (absent) and 
the maximum score is 28 (marked/prolonged) (Huntington 
Study Group 1996).Text moved as this is the first 
mention of UHDRS -TMC rather 
than later 
See new wording column A central reading of the UHDRS -TMC w ill be performed at 
baseline and at w eeks 9, 12, 15/ET, and 16/EOS visits. The 
central rating will be done for all patients, based on the 
videos collected for the central rating of MD -CRS. Video 
review will be assessed periodically in a blinded manner 
(eg, visit and investigator site rating) by a central review 
board. Central reading results performed by the central 
raters w ill not be disclosed to the investigational site. 
Central reading details will be provided in a separate 
charter.Text added to account for the 
addition of the new endpoint
6.2.5. Unified Huntin gtonâ€™s Disease Rating Scale -Total Maxim al Dystonia
The follow ing text was moved from a later section to this 
new section: 
The UHDRS -Total Maximal Dystonia (TMD) is part of the 
UHDRS -TMS assessment and assesses the severity of 
dystonia in the trunk and the 4 extremities. The minimum 
score is 0 (absent) and the maximum score is 20 
(marked/prolonged) (Huntington Study Group 1996). When 
rating dystonia (question #11), buccal -oral-lingual and facial 
dystonia (blepharospasm, jaw  opening and closing) should 
beincluded in the assessment of the truncal region.Text moved as this is not the first 
mention of UHDRS -TMD rather 
than in the later section
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
130Protocol text with changes shown New wording Reason/justification for change
See new wording column A central reading of the UHDRS -TMD w ill be performed at 
baseline and at w eeks 9, 12, 15/ET, and 16/EOS visits. The 
central rating will be done for all patients, based on the 
videos collected for the central rating of MD -CRS. Video 
review will be assessed periodically in a blinded manner 
(eg, visit and investigator site rating) by a central review 
board. Central reading results performed by the central 
raters w ill not be disclosed to the investigational site. 
Central reading details will be provided in a separate 
charter.Text added to account for the 
addition of a new endpoint
6.3.Other E fficacy Measures
See new wording column 6.3.1. Movement Disorder -Childhood Rating Scale Part I 
and Part II Total ScoresNew  section added for 
clarification â€“the numbering for 
the rest of the subsections were 
increased by one but this change 
was not noted here.  
6.3.1. Movement Disorder -Childhood Rating Scale Part I and Part II Total Scores
See new wording column The MD -CRS part I and part II total scores w ill be 
evaluated by the investigator at baseline, week 9, w eek 12, 
week 15/ET, and w eek 16/EOS visits. See Section 6.1 and 
Section 6.2.1 for description of these rating scales.  New  text added for clarification
6.3.3. Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score
See new wording column The protocol refers to UHDRS -TMS as a physician -rated 
scale, but in certain instances, based on the experience of 
the rater, certain non -physicians may be approved to rate the 
UHDRS -TMS.Text added to clarify the role of 
physicians for this efficacy 
measure 
6.3.4.Unified Huntingtonâ€™s Disease Rating Scale -Total Maxim al Chorea
See new wording column The UHDRS -TMC is administered at baseline, w eek 9, 
week 12, and week 15/ET visits, and will be rated by the 
investigator.New  text added for clarification
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
131Protocol text with changes shown New wording Reason/justification for change
6.3.5. Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Dystonia
See new wording column The UHDRS -TMDis administered at baseline, w eek 9, 
week 12, and w eek 15/ET visits, and will be rated by the 
investigator.New  text added for clarification
7.2.1. Childrenâ€™s Columbia -Suicide Severity Rating Scale
See new wording column The childrenâ€™s C -SSRS questionnaire will be presented to 
patients â‰¥12 y ears of age at screening or 11 years of age at 
screening but will turn 12 years of age during the study.Clarification
7.2.4. Epworth Sleepiness Scale (for Children and Adolescents)
See new wording column For patients 6 to 12 years of age, the ESS will be completed 
by the caregiver. For patients â‰¥13 years of age, the ESS will 
be completed by the patient. Input from the caregiver is 
permitted.Clarification
7.8. Electrocardiography
See new wording column The ECG types are defined as follows:
â€¢A â€œstandard ECGâ€ is a â€œstandardâ€ 10 -second 12 -lead 
ECG.
â€¢A â€œsummary ECGâ€ is a continuously recorded ECG of 
longer than 10 seconds. For a â€œsummary ECG,â€ the 
minimal recommended duration is 2 minutes or longer, 
and th e preferred duration is 5 minutes (as it provides the 
most robust result). If a â€œsummary ECGâ€ is less than 2 
minutes, data will still be captured and analyzed to the 
extent possible.
The investigator should review the ECG at screening to 
determine patient eligibility for the study and subsequent 
ECGs for the patientâ€™s continuation in the study. All 
ECGs should be review ed by  the investigator for any 
clinically significant findings during the visit and before 
the patient leaves the clinic. A qualified physi cian at a 
central diagnostic center will be interpreting the ECG.Clarification
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
132Protocol text with changes shown New wording Reason/justification for change
See new wording column The criteria for an abnormal post -baseline QTcF are a value 
>500 msec or change from screening >60 m sec. If one of 
these criteria is met, the investigator must further evaluate 
the QTcF as follows: 
â€¢If a standard ECG is abnormal and meets the above 
protocol criteria, 
oA 5-minute summary ECG recording should be 
performed at the research site, and a repeat standard 
ECG is not required. The site should follow the 
process to have these ECGs read by Spaulding. 
oIf a 5 -minute summary ECG cannot be performed 
(for instance, if patient is evaluated at a facility other 
than the research site, and the summ ary ECG is not 
available), the investigator should obtain 2 repeat 
standard ECGs and determine the average of these 3 
post-screening QTcF values. The site should follow  
the process to have these ECGs read by Spaulding.  
â€¢The investigator should then comp are the post -screening 
QTcF values to the pre -treatment QTcF values at 
screening. As noted above, the post -screening QTcF 
values will use either the average QTcF from the 3 post-
screening standard ECGs or the QTcF from the summary 
ECG. The IMP must be stop ped for any confirmed post -
baseline QTcF average value >500 msec or average 
increase from screening >60 msec.Clarification
Note: Abnormal ECG results at w eek 3 and w eek 7 or at an 
unscheduled visit may result in patient withdrawal from the 
study as detailed in Section 4.3.Note: Abnormal ECG results at w eek 3 and w eek 7 or at an 
unscheduled visit may result in patient withdrawal from the 
study as detailed in Section 4.3.Clarification
9.1. Sample Size and Power Considerations
See new wording column At the time of writing Amendment 05, the initially planned 
sample size has been reduced to approximately 65 patients 
randomized to TEV -50717 versus placebo in a 2:1 ratio 
(approximately 43 in the TEV -50717 group; approximately 
22 in the placebo group).Text added to explain for the 
change in sample size due to 
study feasibility 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
133Protocol text with changes shown New wording Reason/justification for change
The follow ing was deleted:
The sample size may be adjusted in the IA to a maximal 
number of approximately 230 patients. The maximal sample 
size was chosen based on practical considerations, given the 
limited population of patients with DCP. 
Simulations for the study, including the IA for futility and 
sample size re estimation, and the corresponding statistical 
methods to control the Type I error rate w ere performed. 
The overall pow er was approximately 83% under the initial 
assumptions and the overall Type I error rate of less than 
0.025 for the primary analysis was confirmed. Further 
simulations were performed to evaluate the pow er and 
additional operating characteristics of the study under 
different assumptions of the effect size.Text deleted to account for the 
change in sample si ze and the 
removal of the second interim 
analysis
9.3.1. Handling Withdrawals and Missing Data
For all other cases, and for cases classified as above, 
classification as MAR/MNAR w ill be done/revisited in a 
blinded manner on a case -by-case basis prior to the IA for 
futility , the IA for futility and sample size reassessment and 
prior to database lock for final analysis.For all other cases, and for cases classified as above, 
classification as MAR/MNAR w ill be done/revisited in a 
blinded manner on a case -by-case basis prior to the IA for 
futility and prior to database lock for final analysis.Text revised to account for the 
removal of the second interim 
analysis
9.4.1. Patient Disposition
Data from patients screened; patients screened but not 
randomized (and reason not randomized); patients who are 
randomized; patients randomized but not treated; patients re -
randomized; patients in the ITT, mITT, safety, and PP 
analysis sets; patients who c omplete the treatment period; 
patients who complete the EOS visit; patients who intend to 
enroll into the open label extension study; patients who do 
not intend to be enrolled into the open label extension study; 
and patients who withdraw  from the study wi ll be 
summarized using descriptive statistics. Data from patients 
who withdraw  from  the study will also be summarized by 
reason for withdraw al using descriptive statistics.Data from patients screened; patients screened but not 
randomized (and reason not r andom ized); patients who are 
randomized; patients randomized but not treated; patients 
re-randomized; patients in the ITT, mITT, safety, and PP 
analysis sets; patients who complete the treatment period; 
patients who complete the EOS visit; and patients who
withdraw from the study will be summarized using 
descriptive statistics. Data from patients who withdraw from 
the study will also be summarized by reason for w ithdrawal 
using descriptive statistics.Text deleted; these analyses will 
not be done
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
134Protocol text with changes shown New wording Reason/justification for change
9.5.1. Primary Estimand
The primary estimand assesses the effectiveness in the 
reduction of choreiform movements in patients with DCP 
with predominant choreiform movement disorder, evaluated 
by the central reviewers, focusing on the causal effects 
attributable to the IMP.The primary estimand assesses the effectiveness in the 
reduction of choreiform movements in patients with DCP 
with predominant choreiform movement disorder, evaluated 
by the central reviewers, focusi ng on the causal effects 
attributable to the IMP.Text added to account for new 
key secondary endpoints
9.5.2. Prim ary Endpoint
See new wording column 9.5.2.3. Minimal Clinically Important Difference and 
Minimal Clinically Important ChangeNew  section added to account for 
new analyses
9.5.2.3. Minim al Clinically Important Difference and Minimal Clinically Important Change
See new wording column To support the evaluation of the clinical impact of the 
change in dyskinesia as assessed by the primary endpoint, 
the minimal clinically important difference (MCID) and the 
minimal clinically important change (MCIC) will be 
calculated. The MCID and MCIC an alyses will be 
performed based on 3 global impression of improvement 
anchors: caregiver (CaGI -I), investigator (CGI -I), and 
patient (PGI -I). 
The MCID and MCIC analysis will be performed separately 
for each anchor (CaGI -I, CGI -I, and PGI -I) yielding a set of 
thresholds, each reflecting the perspective of the caregiver, 
the clinician, or the patient, depending on the anchor used.
The MCID and MCIC analyses will be based on the 
methods described by Hauser et al 2014 and Hauser et al 
2022. Details will be prov ided in the statistical analysis 
plan.New  analyses
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
135Protocol text with changes shown New wording Reason/justification for change
9.5.3 Secondary Estimands
The secondary estimands are the differences in means 
betw een TEV -50717 and placebo in the target patient 
population for (1) change from baseline to w eek 15 in 
centrally read MD -CRS part I total score; (2) CaGI -I at 
week 15; (3) CGI -I at w eek 15; (4) change from baseline to 
week 15 in centrally read UHDRS -TMC; (5) change from 
baseline to week 15 in centrally read UHDRS -TMD, 
regardless of whether or not dose reduction, suspension, or 
discontinuation occurred, and regardless of treatment -related 
adverse events .
The secondary estimands assess the effectiveness on 
patientsâ€™ ability to perform daily functions, the improvement 
in dyskinesia evaluated by the caregiver and the 
investigator, and the reduction in chorea and dystonia 
evaluated by the central reviewers, allwith a focus on the 
causal effects attributable to the IMP.  The secondary estimands are the differences in means 
betw een TEV -50717 and placebo in the target patient 
population for (1) change from baseline to w eek 15 in 
centrally read MD -CRS part I to tal score, (2) CaGI -I at 
week 15, (3) CGI -I at w eek 15, (4) change from baseline to 
week 15 in centrally read UHDRS -TMC, (5) change from 
baseline to week 15 in centrally read UHDRS -TMD, 
regardless of whether or not dose reduction, suspension, or 
discontinu ation occurred, and regardless of treatment -
related adverse events.
The secondary estimands assess the effectiveness on 
patientsâ€™ ability to perform daily functions, the 
improvement in dyskinesia evaluated by the caregiver and 
the investigator, and the red uction in chorea and dystonia 
evaluated by the central reviewers, all with a focus on the 
causal effects attributable to the IMP.  Text updated to account for new 
key secondary endpoints
9.5.4. Key Secondary Endpoints
See new wording column 4.Change from baseline to week 15 in centrally read 
UHDRS -TMC (TEV -50717 versus placebo)
5.Change from baseline to week 15 in centrally read 
UHDRS -TMD (TEV -50717 versus placebo)New  key secondary endpoints
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
136Protocol text with changes shown New wording Reason/justification for change
9.5.4.1. Secondary Efficacy Analysis
See new wording column 4.UHDRS -TMC (centrally read) change from baseline to 
week 15 w ill be analyzed using an MMRM model in the 
same fashion as the primary analysis, with the exception 
that the baseline value of UHDRS -TMC (centrally read) 
will be included as the covariat e instead of MD -CRS 
part II total score.
5.UHDRS -TMD (centrally read) change from baseline to 
week 15 w ill be analyzed using an MMRM model in the 
same fashion as the primary analysis, with the exception 
that the baseline value of UHDRS -TMD (centrally read ) 
will be included as the covariate instead of MD -CRS 
part II total score.New  key secondary analyses for 
the new endpoints
9.6.Multiple Com parisons and Multiplicity
If the primary endpoint is statistically significant (p -value 
â‰¤0.025), the 5key secondary hypotheses will be tested using 
a hierarchical approach at the 1 -sided significance level of 
Î±=0.025, in the following order: (1) MD- CRS part I total 
score, (2) CaGI -I,and(3) CGI -I, (4) UHDRS -TMC 
(centrally read), and (5) UHDRS -TMD (centrally read).If the primary endpoint is statistically significant (p -value 
â‰¤0.025), the 5 key secondary hypotheses will be tested 
using a hierarchical approach at the 1 -sided significance 
level of Î±=0.025, in the following order: (1) MD- CRS part I 
total score, (2) CaGI -I, (3) CGI -I, (4) UHDRS -TMC 
(centrally read), and (5) UHDRS -TMD (centrally read).New  key secondary analyses for 
the new endpoints
9.7. Planned Interim  Analysis
This is the first study to evaluate the efficacy of TEV -50717 
to reduce the severity of dyskinetic involuntary movements 
associated with CP in pediatric patients with DCP. 
Moreover, limited data are available on the effect of active 
treatment on MD -CRS par t II total score in DCP that can 
support sample size calculations. Therefore, anIAsfor 
futility and sample size re estimation are isplanned.
Based on current initial assumptions, 185 patients is the 
sample size required to obtain a statistically signifi cant 
result in the primary analysis with a pow er of approximately 
90% (see Section 9.1).This is the first study to evaluate the efficacy of TEV -50717 
to reduce the severity of dyskinetic involuntary movements 
associated with CP in pediatric patients with DCP. 
Moreover, limited data are available on the effect of active 
treatment on MD -CRS part II total score in DCP that can 
support sample size calculations. Therefore, an IA for 
futility is planned.Text revised to account for the 
change in sample size and the 
removal of the second interim 
analysis
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
137Protocol text with changes shown New wording Reason/justification for change
The follow ing text was deleted:
When approximately 90 patients have completed the study 
(including follow up), an iDMC will perform an unblinded 
IA for futility and sample size re estimation based on 
centrally re ad MD CRS part II total score. 
The sample size re estimation will be performed using the 
prom ising zone approach (Mehta and Pocock 2011). At the 
IA, the conditional power for the initially planned sample 
size of approximately 185 patients will be estimate d given 
the observed data, and the sample size may be increased up 
to a total maximum of approximately 230 patients.
The Type I error rate w ill be controlled using the Chen, 
DeMets, and Lan method (Chen et al 2004); hence, Î±=0.025 
will be used for the prim ary analysis.Text deleted to account for the 
change in sample size and the 
removal of the second interim 
analysis
The rules for futility recommendation in the first IA, and the 
futility and sample size re estimation in the second IA (eg, 
definition of t he promising zone) will be included in the 
iDMC charter and the SAP. The rules for futility recommendation (eg, definition of the 
prom ising zone) will be included in the iDMC charter and 
the SAP. Text revised to account for the 
change in sample size and the 
removal of the second interim 
analysis
9.8.Safety Endpoints and Analysis
The frequency and severity of suicidal ideation or behavior 
according to the childrenâ€™s C -SSRS questionnaire will be 
presented for all patients aged â‰¥12 years by visit and by 
treatment group.The frequency and severity of suicidal ideation or behavior 
according to the childrenâ€™s C -SSRS questionnaire will be 
presented by visit and by treatment group.Clarification
9.10. Pharm acokinetic/Pharmacodynamic Analysis
 
 
 
 
  
 
 
 
  
  

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
138Protocol text with changes shown New wording Reason/justification for change
15. REFERENCES
The follow ing was deleted:
Bethoux F, Fatemi A, Fowler E, Marciniak C, Mayadev A, 
Waksman J, et al. Safety, tolerability, and sensorimotor 
effects of extended release dalfampridine in adults with 
cerebral palsy: a pilot study. Clin Ther 2017;39(2):337 46.
Chen YH, DeMets DL, Lan KK. Increasing the sample size 
when the unblind ed interim result is promising. Stat Med 
2004;23(7):1023 38.
ClinicalTrials.gov. National Library of Medicine (US). 
Identifier [STUDY_ID_REMOVED], A Safety, Efficacy and 
Tolerability Study of Sativex for the Treatment of Spasticity 
in Children Aged 8 to 18 Years; 2013 Jul 12 [cited 2017 
May 17]; Available at: 
https://clinicaltrials.gov/ct2/show /[STUDY_ID_REMOVED]
Mehta CR, Pocock SJ. Adaptive increase in sample size 
when interim results are promising: a practical guide with 
examples. Stat Med 2011;30(28):3267 84.Refere nces deleted to account for 
the change in sample size and the 
removal of the second interim 
analysis as well changes in the 
introduction
See new wording column Hauser RA, Barkay H, Wilhelm A, Wieman M, Savola J -M, 
Gordon MF. Minimal clinically important change in 
abnormal involuntary movement scale score in tardive 
dyskinesia as assessed in pivotal trials of 
deutetrabenazine. Parkinsonism Related Disorders. In 
Press.
Hauser RA, Gordon MF, Mizuno Y, Poew e W, Barone P, 
Schapira AH, et al. Minimal clinically important 
difference in Parkinsonâ€™s disease as assessed in pivotal 
trials of pramipexole extended release. Parkinsons Dis. 
2014;2014:467131.New  key secondary analyses for 
the new endpoints
AUSTEDOÂ® (deutetrabenazine) tablets (US prescribing 
information). Teva Pharmaceuticals USA, Inc; 2019 2021 . 
Available at: https://austedo.com/hd/pi.AUSTEDOÂ® (deutetrabenazine) tablets (US prescribing 
information). Teva Pharm aceuticals USA, Inc; 2021. 
Available at: https://austedo.com/hd/pi.New  USPI since last amendment
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
139Protocol text with changes shown New wording Reason/justification for change
APPENDIX A. CLINICAL LABORATORIES AND OTHER DEPARTMENTS AND INSTITUTIONS
Row: Sponsorâ€™s Authorized Representative
Column:
Teva Branded Pharmaceutical Industries,  
 
roducts R&D, Inc
Cell: Row: Sponsorâ€™s Authorized Representative
Column: 
Teva Branded Pharmaceutical Products R&D, Inc
Cell: Administrative change
Row: Sponsorâ€™s Representative of Global Patient Safety and 
Pharm acovigilance
Column:  
Teva Pharmaceutical Industries,  
Tel: 
Cell: Row: Sponsorâ€™s Representative of Global Patient Safety and 
Pharm acovigilance
Column:  
Teva Pharmaceutical Industries,  
Tel:  
Cell: Administrative change
Row:  Randomization and Trial Supply Management 
(RTSM) vendor
Column:  
PAREXEL International Corp. Calyx
195 West Street 4 Canal Street
Waltham, MA 02451 Nottingham, United Kingdom, NG1 
7EH
Tel:Row:  Randomization and Trial Supply Management 
(RTSM) vendor
Column:  
Calyx
4 Canal Street
Nottingham, United Kingdom, NG1 7EH
Tel: Administrative change

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
140Protocol text with changes shown New wording Reason/justification for change
APPENDIX B. INDEPENDENT DATA MONITORING COMMITTEE
The follow ing was deleted:
When approximately 90 patients have completed the study 
(including follow up), an iDMC will perform an unblinded 
IA for futility and sample size re estimation based on 
centrally read MD CRS part II. Based o n the results of the 
IA, the study may be stopped or the sample size may be kept 
as planned (approximately 185 total patients) or increased 
(up to approximately 230 total patients).Text deleted to account for the 
change in sample size and the 
removal of the second interim 
analysis
APPENDIX C. STUDY PROCEDURES AND ASSESSMENTS BY VISIT
3.Procedures During Administration of Investigational Medicinal Product (Double -Blind Treatment Period Inclusive of Titration Period)
a. Week 1 (day 7+1 day), week 2 (day 14Â±3 days total from baseline), week 4 (day 28Â±3 days total from  baseline), week 5 (day 35Â±3 days total from  
baseline), and week 6 (day 42Â±3 days total from  baseline)
The follow ing was deleted:
â€¢contact RTSMStudy procedures and assessments 
have been updated for consistency 
with changes made to the protocol 
body and Table 3.
This justification applies to all 
changes indicated within 
Appendix C.
4.Procedures During Administration of Investigational Medicinal Product (Maintenance Period)
a.Week 9 (day 63Â±3 days total from  baseline) and week 12 (day 84Â±3 days total from  baseline)
See new wording column â€¢urine pregnancy test (week 12 only)
5.Follow -Up (Weeks 16 and 17)
a.Week 16/End of Study follow- up visit ( day 112 
1weekÂ±2 day s total from the week 15 visit baseline)a.Week 16/End of Study follow- up visit (1 weekÂ±2 days 
total from the week 15/ET visit)
b.Week 17 follow -up visit ( day 1192 weeksÂ±2 days total 
from week 15 visit baseline, or 2 w eeks after ET visit )b.Week 17 follow -up visit (2 weeksÂ±2 days total from 
week 15 visit, or 2 w eeks after ET visit)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
141Protocol text with changes shown New wording Reason/justification for change
6. Unscheduled Visits
Procedures performed during unscheduled visits may
include any of the following:Procedures performed during unscheduled visits may 
include any of the following:
See new wording column â€¢MD-CRS part I video recording and investigator 
assessment
â€¢MD-CRS part II video recording and investigator 
assessment
â€¢CaGI -I (global, caregiver rated)
â€¢CGI-I and CGI -S (global, physician rated)
â€¢PEDI- CAT (ADL, caregiver completed, 
content -balanced version)
â€¢PedsQL (QoL, patient/caregiver)
â€¢PGI- I (global, patient/caregiver)
â€¢UHDRS -TMS
APPENDIX H. LIST OF ALLOWED AND PROHIBITED MEDICATIONS
Table 10: Allowed Medications
Row:  Benzodiazepines, trihexyphenidyl, â€¦
Column:  Condition
The follow ing text was deleted:
Primary use  must not be for dyskinesia choreaâ€¦Clarification
APPENDIX M. MANAGEMENT OF STUDY ACTIVITIES DURING COVID -19
The changes specified in this appendix will be effective for 
the duration of the COVID -19 pandemic when . Once the 
situation at specific sites/countries will allow returning to 
regular study activities, this appendix will be comevoid for 
those country/sites, except in the case of COVID -19 
resur gence or emergence of another crisis affecting normal 
per-protocol conduct of the study.  The changes specified in this appendix will be effective for 
the duration of the COVID -19 pandemic. Once the situation 
at specific sites/countries will allow returni ng to regular 
study activities, this appendix will become void for those 
country/sites, except in the case of COVID -19 resurgence or 
emergence of another crisis affecting normal per -protocol 
conduct of the study.  Text revised due to the ongoing, 
changing nature of the COVID- 19 
pandemic
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
14216.2. Administrative Letter 07 Dated 05 May 2021

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
143

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
144

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
14516.3. Amendment 04 Dated 09 March 2021
The reasons for this amendment are to clarify  some of the inclusion/exclusion criteria, the 
addition of an IA for futility , to clarify  the collection of additional blood samples due to 
discontinuation due to adverse events, and to clar ify the manner in which patients will be 
enrolled into the open -label extension Study TV50717 -CNS -30081. 
All major changes to the protocol body  are listed below in the table and are reflected in the 
synopsis, as applicable. Minor editorial changes (ty pos, punctuation, etc) have been made to the 
protocol (and protocol s ynopsis, as appropriate).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
146Protocol t ext with changes shown New wording Reason/justification for change
1.1. Introduction
Prem aturity is the most common cause of CP, but other 
causes include stroke, hypoxic ischemic injury, infection, 
andbrain malformation, and genetic abnormalities (CDC 
Causes and Risk Factors of Cerebral Palsy 2018 ; NINDS 
Cerebral Palsy: Hope Through Research 2019 ).Prem aturity is the most common cause of CP, but other 
causes include stroke, hypoxic ischemic injury, infection, 
brain malformation, and genetic abnormalitie s (CDC Causes 
and Risk Factors of Cerebral Palsy 2018; NINDS Cerebral 
Palsy: Hope Through Research 2019).Added one of the causes of CP 
and added the NINDS reference to 
support this addition.
Dyskinesia in cerebral palsy (DCP) is a hyperkinetic 
movement disorder form of CP characterized by abnormal 
involuntary movements of the dystonic and choreiform 
types in approximately 6% to 15% of patients with CP. Dyskinesia in cerebral palsy (DCP) is a form of CP 
characterized by abnormal involuntary movements of the 
dystonic and choreiform types in approximately 6% to 15% 
of patients with CP. Clarified the form of DCP
1.2.2. Clinical Studies
The clinical development plan for TEV -50717 to date 
includes the following:
â€¢Nine Thirteen completed Phase 1 studies in healthy adult 
volunteers
â€¢Two ongoing completed pivotal studies in patients with 
TS with clinical conduct and analysis concluded and 
clinical study report (CSR) finalization pending
â€¢One terminated Phase 3 long -term safety st udy in 
patients with TS with analysis of results ongoingThe clinical development plan for TEV -50717 to date 
includes the following:
â€¢Thirteen completed Phase 1 studies in healthy adult 
volunteers
â€¢Two com pleted pivotal studies in patients with TS w ith 
clinical conduct and analysis concluded and clinical 
study report (CSR) finalization pending
â€¢One terminated Phase 3 long -term safety study in 
patients with TS with analysis of results ongoingUpdated the status of the 
TEV -50717 studies that have been 
cond ucted/completed since the 
last amendment.
1.2.2.1. Clinical Pharm acology Studies
Nine Thirteen Phase 1 clinical pharmacology studies were 
conducted in healthy adult volunteers.Thirteen Phase 1 clinical pharmacology studies were 
conducted in healthy adult volunteers.Updated the status of the 
TEV -50717 studies that have been 
conducted/completed since the 
last amendment.
1.2.2.2. Clinical Safety and Efficacy Studies
See new wording column Studies TV50717 -CNS- 30046 and TV50717 -CNS -30060 
evaluated children and adolescent patients with tics 
associated with TS. Neither study met the primary efficacy 
endpoint. In both studies, TEV -50717 w as generally safe 
and w ell tolerated. No deaths occurred i n either study. One 
patient had 2 serious adverse events. There w ere no trends 
in changes from baseline in serum laboratory, vital signs, Text added for safety results of 
recently completed TS studies
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
147Protocol t ext with changes shown New wording Reason/justification for change
ECG, and physical and neurological parameters. There w as 
no evidence of a new safety signal in pediatric patients with
TS treated w ith TEV -50717 in comparison to the known 
safety profile of this drug in adult patients with HD or TD.
2.1.Prim ary and Secondary Study Objectives and Endpoints (Other sections af fected by anyone of these changes: 9.5.5)
See new wording column The follow ing were added as other efficacy measures and 
endpoints:
â€¢MD-CRS part I total score (general assessment, 
physician rated)
â€¢MD-CRS part II total score (general assessment, 
physician rated)Updated endpoints are in the 
Statistical Analysis Plan; added to 
the protocol for consistency.
â€¢UHDRS -TMS (physician rated)
â€¢UHDRS -TMC (physician rated)
â€¢UHDRS -TMD (physician rated)â€¢UHDRS -TMS (physician rated)
â€¢UHDRS -TMC (physician rated)
â€¢UHDRS -TMD (physician rated)Clarified these scales are to be 
rated by the physician
3.1.General Study Design and Study Schematic Diagram
For patients who are minors, the caregiver is typically a 
parent or legal guardian a legally accepted representative . In 
some countries, an adult (such as grandparent or nurse) can 
be appointed by the parent or legal guardian legally accepted 
representative (as per local regulations and laws) and w ould 
take over this responsibility as a caregiver. The pare nt or 
legal guardian legally accepted representative only has to 
sign the parent/ legal guardian legally accepted 
representative inform ed consent form (ICF) and not the 
caregiver ICF.
For adult patients, a caregiver must be appointed by the 
patient; this c an be the parent, a legal guardian legally 
accepted representative , or other adult, as appropriate and 
according to local laws and regulations.
For patients who are minors, certain responsibilities in the 
protocol can only be completed by the parent/ legal guardian 
legally accepted representative , ie, informed consent, 
withdrawal of consent, requests for discontinuation of the 
IMP, or w ithdrawal from the study for any reason. To For patients who are minors, the caregiver is typically a 
parent or a legally accepted representative. In some 
countries, an adult (such as g randparent or nurse) can be 
appointed by the parent or legally accepted representative 
(as per local regulations and laws) and w ould take over this 
responsibility as a caregiver. The parent or legally accepted 
representative only has to sign the parent/leg ally accepted 
representative informed consent form (ICF) and not the 
caregiver ICF.
For adult patients, a caregiver must be appointed by the 
patient; this can be the parent, a legally accepted 
representative, or other adult, as appropriate and according 
tolocal law s and regulations.
For patients who are minors, certain responsibilities in the 
protocol can only be completed by the parent/legally 
accepted representative, ie, informed consent, withdrawal of 
consent, requests for discontinuation of the IMP, or
withdrawal from the study for any reason. To further clarify, 
the caregiver is not allow ed to m ake decisions on the childâ€™s Clarified one of the terms for 
caregiver for patients who are 
minors
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
148Protocol t ext with changes shown New wording Reason/justification for change
further clarify, the caregiver is not allow ed to make 
decisions on thechildâ€™s h ealth or where â€œparent/ legal 
guardian legally accepted representative â€ is specifically 
indicated in the protocol.health or where â€œparent/legally accepted representativeâ€ is 
specifically indicated in the protocol.
IMP w ill be titrated during the double- blind treatment period 
starting with 6 mg of TEV -50717 or matching placebo IMP 
in the morning of day s2 and 3 . Patients with a in the highest
body weight group ( â‰¥40 kg/88 lbs )will further dose in the
start an evening administration from starting on day 3 and 
for the remainder of the first week.IMP w ill be titrated during the double- blind treatment 
period starting with 6 mg of TEV- 50717 or matching 
placebo IMP in the morning o f day 2. Patients in the highest 
body weight group ( â‰¥40 kg/88 lbs) w ill start an evening 
administration from day 3 and for the remainder of the first 
week.Clarified when the dose may be 
increased for patients in the 
highest body weight group
After week 1,Dose increases may not occur more frequently 
than every 5 days , except for patients â‰¥40 kg/88 lbs. For 
patients â‰¥40 kg/88 lbs, the first dose increase may be 
performed in an interval less than 5 days, only once, on 
day3.Dose increases may not occur mor e frequently than every 
5days, except for patients â‰¥40 kg/88 lbs. For patients 
â‰¥40kg/88 lbs, the first dose increase may be performed in 
an interval less than 5 days, only once, on day 3.Clarified when the dose may be 
increased for patients in the 
highe st body weight group
Washout period and follow -up: â€¦
At the week 16 visit, patients may choose to enter 
Study TV50717 -CNS- 30081 (on that day) or up to 1 w eek 
later (2 weeks from the week 15 visit) . Patients who 
complete treatment ,but choose not to participate in the 
open -label safety extension Study TV50717 -CNS -30081 
any time before w eek17 of Study TV50717 -CNS -30080 
will be contacted for a safety evaluation call occurring 
2weeks after their last dose of IMP. Additional details f or 
patients to enter Study TV50717 -CNS -30081 are provided 
in the TV50717 -CNS- 30081 protocol.Washout period and follow -up: â€¦
At the week 16 visit, patients may choose to enter 
Study TV50717 -CNS- 30081 (on that day) or up to 1 w eek 
later (2 weeks from the we ek 15 visit). Patients who 
complete treatment but choose not to participate in the 
open -label safety extension Study TV50717 -CNS -30081 
any time before w eek17 of Study TV50717 -CNS -30080 
will be contacted for a safety evaluation call occurring 
2weeks after their last dose of IMP. Additional details for 
patients to enter Study TV50717 -CNS -30081 are provided 
in the TV50717 -CNS- 30081 protocol.Clarified the timing of when a 
patient can enter Study TV50717 -
CNS -30081
See new wording column When approximately 50 patients have completed the study 
(including follow -up), an independent Data Monitoring 
Committee (iDMC) will perform an unblinded non -binding 
interim analysis (IA) for futility based on centrally read 
MD-CRS part II total score. Text added for the addit ion of the 
second interim analysis
When approximately 90 patients have completed the study 
(including follow -up), an iDMC will perform an unblinded 
IAfor futility and sample size re- estimation based on 
centrally read MD -CRS part II total score.When approximately 90 patients have completed the study 
(including follow -up), an iDMC will perform an unblinded 
IA for futility and sample size re -estimation based on 
centrally read MD -CRS part II total score.Text updated to account for the 
second interim ana lysis
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
149Protocol t ext with changes shown New wording Reason/justification for change
An iDMC charter will be developed for the IA s, and the 
procedures to ensure the integrity of the study will be 
provided in the charter.An iDMC charter will be developed for the IAs, and the 
procedures to ensure the integrity of the study will be 
provided in the charter.Text updated to account for the 
second interim analysis
At the time of informed consent, the parent/ legal guardian 
legally accepted representative will beâ€¦At the time of informed consent, the parent/legally accepted 
representative will beâ€¦Clarified one of the terms for 
caregiver for patients who are 
minors
See new wording column Patients who screen fail or terminate early from the study 
due to emergency circumstances (such as coronavirus 
disease 2019 [COVID -19]) may be allow ed to re -screen/re -
enter (respectively) the study at a later date, depending on 
the circumstances. Each case should be referred to the 
medical monitor and approved in advance.Text added to allow  patients to 
re-enter study.
3.4. Stopping Rules for the Study and Section 5.10.3 Independent Data Monitoring Committee
See new wording column When approximately 50 patients have completed the study 
(including follow -up), an iDMC will perform an unblinded 
non-binding IA for futility based on the primary endpoint, 
the ce ntrally read MD -CRS part II total score. Based on the 
results of the IA, the study may be stopped for futility.Text added for the addition of the 
second interim analysis
Table 3: Study Procedures and Assessments
See new wording columnTable 3 has been revised as described below :
â€¢The visit window  for day 7 (week 1) w as changed from 
Â±1 day to +1 day and a ne w visit window  for day 14 
(week 2) w as added
â€¢The visit window  for the Titration and Maintenance 
Periods w as revised to include â‰¥5 days from last d ose 
change
â€¢  
 
â€¢For Î²-HCG test, the assessment at week 9 (day 63) w as 
removed
â€¢An assessment for Contact RTS M was added 
â€¢The footnotes were revised to make consistent with the Revised to clarify and align the 
schedule of events and its 
corresponding footnotes against 
the updates included throughout 
the study design and body of the 
protocol

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
150Protocol t ext with changes shown New wording Reason/justification for change
changes to the table and the body of the protocol
4.1.Patient Inclusion Criteria
12.For a patient who is a minor, the parent(s)/ legal 
guardian legally accepted representative (s) provide 
written informed consent, and the patient provides assent 
(in accordance w ith local regulations). Adult patients 
provide their ow n written informed consent (in 
accordance w ith local regulations) and the legally 
acceptable representative will si gn, if needed .
In this study, eligible patients are patients with 
dyskinetic CP who may have some degree of mental, 
motor, and/or communication (eg, speech, w riting, etc) 
limitations or disabilities. The patient may not be able to 
read the assent/consent f orm. Som e patients may only be 
able to provide a limited assent/consent (for instance, by 
verbalizations or gestures). The investigator w ill 
determine the suitability of enrolling such patients in this 
study and will follow the local regulation to obtain t he 
relevant assent/consent. 12.For a patient who is a minor, the parent(s)/legally 
accepted representative(s) provide w ritten informed 
consent, and the patient provides assent (in accordance 
with local regulations). Adult patients provide their own 
written informed consent (in accordance w ith local 
regulations) and the legally acceptable representative 
will sign, if needed.
In this study, eligible patients are patients with 
dyskinetic CP who may have some degree of mental, 
motor, and/or communication (eg, speech, w riting, etc) 
limitations or disabilities. The patient may not be able to 
read the assent/consent form. Some patients may only 
be able to provide a limited assent/consent (for instance, 
by verbalizations or gestures). The investigator will 
determine the suitability of enrolling such patients in 
this study and will follow the local regulation to obtain 
the relevant assent/consent. Text added to provide additional 
guidance in consideration of 
exclusion crtierion â€œiâ€
13.Caregivers provide w ritten informed consent after being 
assigned the role by an adult patient, or if this role is 
delegated by the parent/ legal guardian legally accepted 
representative (s) of a patient who is a minor.13.Caregivers provide w ritten informed consent after being 
assigned the role by an adult patient, or if this role is 
delegated by the parent/legally accepted representative 
of a patient who is a minor.Clarified one of the terms for 
caregiver for patients who are 
minors
4.2.Patient Exclusion Criteria
2.Patient has clinically significant depression at screening 
or baseline. 
-Note: Patients receiving antidepressant therapy may 
be enrolled if on a stable dose for at least 6 w eeks 
before screening and anticipated to remain stable 
(dose and frequency) withi n the study duration .2.Patient has clinically significant depression at screening 
or baseline. 
-Note: Patients receiving antidepressant therapy may 
be enrolled if on a stable dose for at least 6 w eeks 
before screening and anticipated to remain stable 
(dose and frequency) within the study duration.Clarified any antidepressant 
therapy received by the patient 
must remain stable throughout the 
study
3.Patient has a history of suicidal intent or related 
behaviors based on medical or psychiatric history or the 
C-SSRS within 2 years of screening:3.Patient has a history of suicidal intent or related 
behaviors based on medical or psychiatric history or the 
C-SSRS within 2 years of screening:Clarified how  to assess t he 
exclusion criterion
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
151Protocol t ext with changes shown New wording Reason/justification for change
4.Patient has a history of a previous actual, interrupted, or 
aborted suicide attempt based on medical or psychiatric 
history or the C -SSRS .4.Patient has a history of a previous actual, interrupted, or 
aborted suicide attempt bas ed on medical or psychiatric 
history or the C -SSRS.Clarified how  to assess the 
exclusion criterion
Exclusion criteria #6 w as deleted. Upon further consideration of 
exclusion criterion #6, it w as 
decided to remove the criteria 
surrounding BoNT and provide 
clarification in Appendix H.
76.Patient has received any of the following concomitant 
medications for dystonia or chorea within the specified 
exclusionary windows of screening:
Within 3 months: depot neuroleptics
â€“Within 30 days: tetrabenazine, deutetrabenazine, or 
valbenazine
â€“Within 21 days: reserpine
â€“Within 14 days: neuroleptics (oral), typical and 
atypical antipsychotics (see Appendix H),
metoclopramide, levodopa, dopamine agonists, and 
MAOIs
Note: Use of benzodiazepines, muscle relaxants, 
trihexyphenidyl, baclofen (oral and intrathecal), 
gabapentin, and levetiracetam is allowed if the 
dosing has been stable for at least 4 w eeks before 
screening.
â€“Note: Use of topiramate (up to 200 mg/day) is 
allow ed if dosing has been stable for at least 4 w eeks 
before screening.6.Patient has received any of the following concomitant 
medications within the specified exclusionary windows 
of screening:
â€“Within 30 days: tetrabenazine, deutetrabenazine, or 
valbenazine
â€“Within 21 days: reserpine
â€“Within 14 days: levodopa, dopamine agonists, and 
MAOIsClarified the concomitant 
medication types and criteria for 
patient exclusion
1817.Patient has a history of or acknowledges alcohol or 
other substance abuse in the 12 months before 
screening , as defined in the Diagnostic and 
Statistical Manual of Mental Disorders (version 5) .17.Patient has a history of or acknowledges alcohol or 
other substance abuse in the 12 months before 
screening.Clarif ied how  to assess the 
exclusion criterion
1918.Patient has a positive urine drug screen test result 
(with exception of medications listed in Table 9 
Table 10of Appendix H) or is unable to refrain from 18.Patient has a positive urine drug screen test result (w ith 
exception of medications listed in Table 10 of 
Appendix H). Any request to include a patient with a Clarified how  patients with a 
positive urine result may be 
enrolled
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
152Protocol t ext with changes shown New wording Reason/justification for change
substance abuse throughout the study . Any request to
include a patient with a positive urine drug screen 
test result should be discussed w ith, and approved 
by, the medical monitor. Refer to Section 7.5.2.2 
(urine drug screen) for more details.positive urine drug screen test result should be discussed 
with, and approved by, the medical monitor. Refer to 
Section 7.5.2.2 (urine drug screen) for more details.
4.3.Withdrawal Criteria and Procedures for the Patient
See new wording column 5.Patient engages in alcohol or other substance abuse. New  reason for patients to be 
withdrawn
12.If a post -baseline QTcF value >500 msec or change from 
baseline screening >60 msec is found, the investigator 
should repeat the ECG assessment twice more and 
compare the average of these 3 post -baseline screening 
QTcF values to the and com pare to the ave rage of the 2 
pre-treatment QTcF values (baseline and atscreening ) to 
the average of the 3 post baseline QTcF values . The IMP 
must be stopped for any confirmed post- baseline QTcF 
average value >500 msec or average increase from 
baseline screening >60msec. In addition, a patient may 
be w ithdrawn from the study as described in Sections 
3.4, 3.5, and 5.10 and Appendix C.12.If a post -baseline QTcF value >500 msec or change 
from screening >60 msec is found, the investigator 
should repeat the ECG assessment twice more and 
compare the average of these 3 post -screening QTcF 
values to the pre- treatment QTcF values at screening. 
The IMP must be stopped for any confirmed post -
baseline QTcF average value >500 msec or average 
increase from screening >60 msec. In addition, a patient 
may be withdrawn from the study as described in 
Sections 3.4, 3.5, and 5.10 and Appendix C.Clarified when and how a change 
in QTcF w ould require study 
discontinuation
4.5. Rescreening
See new wording column For COVID -19 updates, refer to Appendix M. Updated to cross -reference the 
addition to Appendix M
5.1.1.1. Starting Dose and Dose Levels
Test IMP w ill be supplied in 20 count tablets per dose 
strength per bottle assembling 6, 12, 18, 24, 30, 36, 42, and 
48mg dose kit combinations .Test IMP w ill be supplied in 20 -count tablets per dose 
strength per bottle assembling 6, 12, 18, 24, 30, 36, 42, and 
48mg dose kit combinations.Clarified the tablets in the dose kit
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
153Protocol t ext with changes shown New wording Reason/justification for change
5.1.1.2. Dose Modification and Dose Stratification
â€¢IMP cannot should be swallowed whole. If the IMP is
crushed or split but should be swallowed whole , it 
should not be ingested; it should be replaced with a new 
tablet . The tablets w ill be taken with food (eg, a snack) 
and should not be taken on an empty stomach. Pati ents 
may be offered the optional use of a Medi+StrawÂ®, 
which is a commercially available straw  that can assist 
patients to overcome swallowing difficulties.â€¢IMP should be sw allow ed whole. If the IMP is crushed 
or split, it should not be ingested; it shou ld be replaced 
with a ne w tablet. The tablets will be taken with food 
(eg, a snack) and should not be taken on an empty 
stomach. Patients may be offered the optional use of a 
Medi+StrawÂ®, which is a commercially available straw  
that can assist patients to overcome their swallowing 
difficulties.Clarified how  study  drug should 
be taken
â€¢If there is only a single dose of IMP per day, the dose 
should be taken in the morning. How ever, if apatient s
experiencing somnolence while taking the 6 -mg dose in 
the morning , he/she may switch to taking it as an 
evening dose for the rest of the days up to day 14.â€¢If there is only a single dose of IMP per day, the dose 
should be taken in the morning. How ever, patients 
experiencing somnolence while taking the 6 -mg dose in 
the morning may switch to taking it as an evening dose 
for the rest of the days up to day 14.Clarified w ording
â€¢The starting dose isof6 mg in all for patients. This dose
will be administered in the morning on day s2 and for 
the remainder of the fir st week. Patients in the highest 
body weight group ( â‰¥40 kg/88 lbs) w ill start an evening 
administration from day 3 and , follow ed by  evening 
administration starting on day 3 for the remainder of the 
firstweek (if body weight is â‰¥40 kg/88 lbs) . TEV -50717 
daily doses of 12 mg and higher w ill be administered as 
2 divided equal doses, approximately 8 to 10 hours apart 
during the day. A minimum of 6 hours should elapse 
betw een doses. If a patient misses a dose, and it is within 
6 hours of the next dose, the miss ed dose should be 
skipped. If a patient is on the 6 mg once daily dose (12 
kg to <17 kg; 26 lbs to <37 lbs) and experiences 
somnolence while taking the 6 mg dose in the morning, 
he/she may switch to taking it as an evening dose for the 
rest of the days up to day 14.
â€¢After week 1, dose increases may not occur more 
frequently than every 5 days.â€¢The starting dose of 6 mg will be administered in the 
morning on day 2 and for the remainder of the first 
week. Patients in the highest body weight group 
(â‰¥40kg/88 lbs) will start an evening administration from 
day 3 and for the remainder of the first week. TEV-
50717 daily doses of 12 mg and higher will be 
administered as 2 divided equal doses, approximately 
8to 10 hours apart during the day. A minimum of 
6hours should elapse between doses. If a patient misses 
a dose, and it is w ithin 6 hours of the next dose, the 
missed dose should be skipped. Clarified when the dose may be 
increased for patients in the 
highest body weight group
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
154Protocol t ext with changes shown New wording Reason/justification for change
See new wording column â€¢Dose increases may not occur more frequently than 
every 5 days, except for patients â‰¥40 kg/88 lbs. For 
patients â‰¥40 kg/88 lbs, the first dose increase may be 
performed in an interval less than 5 days, only once, on 
day 3.
â€¢During the week 3 visit, the investig ator or designee will 
make sure the patient receives the last treatment kit back 
so the patient can take the evening dose to complete the 
week 3 dosing for that day. Refer to the pharmacy 
manual for further details.
â€¢For any dose adjustment, the investiga tor or designee 
should confirm that patients have the bottle that contains 
the appropriate tablet strength and quantity to complete 
the recommended daily regimen.Clarified how  study  drug should 
be taken
â€¢During the titration period, the dose of IMP shou ld be 
adjusted weekly according to Table 4â€¦.â€¢During the titration period, the dose of IMP should be 
adjusted according to Table 4â€¦.Clarified how  study  drug should 
be taken
Table 4: Maximum Daily Dose of IMP During the Titration Period by Day and Weight Category at Baseline
See new wording column The follow ing footnote was added: 
aDose increases may not occur more frequently than 
every 5 days, except for patients â‰¥40 kg/88 lbs. Fo r 
patients â‰¥40 kg/88 lbs, the first dose increase may be 
performed in an interval less than 5 days, only once, on 
day 3.Footnote added to align against 
the updates in the body of the 
protocol
c.Patients in this weight category will receive the 6 -mg 
once -daily dose in the morning on day s 2and 3 , 
followed by evening twice -daily adm inistration of 6 mg 
starting on day 3.c.Patients in this weight category will receive the 6 -mg 
once -daily dose in the morning on day 2, followed by 
twice-daily administration of 6 mg starting on day 3.Footnote updated to align against 
the updates in the body of the 
protocol
Table 6: Investigational Medicinal Products Used in the Study
See new wording column Row:  Manufacturer
Column: TEV -50717 Test IMP
Anesta LLC
4745 Wiley Post Way 
Salt Lake City, UT 84116Added new IMP manufacturer
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
155Protocol t ext with changes shown New wording Reason/justification for change
See new wording column Row: Manufacturer
Column: Placebo IMP
Anesta LLC
4745 Wiley Post Way 
Salt Lake City, UT 84116Added new IMP manufacturer
Row:  Storage co nditions
Column:  TEV -50717 Test IMP
Stored at controlled room temperature, 20Â°C -25Â°C 
(68Â°F -77Â°F) , protected from light and moistureRow: Storage conditions
Column: TEV -50717 Test IMP
Stored at controlled room temperature, 20Â°C -25Â°C 
(68Â°F -77Â°F)Clarified IMP storage stipulations
Row:  Storage conditions
Column:  Placebo Test IMP
Stored at controlled room temperature, 20Â°C -25Â°C (68Â°F -
77Â°F) , protected from light and moistureRow: Storage conditions
Column: Placebo Test IMP
Stored at controlled room temperature, 20Â°C -25Â°C (68Â°F -
77Â°F)Clarified IMP storage stipulations
5.2.1. Storage and Security
The IMPs (TEV -50717 and placebo IMP) must be stored 
protected from light, at a controlled room temperature, 20ÂºC 
to 25ÂºC (68ÂºF to 77ÂºF), in a dry,securely locked, 
substantially constructed cabinet or enclosure with access 
limited to authorized staff. 
Diversion is considered to have occurred when the legal 
supply chain of prescription analgesic medicinal products is 
broken, and medicinal products a re transferred from a licit to 
an illicit channel of distribution or use.The IMPs (TEV -50717 and placebo IMP) must be stored at 
a controlled room temperature, 20ÂºC to 25ÂºC (68ÂºF to 77ÂºF), 
in a securely locked, substantially constructed cabinet or 
enclosur e with access limited to authorized staff.Clarified IMP storage stipulations
5.2.3. Accountability
Each IMP shipment will include a packing slip listing the 
contents of the shipment, return instructions, and any 
applicable forms.Each IMP shipment will include a packing slip listing the 
contents of the shipment and any applicable forms.Clarified the content of IMP 
packing slip
A record of IMP accountability (ie, IMP and other study 
materials received, used, retained, returned, or destroyed) 
must be prepared and signed by the principal investigator or 
designee, with an account given for any discrepancies. 
Empty, partially used, Any used (partially used or empty) 
bottles and unused bottles of IMP will be kits/bottles that are A record of IMP accountability (ie, IMP and other study 
materials received, used, retained, returned, or destroyed) 
must be prepared and signed by the pr incipal investigator or 
designee, with an account given for any discrepancies. Any 
used (partially used or empty) bottles and unused 
kits/bottles that are not destroyed at the site are returned to Clarified the instructions for IMP 
disposal
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
156Protocol t ext with changes shown New wording Reason/justification for change
not destroyed at the site are returned to the sponsor or 
designee, as agreed with the sponsor (including expired and 
damaged kits) .the sponsor or designee, as agreed w ith the sponsor 
(includ ing expired and damaged kits).
5.4.Treatm ent after the End of the Study
At the week 16 visit, patients may choose to enter Study 
TV50717 -CNS -30081 (on that day) or up to 1 w eek later 
(2weeks from the week 15 visit) they will have an 
additional w eek to make a decision . Patients who complete 
treatment but choose not to participate in the open -label 
safety extension Study TV50717 -CNS -30081 before w eek 
17 of Study TV507 17-CNS -30080 will be contacted for a 
safety evaluation call occurring 2 w eeks after their last dose 
of IMP. Additional details for patients to enter Study 
TV50717 -CNS -30081 are provided in the TV50717 -CNS-
30081 protocol.At the week 16 visit, patients may choose to enter 
Study TV50717 -CNS- 30081 (on that day) or up to 1 w eek 
later (2 weeks from the week 15 visit). Patients who 
complete treatment but choose not to participate in the 
open -label safety extension Study TV50717 -CNS -30081 
before w eek 17 of Study T V50717 -CNS- 30080 w ill be 
contacted for a safety evaluation call occurring 2 w eeks 
after their last dose of IMP. Additional details for patients to 
enter Study TV50717 -CNS -30081 are provided in the 
TV50717 -CNS -30081 protocol.Clarified the timing of when a 
patient can enter 
Study TV50717 -CNS- 30081
See new wording column Note: Patients can also roll over to the extension study 
within 2 to 4 w eeks after the week 15 visit but will be 
required to complete additional scales and tests as part of 
Study TV50717 -CNS- 30081. Patients will further be 
allow ed to roll over to Study TV50717 -CNS -30081 betw een 
4 weeks and up to 6 months from the week 15 visit and will 
be subject to the full screening process. More details are 
presented in the TV50717 -CNS- 30081 protocol.Clarified the timing of when a 
patient can enter 
Study TV50717 -CNS- 30081
5.6.Prior and Concom itant Medication
Caregivers and patients will be instructed during the course 
of the study to notify the investigator if any new medication 
is prescribed /administered (other than TEV -50717) or if 
there is any change in current medications , including over -
the-counter medications. Any prescribed new  and/or any 
change in current medication should be reviewed with the 
investigator. Indication, dosage, and star t and end dates 
should be entered on the CRF.Caregivers and patients will be instructed during the course 
of the study to notify the investigator if any new medication 
is prescribed/administered (other than TEV- 50717) or if 
there is any change in current medications, including over -
the-counter medications. Any prescribed new  and/or any 
change in current medication should be reviewed with the 
investigator. Indication, dosage, and start and end dates 
should be entered on the CRF.Clarified the investigator s hould 
be notified of any changes to 
current medications 
The medical monitor must be contacted if a patient is 
receiving (or has to begin or stop receiving during the study) 
a medication that is associated w ith QT corrected for heart The medical monitor must be contacted if a patient is 
receiving (or has to begin or stop receiving during the 
study) a medication that is associated w ith QT prolongation Clarified QT prolongation rather 
than QTc
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
157Protocol t ext with changes shown New wording Reason/justification for change
rate (QTc) prolongation or that is a known strong CYP 
inhibitor.or that is a known strong CYP inhibitor.
Prohibited medications that are associated w ith QT c 
prolongation are listed in Appendix H, Table 10 Table 11 . 
Prohibited antipsychotic drugs are listed in Appendix H, 
Table 11.Prohibited medications th at are associated w ith QT 
prolongation are listed in Appendix H, Table 11. Prohibited antipsychotic drugs 
table has been deleted.
5.7.Procedures for Monitoring Patient Com pliance
A check of compliance with IMP intake will be performed 
during each in-clinic visit after the used IMP has been 
dispensed returned , and IMP accountability records w ill be 
completed. At week 3, IMP administration compliance can 
be calculated only for w eeks 1 and 2, as the last kit at 
week 3 is returned to the patient so that the patient can 
complete the week 3 dosing for that evening.A check of compliance with IMP intake will be performed 
during each in -clinic visit after the used IMP has been 
returned, and IMP accountability records w ill be completed. 
At week 3, IMP adminis tration compliance can be 
calculated only for weeks 1 and 2, as the last kit at week 3 is 
returned to the patient so that the patient can complete the 
week 3 dosing for that evening.Clarified calculation of IMP 
compliance
5.8 Tem porary Discontinuation of Investigational Medicinal Product
If a dose reduction occurs before a scheduled clinic visit, the 
clinic visit will be postponed so that efficacy evaluations can 
be performed at least 57days after the change. 
If a dose suspension occurs before a schedu led clinic visit, 
an unscheduled visit should be scheduled as soon as possible 
so that efficacy evaluations can be performed at least 57
days after the change.If a dose reduction occurs before a scheduled clinic visit, the 
clinic visit will be postponed s o that efficacy evaluations 
can be performed at least 7 days after the change. 
If a dose suspension occurs before a scheduled clinic visit, 
an unscheduled visit should be scheduled as soon as 
possible so that efficacy evaluations can be performed at 
least 7 days after the change.Clarified evaluations can occur 
7days after a dose reduction or 
suspension
If a patientâ€™s serum potassium or magnesium level falls 
below  the lower limit of normal, IMP mu stshould be 
suspended.If a patientâ€™s serum potassium or magnesium level falls 
below  the lower limit of normal, IMP should be suspended.Clarification
5.9. Randomization and Blinding
The iDMC will perform anone unblinded non -binding IA for 
futility , another unblinded IA for futility and sample size 
reassessment and safety monitoring throughout the study. 
An iDMC charter will be developed for the interim analyses, 
and the procedures to ensure the integrity of the study will 
be provided in the charter (see Section 5.10.3 for more 
details) .The iDMC will perform one unblinded non -binding IA for 
futility, another unblinded IA for futility and sample size 
reassessment and safety monitoring throughout the study. 
An iDMC charter will be developed for the interim 
analyses, and the procedures to ensure the integrity of the 
study will be provided in the charter (see Section 5.10.3 for 
more details).Text updated to account for the 
second interim analysis
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
158Protocol t ext with changes shown New wording Reason/justification for change
See new wording column Patients re -entering the study will be manually assigned to 
their initial treatment group by th e RTSM unblinded vendor. 
Blinding will be maintained for the patient, investigator, and 
sponsor as described above; the only information that will 
be available is that the patient was assigned to the same 
treatment group previously.Guidance provided on ho w to 
handle blinding for patients who 
re-enter the study
5.10.3. Independent Data Monitoring Committee
See new wording column When approximately 50 patients have completed the study 
(including follow -up), the iDMC will perform an unblinded 
non-binding IA for futility based on centrally read MD -CRS 
part II total score. Text added for the addition of the 
second interim analysis
The iDMC charter will be developed for the IA s, and the 
procedures to ensure the integrity of the study will be 
provided in the charter.The iDMC charter will be developed for the IAs, and the 
procedures to ensure the integrity of the study will be 
provided in the charter.Text updated to account for the 
second interim analysis
6.ASSESSMENT OF EFFICACY
See new wording column Efficacy in this study will be evaluated using MD -CRS part 
I total score, MD- CRS part II total score, CaGI -I, CGI -I, 
CGI-S, PEDI- CAT, UHDRS -TMS, UHDRS -TMC, 
UHDRS -TMD, and PGI -I. It is recommended that the same 
order of administration/completion of the scales be kept per 
patient throughout the study, as best as possible (refer to the 
Study TV50717 -CNS- 30080 RECLAIM -DCP: Order of
scales administration/completion document). At all relevant 
visits where collected, PGI -I and CaGI -I are to be 
completed before all other investigator -rated scales.
The investigator should review all scales and questionnaires 
in a timely manner for any po tential reporting of adverse 
events and document this review accordingly. At each study 
visit, as applicable, the investigator should compare the 
current scores to the baseline scores.Stated the efficacy assessments 
and clarified the timing of those 
asses sments
6.1. Prim ary Efficacy Measure
The MD -CRS part II w ill be administered by the 
investigational center physician , or other appropriately 
trained study team member, and video recorded at screening, The MD -CRS part II w ill be administered by the 
investigational center physician, or other appropriately 
trained study team member, and video recorded at Clarified who can administered 
the MD -CRS
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
159Protocol t ext with changes shown New wording Reason/justification for change
baseline, week 9, w eek 12, w eek 15/ET, and w eek 16/EOS 
visits.screening, baseline, week 9, week 12, w eek 15/ET, and 
week 16/EOS visits.
See new wording column The MD -CRS has been updated to version 2 w ith changes 
to the scoring language. This version should be used when 
available. How ever, a patient will complete all study visits 
using the same version.Clarified the version of the 
MD-CRS
â€¢Central reading (baseline, week 9, w eek 12, w eek 15/ET, 
and w eek 16/EOS): Video review  of MD CRS part II w ill 
be assessed periodically in a blinded manner (ie, visit, 
investigator site rating , and other study related 
information) by a central review board.â€¢Central reading (baseline, week 9, w eek 12, w eek 15/ET, 
and w eek 16/EOS): Video review  of MD CRS part II 
will be assessed periodically in a blinded manner (ie, 
visit, investigator site rating, and other study relat ed 
information) by a central review board.Clarification
6.2.1. Movem ent Disorder- Childhood Rating Scale Part I Total Score
See new wording column The protocol refers to MD -CRS as a physician -rated scale, 
but in certain instances, based on the experience of the rater, 
certain non -physicians may be approved to rate the MD -
CRS.Clarified who can administered 
the MD -CRS
6.2.2. Caregiver Global Impression of Improvement Scale
The CaGI -I is to be completed assessed before all other 
investigator -rated scales during visits where CaGI -I is 
collected (Table 3).The CaGI -I is to be completed before all other investigator -
rated scales during visits where CaGI -I is collected 
(Table 3).Clarification
6.3.2. Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score
The UHDRS -TMS is administered at baseline, w eek 9, w eek 
12, and w eek 15/ET visits and w ill be rated by the 
investigator .The UHDRS -TMS is administered at baseline, w eek 9, 
week 12, and w eek 15/ET visits and will be rated by the 
investigator.Clarified who can rate the 
UHDRS -TMS
6.3.4. Unified Huntingtonâ€™s Disease Rating Scale -Total Maxim al Dystonia
See new wording column When rating dystonia (question #11) buccal -oral-lingual and 
facial dystonia (blepharospasm, jaw  opening and closing) 
should be included in the assessment of the truncal region.Clarified what should be part of 
the assessment for dystonia
6.3.7. Patient Global Impression of Improvement Scale
The PGI- I is to be completed assessed before all other 
investigator -rated scales during visits where PGI -I is 
collected (Table 3).The PGI- I is to be completed before all other investigator-
rated scales during visits where PGI -I is collected (Table 3).Clarification
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
160Protocol t ext with changes shown New wording Reason/justification for change
7.ASSESSMENT OF SAFETY
See new wording column The investigator should review all scales and questionnaires 
in a timely manner for any potential reporting of adverse 
events and document this review  accordingly.Guidance provided on timing of 
the assessments of all scales and 
questionnaires
7.1.2. Recording and Reporting of Adverse Events
The follow -up period of recording of adverse events is 
defined as 2 weeks after the last dose of IMP for patients 
who will not roll over into or up to baseline/day 1 in the 
open -label safet y extension study Study TV50717 -CNS-
30081 (whichever comes first) or 2 w eeks after the ET visit 
for patients who terminate early from the study, or the date 
of enrollment in the open label extension (OLE) study 
TV50717 CNS 30081 for patients rolling over t o the OLE 
study.The follow -up period of recording of adverse events is 
defined as 2 weeks after the last dose of IMP or up to 
baseline/day 1 in the open -label extension 
Study TV50717 -CNS- 30081 (whichever comes first) or 
2weeks after the ET visit for pati ents who terminate early 
from the study.Clarified the timing of when a 
patient can enter Study TV50717 -
CNS -30081
See new wording column To enable the assessment of the potential relationship of an 
adverse event and plasma concentration of IMP and 
metabolites, blood samples will be collected based on the 
scenarios described in Table 9.  Additional guidance provided on 
how to handle blood s amples for 
plasma concentration of IMP and 
metabolites
7.2. Safety Rating Scales
See new wording column The investigator should review all scales and questionnaires 
in a timely manner for any potential reporting of adverse 
events and document this review  accordingly. At each study 
visit, as applicable, the investigator should compare the 
current scores to the baseline scores.Guidance provided on timing of 
the assessments of all scales and 
questionnaires
7.2.1. Childrenâ€™s Columbia -Suicide Severity Rating Scale
For children over 13 years of age, parent/legal guardian
legally accepted representative involvement is strongly 
encouraged. Questions should be directed to the child, but 
the caregiver parent/ legal guardian legally accepted 
representative should be encouraged to add relevant 
information.For children over 13 years of age, parent/legally accepted 
representative involvement is strongly encouraged. 
Questions should be directed to the child, but the caregiver 
parent/legally accepted representat ive should be encouraged 
to add relevant information.Clarified one of the terms for 
caregiver for patients who are 
minors
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
161Protocol t ext with changes shown New wording Reason/justification for change
7.3. Pregnancy
See new wording column Note: Female partnersâ€™ pregnancies of male participants are 
not required to be proactively monitored.Clarification
7.5.1. Serum  Chemistry, Hematology, and Urinalysis
See new wording column Laboratory tests performed at screening may be repeated to 
determine patient eligibility.Text added to allow  for repeat 
testing for study entry
7.5.2.1. Beta -Hum an Chorionic Gonadotropin Tests
Î²-HCG tests in urine will be performed for all female 
patients aged 12 years or older of childbearing potential at 
baseline and other in -clinic visits as detailed in Table 3 .Î²-HCG tests in urine will be performed for all female 
patients aged 12 years or older of childbearing potential at 
baseline and other in -clinic visits as detailed in Table 3.Clarified when pregnancy tests 
should be performed
7.5.2.2. Urine Drug Screen
See new wording column A urine drug scr een performed at screening may be repeated 
to determine patient eligibility.Text added to allow  for repeat 
testing for study entry
If a given parameter cannot be tested using urine, or if the 
investigator considers additional testing is needed , an 
alternative matrix (eg, serum) may be considered acceptable. 
Such tests may be performed locally.If a given parameter cannot be tested using urine, or if the 
investigator considers additional testing is needed, an 
alternative matrix (eg, serum) may b e considered 
acceptable. Such tests may be performed locally.Clarification on the possible 
additional testing that may be 
considered upon conducting the 
urine drug screen
See new wording column Some of the drugs listed in this urine drug screen may be 
permitted in certain cases when the particular medication is 
being used under a physicianâ€™s or clinicianâ€™s guidance and 
in compliance with the physicianâ€™s or clinicianâ€™s 
recommendation for a specific condition (for example, 
phenobarbital [barbiturates] for s eizures, stimulant 
medications [including amphetamine, methylphenidate, and 
lisdexamfetamine] for attention deficit hyperactivity 
disorder, and opiates or oxycodone for pain) and if the 
dosing has been stable for at least 4 w eeks before screening 
and no ch anges to dose or frequency are anticipated during 
the course of the study. Such cases should be discussed with 
the medical monitor. Patients who either are using these 
medications or have a positive drug screen for these 
substances or derivatives should be submitted to the medical 
monitor for consideration of participation in this study. Clarification on the possible 
exceptions that may be considered 
upon conducting the urine drug 
screen
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
162Protocol t ext with changes shown New wording Reason/justification for change
Patients with a substance use disorder are excluded from 
this clinical trial. How ever, if per the investigatorâ€™s 
judgment, a patient does not meet the criteria for substanc e 
use disorder, a positive drug screen result for these 
medications or derivatives, without medical explanation, 
should be discussed on a case -by-case basis with the 
medical monitor to determine the patientâ€™s eligibility, based 
on the information available.
7.7. Vital Signs
(The same position and arm or leg should be used each time 
vital signs are measured for a given patient.)(The same position and arm or leg should be used each time 
vital signs are measured for a given patient.)Specified the leg could be used 
for vital sign measurement
See new wording column For patients who find standing difficult or do not allow  for a 
reliable blood pressure and pul se measurement, alternative 
methods to collect orthostatic blood pressure and pulse 
should be discussed with the medical monitor.Clarified that alternative methods 
for assessing vital signs can be 
discussed with the medical 
monitor
7.8. Electrocardiography
See new wording column The investigator should review the ECG at screening to 
determine patient eligibility for the study and subsequent 
ECGs for the patientâ€™s continuation in the study. All ECGs 
should be review ed by  the investigator for any clinically 
significant findings during the visit and before the patient 
leaves the clinic.Clarified screening ECGs should 
be review ed for eligibility
If a post -baseline QTcF value >500 msec or change from 
baseline screening >60 msec is found, the investigator should 
repeat the ECG assessment twice and compare the average 
ofthe 2 these 3 post -screening QTcF values to the 
pre-treatment QTcF values (baseline and screening) to the 
average of the 3 post baseline QTcF values at scr eening. 
The IMP must be stopped for any confirmed post -baseline 
QTcF average value >500 msec or average increase from 
baseline screening >60 m sec. If a post -baseline QTcF value >500 msec or change from 
screening >60 msec is found, the investigator should repeat 
the ECG assessment twice and compare the average of these 
3 post -screening QTcF values to the pre- treatment QTcF 
values at screening. The IMP must be stopped for any 
confirmed post -baseline QTcF average value >500 msec or 
average increase from screening >60 msec. Clarification when and how 
change in QTcF w ould require 
study discontinuation
See new wording column Note: Abnormal ECG results at w eek 3 and w eek 7 m ay 
result in patient withdrawal from the study as detailed in 
Section 4.3.Cross -reference added for 
possibility of patient withdrawal 
due to abnormal ECG results
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
163Protocol t ext with changes shown New wording Reason/justification for change
7.12. Concom itant Medication or Treatm ent
Parents/patients will be instructed during the course of the 
study to notify the investigator if any ne w medication is 
prescribed/administered (other than TEV 50717) or if there 
is any change in current medications , including over -the-
counter medications. Any new prescribed/administered 
medication and/or any change in current 
prescribed/administered medication should be reviewed with 
the investigator.Parents/patients will be instructed during the course of the 
study to notify the investigator if any ne w medication is 
prescribed/administered (other than TEV 50717) or if there 
is any change in current medications, including over -the-
counter medications. Any new prescribed/administered 
medication and/or any change in current 
prescribed/administered medication should be reviewed 
with the investigator.Revisions to concomitant 
medication stipulations
Text added to provide additional 
clarity around patient 
considerations pertaining to 
concomitant medications and the 
responsibilities of the medical 
monitor
Patient s may be included in this study if they are using 
cannabis or formulations or derivatives of cannabis in 
relatively stable amounts, for medical purposes (where 
applicable according to local regulation), under the 
guidance, supervision, or prescription of a clinician and 
anticipated to remain stable (dose and frequency) within the 
study duration .Patients may be included in this study if they are using 
cannabis or formulations or derivatives of cannabis in 
relatively stable amounts, for medical purposes (whe re 
applicable according to local regulation), under the 
guidance, supervision, or prescription of a clinician and 
anticipated to remain stable (dose and frequency) within the 
study duration.
Patients with a substance use disorder (by Diagnostic and 
Statistical Manual of Mental Disorders, 5th edition, criteria ) 
are excluded from this clinical trial.Patients with a substance use disorder are excluded from 
this clinical trial.
See new wording column Certain considerations mentioned in the table requi re the 
review of the medical monitor. Changes to the allowed 
medications may be permitted in the context of this study 
and should be discussed w ith the medical monitor. If the 
wellbeing of the patient and the urgency of the clinical 
decision do not allow  discussion with the medical monitor 
prior to the medication change, the investigator should 
notify the medical monitor in a timely manner following 
this decision.
The medical monitor must be contacted if a patient is 
receiving (or has to begin or stop rec eiving during the study) 
a medication that is associated w ith QT cprolongation or 
that is a known strong CYP2D6 inhibitor. Prohibited 
medications that are associated w ith QT cprolongation are 
listed in Appendix H, Table 10 Table 11 , while prohibited 
antips ychotic drugs are listed in Appendix H, Table11 .The medical monitor must be contacted if a patient is 
receiving (or has to begin or stop receiving during the 
study) a medication that is associated w ith QT prolongation 
or that is a known strong CYP2D6 inhi bitor. Prohibited 
medications that are associated w ith QT prolongation are 
listed in Appendix H, Table 11.Prohibited antipsychotic drugs 
table has been deleted
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
164Protocol t ext with changes shown New wording Reason/justification for change
8.1.Pharm acokinetic Assessment
See new wording column  
 
 
  
 
See new wording column Table 9 (Blood Sampling Scenarios) has been added
9.1. Sample Size and Power Considerations
Simulations for the study, including the IA for futility and 
sample size re -estimation, and the corresponding statistical 
methods to control the Type I error rate w ere performed. 
The overall pow er of wasapproximately 9083% under the 
initial assumptions, an d the overall Type I error rate of less 
than 0.025 for the primary analysis were wasconfirmed. 
Further simulations were performed to evaluate the pow er 
and additional operating characteristics of the study under 
different assumptions of the effect size.Simulations for the study, including the IA for futility and 
sample size re -estimation, and the corresponding statistical 
methods to control the Type I error rate w ere performed. 
The overall pow er was approximately 83% under the initial 
assumptions, and the overall Type I error rate of less than 
0.025 for the primary analysis was confirmed. Further 
simulations were performed to evaluate the pow er and 
additional operating characteristics of the study under 
different assumptions of the effect size.Text updated to account for the 
second interim analysis
9.2.1. Intent -to-Treat Analysis Set
See new wording column For patients who discontinue the study and re- enter it 
(repeating the study from baseline), only the data from the 
repeated participation w ill be included in the ITT analysis 
set.Clarification for patients who 
re-enter the study
9.2.3. Safety Analysis Set
See new wording column Rules for handling safety data for patients who discontinue 
the study and re- enter it will be provided in the SAP.Clari fication for patients who 
re-enter the study

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
165Protocol t ext with changes shown New wording Reason/justification for change
9.3.1. Handling Withdrawals and Missing Data
The follow ing cases will be considered as MNAR: 
â€¢early terminations related to tolerability
â€¢treatment -related adverse events
â€¢early terminations related to lack of efficacy 
The follow ing cases will be considered as MAR:
â€¢intermittent missing data
â€¢early termination for patients who are lost to follow -up 
â€¢early terminations due to COVID- 19The follow ing cases will be considered as MNAR: 
â€¢early terminations related to tolerability
â€¢treatment -related adverse events
â€¢early terminations related to lack of efficacy 
The follow ing cases will be considered as MAR:
â€¢intermittent missing data
â€¢early termination for patients who are lost to follow -up 
â€¢early terminations due to COVID- 19Text added to provide additional 
clarity around the cases for 
missing data
For all other cases, and for cases classified as above,
classification as MAR/MNAR w ill be done/revisited in a 
blinded manner on a case -by-case basis prior to the IA for 
futility , the IA for futility and sample size reassessment and 
prior to database lock for final analysis.For all other cases, and for cases classified as above, 
classification as MAR/MNAR w ill be done/revisited in a 
blinded manner on a case -by-case basis prior to the IA for 
futility, the IA for futility and sample size reassessment and 
prior to database lock for final analysis.Text added to provide additional 
clarity around the cases for 
missing data
9.4.1. Patient Disposition
Data from patients screened; patients screened but not 
randomized (and reason not randomized); patients who are 
randomized; patients randomized but not treated (and reason 
not treated) ; patients re-randomized; patient sin the ITT, 
mITT, safety, and PP analysis sets; patients who complete 
the treatment period; patients who complete the EOS visit; 
patients who intend to enroll into the open -label extension 
study; patients who do not intend to be enrolled into the 
open -label extension study (and reason for not enrolling) ; 
and patients who withdraw  from the study will be 
summarized using descriptive statistics. Data from patients screened; patients screened but not 
randomized (and reason not randomized); patients who are 
randomized; patients randomized but not treated; patients 
re-randomized; patients in the ITT, mITT, safety, and PP 
analysis sets; patients who complete the treatment period; 
patients who complete the EOS visit; patients who intend to 
enroll into the open -label extension study; patients who do 
not intend to be enrolled into the open -label extension 
study; and patients who withdraw  from  the study will be 
summarized using descriptive statistics. Clarified that the reasons patient 
were not treated or not enrolled 
would not be collected and added 
re-randomized patients
9.5.5. Other Efficacy Endpoints
Other efficacy endpoints (change from baseline to week 
15/proportion at w eek 15; TEV -50717 versus placebo) are 
the following:
â€¢MD-CRS part I total score (ge neral assessment, 
physician rated)
â€¢MD-CRS part II total score (general assessment, Other efficacy endpoints (change from baseline to 
week 15/proportion at w eek 15; TEV -50717 versus placebo) 
are the following:
â€¢MD-CRS part I total score (general assessment, 
physician rated)
â€¢MD-CRS part II total score (general assessme nt, Text added to provide additional 
clarity around the MD -CRS
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
166Protocol t ext with changes shown New wording Reason/justification for change
physician rated)
â€¢MD-CRS Global Index (calculated from MD -CRS 
parts I and II total scores)
â€¢UHDRS -TMS (physician rated)
â€¢UHDRS -TMC (physician rated)
â€¢UHDRS -TMD (physician rated)physician rated)
â€¢MD-CRS Global Index (calculated from MD -CRS 
parts I and II total scores)
â€¢UHDRS -TMS (physician rated)
â€¢UHDRS -TMC (physician rated)
â€¢UHDRS -TMD (physician rated)
9.7. Planned Interim  Analysis
Therefore, an IAsfor futility and sample size re- estimation 
isareplanned.Therefore, IAs for futility and sample size re -estimation are 
planned.Change made to account for the 
multiple IA
See new wording column When approximately 50 patients have completed the study 
(including follow -up), an iDMC will perform an unblinded 
non-binding IA for futility based on centrally read MD -CRS 
part II total score.  Text updated to account for the 
second interim analysis
The rules for futility recommendation in the first IA, and the 
futility and sample size re -estimation in the second IA (eg, 
definition of the promising zone) will be included in the 
iDMC charter and the SAP. The iDMC charter will also 
provide the w ording t hat will be used to communicate the 
iDMC recommendation. The SAP w ill be finalized before 
the IA swill be performed.The rules for futility recommendation in the 1st IA, and the 
futility and sample size re -estimation in the 2nd IA (eg, 
definition of the pr omising zone) will be included in the 
iDMC charter and the SAP. The iDMC charter will also 
provide the w ording that will be used to communicate the 
iDMC recommendation. The SAP w ill be finalized before 
the IAs will be performed.Text updated to account for the 
second interim analysis
9.8. Safety Endpoints and Analysis
Changes in laboratory, ECG, and vital signs measurements 
data w ill be summarized descriptively. AllECG and vital 
signs values will be compared w ith predefined criteria to 
identify potentially clinically significant values or changes, 
and such values will be listed.Changes in laboratory, ECG, and vital signs measurements 
data w ill be summarized descriptively. ECG and vital signs 
values will be compared w ith predefined criteria to identify 
potentially clinically significant values or changes, and such 
values will be listed.Change made to clarify which 
data should be compared w ith 
predefined criteria
REFERENCES
See new wo rding column National Institute of Neurological Disorders and Stroke 
(NINDS). Cerebral Palsy: Hope Through Research. 
Available at: https://www ninds nih.gov/Disorders/Patient -
Caregiver -Education/Hope -Through -Research/Cerebral -
Palsy -Hope -Through -Research. A ccessed 27 February 
2020.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
167Protocol t ext with changes shown New wording Reason/justification for change
Posner K, Brow n G, Stanley B, Brent, D, Yershova K, 
Oquendo M, et al. The Columbia â€“Suicide Severity Rating 
Scale: Initial Validity and Internal Consistency Findings 
From  Three Multisite Studies With Adolescents and Adults. 
American Journal of initial validity and internal consistency 
findings from three multisite studies with adolescents and 
adults. Am J Psychiatry 2011;168(12):1266 -77.Posner K, Brow n G, Stanley B, Brent, D, Yershova K, 
Oquendo M, et al. The Columbia â€“Suicide Severity Rating 
Scale: initial validity and internal consistency findings from 
three multisite studies with adolescents and adults. Am J 
Psychiatry 2011;168(12):1266 -77.
APPENDIX A. CLINICAL LABORATORIES AND OTHER DEPARTMENTS AND INSTITUTIONS
Row:  Scales and Central Rater for MD -CRS
Column:
Bracket Global LLC
575 East Sw edesford Road
Suite 200
Wayne Signant Health
785 Arbor Way
Blue Bell , PA
19087
19422
Tel: Row:  Scales and Central Rater for MD -CRS
Column:
Signant Health
785 Arbor Way
Blue Bell, PA 19422
Tel: Administrative change
APPENDIX B. INDEPENDENT DATA MONITORING COMMITTEE
When approximately 9050patients have completed the 
study (including follow -up), an independent Data 
Monitoring Committee (iDMC) will perform an unblinded 
non-binding interim analysis (IA) for futility and sample 
size re estimation based on centrally read Movement 
Disorder -Child hood Rating Scale part II .(MD -CRS part II) 
total score. Based on the results of the interim analysis IA, 
the study may be stopped.When approximately 50 patients have completed the study 
(including follow -up), an independent Data Monitoring 
Committee (iDMC) will perform an unblinded non -binding 
interim analysis (IA) for futility based on centrally read 
Movement Disorder -Childhood Rating Scale part II (MD -
CRS part II) total score. Based on the results of the IA, the 
study may be stopped.
When approxim ately  90 patients have completed the study 
(including follow -up), an iDMC will perform an unblinded 
IA for futility and sample size re -estimation based on 
centrally read MD CRS part II. Based on the results of the 
IA,the study may be stopped or the sample size may be kept 
as planned (approximately 185 total patients) or increased 
(up to approximately 230 total patients).When approximately 90 patients have completed the study 
(including follow -up), an iDMC will perform an unblinded 
IA for futility and samp le size re -estimation based on 
centrally read MD CRS part II. Based on the results of the 
IA, the study may be stopped or the sample size may be 
kept as planned (approximately 185 total patients) or 
increased (up to approximately 230 total patients).

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
168Protocol t ext with changes shown New wording Reason/justification for change
APP ENDIX C. STUDY PROCEDURES AND ASSESSMENTS BY VISIT
1.Procedures for Screening (Day -31)
â€¢patients, parent(s)/ legal guardian legally accepted 
representative (s), and caregivers must provide their 
respective written informed consent and/or assent (as 
appropriate) before any study related procedures are 
performed.â€¢patients, parent(s)/legally accepted representative(s), and 
caregivers must provide their respective written 
informed consent and/or assent (as appropriate) before 
any study related procedur es are performed.Study procedures and assessments 
have been updated for consistency 
with changes made to the protocol 
body and Table 3.
This justification applies to all 
changes indicated within 
Appendix C.
â€“ use of patientâ€™s study videos for future analysis of 
gait digital markers and release of patientâ€™s study 
videos for use in publications or educational 
presentationsâ€“ use of patientâ€™s study videos for future analysis of 
gait digital markers and release of patientâ€™s study 
videos for use in publicati ons or educational 
presentations
â€¢clinical laboratory tests (chemistry, hematology, and 
urinalysis) ; these tests may be repeated to determine 
patient eligibility
â€¢urine drug screen ; these tests may be repeated to 
determine patient eligibilityâ€¢clinica l laboratory tests (chemistry, hematology, and 
urinalysis); these tests may be repeated to determine 
patient eligibility
â€¢urine drug screen; these tests may be repeated to 
determine patient eligibility
See new wording column â€¢contact RTMS
2. Procedures Before Adm inistration of Investigational Medicinal Product (Baseline [Day 1Â±0 days])
See new wording column The investigator should review all available data to 
determine patient eligibility before randomizing to the 
study.  
â€¢assignment of randomization/treatment numbers after 
patient eligibility is confirmed based on all available 
visit assessments, and entry into case report form (CRF)â€¢assignment of randomization/treatment numbers after 
patient eligibility is confirmed base d on all available 
visit assessments, and entry into case report form (CRF)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
169Protocol t ext with changes shown New wording Reason/justification for change
3. Procedures During Administration of Investigational Medicinal Product (Double -Blind Treatment Period Inclusive of Titration Period).
a.Week 1 (day 7+1 day), week 2 (day 14Â±3 days total from  baseline), week 4 (day 28Â±3 days total from  baseline), week 5 (day 35Â± 3 days total from 
baseline), and week 6 (day 42Â±3 days total from  baseline)
See new wording column â€¢contact RTMS
b. Week 3 (da y 21Â±3 days total from  baseline) and week 7 (day 49Â±3 days total from  baseline)
The follow ing procedures and assessments will be 
performed at weeks 3 and 7:
â€¢Caregiver Global Impression of Improvement (CaGI -
I) (global, caregiver rated). The CaGI -I is to be 
completed assessed before all other investigator -rated 
scales during visits where CaGI -I is collected.
â€¢Patient Global Impression of Improvement Scale 
(PGI- I) (global, patient/caregiver). The PGI -I is to be 
completed assessed before all other investigator -
rated scales during visits where PGI -I is collected.The follow ing procedures and assessments will be 
performed at weeks 3 and 7:
â€¢Caregiver Global Impression of Improvement 
(CaGI -I) (global, caregiver rated). The CaGI -I is to 
be completed before all other investigator -rated 
scales during visits where CaGI -I is collected.
â€¢Patient Global Impression of Improvement Scale 
(PGI- I) (global, patient/caregi ver). The PGI -I is to be 
completed before all other investigator -rated scales 
during visits where PGI -I is collected.
â€¢dispense/collect IMP
During the week 3 visit, the last dose bottle is to be 
returned to the patient in order to take 1 last tablet in the 
evening to complete the week 3 dosing for that day. 
Refer to the pharmacy manual for further details.â€¢dispense/collect IMP
During the week 3 visit, the last dose bottle is to be 
returned to the patient in order to take 1 last tablet in the 
evening to complete the week 3 dosing for that day. 
Refer to the pharmacy manual for further details.
See new wording column â€¢contact RTMS
4. Procedures During Administration of Investigational Medicinal Product (Maintenance Period)
a. Week 9 (day 63Â±3 days total from  baseline) and week 12 (day 84Â±3 days total from  baseline)
The follow ing was deleted:
â€¢urine pregnancy test
See new wording column â€¢contact RTMS
b.Week 15 (day 105Â±3 days total from  baseline) or early termination (ET)
See new wording column â€¢contact RTMS
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
170Protocol t ext with changes shown New wording Reason/justification for change
6. Unscheduled Visits
See new wording column
APPENDIX D. QUALITY CONTROL AND QUALITY ASSURANCE
Audit and Inspection
See new wording column For COVID -19 updates, refer to Appendix M. Updated to cross -reference the 
addition to Appendix M
APPENDIX E. ETHICS
See new wording column Patients who started the study as minors and reached the age 
of majority during the study should sign the adult ICF.Added text for clarification
APPENDIX H. LIST OF ALLOWED AND PROHIBITED MEDICATIONS
Prohibited medications that are associated w ith QTc 
prolongation are listed in Table 10Table 11 , whereas 
prohibited antipsychotic drugs are listed in Table 11 .Prohibited medications that are associated w ith QTc
prolongation are listed in Table 11.Prohibited antipsychotic drugs 
table has been deleted.
Table 910: Allowed Medications
See new wording column Table 10 has been revised as described below :
â€“added text to include dose w as â€œand anticipated to 
remain stable (dose and frequency) within the study 
durationâ€
â€“included additional allow ed medications
â€“provided clarification around permissible use/receipt of 
botulinum neurotoxin (BoNT) w ith approval from the 
medical monitor
Added a table note that changes to an y dose required pre-
approval from medical monitorTable 10 has been revised to 
clarify the updated expectations 
surrounding allowed medications 
in alignment with recent updates 
to the protocol body and 
inclusion/exclusion criteria 
Table 1011:Prohibited QTc Prolonging Drugs
See new wording column Hydroxychloroquine was added as a new  prohibited drug. 
The follow ing description was also added:
Hydroxychloroquine is contraindicated in this trial due to 
the risk of QT prolongation and should be considered as not Hydroxychloroquine was added as 
a new prohibited drug.  

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
171Protocol t ext with changes shown New wording Reason/justification for change
allow ed. If there is a medical decision to initiate 
chloroquine, hydroxychloroquine, mefloquine, or other 
drugs related to chloroquine, t he IMP should be suspended 
or discontinued and an ECG should be obtained. Please 
consult with the medical monitor for further advice.
Table 11: Prohibited Antipsychotic Drugs
Table deleted Prohibited antipsychotic drugs 
table has been deleted.
APPENDIX I. TOTAL BLOOD VOLUME
Table 12: Total Blood Volum es Table 12: Total Blood Volum es Table number updated
See new wording column  
  
 
 
  
 
APPENDIX K. DATA MANAGEMENT AND RECORD KEEPING
Data Collection
If data are processed from other sources (eg, central 
laboratory, bioanalytical laboratory, central image center, 
electronic diary data, and electronic patient -reported 
outcome tablet or phone) , these data w ill be sent to the 
investigational centerâ€¦If dat a are processed from other sources (eg, central 
laboratory, bioanalytical laboratory, central image center, 
electronic diary data, and electronic patient -reported 
outcome tablet or phone), these data w ill be sent to the 
investigational centerâ€¦Added another device for possible 
other sources
APPENDIX M. MANAGEMENT OF STUDY ACTIVITIES DURING COVID -19
Section 3.5. Schedule of Study Procedures and Assessments
It will further allow a visual confirmation of a patientâ€™s 
condition using FaceTimeÂ® non-recording live video and 
assessment of any new adverse events, as possible, 
depending on patient cooperation and the communication 
platform being in good w orking order.It will further allow a visual confirmation of a patientâ€™s 
condition using non -recording live video and assessment of 
any new adverse events, as possible, depending on patient 
cooperation and the communication platform being in good 
working order.Clarification

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
172Protocol t ext with changes shown New wording Reason/justification for change
The remote visit will not allow for measuring vital signs or 
obtaining an electrocardiogram (ECG) or urine beta 
chorionic gonadotropin (Î² -HCG) test , unless a home nursing 
vendor is at the patientâ€™s home to provide that service where 
available .The remote visit will not allow for measuring vital signs or 
obtaining an electrocardi ogram (ECG) or urine beta 
chorionic gonadotropin (Î² -HCG) test, unless a home 
nursing vendor is at the patientâ€™s home to provide that 
service where available.Clarification
All shipping arrangements will be the siteâ€™s responsibility 
and will occur between site and patient or as a direct -to-
patient shipment from the site to patient coordinated by the 
sponsorâ€™s third party shipping vendor, where available, and 
according to local practices and regulations.All shipping arrangements will be the siteâ€™s responsib ility 
and will occur between site and patient or as a direct -to-
patient shipment from the site to patient coordinated by the 
sponsorâ€™s third party shipping vendor, where available, and 
according to local practices and regulations.Clarification
See new wo rding column Section 4.5. Rescreening
Patients who screen fail or terminate early from the study 
due to emergency circumstances (such as coronavirus 
disease 2019 [COVID -19] restrictions) may be allowed to 
re-screen/re -enter (respectively) the study at a la ter date, 
depending on the circumstances. Each case should be 
referred to the medical monitor and approved in advance. 
Patients re -entering the study will be manually assigned to 
their initial treatment group. Patients will have to redo the 
entire study fr om the start, aside from the blinded CYP2D6 
genotyping; these results will carried over from the first 
participation.Clarification for possible re- entry 
into the study in an emergency 
situation
See new wording column Section 5.9. Random ization and Blinding
Patients re -entering the study will be manually assigned to 
their initial treatment group by the RTSM unblinded vendor. 
Blinding will be maintained for the patient, investigator, and 
sponsor as described above; the only information that will 
be av ailable is that the patient was assigned to the same 
treatment group as previously.Clarification for possible re- entry 
into the study in an emergency 
situation
Section 7. Assessment of Safety
In the event of an emergency situation (eg, the COVID -19 
pandemic), in case a patient cannot return to the clinic for 
the scheduled visits (eg, due to quarantine, isolation, 
patientâ€™s concern, or closure of the site clinic), patients will 
be allow ed to obt ain vital signs and ECGs using local clinics In the event of an emergency situation (eg, the COVID -19 
pandemic), in case a patient cannot return to the clinic for 
the scheduled visits (eg, due to quarantine, isolation, 
patientâ€™s concern, or closure of the site clinic), patients will 
be allow ed to obtain vital signs and ECGs using local 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
173Protocol t ext with changes shown New wording Reason/justification for change
(primary health care provider) or home nursing service, 
where available.clinics (primary health care provider) or home nursing 
service, where available
Appendix D. Quality Control and Quality Assurance
Study Monitoring
In case of an emergency situation (eg, the COVID -19 
pandemic), where study monitors may not be able to access 
the investigational centers for on -site visits in a timely 
manner. A remote monitoring risk mitigation plan , sites will 
be utilized for sites where onsite monitoring visits are not 
permitted. Details monitored remotely where allowed and in 
accordance w ith the local regulations. Additional details are 
provided in the monitoring plan.Study Monito ring
In case of an emergency situation (eg, the COVID -19 
pandemic), where study monitors may not be able to access 
the investigational centers for on -site visits, sites will be 
monitored remotely where allow ed and in accordance with 
the local regulations. Additional details are provided in the 
monitoring plan.Minor clarification for remote 
monitoring considerations in an 
emergency situation
See new wording column Audit and Inspection
In case of an emergency situation (eg, the COVID -19 
pandemic), where auditors may not be able to access the 
investigational centers for on -site visits, investigational 
centers will be audited remotely where allow ed and in 
accordance w ith local regulations.Minor clarification for remote 
auditing considerations in an 
emergen cy situation
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
17416.4. Amendment 03 Dated 08 June 2020
The primary  reason for this amendment is to provide the management of coronavir us disease 
2019 (COVID -19) pandemic -related operational updates as detailed in a new appendix 
(Appendix M). Administrative changes have been applied, including updating the Table of 
Contents.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
175Original text with changes shown New wording Reason/Justification for change
3.1. General Study Design and Study Schematic Diagram
See New Wording Column For coronavirus disease 2019 (COVID -19) 
updates, refer to Appendix M.Updated sections to cross -reference the addition of Appendix M
3.5. Schedule of Study Procedures and Assessments
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
4.3.Withdrawal Criteria and Procedures for the Patient
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
6.ASSESSMENT OF EFFICACY
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
7.ASSESSMENT OF SAFETY
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
7.5.2.1. Beta -Hum an Chorionic Gonadotropin Tests
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
7.5.2.2. Urine Drug Screen
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
9. Statistics
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
10. Quality Control and Quality Assurance
See New Wording Column For COVID -19 updates, refer to Appendix M. Updated sections to cross -reference the addition of Appendix M
Appendix D. Quality Control and Quality Assurance
See New Wording Column For coronavirus disease 2019 (COVID -19) 
updates, refer to Appendix M.Updated sections to cross -reference the addition of Appendix M
Appendix E. Ethics
See New Wording Column For coronavirus disease 2019 (COVID -19) 
updates, refer to Appendix M.Updated sections to cross -reference the addition of Appendix M
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
176Original text with changes shown New wording Reason/Justification for change
Appendix H. List Of Allowed And Prohibited Medications
See New Wording Column For coronavirus disease 2019 (COVID- 19) 
updates, refer to Appendix M.Updated sections to cross -reference the addition of Appendix M
Appendix M. Managem ent of Study Activities During COVID -19
New appendix and text Additional text too numerous to include in this 
table; refer to Appendix M of this protocol.Updated to manage study conduct during the COVID -19 
pandemic.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
17716.5. Amendment 02 Dated 17 October 2019
The primary  reason for this amendment is to add new secondary  endpoints, provide additional 
withdrawal criteria ,and to clarify  the inclusion/exclusion criteria.  
This amendment is considered to be substantial b y the sponsorâ€™s authorized representati ve. These 
substantive changes included revised inclusion criteria and new criteria for earl y withdrawal of 
study  treatment.  
Other minor or editorial changes have been made to the protocol (and protocol sy nopsis, as 
appropriate). These changes are unlikel y to affect the safet y or rights (ph ysical or mental 
integrit y) of the patients in this clinical study or the scientific value of the clinical study.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
178Original text with changes shown New wording Reason/Justification for change
Synopsis and throughout the protocol 
Parent/ caregiver caregiver
Clarification 
Caregiver /adult caregiver
Synopsis [Regions Planned]
North America , Asia, and the Europe an Union North America, Asia, and Europe Clarification 
Synopsis [General Study Design] (Other sections affected by anyone of these changes: 3.1)
This is a Phase 3, 21 -week, multicenter, randomized, 
double- blind, placebo -controlled, parall el group study to 
evaluate the efficacy and safety of TEV -50717 
administered as oral tablets at a starting dose of 6 mg 
once daily in patients (age 6 through 18 years) with 
DCP w ith predominant choreiform movement disorder, 
who have had CP symptoms, of a n on-progressive 
nature, since infancy ( â‰¤2 years of age). â€œPredominantâ€ 
in this instance indicates that the choreiform movement 
disorder is the main cause of impairment or distress. This is a Phase 3, 21 -week, multicenter, randomized, 
double- blind, placebo -controlled, parallel group study to 
evaluate the efficacy and safety of TEV -50717 
administered as oral tablets at a starting dose of 6 mg 
once daily in patients (age 6 through 18 years) with 
DCP w ith predominant choreiform movement disorder, 
who have had C P symptoms, of a non -progressive 
nature, since infancy (â‰¤2 years of age). â€œPredominantâ€ 
in this instance indicates that the choreiform movement 
disorder is the main cause of impairment or distress.Clarification 
Synopsis [General Study Design] (Other sections affected by anyone of these changes: 3.1)
For the purposes of this protocol, a caregiver is defined 
as an adult, who is familiar with the patient and 
responsible for daily care, enabling that person to 
effectively complete the protocol requiremen ts. The 
caregiver accompanies the patient to the visits and 
provides input to the relevant scales as required by the 
protocol.  
For patients who are minors, the caregiver is typically a 
parent or legal guardian. In some countries an adult 
(such as grandpa rent or nurse) can be appointed by the 
parent or legal guardian (as per local regulations and 
laws) and w ould take over this responsibility as 
acaregiver. The parent or legal guardian only has to sign 
the parent/legal guardian informed consent form (ICF) 
and not the caregiver ICF.
For adult patients, a caregiver must be appointed by the For the purposes of this protocol, a caregiver is defined 
as an adult who is familiar with the patient and 
responsible for daily care, enabling tha t person to 
effectively complete the protocol requirements. The 
caregiver accompanies the patient to the visits and 
provides input to the relevant scales as required by the 
protocol.  
For patients who are minors, the caregiver is typically a 
parent or legal guardian. In some countries, an adult 
(such as grandparent or nurse) can be appointed by the 
parent or legal guardian (as per local regulations and 
laws) and w ould take over this responsibility as a 
caregiver. The parent or legal guardian only has to sign 
the parent/legal guardian informed consent form (ICF) 
and not the caregiver ICF.
For adult patients, a caregiver must be appointed by the Clarification 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
179Original text with changes shown New wording Reason/Justification for change
patient; this can be the parent, a legal guardian, or other 
adult, as appropriate and according to local laws and 
regulations.
For patients who are minors, certain responsib ilities in 
the protocol can only be completed by the parent/legal 
guardian, ie, informed consent, w ithdraw al of consent, 
requests for discontinuation of IMP, or w ithdrawal from 
the study for any reason. To further clarify, the 
caregiver is not allowed to m ake decisions on childâ€™s 
health, or w here â€œparent/legal guardianâ€ is specifically 
indicated in the protocol.patient; this can be the parent, a legal guardian, or other 
adult, as appropriate and according to local laws an d 
regulations.
For patients who are minors, certain responsibilities in 
the protocol can only be completed by the parent/legal 
guardian, ie, informed consent, w ithdraw al of consent, 
requests for discontinuation of the IMP, or w ithdraw al 
from the study for any reason. To further clarify, the 
caregiver is not allowed to make decisions on childâ€™s 
health or where â€œparent/legal guardianâ€ is specifically 
indicated in the protocol.
IMP w ill be titrated during the double- blind treatment 
period start ing with 6 mg of TEV- 50717 or matching 
placebo IMP in the morning of days 2 and 3 ., followed 
byPatients with a body weight â‰¥40 kg/88 lbs w ill 
further dose in the evening administration starting on 
day 3 andfor the remainder of the first week (if body 
weight is â‰¥40 kg/88 lbs) . IMP w ill be titrated during the double- blind treatment 
period starting with 6 mg of TEV- 50717 or matching 
placebo IMP in the morning of days 2 and 3. Patients 
with a body weight â‰¥40 kg/88 lbs w ill further dose in 
the evening startin g on day 3 and for the remainder of 
the first week. Clarification 
Synopsis [Screening Period]
After written informed consent /(and w ritten assent 
and/or co consent for patients 14 years of age and older , 
as appropriate,) is obtained, ... After written informed consent/assent, as appropriate, is 
obtained, ...Clarification 
...The EAB will also confirm, based on video 
recordings, that choreiform is clinically the predominant 
movement disorder of the patientâ€™s DCP. EAB 
assessment results will be availabl e to the investigator 
prior to baseline and randomization. At all other visits, 
Tthe MD -CRS part II will be administered by the 
investigational center physician and video review, for 
central -blinded reading. In this study, the MD -CRS 
partII will be scored only based on chorea....The EAB will also confirm, based on video 
recordings, that choreiform is clinically the predominant 
movement disorder of the patientâ€™s DCP. EAB 
assessment results will be available to the investigator 
prior to baseline and randomi zation. The MD -CRS 
partII will be administered by the investigational center 
physician and video review, for central -blinded reading. 
In this study, the MD -CRS part II will be scored only 
based on chorea.Clarification 
Synopsis [Titration Period]
Patients will be classified as CYP2D6 impaired if they 
are receiving a strong CYP2D6 inhibitor or are a 
CYP2D6 poor metabolizer. At the baseline visit, a Patients will be classified as CYP2D6 impaired if they 
are receiving a strong CYP2D6 inhibitor or are a 
CYP2D6 poor metabol izer. At the baseline visit, a Clarification 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
180Original text with changes shown New wording Reason/Justification for change
telephone for non -recording live video will be provided 
to the patient and caregiver. Patients and the ir 
caregiver /adult will interact weekly with the 
investigator/staff, either by telephone contact (with non -
recording live video) ...telephone for non -recording live video will be provided 
to the patient and caregiver. Patients and their caregiver 
will interact weekly with the investigator/staff, either by 
telephone contact (with non -recording live video) 
Synopsis [Washout Period] (Other sections affected by anyone of these changes: Synopsis [Plan for Treatm ent or Care], 3.1, and 5.4)
Patients who complete treatment, but choose not to 
participate not participating in the open -label safety 
extension Study TV50717 -CNS -30081 will be 
contacted have a follow up telephone contact for a
safety evaluation call occurring 1week after the end of 
the washout period ( 2weeks after their last dose of IMP
[week17]).Patients who complete treatment, but choose not to 
participate in the open -label safety extension Study 
TV50717 -CNS -30081 will be contacted for a safety 
evaluation call occurring 2 weeks after their last dose of 
IMP.Clarification 
Synopsis [Washout Period] (Other sections affected by anyone of these changes: 3.1)
All patients who discontinue early will have a follow -up 
telephone contact for safety evaluation 2 weeks after 
their last dose of IMP ET; evaluations will be as 
described for w eek 17. All patients who discontinue early will have a follow -up 
telephone contact for safety evaluation 2 weeks after 
ET; evaluations will be as described for w eek 17. Change originally included in Letter of 
Clarification #5 (Section 16.2).
Synopsis [Inclusion Criteria] (Other sections affected by anyone of these changes: 4.1)
5.Patient has an MD -CRS part II total score of â‰¥10 at 
the baseline visit, based on investigator scoring of 
chorea.
7.Choreiform is the predominant (ie, the main cause 
of impairment or distress) movement disorder as 
assessed at screening.
12.Patient and caregiver/adult provided w ritten 
informed consent according to local regulations 
(eg,for patients/adolescents, the patient has 
provided w ritten assent and/or co consent for 
patients 14 years of age and older, as appropriate).
For a patient who is a minor, the parent(s)/legal 
guardian(s) provide w ritten informed consent, and 
the patient provides assent (in accordance w ith local 
regulations). Adult patients provide their own 
written inform ed consent (in accordance w ith local 5.Patient has an M D-CRS part II total score of â‰¥10 at 
the baseline visit, based on investigator scoring of 
chorea.
7.Choreiform is the predominant (ie, the main cause 
of impairment or distress) movement disorder as 
assessed at screening.
12.For a patient who is a minor, t he parent(s)/legal 
guardian(s) provide w ritten informed consent, and 
the patient provides assent (in accordance w ith local 
regulations). Adult patients provide their own 
written informed consent (in accordance w ith local 
regulations).
13.Caregivers provid e written informed consent after 
being assigned the role by an adult patient, or if this 
role is delegated by the parent/legal guardian of a Clarification 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
181Original text with changes shown New wording Reason/Justification for change
regulations).
13.Caregivers provide w ritten informed consent after 
being assigned the role by an adult patient, or if this 
role is delegated by the parent/legal guardian of a 
patient who is a minor.patient who is a minor.
Synopsis [Exclusion Criteria]
6.Patient who is currently receiving or who, in the last 
4 months before screening, has received botulinum 
neurotoxin (BoNT) in an investigational clinical 
trial.
â€“Note: Patients may be included in the study if 
they have at least 2 treatments of Food and 
Drug Administration -approved BoNT at a 
regular interval (eg, every 3 to 4 months), 
in reasonably stable dosages and locations 
(subject to investigatorâ€™s judgment) to 
treat low er limb spasticity or dystonia, and 
if they are expected to continue this stable 
regimen of BoNT injections for the 
duratio n of this study. The patient is 
expected to continue on this stable 
regimen of BoNT injections on a regularly 
scheduled interval every 3 months for the 
duration of this study. The injection for 
spasticity or dystonia must be in a 
muscular region that is se parate from the 
main areas affected by choreiform 
movement disorder.
â€œFood and Drug Administration -approved 
BoNTâ€ is to be defined as an FDA -
approved compound, not necessarily an 
FDA -approved treatment for children. 
BoNT treatments other than FDA-
approved drugs can be submitted to the 
medical monitor for consideration.
â€“Note: Patients who received BoNT injections 6.Patient who is currently receiving or who, in the last 
4 months before screening, has received botulinum 
neurotoxin (BoNT) in an investigational clinical 
trial.
â€“Note: Patients may be included in the study if 
they have at least 2 treatments of Food and 
Drug Administration -approved BoNT at a 
regular interval (eg, every 3 to 4 months), 
in reasonably stable dosages and locations 
(subject to investigatorâ€™s judgment) to 
treat low er limb spasticity or dystonia, and 
if they are expected to continue this stable 
regimen of BoNT injections f or the 
duration of this study. The patient is 
expected to continue on this stable 
regimen of BoNT injections on a regularly 
scheduled interval every 3 months for the 
duration of this study. The injection for 
spasticity or dystonia must be in a 
muscular reg ion that is separate from the 
main areas affected by choreiform 
movement disorder.
â€œFood and Drug Administration -approved 
BoNTâ€ is to be defined as an FDA -
approved compound, not necessarily an 
FDA -approved treatment for children. 
BoNT treatments other tha n FDA -
approved drugs can be submitted to the 
medical monitor for consideration.
â€“Note: Patients who received BoNT injections Clarification
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
182Original text with changes shown New wording Reason/Justification for change
more than 4 months before screening and 
who do not plan to continue these 
injections may be considered for this 
study.more than 4 months before screening and 
who do not plan to continue these 
injections may be considered for this 
study.
13.Patient has evidence of diminished hepatic 
impairm entfunction , as indicated by the following:13.Patient has evidence of diminished hepatic function, 
as indicated by the following:Clarification 
19.Patient has a positive urine drug screen test result 
(with exception of medications listed in Table 9 of 
Appendix H) or is unable to refrain from substance 
abuse throughout the study.19.Patient has a positive urine drug screen test result 
(with exception of medications listed in Table 9 of 
Appendix H) or is unable to refrain from substance 
abuse throughout the study.Clarification 
1.2.2. Clinical Studies
The clinical development plan for TEV -50717 to date 
includes the following:
1.SixNine completed Phase 1 studies in healthy adult 
volunteersThe clinical development plan for TEV -50717 to date 
includes the following:
2.Nine completed Phase 1 studies in healthy adult 
volunteersUpdate
1.2.2. Clinical Pharm acology Studies
SixNine Phase 1 clinical pharmacology studies were 
conducted in healthy adult volunteers. Nine Phase 1 clinical pharmacology studies were 
conducted in healthy adult volunteers. 
3.1. General Study Design
...and assessment of sedation according to the Epworth 
Sleepiness Scale (for children and adolescents) (ESS) 
questionnaire of using a telephone with non recording 
live video w ill be made possible, and the adoption of 
live video to support patient/caregiver intervie w will 
then be maintained throughout the study for the 
evaluation of safety/tolerability and dyskinesia severity . ...and assessment of sedation according to the Epworth 
Sleepiness Scale (for children and adolescents) (ESS) 
questionnaire. Clarification 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
183Original text with changes shown New wording Reason/Justification for change
Figure 1:Overall Study Schem atic Diagram
Clarification 
3.2 Planned Number of Patients and Regions
This study is planned to be conducted in approximately 
70investigational centers in North America , Asia, and 
the Europe an Union (EU) . This study is planned to be conducted in approximately 
70investigational centers in North America, Asia, and 
Europe. Clarification 
Table 3:Study Procedures and Assessments 
First Column
Row: Informed consent/assent and/or co consent for 
patients (as applicable)jFirst Column
Row: Informed consent/assentjClarification 
dFor patients who withdraw prematurely, an ET visit 
should be conducted as soon as possible after the last 
dose of IMP. All patients who discontinue early will 
have a follow -up telephone contact for safety 
evaluation 2 weeks after their la st dose of IMP ET; 
evaluations will be as described for w eek 17.
j  
rFor females who are postmenarchal or aged â‰¥12 
years of childbearing potential. Serum test will be 
administered at baseline screening and week 15, 
whereas a urine test will be administered at 
screening baseline and all other in-clinic visits.
zParents /Caregi vers and patients will be instructed 
during the course of the study to notify the 
investigator if any new medication is prescribed, 
including over -the-counter medications. Any 
prescribed medication should be review ed with the 
investigator.dFor patients w ho withdraw prematurely, an ET visit 
should be conducted as soon as possible after the last 
dose of IMP. All patients who discontinue early will 
have a follow -up telephone contact for safety 
evaluation 2 weeks after ET; evaluations will be as 
described for week 17
j  
rFor females who are postmenarchal or aged â‰¥12 
years of childbearing potential. Serum test will be 
administered at screening and week 15, whereas a 
urine test will be administered at baseline and all 
other in -clinic visits.
zCaregivers and patients will be instructed during the 
course of the study to notify the investigator if any 
new medication is prescribed, including over -the-
counter medications. Any prescr ibed medication 
should be review ed with the investigator.Clarification 
4.2. Exclusion Criteria
6.Patient who is currently receiving or who, in the last 
4 months before screening , has received botulinum 6.Patient who is currently receiving or who, in the last 
4 months before screening, has received botulinum 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
184Original text with changes shown New wording Reason/Justification for change
neurotoxin (BoNT) in an investigational clinical 
trial.
â€“ Note: Patients may be included in the study if they 
have at least 2 treatments of Food and Drug 
Administration -approved BoNT at a regular 
interval (eg, every 3 to 4 months), in reasonably 
stable dosages and locations (subject to 
investigatorâ€™s judge ment) to treat low er limb 
spasticity or dystonia, and if they are expected 
to continue this stable regimen of BoNT 
injections for the duration of this study. The 
patient is expected to continue on this stable 
regimen of BoNT injections on a regularly 
sched uled interval every 3 months for the 
duration of this study. The injection for 
spasticity or dystonia must be in a muscular 
region that is separate from the main areas 
affected by choreiform movement disorder.
â€œFood and Drug Administration -approved 
BoNTâ€ is to be defined as an FDA -approved 
compound, not necessarily an FDA -approved 
treatment for children. BoNT treatments other 
than FDA -approved drugs can be submitted to 
the medical monitor for consideration.
â€“ Note: Patients who received BoNT injections more 
than 4 months before screening and who do not 
plan to continue these injections may be 
considered for this study.neurotoxin (BoNT) in an investigat ional clinical 
trial.
â€“ Note: Patients may be included in the study if they 
have at least 2 treatments of Food and Drug 
Administration -approved BoNT at a regular 
interval (eg, every 3 to 4 months), in reasonably 
stable dosages and locations (subject to 
inves tigatorâ€™s judgement) to treat low er limb 
spasticity or dystonia, and if they are expected 
to continue this stable regimen of BoNT 
injections for the duration of this study. The 
patient is expected to continue on this stable 
regimen of BoNT injections on a regularly 
scheduled interval every 3 months for the 
duration of this study. The injection for 
spasticity or dystonia must be in a muscular 
region that is separate from the main areas 
affected by choreiform movement disorder.
â€œFood and Drug Administration -approved 
BoNTâ€ is to be defined as an FDA -approved 
compound, not necessarily an FDA -approved 
treatment for children. BoNT treatments other 
than FDA -approved drugs can be submitted to 
the medical monitor for consideration.
â€“ Note: Patients who received BoNT i njections more 
than 4 months before screening and who do not 
plan to continue these injections may be 
considered for this study.
13.Patient has evidence of diminished hepatic 
impairm entfunction , as indicated by the following:13.Patient has evidence of diminished hepatic function, 
as indicated by the following:
19.Patient has a positive urine drug screen test result 
(with exception of medications listed in Table 9 of 
Appendix H) or is unable to refrain from substance 
abuse throughout the study.19.Patient has a positive urine drug screen test result 
(with exception of medications listed in Table 9 of 
Appendix H) or is unable to refrain from substance 
abuse throughout the study.
4.3.Withdrawal Criteria and Procedures for the Patient
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
185Original text with changes shown New wording Reason/Justification for change
9.Patient has evidence of diminished hepatic function 
based on the following liver function laboratory test 
results:
a.AST or ALT >2.5 Ã— ULN
b.ALP or total bilirubin >2 Ã—ULN
10.Patient develops Neuroleptic Malignant Syndrome 
(NMS)9.Patient has evidence of diminished hepatic function 
based on the following liver function laboratory test 
results:
a.AST or ALT >2.5 Ã— ULN
b.ALP or total bilirubin >2 Ã—ULN
10.Patient develops Neuroleptic Malignant Syndrome 
(NMS)Clarification 
5.5. Restrictions
If the removal of a strong CYP2D6 inhibitor is required 
from a clinical perspective, the medical monitor should 
be contacted so that an appropriate change in IMP 
dosing can be made. The addition of a strong CYP 2D6
inhibitor is prohibited during the study.If the removal of a strong CYP2D6 inhibitor is required 
from a clinical perspective, the medical monitor should 
be contacted so that an appropriate change in IMP 
dosing can be made. The addition of a strong CYP2D6 
inhibitor is prohibited during the study.Clarification 
As with other VMAT2 inhibitors (tetrabenazine and 
reserpine), patients should be advised that the 
concomitant use of alcohol or other sedating drugs with 
TEV -50717 may have additive effects and cause or 
worsen somnolence. Given the age of the study 
population, the use of alcohol during this study is 
prohibited. As with other VMAT2 inhibitors (tetrabenazine and 
reserpine), patients should be advised that the 
concomitant use of alcohol or other sedating drugs with 
TEV -50717 may have additive effects and cause or 
worsen somnolence. 
Use of illicit non-approved drugs (per protocol) is 
prohibited from the time of signing of the ICF and 
throughout study participation.Use of non -approved drugs (per protocol) is prohibited 
from t he time of signing of the ICF and throughout 
study participation.
5.6. Prior and Concom itant Medication
At each clinic visit after the screening visit, the 
investigator will ask patients and/or parent(s)/ caregiver 
whether they or the patient , respectively, have hastaken 
any medications (other than IMP), including over -the-
counter medications, vitamins, or herbal or nutritional 
supplements, since the previous visit. Parents Caregivers 
and patients will be instructed during the course of the 
study to notify the investigator if any ne w medication is 
prescribed, including over -the-counter medications. Any 
prescribed medication should be review ed with the At each clinic visit after the screening visit, the 
investigator will ask patients and/or caregiver whether 
the patient has taken any medications (other than IMP), 
including over -the-counter medications, vitamins, or 
herbal or nutritional supplements, since the p revious 
visit. Caregivers and patients will be instructed during 
the course of the study to notify the investigator if any 
new medication is prescribed, including over -the-
counter medications. Any prescribed medication should 
be review ed with the investigator. Indication, dosage, Clarification 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
186Original text with changes shown New wording Reason/Justification for change
investigator. Indication, dosage, and start and end dates 
should be entered on the CRF. and start and end dates should be entered on the CRF. 
5.8. Tem porary Discontinuation of Investigational Medicinal Product
If a patientâ€™s serum potassium or magnesium level falls 
below  the lower limit of normal, IMP m ust be 
suspended. Since TEV -50717 does not have any known 
effect on potassium and magnesium levels, the reference 
to potassium and magnesium is in the context of other 
factors related to any current underlying condition, such 
as severe diarrhea or intake of drugs that lower serum 
potassium and magnesium. The investigator w ill be 
responsible to manage the patientâ€™s condition per the 
siteâ€™s standard of care and assess continuation of 
treatment. The m edical monitor must should be 
contacted to discuss the suspension and possible 
resumption of the IMP determine the appropriate 
investigation and treatment . IMP treatment may only be 
restarted once serum potassium and/or magnesium 
levels have normalized.
The p Patients who restart IMP treatment will follow  the 
visit schedule as outlined in Table 3 . If a patientâ€™s serum potassium or magnesium level falls 
below  the lower limit of normal, IMP must be 
suspended. Since TEV -50717 does not have any known 
effect on potassium and magnesium levels, the 
reference to potassium and magnesium is in the context 
of other factors related to any current underlying 
condition, such as severe diarrhea or intake of drugs that 
lower serum potassium and magnesium. The 
investigator will be responsible to manage the patientâ€™s 
condition per the siteâ€™s standard of care and asses s 
continuation of treatment. The medical monitor should 
be contacted to discuss the suspension and possible 
resumption of the IMP. IMP treatment may only be 
restarted once serum potassium and/or magnesium 
levels have normalized.
Patients who restart IMP t reatment will follow  the visit 
schedule as outlined in Table 3 . Clarification 
6.1. Prim ary Efficacy Measure
Assessment of MD -CRS part II items will be based 
solely on chorea in this study and performed as follows: 
â€¢Local assessment (all time points): the 
investigational center physician will administer the 
MD-CRS part II and complete the assessment of item 
scores. Note: the physicians will receive training on 
MD-CRS scoring prior to the study.
â€¢EAB review (screening): EAB w ill review the MD -
CRS part II at the screening visit to confirm that 
dyskinesia severity is aligned with the protocol 
criteria for inclusion into the study. The review will 
include determination of the predominant dyskinesia 
type and scoring of MD -CRS part II items. The EAB Assessment of MD -CRS part II items will be based 
solely on chorea in this study and performed as follows: 
â€¢Local assessment (all time points): the 
investigational center physician will administer the 
MD-CRS part II and complete the assessment of item 
scores. Note: the physicians will receive training on 
MD-CRS scoring prior to the study.
â€¢EAB review (screening): EAB w ill review the MD -
CRS part II at the screening visit t o confirm that 
dyskinesia severity is aligned with the protocol 
criteria for inclusion into the study. The review will 
include determination of the predominant dyskinesia 
type and scoring of MD -CRS part II items. The EAB 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
187Original text with changes shown New wording Reason/Justification for change
will inf orm the site prior to the baseline visit if there 
are any discrepancies betw een the local and central 
assessments , and offer to discuss with the 
investigator. Ultimately, it is the investigator who 
determines the patientâ€™s eligibility. EAB assessment 
of sc reening MD -CRS part II total score w ill not be 
included in the statistical analysis.will inform the site prior to the b aseline visit if there 
are any discrepancies betw een the local and central 
assessments, and offer to discuss with the 
investigator. Ultimately, it is the investigator who 
determines the patientâ€™s eligibility. EAB assessment 
of screening MD- CRS part II total score w ill not be 
included in the statistical analysis.
6.3.2. Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score
The Total Motor Score assessment of the UHDRS 
(UHDRS TMS) comprises 15 items and assesses eye 
movements, speech, alternating hand movements, 
dystonia, chorea, and gait. The UHDRS -TMS is 
calculated as the sum of the 31 motor assessments; each 
of which range s between 0 to 4. The m inimum score is 
0 (absent) and the maximum score is 124108 (worst) 
(Huntington Study Group 1996).The Total Motor Score assessment of the UHDRS 
(UHDRS TMS) comprises 15 items and assesses eye 
movements, speech, alternating hand movem ents, 
dystonia, chorea, and gait. The UHDRS -TMS is 
calculated as the sum of the 31 motor assessments; each 
of which ranges between 0 to 4. The minimum score is 
0 (absent) and the maximum score is 124 (w orst) 
(Huntington Study Group 1996).
6.3.6. Pediatri c Quality of Life Inventory, Cerebral Palsy Module
The scales comprise parallel child self -report and parent 
proxy -report formats. Child self report includes For 
children ages 5 to6 and 7 years ,and8 to 12 years, and 
13 to 18 years. A a child self -report and a parent proxy 
report are completed. is included in reports for ages 2 to 
4 years (toddler), 5 to 7 years (young child), 8 to 12 
years (child), and 13 to 18 years (adolescent), and The 
parent proxy report assesses parentsâ€™ perceptions of 
their childâ€™s health -related quality of life (QoL). For 
children ages 13 to 18 years, no parent proxy report is 
required. The instructions ask how  much of a problem 
each item has been during the past 1 month. A 5 -point 
response scale is utilized across child self -report and 
parent proxy report as follows:The scales comprise parallel child self -report and parent 
proxy -report formats. For children ages 6 and 7 years 
and 8 to 12 years, a child self -report and a parent proxy 
report are completed. The parent proxy report as sesses 
parentsâ€™ perceptions of their childâ€™s health -related 
quality of life (QoL). For children ages 13 to 18 years, 
no parent proxy report is required. The instructions ask 
how much of a problem each item has been during the 
past 1 month. A 5 -point respon se scale is utilized across 
child self -report and parent proxy report as follows:Clarification 
7.1.2. Recording and Reporting of Adverse Events
The follow -up period of recording of adverse events is 
defined as 2 weeks after the last dose of IMP for 
patients who will not roll over into the open -label safety The follow -up period of recording of adverse events is 
defined as 2 weeks after the last dose of IMP for 
patients who will not roll over into the open -label safety Clari fication 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
188Original text with changes shown New wording Reason/Justification for change
extension study or 2 w eeks after the ET visit for patients 
who terminate early from the study, or the d ate of 
enrollment in the open label extension (OLE) study 
TV50717 -CNS -30081 for patients rolling over to the 
OLE study .extension study or 2 w eeks after the ET visit for patients 
who terminate early from the study, or the date of 
enrollment in the open label extension (OLE) study 
TV50717 -CNS -30081 for patients rolling over to the 
OLE study.
The clinical course of each adverse event will be 
monitored at suitable intervals until resolved, stabilized, 
or returned to baseline; until the patient is referred for 
continued care to a health care professional; or until a 
determination of a cause unrelated to the IMP or study 
procedure is made. Adverse events of patients rolling 
over to the OLE study TV50717 -CNS -30081 w ill 
continue to be monitored as part of the OLE study.The clinical course of each adverse event will be 
monitored at suitable intervals until resolved, stabilized, 
or returned to baseline; until the patient is referred for 
continued care to a health care professional; or until a 
determination of a cause unrelated to the IMP or study 
procedure is made. Adverse events o f patients rolling 
over to the OLE study TV50717 -CNS -30081 w ill 
continue to be monitored as part of the OLE study. Clarification 
7.2.2. Child Behavior Checklist (for Ages 6 -18)
The Syndrome Scale comprises 11 38questions related 
to problem behaviors. This study will use a recall period 
of â€œnow or w ithin the last week,â€ representing a 
modification from the original scale, which was â€œnow  or 
within the last 6 monthsâ€. For each item, the 
parent/ caregiver will circle 0 if the item is not true of 
their child, 1 if the item is somewhat or sometimes true, 
and 2 if the item is very true or often true.The Syndrome Scale comprises 113 questions related to 
problem behaviors. This study w ill use a recall period of 
â€œnow  or wi thin the last week,â€ representing a 
modification from the original scale, which was â€œnow  or 
within the last 6 monthsâ€. For each item, the caregiver 
will circle 0 if the item is not true of their child, 1 if the 
item is somewhat or sometimes true, and 2 if the item is 
very true or often true.Clarification 
7.4. Medication Error and Special Situations Related to the Investigational Medicinal Products
Any administration of IMP that is not in accordance 
with the study protocol should be reported inonthe CRF 
and in the patients source documents either as a 
violation deviation if it the event meets the 
violation deviation criteria specified in the protocol 
(Appendix D ), or as a deviation, in the patients source 
documents, regardless of whether or not an adverse 
event occurs as a result.Any administration of IMP that is not in accordance 
with the study protocol should be reported in the CRF 
and in the patientâ€™s source documents as a deviation if 
the event meets the violation criteria specified in the 
protocol (Appendix D), regardless of whether or not an 
adverse event occurs as a result.Clarification 
7.12. Concom itant Medication or Treatm ent
Concomitant therapy or medication usage will be 
monitored throughout the study according to time points 
detailed in Table 3 . Parents/patients will be instructed Concomitant therapy or medication usage will be 
monitored throughout the study according to time points 
detailed in Table 3 . Parents/patients will be instructed Clarification 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
189Original text with changes shown New wording Reason/Justification for change
during the course of the study to notify the investigator 
if any new medication is prescribed/adm inistered, 
including over -the-counter medications. Any 
prescribed/administered medication should be reviewed 
with the investigator. Of note, any 
formulation/derivative of cannabis is prohibited during 
the study.
Patients may be included in this study if they are using 
cannabis or formulations or derivatives of cannabis in 
relatively stable amounts, for medical purposes (where 
applicable according to local regulation), under the 
guidance, supervision, or prescription of a clinician. 
Patients who are either using cannabis or its derivatives 
or formulations or patients who have a positive drug 
screen for cannabis or its derivatives or formulations 
can be submitted to the medical monitor for 
consideration of participation in this study. Patients with 
a substan ce use disorder (by Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition, criteria) are 
excluded from this clinical trial. If per the investigatorâ€™s 
judgment, however, a patient does not meet the criteria 
for substance use disorder, a positiv e drug screen for 
cannabis or its metabolites, without medical 
explanation, will be discussed on a case -by-case basis 
betw een the research site, the Medical Monitor, and the 
sponsor to determine the patientâ€™s eligibility, based on 
the information available. Patients should be advised 
that the recreational use of cannabis or its derivatives or 
formulations should be avoided during this study. 
The medical monitor must be contacted if a patient is 
receiving (or has to begin or stop receiving during the 
study) a medication that is associated w ith QTc 
prolongation or that is a known strong CYP 2D6
inhibitor. Prohibited medications that are associated 
with QTc prolongation are listed in Appendix H, Table 
10, while prohibited antipsychotic drugs are listed in 
Appen dix H, Table 11.during the course of the study to notify the investigator 
if any new medicatio n is prescribed/administered, 
including over -the-counter medications. Any 
prescribed/administered medication should be reviewed 
with the investigator. 
Patients may be included in this study if they are using 
cannabis or formulations or derivatives of cann abis in 
relatively stable amounts, for medical purposes (where 
applicable according to local regulation), under the 
guidance, supervision, or prescription of a clinician. 
Patients who are either using cannabis or its derivatives 
or formulations or patients who have a positive drug 
screen for cannabis or its derivatives or formulations 
can be submitted to the medical monitor for 
consideration of participation in this study. Patients with 
a substance use disorder (by Diagnostic and Statistical 
Manual of Menta l Disorders, 5th edition, criteria) are 
excluded from this clinical trial. If per the investigatorâ€™s 
judgment, however, a patient does not meet the criteria 
for substance use disorder, a positive drug screen for 
cannabis or its metabolites, without medical
explanation, will be discussed on a case -by-case basis 
betw een the research site, the Medical Monitor, and the 
sponsor to determine the patientâ€™s eligibility, based on 
the information available. Patients should be advised 
that the recreational use of cann abis or its derivatives or 
formulations should be avoided during this study. 
The medical monitor must be contacted if a patient is 
receiving (or has to begin or stop receiving during the 
study) a medication that is associated w ith QTc 
prolongation or that is a known strong CYP2D6 
inhibitor. Prohibited medications that are associated 
with QTc prolongation are listed in Appendix H, Table 
10, while prohibited antipsychotic drugs are listed in 
Appendix H, Table 11.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
190Original text with changes shown New wording Reason/Justification for change
8.1. Pharm acokinetic Assessment
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 Bolded text added for emphasis
9.10. Pharm acokinetic/Pharmacodynamic Analysis
 
 
 
 
 
  
 
 
 
 
 Clarification
10. QUALITY CONTROL AND QUALITY ASSURANCE
Refer to Appendix D for information regarding quality 
control and quality assurance. This includes information 
about protocol amendments , deviations and violations , 
responsibilities of the investigator to study personnel, 
study monitoring, and audit and inspection.Refer to Appendix D for information regarding quality 
control and quality assurance. This includes information 
about protocol amendments, deviations, responsibilities 
of the investigator to study personnel, study monitoring, 
and audit and inspection.Clarification 
15. REFERENCES 
AUSTEDOÂ®(deutetrabenazine) tablets (US prescribing 
information). Teva Pharmaceuticals USA, Inc; 201 79. 
Available at: https://austedo.com/hd/pi.AUSTEDOÂ®(deutetrabenazine) tablets (US prescribing 
information). Teva Pharmaceuticals USA, Inc; 2019. 
Available at: ht tps://austedo.com/hd/pi.Clarification 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
191Original text with changes shown New wording Reason/Justification for change
Xenazine: Highlights of Prescribing Information. 
20185 . Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/20
15/021894s010lbl.pdf https://dailymed.nlm.nih.gov/dail
ymed/drugInfo.cfm? setid=ac768bab -8afa- 4446- bc7f-
caeeffec0cda. Accessed 27 Oct 2015 05 Aug 2019 .Xenazine: Highlights of Prescribing Information. 2018. 
Available at: 
https://dailymed nlm.nih.gov/dailymed/drugInfo.cfm? se
tid=ac768bab -8afa- 4446- bc7f-caeeffec0cda. Accessed 
05 Aug 2019.
Appendix A. CLINICAL LABORATORIES AND OTHER DEPARTMENTS AND INSTITUTIONS
Sponsorâ€™s Authorized Representative:
Teva Pharmaceutical Industries, 
 
Cell: Sponsorâ€™s Authorized Representative:
Teva Pharmaceutical Industries,  
 
Cell: Clarification 
Pharm acokinetic Samples
Watson Pharma Pvt. Ltd. 
Seaw oods Grand Central, Tower 2
Level -11, Win g-E, Plot No. R -1
Sector 40, Nerul, Navi Mumbai 400706 
Tel: 
Contact: Pharm acokinetic Samples
Watson Pharma Pvt. Ltd. 
Seaw oods Grand Central, Tower 2
Level -11, Wing -E, Plot No. R -1
Sector 40, Nerul, Navi Mumbai 400706 
Tel: 
Contact: Addition
Scales and Central Rater for MD -CRS
Bracket Global LLC
575 East Sw edesford Road
Suite 200
Wayne, PAScales and Central Rater for MD -CRS
Bracket Global LLC
575 East Sw edesford Road
Suite 200
Wayne, PAAddition

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
192Original text with changes shown New wording Reason/Justification for change
19087
Tel: 19087
Tel: 
APPENDIX C. STUDY PROCEDURES AND ASSESSMENTS BY VISIT
ï‚·patient s,or parent(s)/ legally acceptable 
representative must provide legal guardian(s), and 
caregivers must provide their respective written 
informed consent ,and/or assent (as appropriate) the 
patients must give assent (as applicable) before any 
study related procedures are performed . 
Assent/consent may also be provided to 2 optional 
ICFs:
â€“  
 
â€“use of patientâ€™s study videos for future analysis 
of gait digital markers and release of patientâ€™s 
study videos for use in publications or 
educational presentations ï‚·patients, parent(s)/legal guardian(s), and caregi vers 
must provide their respective written informed 
consent and/or assent (as appropriate) before any 
study -related procedures are performed. 
Assent/consent may also be provided to 2 optional 
ICFs:
â€“
 
â€“use of patientâ€™s study videos for future analysis 
of gait digital markers and release of patientâ€™s 
study videos for use in publications or 
educational presentations Clarification 
5.Follow -Up (Weeks 16 and 17)
a.Week 16/End of Study follow -up visit (day 
112Â±2 days total from  baseline) , or 1 week 
after ET)5.Follow -Up (Weeks 16 and 17)
a.Week 16/End of Study follow -up visit (day 
112Â±2 days total from  baseline)Change originally included in Letter of 
Clarification #5 (Section 16.3).

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
193Original text with changes shown New wording Reason/Justification for change
6.Unscheduled Visits
An unscheduled visit may be performed at any time 
during the study at the patientâ€™s or parentâ€™s/legally 
acceptable representativeâ€™s caregiverâ€™s request and as 
deemed necessary by the investigator. The date and 
reason for the unscheduled visit will be recorded on the 
CRF as well as any other data obtained from procedures 
and assessments.6.Unscheduled Visits
An unscheduled visit may be performed at any time 
during the study at the patientâ€™s or parentâ€™s/caregiverâ€™s 
request and as deemed necessary by the investigator. 
The date and reason for the unscheduled visit will be 
recorded on the CRF as well as any other data obtained 
from procedures and assessments.Clarification 
APPENDIX D. QUALITY CONTROL AND QUALITY ASSURANCE
Protocol Amendments and Protocol Deviations and 
Violations
Important Protocol Deviations Violations
Any deviation from the protocol that affects, to a 
significant degree, (a) the safety, physical, or mental 
integrity of the patients in th e study and/or (b) the 
scientific value of the study will be considered a n
important protocol deviation violation . PImportant 
protocol deviations violations may include non -
adherence on the part of the patient, the investigator, or 
the sponsor to protocol -specific inclusion and exclusion 
criteria, primary objective variable criteria, or Good 
Clinical Practice (GCP) guidelines; noncompliance to 
IMP administration; and use of prohibited medications. 
Protocol v iolations will be identified and recorded by 
investi gational center personnel in the case report form 
(CRF). All important protocol deviations violations will 
be reported to the responsible IEC/IRB, as required.
When animportant protocol deviation violation is 
reported, the sponsor w ill determine whether to 
withdraw the patient from the study or permit the 
patient to continue in the study, with documented 
approval from the medical expert. The decision will be 
based on ensuring the safety of the patient and 
preserving the integrity of the study.
Changes in the inclusion and exclusion criteria of the 
protocol are not prospectively granted by the sponsor. If Protocol Amendments and Protocol Deviations
Important Protocol Deviations
Any deviation from the protocol that affects, to a 
significant degree, (a) the safety, physical, or mental 
integrity of the patients in the study and/or (b) the 
scientific value of the study will be considered an 
important protocol deviation . Important protocol 
deviations may include non -adherence on the part of the 
patient, the investigator, or the sponsor to protocol -
specific inclusion and exclusion criteria, primary 
objective variable criteria, or Good Clinical Practice 
(GCP) guidelines; noncompliance to IMP 
administration; an d use of prohibited medications. All 
important protocol deviations will be reported to the 
responsible IEC/IRB, as required.
When an important protocol deviation is reported, the 
sponsor w ill determine whether to withdraw the patient 
from the study or perm it the patient to continue in the 
study, with documented approval from the medical 
expert. The decision w ill be based on ensuring the 
safety of the patient and preserving the integrity of the 
study.
Changes in the inclusion and exclusion criteria of the 
protocol are notprospectively granted by the sponsor. If 
investigational center personnel learn that a patient who 
did not meet protocol inclusion and exclusion criteria 
was entered in a study, they must immediately inform Clarification 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
194Original text with changes shown New wording Reason/Justification for change
investigational center personnel learn that a patient who 
did not meet protocol inclusion and exclusion criteria 
was entered in a study, they must immediatel y inform 
the sponsor of the important protocol deviation violation . 
If such patient has already completed the study or has 
withdrawn early, no action will be taken, but the 
deviation violation will be recorded.the sponsor of the important proto col deviation. If such 
patient has already completed the study or has 
withdrawn early, no action will be taken, but the 
deviation will be recorded.
APPENDIX F. BIRTH CONTROL METHODS AND PREGNANCY TESTING
Fem ales (aged 12 years or older) of childbearing 
potential are defined as the following:Fem ales of childbearing potential are defined as the 
following:Clarification
APPENDIX H. LIST OF ALLOWED AND PROHIBITED MEDICATIONS
Medications that are allow ed, provided that conditions 
outlined in the table are met, are shown in Table 9. 
Investigators are encouraged to contact the medical 
monitor for any questions regarding the medications 
listed below .  Medications that are allow ed, provided that conditions 
outlined in the table are met, are shown in Table 9. 
Investigators are encouraged to contact the medical 
monitor for any questions regarding the medications 
listed below .  
Table 9: Allowed Medications
Row: Allowed strong CYP 2D6 inhibitorsaRow: Allowed strong CYP2D6 inhibitorsaClarification
Column: Generic/Drug class
Row: Cannabis or formulations or derivatives of 
cannabisColumn: Generic/Drug class
Row: Cannabis or formulations or derivatives of 
cannabis 
Column: Condition
Row: Patients may be included in this study if they are 
using cannabis or formulations or derivatives of 
cannabis in relatively stable amounts, for medical 
purposes, under the guidance, supervision, or 
prescription of a clinician.Column: Condit ion
Row: Patients may be included in this study if they are 
using cannabis or formulations or derivatives of 
cannabis in relatively stable amounts, for medical 
purposes, under the guidance, supervision, or 
prescription of a clinician. 
Table 12: Total Blood Volum es
Row  1
Column 4: Week 16 /EOSRow  1
Column 4: Week 16/EOSClarification
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study Protocol Amendment 05 Study  TV50717- CNS -30080
19516.6. Letter of Clarification 06 Dated 05 August 2019

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study Protocol Amendment 05 Study  TV50717- CNS -30080
19616.7. Letter of Clarification 05 Dated 16 January 2019

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study Protocol Amendment 05 Study  TV50717- CNS -30080
197

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study Protocol Amendment 05 Study  TV50717- CNS -30080
19816.8. Amendment 01 Dated 20 December 2018
The primary  reason for this amendment is to address comments and recommendations from the 
Food and Drug Administration in relation to study design an d the scales used to perform 
assessments. This amendment is considered to be substantial (ie, requires approval by  competent 
authorities, IEC, and/or IRB) b y the sponsorâ€™s Authorized Representative. Other nonsubstantial 
changes have been made to the protoc ol (and protocol sy nopsis, as appropriate). These changes 
are unlikel y to affect the safet y or rights (ph ysical or mental integrity ) of the patients in this 
clinical study  or the scientific value of the clinical study .
Table 3(Study  Procedures and Assessments) has been revised to reflect changes described 
below.
Other minor or editorial changes have been made to the protocol (and protocol sy nopsis, as 
appropriate). These changes are unlikel y to affect the safet y or rights (ph ysical or mental 
integrit y) of the patients in this clinical study or the scientific value of the clinical study.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
199Original text with changes shown New wording Reason/Justification for change
TITLE PAGE affected by this change:
Confidentiality Statem ent
This document contains confidential and proprietary 
information (including confidential commercial 
information pursuant to 21CFRÂ§20.61) and is a 
confidential communication of Teva Branded 
Pharm aceutical Products R&D .and/or its affiliates .Confidentiality Statem ent
This document contains confidential and pr oprietary 
information (including confidential commercial 
information pursuant to 21CFRÂ§20.61) and is a 
confidential communication of Teva Branded 
Pharm aceutical Products R&D and/or its affiliates.Confidentiality language updated per 
template. Letter of Cl arification 04
2.STUDY OBJECTIVES AND ENDPOINTS
2.1Prim ary and Secondary Study Objectives and Endpoints â€œIntext tableâ€ (Other sections affected by anyone of these changes: Sect ions 2.1, 2.1.2, 3.1, 
3.4, 3.5, 4.1, 5.2.3, 5.10.3, 6.2.1, 6.3.5, 7, 7.2, 9.2.2, 9.5.1, 9.5.2, 9.5.2.1, 9.5.2.2, 9.5.3, 9.5.4, 9.5.4.1, 9.5.5, 9.6, 9.7, Table 3, and Appendix C)
The primary efficacy endpoint is the change from 
baseline to week 15 in the MD -CRS partII total score
(movement disorder severity, centrally read) (TE V-
50717 versus placebo).The primary efficacy endpoint is the change from 
baseline to week 15 in the MD -CRS part II total score 
(movement disorder severity, centrally read) (TEV -
50717 versus placebo).Updating the verbiage associated w ith 
MD-CRS II and how the scale is to be 
measured for clarity.
The key secondary efficacy endpoints (TEV- 50717 
versus placebo) are the following:
â€¢MD-CRS partI total score (general assessment, 
centrally read) change from baseline to week 15
Other efficacy measures and endpoints (TEV -50717 
versus placebo) include the follow ing:
â€¢MD-CRS Global Index (calculated from MD CRS 
parts I and II total scores )
â€¢PEDI- CAT (ADL, parent/caregiver completed, 
counter content -balanced version)
The safety variables include adverse event s (and the 
number of patients who withdraw  from  the study due to 
adverse events), vital signs, laboratory tests 
(hematology, chemistry, and urinalysis), ECG 
measurements, CBCL, ESRS, ESS , and the childrenâ€™s 
C-SSRS.The key secondary efficacy endpoints (TEV- 50717 
versus placebo) are the following:
â€¢MD-CRS part I total score (general assessment, 
centrally read) change from baseline to week 15
Other efficacy measures and endpoints (TEV -50717 
versus placebo) include the follow ing:
â€¢MD-CRS Global Index (calcu lated from MD CRS 
parts I and II total scores)
â€¢PEDI- CAT (ADL, parent/caregiver completed, 
content -balanced version)
The safety variables include adverse events (and the 
number of patients who withdraw  from  the study due to 
adverse events), vital signs, laboratory tests 
(hematology, chemistry, and urinalysis), ECG 
measurements, CBCL, ESRS, ESS, and the childrenâ€™s 
C-SSRS.Updating the verbiage associated w ith 
MD-CRS I and how the scale is to be 
measured for clarity.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
200Original text with changes shown New wording Reason/Justification for change
2.1.1. Justification of Prim ary Endpoint 
The MD -CRS has 2 parts: part I for general assessment 
of the functioning and impact of CP on the activities of 
the patient, and part II for a specific motor assessment 
of the severity of the movement disorder. The raw  score 
of part II (0 to 28) is normalized in a scale of 0 to 1 as 
Index II (MD CRS II). Similar normalization is done for 
the part I raw  score as Index I (0 to 1) and for the sum 
of the raw scores of parts I and II as the Global Index (0 
to 1).The MD -CRS h as 2 parts: part I for general assessment 
of the functioning and impact of CP on the activities of 
the patient, and part II for a specific motor assessment 
of the severity of the movement disorder.Changes following FDA request..
3.STUDY DESIGN
3.1.General Study Design and Study Schematic Diagram  (Other sections affected by this change: Appendix C)
Screening period (up to 31 days): After informed 
consent (and w ritten assent and/or co -consent for 
patients 14 years of age and older, as appropriate) is
obtained, patients who are stable from a medical and 
psychiatric standpoint will undergo a screening 
evaluation, including medical history ,;physical and 
neurological examination ,;laboratory testing ,;12-lead 
ECG ,;along with MD -CRS part II rating scale 
(physician rated, with video recorded recording , 
centrally read with video review , centrally read by the 
Enrollment Adjudication Board [EAB]) to assess 
severity of dyskinesia; Clinical Global Impression of 
Severity (CGI -S) to assess global clinical impressi on of 
DCP severity , com orbid CP symptoms, and behavioral 
status . The option ; childrenâ€™s Columbia- Suicide 
Severity Rating Scale (C -SSRS); assessment of drug -
induced parkinsonism according to the Extrapyramidal 
Symptom Rating Scale (subscales I and II; ESRS) ; 
assessment of change in behavior according to the Child 
Behavior Checklist (for ages 6 -18) (CBCL) 
questionnaire; and assessment of sedation according to 
the Epw orth Sleepiness Scale (for children and 
adolescents) (ESS) questionnaire of using a telephone 
with non -recording live video will be made possible, Screening period (up to 31 days): After informed 
consent (and w ritten assent and/or co -consent for 
patients 14 years of age and older, as appropriate) is 
obtained, pati ents who are stable from a medical and 
psychiatric standpoint will undergo a screening 
evaluation, including medical history; physical and 
neurological examination; laboratory testing; 12 -lead 
ECG; along with MD -CRS part II (physician rated, with 
video recording, centrally read w ith video review , 
centrally read by the Enrollment Adjudication Board 
[EAB]) to assess severity of dyskinesia; Clinical Global 
Impression of Severity (CGI -S) to assess global clinical 
impression of DCP severity, comorbid CP symptoms , 
and behavioral status; childrenâ€™s Columbia -Suicide 
Severity Rating Scale (C -SSRS); assessment of drug -
induced parkinsonism according to the Extrapyramidal 
Symptom Rating Scale (subscales I and II; ESRS); 
assessment of change in behavior according to the Child 
Behavior Checklist (for ages 6 -18) (CBCL) 
questionnaire; and assessment of sedation according to 
the Epw orth Sleepiness Scale (for children and 
adolescents) (ESS) questionnaire of using a telephone 
with non -recording live video will be made possible,
and the adoption of live video to support Clarification has been provided for 
assessments to be completed during the 
screening period, and new assessments 
have been included.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
201Original text with changes shown New wording Reason/Justification for change
and the adoption of live video to support 
patient/caregiver interview will then be maintained 
throughout the study for the evaluation of 
safety/tolerability and dyskinesia severity. Screening 
may be cond ucted over 2 separate visits at the discretion 
of the investigator. The diagnosis of CP and DCP will 
be established based on clinical features as described in 
the inclusion/exclusion criteria. The EAB w ill also 
confirm, based on video recordings, that chor eiform is 
clinically the predominant movement disorder of the 
patientâ€™s DCP. EAB assessment results will be available 
to the investigator prior to baseline and randomization. 
At all other visits, the MD -CRS part II rating scale will 
be administered by the investigational center physician 
and video recorded review for central -blinded reading.patient/caregiver interview will then be maintained 
throughout the study for the evaluation of 
safety/tolerability and dyskinesia severity. Screening 
may be conducted over 2 separate visits at the discretion 
of the investigator. The diagnosis of CP and DCP will 
be established based on clinical features as described in 
the inclusion/exclusion criteria. The EAB w ill also 
confirm, based on video recordings, that choreiform is 
clinically the predominant movement disord er of the 
patientâ€™s DCP. EAB assessment results will be available 
to the investigator prior to baseline and randomization. 
At all other visits, the MD -CRS part II w ill be 
administered by the investigational center physician and 
video review for central bli nded reading.
Titration period (7 w eeks): Patients who remain eligible 
for participation in the study will be randomized a t the 
baseline visit (day 1) and instructed to take the first dose 
of blinded IMP the following morning, without regard 
to food. with food (eg, a snack) and should not be taken 
on an empty stomach.
Safety/tolerability in -clinic evaluations during titration
include assessment of vital signs, monitoring for 
adverse events and concomitant medications, 12 -lead 
ECGs, and rating scales for depression and 
suicidality. identifying subjects at risk for suicide 
according to the C -SSRS questionnaire, assessment of 
drug-induced parkinsonism according to the ESRS 
(subscales I and II), assessment of change in behavior 
according to the CBCL questionnaire, and assessment 
of sedation according to the ESS questionnaire .Titration period (7 w eeks): Patients who remain eligible 
for participation in the study will be randomized at the 
baseline visit (day 1) and instructed to take the first dose 
of blinded IMP the following morning, with food (eg, a 
snack) and should not be taken on an empty stomach.
Safety/tolerability in -clinic evaluations during titration 
include assessment of vital signs, monitoring for 
adverse events and concomitant medications, 12 -lead 
ECGs, identifying subjects at risk for suicide according 
to the C -SSRS questionnaire, assessment of drug -
induced parkinsonism according to the ESRS (subscales 
I and II), assessment of change in behavior according to 
the CBCL questionnaire, and assessment of sedation 
according to the ESS questionnaire.Clarification has been provided that the 
IMP should be administered with food.
Assessments to be completed during the 
titration period have been updated and 
added.
3.5.Schedule of Study Procedures and Assessments (Other sections affected by any one of these changes: Section 6.1, 6.2.1, 6.2.2, 6.2.3, 6.3.7, 6.3.8, 
Appendix C, and Appendix I)
Row: Study week
Column: Follow -up
16/EOS (Day 112)Row: Study week
Column: Follow -up
16/EOS (Day 112)The Schedule of Assessments has been 
updated to reflect all changes made to the 
study design. Assessments and time points 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
202Original text with changes shown New wording Reason/Justification for change
Row: Vital signs and weight
Column: Screening, -31 days
XRow: Vital signs and weight
Column: Screening, -31 days
Xfor assessments have been added and/or 
removed as indicated (left). Three new 
safety scales have been included. 
Footnotes have also been updated for 
clarity and to align with updates made to 
the study design.Row: Physical examination
Column: BL, Day 1
XRow: Physical examination
Column: BL, Day 1
X
Row: Neurological examination
Column: BL, Day 1
XRow: Neurological examination
Column: BL, Day 1
X
Row: Urine drug screen
Column: Titration, Week 3 (Day 21) 
XRow: Urine drug screen
Column: Titration, Week 3 (Day 21) 
X
Row: Urine drug screen
Column: Maintenance, Week 9 (Day 63)
XRow: Urine drug screen
Column: Maintenance, Week 9 (Day 63)
X
Row: Urine drug screen
Column: Follow -up, Week 16/EOS (Day 112)  
XRow: Urine drug screen
Column: Follow -up, Week 16/EOS (Day 112)  
X
Row: Î² -HCG test
Column: Titration, Week 3 (Day 21) 
XRow: Î² -HCG test
Column: Titration, Week 3 (Day 21) 
X
Row: Î² -HCG test
Column: Titration, Week 7 (Day 49)
XRow: Î² -HCG test
Column: Titration, Week 7 (Day 49)
X
Row: Î² -HCG test
Column: Maintenance, Week 9 (Day 63)
XRow: Î² -HCG test
Column: Maintenance, Week 9 (Day 63)
X
Row: Î² -HCG test Row: Î² -HCG test
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
203Original text with changes shown New wording Reason/Justification for change
Column: Maintenance, Week 12 (Day 84)
XColumn: Maintenance, Week 12 (Day 84)
X
Row: Î² -HCG test
Column: Follow -up, Week 16/EOS (Day 112)  
X Row: Î² -HCG test
Column: Follow -up, Week 16/EOS (Day 112)  
X
Row: MD -CRS part I (physician rated, with video 
recording)
Column: Study weekMD-CRS part I (physician rated, with video recording)
Row: MD -CRS part I (physician rated, with video 
recording)
Column: Screening, -31 days
XRow: MD -CRS part I (physician rated, with video 
recording)
Column: Screening, -31 days
Row: MD -CRS part I (physician rated, with video 
recording)
Column: Follow -up, Week 16/EOS (Day 112)  
XRow: MD -CRS part I (physician rated, with video 
recording)
Column: Follow -up, Week 16/EOS (Day 112)  
X
Row: MD -CRS part I (centrally read, with video review)
Column: Study weekRow: MD -CRS part I (centrally read, with video review)
Column: Study week
Row: MD -CRS part I (centrally read, with video review)
Column: BL, Day 1
XRow: MD -CRS part I (centrally read, with video review)
Column: BL, Day 1
X
Row: MD -CRS part I (centrally read, with video review)
Column: Maintenance, Week 9 (Day 63)
XRow: MD -CRS part I (centrally read, with video review)
Column: Maintenance, Week 9 (Day 63)
X
Row: MD -CRS part I (centrally read, with video review)
Column: Mai ntenance, Week 12 (Day 84)
XRow: MD -CRS part I (centrally read, with video review)
Column: Maintenance, Week 12 (Day 84)
X
Row: MD -CRS part I (centrally read, with video review)
Column: Maintenance, Week 15/ET (Day 105)Row: MD -CRS part I (centrally read, with video review)
Column: Maintenance, Week 15/ET (Day 105)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
204Original text with changes shown New wording Reason/Justification for change
X X
Row: MD -CRS part I (centrally read, with video review)
Column: Follow -up, Week 16/EOS (Day 112)
XRow: MD -CRS part I (centrally read, with video review)
Column: Follow -up, Week 16/EOS (Day 112)
X
Row: MD -CRS part II (physician rated, with video 
recording)
Column: Follow -up, Week 16/EOS (Day 112)
XRow: MD -CRS part II (physician rated, with video 
recording)
Column: Follow -up, Week 16/EOS (Day 112)
X
Row: MD -CRS part II (centrally rea d, with video 
recording review)
Column: Follow -up, Week 16/EOS (Day 112)
XRow: MD -CRS part II (centrally read, with video 
review)
Column: Follow -up, Week 16/EOS (Day 112)
X
Row: CaGI -I
Column: Follow -up, Week 16/EOS (Day 112)
XRow: CaGI -I
Column: Follow -up, Week 16/EOS (Day 112)
X
Row: CGI -I (global, physician rated)
Column: Follow -up Week 16/EOS (Day 112)
XRow: CGI -I (global, physician rated)
Column: Follow -up, Week 16/EOS (Day 112)
X
Row: CGI -S (global, physician rated)
Column: Screening, -31 days
XRow: CGI -S (global, physician rated)
Column: Screening, -31 days
X
Row: CGI -S (global, physician rated)
Column: Follow -up, Week 16/EOS (Day 112)
XRow: CGI -S (global, physician rated)
Column: Follow -up, Week 16/EOS (Day 112)
X
Row: PGI -I (global, patient/caregiver)
Column: Follow -up, Week 16/EOS (Day 112)
XRow: PGI -I (global, patient/caregiver)
Column: Follow -up, Week 16/EOS (Day 112)
X
Row: ESRS subscales I and II
Column: Study weekRow: ESRS subscales I and II
Column: Study week
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
205Original text with changes shown New wording Reason/Justification for change
Row: ESRS subscales I and II
Column: Screening, -31 days
XRow: ESRS subscales I and II
Column: Screening, -31 days
X
Row: ESRS subscales I and II
Column: BL, Day 1
XRow: ESRS subscales I and II
Column: BL, Day 1
X
Row: ESRS subscales I and II
Column: Titration, Week 3 (Day 21)
XRow: ESRS subscales I and II
Column: Titration, Week 3 (Day 21)
X
Row: ESRS subscales I and II
Column: Titration, Week 7 (Day 49)
XRow: ESRS subscales I and II
Column: Titration, Week 7 (Day 49)
X
Row: ESRS subscales I and II
Column: Maintenance, Week 9 (Day 63)
XRow: ESRS subscales I and II
Column: Maintenance, Week 9 (Day 63)
X
Row: ESRS subscales I and II
Column: Maintenance, Week 12 (Day 84)  
XRow: ESRS subscales I and II
Column: Maintenance, Week 12 (Day 84)  
X
Row: ESRS subscales I and II
Column: Maintenance, Week 15/ET (Day 105)  
XRow: ESRS subscales I and II
Column: Maintenance, Week 15/ET (Day 105)  
X
Row: ESRS subscales I and II
Column: Follow -up, Week 16/EOS (Day 112)  
XRow: ESRS subscales I and II
Column: Follow -up, Week 16/EOS (Day 112)  
X
Row: ESRS subscales I and II
Column: Unscheduled  
XRow: ESRS subscales I and II
Column: Unscheduled  
X
Row: CBCL Row: CBCL
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
206Original text with changes shown New wording Reason/Justification for change
Column: Study week Column: Study week
Row CBCL
Column: Screening, -31 days
XRow: CBCL
Column: Screening, -31 days
X
Row: CBCL
Column: BL, Day 1
XRow: CBCL
Column: BL, Day 1
X
Row: CBCL
Column: Titration, Week 3 (Day 21)
XRow: CBCL
Column: Titration, Week 3 (Day 21)
X
Row: ESRS subscales I and II
Column: Titration, Week 7 (Day 49)
XRow: ESRS subscales I and II
Column: Titration, Week 7 (Day 49)
X
Row: CBCL
Column: Maintenance, Week 9 (Day 63)
XRow: CBCL
Column: Maintenance, Week 9 (Day 63)
X
Row: CBCL
Column: Maintenance, Week 12 (Day 84)  
XRow: CBCL
Column: Maintenance, Week 12 (Day 84)  
X
Row: CBCL
Column: Maintenance, Week 15/ET (Day 105)  
XRow: CBCL
Column: Maintenance, Week 15/ET (Day 105)  
X
Row: CBCL
Column: Follow -up, Week 16/EOS (Day 112)  
XRow: CBCL
Column: Follow -up, Week 16/EOS (Day 112)  
X
Row: CBCL
Column: Unscheduled  
XRow: CBCL
Column: Unscheduled  
X
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
207Original text with changes shown New wording Reason/Justification for change
Row: Assess adverse events
Column: Screening, -31 days
XRow: Assess adverse events
Column: Screening, -31 days
4.2Patient Exclusion Criteria 
Not applicable. 12.Patients with a history of torsade de pointes, 
congenital long QT syndrome, bradyarrhythmias, other 
cardiac arrhythmias, or uncompensated heart failure.Included an additional exclusion criteria 
pertaining t o cardiac history.
Letter of Clarification 03
1314.Patient has evidence of clinically significant 
renal impairment , indicated by a serum creatinine >1.5 
Ã— ULN at screening .14.Patient has evidence of clinically significant renal 
impairm ent, indicated by a serum creatinine >1.5 Ã— 
ULN at screening.Added the serum creatinine range that will 
indicate clinically significant renal 
impairm ent for clarity.
Letter of Clarification 03
5.1.Investigational Medicinal Products Used in the Study
5.1.1. Test Investi gational Medicinal Product (Other sections affected by this change: Section 3.1, 5.1.1.1, and 5.1.1.2)
Test IMP (TEV -50717 [deutetrabenazine, previously 
SD-809]) w ill be administered as oral tablets . The IMP 
is a matrix formulation and is designed to be taken 
without regard to food. The effects of food on the 
bioavailability of TEV 50717 were studied in patients 
administered a single dose with and without food. Food 
had no effect on the area under the plasma drug 
concentration time curve of Î± HTBZ or Î² HTBZ, 
although the maximum serum concentration was 
increased by approximately 50% in the presence of food 
(AUSTEDO USPI 2017). with food (eg, a snack) and 
should not be taken on an empty stomach.Test IMP (TEV -50717 [deutetrabenazine, previously 
SD-809]) w ill be administered as oral tablets w ith food 
(eg, a snack) and should not be taken on an empty 
stomach.Updated guidance of administration of 
IMP.
5.8.Temporary Discontinuation of Investigational Medicinal Product
Dose adjustments should be made based on all available 
information, including the patientâ€™s and 
parentâ€™s/caregiverâ€™s reports of adverse events and motor 
function improvement, the clinical assessment of safety 
and efficacy by the investigator, and information from 
rating scales. If more than 1 do se reduction is 
required for an adverse event, the m edical monitor Dose adjustments should be made based on all available 
information, including the patientâ€™s and 
parentâ€™s/caregiverâ€™s reports of adverse events and motor 
function improvement, the clinical assessment of safety 
and efficacy by the investigator, and information from 
rating scales. If more than 1 dose reduction is 
required for an adverse event, the m edical monitor Updated guidance on dose adjustm ents for 
temporary discontinuation of IMP based 
on the number of dose reductions or 
duration of dose suspension.
Letter of Clarification 04
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
208Original text with changes shown New wording Reason/Justification for change
should be notified. Suspension of IMP treatment for up 
to 1 w eek, if warranted, is allowed. If the patient restarts 
IMP w ithin 7 days of suspension, the full dose of IMP 
may be resumed with out titration at the same dose level 
or 1 dose low er (last tolerated dose). Suspension of IMP 
treatment for adverse events must be reviewed with the 
medical monitor before IMP treatment is restarted. 
Suspensions for more than 7 days must be reviewed by 
themedical monitor before therapy is restarted, and also 
to determine if there is adequate time for patients to be 
reinstated and complete study evaluations. The reason 
for a dose reduction or suspension must be clearly 
documented in the related adverse even t form .
Dose reduction or suspension is allowed once during the 
titration period and once during the maintenance period. 
Patients who restart IMP treatment will remain at the 
current dose throughout that period w ith no further dose 
changes and will, otherw ise, follow  the visit schedule as 
outlined in the protocol. If a dose reduction occurs 
before a scheduled clinic visit, the clinic visit will be 
postponed so that efficacy evaluations can be performed 
at least 5 days after the change.
If a dose suspension occurs before a scheduled clinic 
visit, an unscheduled visit should be scheduled as soon 
as possible so that efficacy evaluations can be 
performed at least 5 days after the change. 
If the determination that a patient requires a dose 
reduction or suspension is made during a telephone 
contact, an unscheduled clinic visit should be conducted 
as soon as practicable thereafter.
If a patientâ€™s serum potassium or magnesium level falls 
below  the lower limit of normal, IMP must be 
suspended. The medical mo nitor must be contacted to 
determine the appropriate investigation and treatment. 
IMP treatment may only be restarted once serum 
potassium and/or magnesium levels have normalized. 
The patients who restart IMP treatment will follow  the should be notified. Suspension of IMP treatment for up 
to 1 w eek, if warranted, is allowed. If the patient restarts 
IMP w ithin 7 days of suspension, the full dose of IMP 
may be resumed without titration at the same dose level 
or 1 dose low er (last tolerated dose). Suspension of IMP 
treatment for adverse ev ents must be reviewed with the 
medical monitor before IMP treatment is restarted. 
Suspensions for more than 7 days must be reviewed by 
the medical monitor before therapy is restarted, and also 
to determine if there is adequate time for patients to be 
reins tated and complete study evaluations. The reason 
for a dose reduction or suspension must be clearly 
documented in the related adverse event form.
Dose reduction or suspension is allowed once during the 
titration period and once during the maintenance perio d. 
Patients who restart IMP treatment will remain at the 
current dose throughout that period w ith no further dose 
changes and will, otherwise, follow  the visit schedule as 
outlined in the protocol. If a dose reduction occurs 
before a scheduled clinic visit , the clinic visit will be 
postponed so that efficacy evaluations can be performed 
at least 5 days after the change. 
If a dose suspension occurs before a scheduled clinic 
visit, an unscheduled visit should be scheduled as soon 
as possible so that efficacy evaluations can be 
performed at least 5 days after the change. 
If the determination that a patient requires a dose 
reduction or suspension is made during a telephone 
contact, an unscheduled clinic visit should be conducted 
as soon as practicable thereaft er.
If a patientâ€™s serum potassium or magnesium level falls 
below  the lower limit of normal, IMP must be 
suspended. The medical monitor must be contacted to 
determine the appropriate investigation and treatment. 
IMP treatment may only be restarted once serum 
potassium and/or magnesium levels have normalized. 
The patients who restart IMP treatment will follow  the 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
209Original text with changes shown New wording Reason/Justification for change
visit schedule as ou tlined in Table 3. Patients who 
withdraw from the study will proceed as described in 
Section 4.3.visit schedule as outlined in Table 3. Patients who 
withdraw from the study will proceed as described in 
Section 4.3.
5.11. Total Blood Volum e (Other sections affected by this change: Appendix I)
The total blood volume to be collected for each patient 
in this study is approximately 4140 mL (at maximum), 
as detailed in Appendix I.The total blood volume to be collected for each patient 
in this study is approximately 40 mL (at maximum), as 
detailed i n Appendix I.Updated total blood draw  volumes to align 
with updated volumes presented in table 
12.
6.1.Prim ary Efficacy Measure
The MD -CRS partII does not differentiate whether the 
dyskinesia is of the dystonic or choreiform phenotype, 
and the worst d yskinesia in any of the regions observed 
during the assessment session will be taken as the score 
for each affected body region. The minimum score is 0 
(absent) and the maximum score is 28 
(marked/prolonged).
For data analysis, the raw score of MD CRS part II 
items (0 to 28) is normalized to a 0 to 1 range as Index 
II (MD CRS II). Raw  scores (0 to 28) reflecting severity 
of the movement disorder w ill be used to qualify a 
patient for inclusion in the study.The MD -CRS part II does not differentiate whether t he 
dyskinesia is of the dystonic or choreiform phenotype, 
and the worst dyskinesia in any of the regions observed 
during the assessment session will be taken as the score 
for each affected body region. The minimum score is 0 
(absent) and the maximum score is 28 
(marked/prolonged).Streamlined the description of the 
MD-CRS part II to include only necessary 
protocol details. Further details to be 
provided in the SAP.
6.2.Key Secondary Efficacy Measures
6.2.1. Movem ent Disorder- Childhood Rating Scale Part I Total Score
The MD -CRS part I evaluates impact of DCP on the 
activities of the patient and provides a general 
assessment of the movement disorder of motor function 
(7 items), oral/verbal function (3 items), self -care (3 
items), and attention/alertness ( 2 items) on a scale of 0 
(present) to 4 (absent) (Battini et al 2008, Battini et al 
2014). The rawminimum score of MD CRS part I ( is 0 
toand the maximum score is 60 ) is normalized to a 0 to 
1 range as Index I (MD CRS I) .The MD -CRS part I evaluates impact of DCP on the 
activities of the patient and provides a general 
assessment of the movement disorder of motor function 
(7 items), oral/verbal function (3 items), self -care (3 
items), and attention/alertness (2 items) on a scale of 0 
(present) to 4 (absent) ( Battini et al 2008, Battini et al 
2014). The minimum score of MD -CRS part I is 0 and 
the maximum score is 60).Streamlined the description of the 
MD-CRS part I to include only necessary 
protocol details. Further details to be 
provided in the SAP.
6.3.Other Efficacy Measures
6.3.1. Movem ent Disorder- Childhood Rating Scale Global Index
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
210Original text with changes shown New wording Reason/Justification for change
The MD -CRS Global Index is a global measure of the 
MD-CRS that consolidates the information from 
Indexes parts I and II using the method of weighted 
means of the 2 norm alized indexes obtained from each 
part (Battini et al 2008). The minimum score is 0 and 
the maximum score is 1.The MD -CRS Global Index is a global measure of the 
MD-CRS that consolidates the information from parts I 
and II using the method of weighted means of the 2 
norm alized indexes obtained from each part (Battini et 
al 2008). The minimum score is 0 and the maximum 
score is 1.Streamlined the description of the 
calculation of the MD- CRS Global Index.
6.3.4. Unified Huntingtonâ€™s Disease Rating Scale -Total Maximal Dystonia
The UHDRS -Total Maximal Dystonia (TMD) is part of 
the UHDRS -TMS assessment and assesses the severity 
of dystonia in the trunk and the 4 extremities. The 
minimum score is 0 (absent) and the maximum score is 
20 (marked/prolonged) (Huntingt on Study Group 1996).The UHDRS -Total Maximal Dystonia (TMD) is part of 
the UHDRS -TMS assessment and assesses the severity 
of dystonia in the trunk and the 4 extremities. The 
minimum score is 0 (absent) and the maximum score is 
20 (marked/prolonged) (Hunti ngton Study Group 1996).Streamlined the description of the method 
to measure the UHDRS -TMD.
7.1.6. Protocol -Defined Adverse Events of Special Interest
No protocol defined adverse events of special interest 
for expedited reporting were identified for this study. 
Events of drug -induced parkinsonism, changes in 
behavior, and sleepiness will be monitored using 
standardized scores and presented as part of safety 
analysis (see Section 7.2).No protocol defined adverse events of special interest 
for expedited reporting w ere identified for this study. 
Events of drug -induced parkinsonism, changes in 
behavior, and sleepiness will be monitored using 
standardized scores and presented as part of safety 
analysis (see Section 7.2).Updated language based on 
communications with regulatory 
authorities and their feedback.
7.2.2. Child Behavior Checklist (for Ages 6 -18) (Other sections affected by this change: Section 3.5, Table 3)
Not applicable. The CBCL assesses behavioral and emotional sta tus in 
children ages 6 through 18 years of age as reported by 
the parent/caregiver (Achenbach and Ruffle 2000; 
Achenbach 2005). The full CBCL has two parts, a 
Com petence Scale (Parts I to VII) and a Syndrome 
Scale (behavioral items).
The Competence Scale ( Parts I to VII) assesses various 
activities (eg, sports, hobbies, games, organizations, 
clubs, teams, groups, jobs, and chores), interpersonal 
relationships, and academic performance. 
The Syndrome Scale comprises 118 questions related to 
problem behaviors . This study w ill use a recall period of 
â€œnow  or within the last week,â€ representing a 
modification from the original scale, which was â€œnow  or Added section to include a description of 
an additional safety scale to be assessed in 
the study (ie, CBCL).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
211Original text with changes shown New wording Reason/Justification for change
within the last 6 monthsâ€. For each item, the 
parent/caregiver will circle 0 if the item is not true of 
their chi ld, 1 if the item is somewhat or sometimes true, 
and 2 if the item is very true or often true. 
The CBCL is part of the Achenbach System of 
Empirically Based Assessment that identifies 
syndromes that are behavioral clusters that indicate 
certain types of b ehavioral, social, or emotional 
problems. The problem behaviors are scored on the 
following 8 empirically based syndromes: 
anxious/depressed, withdrawn/depressed, somatic 
complaints, social problems, thought problems, 
attention problems, rule -breaking behavior, and 
aggressive behavior. 
The Competence and Syndrome Scales are displayed on 
profiles in relation to gender and age -specific 
percentiles and T scores based on national normative 
samples.  
The full CBCL assessment (Competence and Syndrome 
Scales) will be completed at screening and at week 
15/ET. Only the CBCL Syndrome scale will be 
completed at baseline, weeks 3, 7, 9, 12, and 16/EOS.
7.2.3 .Extrapyramidal Sympto m Rating Scale
Not applicable. The ESRS was designed to assess 4 types of drug -
induced movement disorders: parkinsonism, akathisia, 
dystonia, and TD (Chouinard and Margolese 2005). In 
this study, parkinsonism and akathisia will be e valuated 
with subscales I (subjective questionnaire) and II 
(evaluation for parkinsonism/akathisia). The ESRS is 
administered at screening; baseline; and w eeks 3, 7, 9, 
12, 15/ET, and 16/EOS.
The subscale I of the ESRS questionnaire rates 
subjective parkin sonism/akathisia at periods other than 
the day of examinations during the last 7 days. It is 
scored on a 4 -point scale (0=Absent, 1=Mild, 
2=Moderate, or 3=Severe). The evaluation takes into Added section to include a description of 
an additional safety scale to be assessed in 
the study (ie, ESRS).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
212Original text with changes shown New wording Reason/Justification for change
account the verbal report of the patient on: 1) the 
frequency and duration of the symptom during the day, 
2) the number of days the symptom was present during 
the last week, and 3) the subjective evaluation of the 
intensity of the symptom by the patient. 
The subscale II of the ESRS questionnaire for 
evaluation of parkin sonism and akathisia includes 17 
items with scores ranging from 0 -102 to assess the 
following: tremor (0 â€“48), gait and posture (0 â€“6), 
postural stability (0 6), rigidity (0 â€“24), expressive 
automatic movements (0 â€“6), bradykinesia (0 -6), and 
akathisia (0 â€“6).
7.2.4. Epworth Sleepiness Scale (for Children and Adolescents)
Not applicable. The ESS is a self -administered questionnaire composed 
of 8 questio ns that provide a measure of a patientâ€™s 
general level of daytime sleepiness (Johns 1991). Johns 
(2015) proposed the ESS as the official modified 
version of the ESS for children and adolescents. In 
2017, Janssen et al published results of their validation 
analysis and concluded that the ESS developed for 
children and adolescents is a reliable and internally 
valid measure of daytime sleepiness in adolescents 12 to 
18 years of age, but further studies are needed to 
establish the internal validity of the quest ionnaire for 
children under 12 years and the external validity and 
accuracy of cut -off points for children and adolescents. 
The ESS is administered at screening; baseline; and 
weeks 3, 7, 9, 12, 15/ET, and 16/EOS. The ESS asks 
respondents to rate, on a 4 p oint Likert scale (0 â€“3), their 
usual chances of dozing off or falling asleep in different 
situations or activities that most people engage in as part 
of their daily lives. The total ESS score is the sum of 8 
item scores and can range between 0 and 24 w ith the 
higher the score indicating a higher level of daytime 
sleepiness. Most people can complete the ESS without 
assistance in 2 or 3 minutes.
CategoriesAdded section to include a description of 
an additional safety scale to be assessed in 
the study (ie, ESS).
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
213Original text with changes shown New wording Reason/Justification for change
â€¢0=would never fall asleep
â€¢1=slight chance of falling asleep
â€¢2=moderate chance of falling asleep
â€¢3=high chance of falling asleep
7.11. Neurological Examinations
Any neurological examination finding that is judged by 
the investigator as a poten tially clinically significant 
change (w orsening) compared w ith the 
screening baseline value will be considered an adverse 
event, recorded on the CRF, and monitored as described 
in Section 7.1.2.Any neurological examination finding that is judged by 
the inv estigator as a potentially clinically significant 
change (w orsening) compared w ith the baseline value 
will be considered an adverse event, recorded on the 
CRF, and monitored as described in Section 7.1.2.Updated to clarify that the baseline value 
will be used as a comparator for 
neurological examination findings.
7.12. Concom itant Medication or Treatm ent
Concomitant therapy or medication usage will be 
monitored throughout the study according to time points 
detailed in Table 3. Parents/patients will be instructed 
during the course of the study to notify the investigator 
if any new medication is prescribed/adm inistered, 
including over -the-counter medications. Any 
prescribed/administered medication should be reviewed 
with the investigator. Of note, any 
formulation/derivative of cannabis is prohibited during 
the study.Concomitant therapy or medication usage wi ll be 
monitored throughout the study according to time points 
detailed in Table 3. Parents/patients will be instructed 
during the course of the study to notify the investigator 
if any new medication is prescribed/administered, 
including over -the-counter me dications. Any 
prescribed/administered medication should be reviewed 
with the investigator. Of note, any 
formulation/derivative of cannabis is prohibited during 
the study.Updated language to include a statement 
on the prohibition of cannabis during the 
study.
8.3.1. CYP2D6 Genotyping/Pharmacogenetics (Other sections affected by this change: Appendix I)
At the screening visit, a mandatory blood sample ( 43.0 
to 5.0 mL) will be obtained for analysis of CYP2D6 
genotype from all patients in the study at the time point 
detailed in Table 3. The CYP2D6 genotype results will 
be provided to the RTSM, w hich drives each patientâ€™s 
dose regimen, and the patientâ€™s genotype for CY P2D6 
will remain blinded during the conduct of the study. 
 
 
 At the screening visit, a mandatory blood sample (3.0 to 
5.0 mL) will be obtained for analysis of CYP2D6 
genotype from all patients in the study at the time point 
detailed in Table 3. The CYP2D6 genotype results will 
be provided to the RTSM, w hich drives each patientâ€™s 
dose regimen, and the patientâ€™s genotype for CYP2D6 
will remain blinded during the conduct of the s tudy. 
 
 
 
 Updated to correct the blood volume to be 
taken at screening.  

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
214Original text with changes shown New wording Reason/Justification for change
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
9.1.Sample Size and Power Considerations
The initial sample size estimation of approximately 185 
patients randomized to TEV -50717 versus placebo in a 
2:1 ratio (approximately 124 in the TEV -50717 group; 
approximately 61 in the placebo group) is the sample 
size required to obtain a statistically si gnificant result in 
the primary analysis based on a 1 -sided test for mean 
difference at a significance level of Î±=0.025 with a 
power of approximately 90%, assuming a mean 
difference of 0.063 1.8and a standard deviation (SD) of 
0.126 3.5in each treatment gr oup. 
The initial assumptions regarding the mean difference 
and SD are based on the change from baseline to month 
6 in patients treated with trihexyphenidyl reported by 
Battini et al (2014), assuming an effect size of 55% for 
TEV -50717 versus placebo. The effect size of 55% w as 
assumed based on the observed effect sizes of TEV -
50717 in the pivotal studies in HD and TD. In the 
current study, these assumptions correspond to a mean 
difference of 2.0.07 in MD -CRS partII total score and 
an SD of 0.126 3.5in eac h treatment group.
The rate of missing not at random (MNAR) data for the 
primary analysis is expected to be 10%. MNAR data 
will be imputed in a conservative manner as if they were 
obtained from patients in the placebo treatment group, The initial sample size estimation of approximately 185 
patients randomized to TEV -50717 versus placebo in a 
2:1 ratio (approximately 124 in the TEV -50717 group; 
approximately 61 in the placebo group) is the sample 
size required to obtain a statistically significant result in 
the primary analysis based on a 1 -sided test for mean 
difference at a significance level of Î±=0.025 with a 
power of approximately 90%, assuming a mean 
difference of 1.8 and a standard deviation (SD) of 3.5 in 
each treatment group. 
The initial assumptions regarding the mean difference 
and SD ar e based on the change from baseline to month 
6 in patients treated with trihexyphenidyl reported by 
Battini et al (2014), assuming an effect size of 55% for 
TEV -50717 versus placebo. The effect size of 55% w as 
assumed based on the observed effect sizes of TEV -
50717 in the pivotal studies in HD and TD. In the 
current study, these assumptions correspond to a mean 
difference of 2.0 in MD -CRS part II total score and an 
SD of 3.5 in each treatment group.
The rate of missing not at random (MNAR) data for the 
primary analysis is expected to be 10%. MNAR data 
will be imputed in a conservative manner as if they 
were obtained from patients in the placebo treatment Updated the mean difference and SD 
values used for this study to more 
accurately repres ent sample size and 
power considerations.

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
215Original text with changes shown New wording Reason/Justification for change
regardless of the act ual treatment group. As a result, the 
mean difference is expected to be reduced from 2.0.07
to 0.063 1.8in the primary analysis. The impact of the 
missing data imputation on the SD is negligible.group, regardless of the actual treatment group . As a 
result, the mean difference is expected to be reduced 
from 2.0 to 1.8 in the primary analysis. The impact of 
the missing data imputation on the SD is negligible.
9.2.2. Modified Intent to Treat Analysis Set
The modified intent -to-treat (mITT) analysis set is a 
subset of the ITT analysis set including all randomized
patients with centrally read total raw  scores of â‰¥10 on 
MD CRS part II items at baseline, and at least 1 post -
baseline centrally read MD -CRS partII assessment.The modified intent -to-treat (mITT) analysis set is a 
subset of the ITT analysis set including all randomized 
patients with at least 1 post -baseline ce ntrally read MD -
CRS part II assessment.The mITT analysis set was clarified to 
state that all randomized patients who had 
at least 1 post -baseline centrally read MD -
CRS part II assessment were included.
9.2.4. Per-Protocol Analysis Set
The per- protocol (PP) analysis set is a subset of the 
mITT analysis set including only patients who meet the 
following criteria:
â€¢compliant with study medication (80% to 105%)
â€¢complete the study without any major protocol 
deviations that may impact efficacy 
â€¢centrally read baseline MD -CRS part II total score 
of â‰¥10The per- protocol (PP) analysis set is a subset of the 
mITT analysis set including only patients who meet the 
following criteria:
â€¢compliant with study medication (80% to 105%)
â€¢complete the study without a ny major protocol 
deviations that may impact efficacy 
â€¢centrally read baseline MD -CRS part II total score 
of â‰¥10An additional criteria based on the 
MD-CRS part II total score was included 
for the PP analysis set.
9.5.4.1. Secondary Efficacy Analysis
Not applicable. In addition, sensitivity analyses for the key secondary 
endpoints will be performed in the same fashion as the 
primary endpoint.Updated to clarify sensitivity analysis of 
key secondary endpoints.
9.8.Safety Endpoints and Analysis
Not ap plicable. Assessment of drug -induced parkinsonism according to 
the ESRS (subscales I and II), assessment of change in 
behavior according to the CBCL questionnaire, and 
assessment of sedation according to the ESS 
questionnaire will be summarized descriptively.Updated the safety analysis to include the 
3 new  safety scales that will be assessed 
during the study.
APPENDIX H. LIST OF ALLOWED AND PROHIBITED MEDICATIONS
Benzodiazepines, muscle relaxants, ( including 
tizanidine ), trihexyphenidyl, baclo fen (oral and Benzodiazepines, muscle relaxants, (including 
tizanidine), trihexyphenidyl, baclofen (oral and Letter of Clarification 01
Updated the list of allowed medi cations to 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 05 Study  TV50717- CNS -30080
216Original text with changes shown New wording Reason/Justification for change
intrathecal), gabapentin, and levetiracetam intrathecal), gabapentin, and levetiracetam include tizanidine.
APPENDIX I. TOTAL BLOOD VOLUME
Table 12 from the original amendment has been 
reconstructed. Table 12 w as revised to reflect the following changes:
1.Maximum blood draw  was revised to a maximum 
of 40 mL (from 41 mL)
2.Blood volume per test per visit and the total for 
each visit was added.
3.Î²-HCG and prothrombin/INR were added.
Blood draws at week 16/EOS and unscheduled visits 
were clarified as obtained at the investigatorâ€™s 
discretion.Letter of Clarification 04
Blood draw  volumes were updated, so 
table 12 w as updated to align with blood 
draw s dictated throughout the protocol.
Global
Updated amendment number, dates, section numbers, 
and tables of contents. Corrected typos; errors in 
punctuation, grammar, and formatting; and 
inconsistencies in style.Not applicable. Clarification
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
21716.9. Letter of Clarification 04 Dated 05 December 2018

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
218

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
219

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
22016.10. Letter of Clarification 03 Dated 22 November 2018

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
221

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
22216.11. Letter of Clarification 02 Dated 16 November 2018

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
223

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
224

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
22516.12. Letter of Clarification 01 Dated 17 October 2018

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
226

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
227APPENDIX A. CLINICAL LABORATORIE S AND OTHER 
DEPARTMENTS AND INST ITUTIONS
Sponsorâ€™s Authorized Representative
Teva Branded Pharmaceutical Products R&D, Inc
Cell
Legal Representative of the Sponsor in the EU
Merckle GmbH, Graf -Arco -Str. 3, 89079 Ulm, 
Germ any | Registry Court: Ulm HRB 5125
Tel: 
Sponsorâ€™s Medical Expert/Contact Point designated 
by the Sponsor for Further Inform ation on the Study Teva Pharmaceutical Industries,  
Cell: 
Study Principal Investigator
Vanderbilt University Medical Center, Department of 
Neurology
1161 21st Avenue South
A-0118 MCN
Nashville, TN 37232 -2551
Tel: 
Sponsorâ€™s Representative of Global Patient Safety 
and Pharm acovigilance
For serious adverse events:
Send by email to the local safety officer/contract research 
organization (LSO/ CRO). The email address will be 
provided in the serious adverse event report form. In the 
event of difficulty transmitting the form, contact the 
sponsorâ€™s study personnel identified above for further 
instruction.Teva Pharmaceutical I ndustries,  
Tel:  
Cell
Contract Research Organization ICON plc
South County Business Park
Leopardstown
Dublin 18, Ireland
Tel: 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
228Central Clinical Laboratory Q2 Solutions â€“Global Headquarters
5827 South Miami Blvd.
Morrisville, NC 27560
Tel: 
Pharm acokinetic Samples Watson Pharma Pvt. Ltd. 
Seaw oods Grand Central, Tower 2
Level -11, Wing -E, Plot No. R -1
Sector 40, Nerul, Navi Mumbai 400706 
Tel: 
Contact: 
Bioanalytical Operations
Central Electrocardiogram  Evaluation Spaulding Medical, LLC
525 S. Silverbrook Drive
West Bend, WI 53095
Tel: 
Randomization and Trial Supply Managem ent 
(RTSM) vendorCalyx
4 Canal Street
Nottingham, United Kingdom, NG1 7EH
Tel: 
Scales and Central Rater for MD -CRS Signant Health
785 Arbor Way
Blue Bell, PA 19422
Tel: 

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
229APPENDIX B. INDEPENDENT DATA MONITORING COMMITTEE
When approximately  50 patients have completed the study  (including follow -up), an independent 
Data Monitoring Committee (iDMC) will perform an unblinded non-binding interim analy sis 
(IA) for futility  based on centrall y read Movement Disorder -Childhood Rating Scale part II 
(MD -CRS part II) total score. Based on the results of the IA, the study  may  be stopped.
The iDMC sessions can be open or closed. During open sessions, representatives of the sponsor 
and the Steering Committee may  be present, and information is provided and discussed in a 
blinded fashion. During closed sessions, the only  participants are members of the iDMC and the 
designated unblinded stat istician (if approved to be present).
Details on how the iDMC chairperson will communicate with the sponsor in regard to issues 
resulting from the conduct and clinical aspects of the study  can be seen in the iDMC charter. The 
sponsor will work closely  with the committee to provide the necessary data for review.
The conduct and specific details regarding the iDMC sessions and requests to unblind any  
investigational medicinal product assignments are outlined in the iDMC charter.
Further details are given in t he Data Monitoring Plan and iDMC Statistical Analy sis Plan. 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
230APPENDIX C.STUDY PROCEDURES AND ASSESSMENTS BY VISIT
1.Procedures for Screening (Day -31)
The screening visit will take place not more than 31 days before the baseline visit . Screening 
may be conducted over 2 separate visits at the discretion of the investigator. The following 
procedures/assessments will be performed at the screening visit:
ï‚·patients, parent(s)/ legally accepted representative (s), and caregivers must provide 
their respective written informed con sent and/or assent (as appropriate) before any  
study -related procedures are performed. Assent/consent may  also be provided to 2 
optional I CFs:
ï€­  
ï€­use of patientâ€™s stud y videos for future anal ysis of gait digital markers and release 
of patientâ€™s study  videos for use in publications or educational presentations 
ï‚·review of eligibility  criteria
ï‚·medical and ps ychiatric history
ï‚·demographics
ï‚·vital signs me asurements (including orthostatic blood pressure) and weight
ï‚·physical examination
ï‚·neurological examination
ï‚·height
ï‚·12-lead electrocardiogram (ECG)
ï‚·clinical laboratory  tests (chemistry , hematology , and urinaly sis); these tests may  be 
repeated to determine pa tient eligibility
ï‚·urine drug screen; these tests may  be repeated to determine patient eligibility
ï‚·cytochrome P450 2D6 (CYP2D6) genot ype
ï‚·beta-human chorionic gonadotropin (Î² -HCG) serum pregnancy  test (for females aged 
12 years or older of childbearing poten tial)
ï‚·MD-CRS part II video recording and investigator assessment
ï‚·Clinical Global I mpression of Severit y (CGI -S) (global, phy sician rated)
ï‚·Childrenâ€™s Columbia -Suicide Severit y Rating Scale (C -SSRS) (Baseline/Screening)
ï‚·Child Behavior Checklist (for ages 6- 18) (CBCL), full version (Competence and 
Syndrome)
ï‚·Extrapy ramidal S ymptom Rating Scale ( subscales I  and II; ESRS)
ï‚·Epworth Sleepiness Scale (for children and adolescents) (ESS)

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
231ï‚·concomitant medications
ï‚·contact RTSM
2.Proced ures Before Administration of Investigational Medicinal Product (Baseline 
[Day 1Â±0days])
Patients who meet the inclusion and exclusion criteria at the screening visit will continue to 
the baseline visit when baseline assessments will be conducted. The inv estigator should 
review all available data to determine patient eligibility  before randomizing to the study . 
The following procedures /assessments will be performed at the baseline visit:
ï‚·review of eligibility  criteria
ï‚·assignment of randomization/treatment numbers after patient eligibility  is confirmed 
based on all available visit assessments, and entry  into case report form (CRF)
ï‚·vital signs measurements (including orthostatic blood pressure) and weight
ï‚·physical examination
ï‚·neurological examination
ï‚·urine pregnancy  test
ï‚·MD-CRS part I  video recording and investigator assessment
ï‚·MD-CRS part II video recording and investigator assessment
ï‚·Clinical Global I mpression of Severit y (CGI -S) (global, phy sician rated)
ï‚·Pediatric Evaluation Disability  Inventory -Computer Adapted Test (PEDI -CAT) 
(activities of dail y living [ADL ], caregiver completed, content -balanced version)
ï‚·Cerebral Pals y module of Pediatric Quality of Life I nventory  (PedsQL) (quality  of 
life [QoL ], patie nt/caregiver)
ï‚·Unified Huntingtonâ€™s Disease Rating Scale -Total Motor Score (UHDRS -TMS) 
assessment
ï‚·Childrenâ€™s C -SSRS (Since Last Visit)
ï‚·CBCL , Syndrome scale only  (since last visit) 
ï‚·ESRS (subscales I  and II)
ï‚·ESS 
ï‚·adverse events assessment
ï‚·concomitant medicat ions
ï‚·dispense investigational medicinal product (IMP)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
2323.Procedures During Administration of Investigational Medicinal Product 
(Double -Blind Treatment Period Inclusive of Titration Period)
a. Week 1 (day 7+1 day), week 2 (day 14Â±3 days total from baseline), week 4 
(day 28Â±3 days total from baseline), week 5 (day 35Â±3 days total from baseline), 
and week 6 (day 42Â±3 days total from baseline)
The following procedures and assessments will be performed at weeks 1, 2, 4, 5, and 6:
ï‚·telephone contact (with non -recording live video)
ï‚·Clinical Global I mpression of I mprovement (CGI -I) (global, ph ysician -rated)
ï‚·assessment of IMP accountability /compliance/supply
ï‚·adverse events assessment
ï‚·concomitant medications
ï‚·evaluation/adjustment of IMP dose
b.Week 3 (day 21Â±3 days total from baseline) and week 7 (day 49Â±3 days total 
from baseline)
The following procedures and assessments will be performed at weeks 3 and 7:
ï‚·vital signs measurements and weight
ï‚·12-lead ECG
ï‚·urine drug screen (week 3 only )
ï‚·urine pregnancy  test
ï‚·Caregiver Global Impr ession of I mprovement (CaGI -I) (global, caregiver rated). The 
CaGI -I is to be completed before all other investigator- rated scales during visits 
where CaGI -I is collected.
ï‚·Patient Global I mpression of I mprovement Scale (PGI -I) (global, patient/caregiver). 
The PGI -
I is to be completed before all other investigator-rated scales during visits 
where PGI -I is collected.
ï‚·Childrenâ€™s C -SSRS (Since Last Visit)
ï‚·CBCL , Syndrome scale only  (since last visit)
ï‚·ESRS (subscales I  and II)
ï‚·ESS 
ï‚·CGI-I and CGI -S (global, phy sician rated) 
ï‚·dispense/collect IMP
During the week 3 visit, the last dose bottle is to be returned to the patient in order to 
take 1 last tablet in the evening to complete the week 3 dosing for that day . Refer to 
the pharmacy  manual for further details.
ï‚·assessment of IMP accountability /compliance/supply
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
233ï‚·adverse events assessment
ï‚·concomitant medications
ï‚·evaluation/adjustment of IMP
ï‚·contact RTSM
4.Procedures During Administration of Investigational Medicinal Product 
(Maintenance Period)
a.Week 9 (day 63Â±3 days total from baseline) and week 12 (day 84Â±3 days total 
from baseline)
The following procedures and assessments will be performed at weeks 9 and 12:
ï‚·vital signs measurements and weight
ï‚·urine drug screen (week 9 only )
ï‚·urine pregnancy  test (week 12 only )
ï‚·MD-CRS part I  video recording and investigator assessment
ï‚·MD-CRS part II video recording and investigator assessment
ï‚·CaGI -I (global, caregiver rated)
ï‚·CGI-I and CGI -S (global, phy sician rated)
ï‚·PGI-I (global, patient/caregiver)
ï‚·UHDRS -TMS
ï‚·Childrenâ€™s C -SSRS (Since Last Visit)
ï‚·CBCL , Syndrome scale only  (since last visit)
ï‚·ESRS (subscales I  and II)
ï‚·ESS 
ï‚·dispense/collect IMP
ï‚·assessment of IMP accountability /compliance/supply
ï‚·adverse events assessment
ï‚·concomitant medications
ï‚·contact RTSM
b.Week 15 (day 105Â±3 days total from baseline) or early termination (ET)
The following procedures and assessments will be performed at week 15 or ET :
ï‚·vital signs measurements (including orthostatic blood pressure) and weight
ï‚·physical examination
ï‚·neurological examination
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
234ï‚·height
ï‚·12-lead ECG
ï‚·
ï‚·clinical laboratory  tests (chemistry , hematology , and urinaly sis)
ï‚·urine drug screen
ï‚·Î²-HCG serum pregnancy test (for females aged 12 y ears or older of childbearing 
potential)
ï‚·MD-CRS part I  video recording and investigator assessment
ï‚·MD-CRS part II video recording and investigator assessment
ï‚·CaGI -I (global, caregiver rated)
ï‚·CGI-I and CGI -S (global, phy sician rated)
ï‚·PEDI -CAT (ADL, caregiver completed, content -balanced version)
ï‚·PedsQL  (QoL, patient/caregiver)
ï‚·PGI-I (global, pa tient/caregiver)
ï‚·UHDRS -TMS
ï‚·Childrenâ€™s C -SSRS (Since Last Visit) 
ï‚·CBCL , full version (since last visit) (Competence and Sy ndrome)
ï‚·ESRS (subscales I  and II)
ï‚·ESS
ï‚·collect IMP
ï‚·assessment of IMP accountability /compliance/supply
ï‚·adverse events assessment
ï‚·concomitant medications
ï‚·obtain reason for early
 termination (if applicable)
ï‚·contact RTSM
5.Follow -Up (Weeks 16 and 17)
a.Week 16/End of Study follow -up visit (1 week Â±2 days total from the week 
15/ET visit)
The following procedures and assessments will be performed at the week 16 follow -up visit:
ï‚·vital signs measurements and weight
ï‚·12-lead ECG (if there is an abnormalit y at the week 15/ET visit)

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
235ï‚·clinical laboratory  tests (chemistry , hematology , and urinaly sis) (if there is an 
abnormality  at the week 15/ET v isit)
ï‚·urine drug screen
ï‚·urine pregnancy  test
ï‚·MD-CRS part I  video recording and investigator assessment
ï‚·MD-CRS part II video recording and investigator assessment
ï‚·CaGI -I (global, caregiver rated)
ï‚·CGI-I and CGI -S (global, phy sician rated)
ï‚·PGI-I (global, pati ent/caregiver)
ï‚·Childrenâ€™s C -SSRS (Since Last Visit)
ï‚·CBCL , Syndrome scale only  (since last visit)
ï‚·ESRS (subscales I  and II)
ï‚·ESS 
ï‚·adverse events assessment
ï‚·concomitant medications
b.Week 17 follow -up visit (2 weeks
Â±2 days total from week 15 visit , or 2 weeks 
after ET visit )
The following procedures and assessments will be performed at the week 17 follow -up visit:
ï‚·telephone contact 
ï‚·adverse events assessment
ï‚·concomitant medications
6.Unscheduled Visits
An unscheduled visit may  be performed at any  time during the study  at the patientâ€™s or 
parentâ€™s/caregiverâ€™s request and as deemed necessary  by the investigator. The date and 
reason for the unscheduled visit will be recorded on the CRF as well as any other data 
obtained from procedures and assessments.
Procedures per formed during unscheduled visits may include any of the following:
ï‚·telephone contact (at the investigatorâ€™s discretion)
ï‚·evaluation/adjustment of IMP
ï‚·vital signs measurements and weight
ï‚·physical examination (at the investigatorâ€™s discretion)
ï‚·neurological ex amination (at the investigatorâ€™s discretion)
ï‚·12-lead ECG (at the investigatorâ€™s discretion)
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
236ï‚·clinical laboratory  tests (chemistry , hematology , and urinaly sis) (at the investigatorâ€™s 
discretion)
ï‚·Î²-HCG serum pregnancy test (for females aged 12 y ears or older of childbearing 
potential) (at the investigatorâ€™s discretion)
ï‚·MD-CRS part I  video recording and investigator assessment
ï‚·MD-CRS part II video recording and investigator assessment
ï‚·CaGI -I (global, caregiver rated)
ï‚·CGI-I and CGI -S (global, phy sician rated)
ï‚·PEDI-CAT (ADL, caregiver completed, content- balanced version)
ï‚·PedsQL  (QoL, patient/caregiver)
ï‚·PGI-I (global, patient/caregiver)
ï‚·UHDRS -TMS
ï‚·CBCL , Syndrome scale only  (since last visit)
ï‚·ESRS (subscales I  and II)
ï‚·ESS 
ï‚·Childrenâ€™s C -SSRS (Since Last Visit) (at the investigatorâ€™s discretion)
ï‚·CBCL , Syndrome scale only  (since last visit) (at the investigatorâ€™s discretion)
ï‚·ESRS (subscales I  and II) (at the investigatorâ€™s discretion)
ï‚·ESS (at the investigatorâ€™s discretion)
ï‚·dispense/collect IMP (at the investigatorâ€™s disc retion)
ï‚·assessment of IMP accountability /compliance/supply  (at the investigatorâ€™s discretion)
ï‚·
ï‚·adverse event assessment
ï‚·concomitant medications

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
237APPENDIX D.QUALITY CONTROL AND QUALITY ASSURANCE
Protocol Amendments and Protocol Deviations
Protocol Amendments
No changes from the final approved (sign ed) protocol will be initiated without the prior written 
approval or favorable opinion of a written amendment by  the Independent Ethics Committee 
(IEC)/institutional review board (I RB) and national and local competent authorities, as 
applicable , except whe n necessary  to address immediate safety  concerns to the patients or when 
the change involves onl y nonsubstantial logistics or administration. The principal investigator at 
each investigational center, the coordinating investigator (if applicable), and the sponsor will 
sign the protocol amendment.
Important Protocol Deviations
Any deviation from the protocol that affects, to a significant degree, (a) the safet y, ph ysical, or 
mental integrit y of the patients in the study  and/or (b) the scientific value of the study  will be 
considered an important protocol deviation . Important protocol deviations may include non -
adherence on the part of the patient, the investigator, or the sponsor to protocol -specific inclusion 
and exclusion criteria, primary  objective variabl e criteria, or Good Clinical Practice (GCP) 
guidelines; noncompliance to IMP administration; and use of prohibited medications. All 
important protocol deviations will be reported to the responsible IEC/IRB, as required.
When an important protocol deviation is reported, the sponsor will determine whether to 
withdraw the patient from the study  or permit the patient to continue in the study, with 
documented approval from the medical expert. The decision will be based on ensuring the safety 
of the patient and p reserving the integrit y of the study.
Changes in the inclusion and exclusion criteria of the protocol are notprospectivel y granted b y 
the sponsor. If investigational center personnel learn that a patient who did not meet protocol 
inclusion and exclusion c riteria was entered in a study , they  must immediately  inform the 
sponsor of the important protocol deviation . If such patient has alread y completed the study  or 
has withdrawn earl y, no action will be taken, but the deviation will be recorded.
For coronavi rus disease 2019 (COVID -19) updates, refer to Appendix M.
Information to Study Personnel
The investigator is responsible for giving information about the study  to all personnel members 
involved in the study  or in any  element of patient management, both before starting the study  and 
during the course of the study  (eg, when new personnel become involved). The investigator must 
ensure that all stud y perso nnel are qualified b y education, experience, and training to perform 
their specific task. These study  personnel members must be listed on the investigational center 
authorization form, which includes a clear description of each personnel memberâ€™s 
responsibilities. This list must be updated throughout the study , as necessary .
The study  monitor is responsible for explaining the protocol to all study  personnel, including the 
investigator, and for ensuring they  comply  with the protocol.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
238Study Monitoring
To ensure compliance with GCP guidelines, the study  monitor or representative is responsible 
for ensuring that patients have signed the informed consent form and that the study  is conducted 
according to applicable standard operating procedures, the protocol, and other written 
instructions and regulatory guidelines.
The study  monitor is the primary  association between the sponsor and the investigator. The main 
responsibilities of the study  monitor(s) are to visit the investigator before, during, and after the 
study to ensure adherence to the protocol, that all data are correctl y and completely  recorded and 
reported, and that informed consent is obtained and recorded for all patients before they  
participate in the stud y and when changes to the consent form are warran ted, in accordance with 
IEC/IRB approvals.
The study  monitor(s) will contact the investigator and visit the investigational center according 
to the monitoring plan. The study  monitor will be permitted to review and verify  the various 
records (CRFs and othe r pertinent source data records, including specific electronic source 
document relating to the study ) to verify  adherence to the protocol and to ensure the 
completeness, consistency, and accuracy  of the data being recorded.
As part of the supervision of study  progress, other sponsor personnel may , on request, 
accompan y the study  monitor on visits to the investigational center. The investigator and 
assisting personnel must agree to cooperate with the study  monitor to resolve any  problems, 
errors, or possible misunderstandings concerning the findings detected during the course of these 
monitoring visits or provided in follow- up written communication.
For COVID -19 updates, refer to Appendix M.
Audit and Inspection
The sponsor may  audit the investigational center to evaluate study  conduct and compliance with 
protocols, standard operating procedures, GCP guidelines, and applicable regulatory  
requirements. T he sponsorâ€™s Global Clinical Quality  Assurance, independent of Global Specialty  
Development, is responsible for determining the need for (and timing of) an investigational 
center audit.
The investigator must accept that competent authorities and sponsor re presentatives may  conduct 
inspections and audits to verify  compliance with GCP guidelines.
For COVID -19 updates, refer to Appendix M.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
239APPENDIX E.ETHICS
Informed Consent
The investigator, or a qualified person designated by  the investigator, should fully  inform the 
patient and parent(s)/legally  acceptable representative (as applicable) of all pertinent aspects of 
the study , including the written information approved by  the Independent Ethics Committee 
(IEC)/institutional review board (I RB). All written and oral information about the study  will be 
provided in a language as nontechnical a s practical to be understood by  the patient and 
parent(s)/legally  acceptable representative. The patient and parent(s)/legally  acceptable 
representative should be given ample time and opportunity  to inquire about details of the study  
and to decide whether or not to participate in the study . The above should be detailed in the 
source documents.
A personall y signed and dated Informed Consent Form (ICF) will be obtained from each 
parent(s)/legally  acceptable representative, and a signed and dated assent form w ill be obtained 
from each patient (if the patient is able/as applicable) before an y stud y-specific procedures or 
assessments are done and after the aims, methods, anticipated benefits, and potential hazards are 
explained, according to IEC/I RB requirements. The forms will also be signed and dated b y the 
person who conducted the informed consent discussion. The investigator will keep the original 
informed consent and assent forms, and copies will be given to the patients (and each 
parent(s)/legally  acceptable representative). It will also be explained to the patients (and each 
parent(s)/legally  acceptable representative) that they are free to refuse participation in the study  
and free to withdraw from the study  at an y time without prejudice to future treatment . Patients 
who started the study as minors and reached the age of majorit y during the study should sign the 
adult I CF. 
For coronavirus disease 2019 (COVID -19) updates, refer to Appendix M.
Competent Authorities and IECs/IRBs
Before this study  starts, the protocol will be submitted to the national competent authority  and to 
the respective IEC/I RB for review. As required, the study  will not start at a g iven investigational 
center before the IEC/IRB and competent authority  (as applicable) for the investigational center 
give written approval or a favorable opinion.
Confidentiality Regarding Study Patients
The investigator must ensure that the privacy  of th e patients, including their identity  and all 
personal medical information, will be maintained at all times. I n case report files and other 
documents or image material submitted to the sponsor, patients will be identified not by  their 
names but by an identi fication number.
Personal medical information may  be reviewed for the purpose of patient safet y or for verify ing 
data in the source and the case report file. This review may  be conducted b y the study  monitor, 
properl y authorized persons on behalf of the sp onsor, Global Quality  Assurance, or competent 
authorities. Personal medical information will alway s be treated as confidential.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
240Registration of the Clinical Study
In compliance with national and local regulations and in accordance with Teva standard 
proced ures, this clinical study  will be registered on trials registry  websites.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
241APPENDIX F.BIRTH CONTROL METHODS AND PREGNANCY 
TESTING
Females of childbearing potential are defined as the following:
ï‚·not surgically  (documented hy sterectomy , bilateral oophorectomy , or bilateral 
salpingectomy ) or congenitally  sterile
ï‚·postmenarchal or â‰¥12 y ears of age
Females who are not of childbearing potential are defined as the following:
ï‚·premenarchal or being in the period of a femaleâ€™s life before the first menstrual period 
occurs 
Highly effective birth control methods:
Highl y effective birth control methods are methods that can achieve a failure rate of less than 1% 
per year when used consistently  and correctly  are considered. Such methods include the 
following:
ï‚·Combined estrogen a nd progestogen hormonal contraception (oral, intravaginal, and 
transdermal) associated with inhibition of ovulation; these should be initiated at least 
1month (for IMPs potentially  teratogenic/genotoxic) before the first dose of IMP
ï‚·Progestogen -only hormo nal contraception (oral, injectable, and implantable) 
associated with inhibition of ovulation; these should be 1 month (for IMPs potentially  
teratogenic/genotoxic) before the first dose of IMP
ï‚·Intrauterine device and intrauterine hormone-releasing s ystem need to be in place at 
least 2 months before screening
ï‚·Bilateral tubal occlusion
ï‚·Vasectomized partner, provided that he is the sole sexual partner and has received 
medical assessment of the surgical process
ï‚·Sexual abstinence is only considered a highl y effective method if defined as 
refraining from heterosexual intercourse in the defined period. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of the clinical study  
and the preferred and usual lifesty le of the patient.
ï‚·Periodic abstinence (eg, calendar, ovulation, sy mptothermal, and post -ovulation 
methods), declaration of abstinence for the duration of a study , and withdrawal are 
not acceptable methods of contraception (according to Medicines and Healthcare 
Products Regulatory  Agency ).
Unacceptable birth control methods:
Periodic abstinence (calendar, s ymptothermal, and post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only , and lactational amenorrhea method are not acceptable methods of 
contraception. Female condom and male condom should not be used together.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
242APPENDIX G.LOST TO FOLLOW-UP
A patient will be considered lost to follow -up if he/she repeatedl y fails to return for scheduled 
visits and is unable to be contacted b y the investigational center.
The followin g actions must be taken if a patient fails to return to the investigational center for a 
required stud y visit:
ï‚·The investigational center must attempt to contact the patient and reschedule the 
missed visit as soon as possible and counsel the patient and parent(s)/caregiver, as 
applicable, on the importance of maintaining the assigned visit schedule and ascertain 
whether or not the patient wishes to and/or should continue in the study .
ï‚·In cases in which the patient is deemed lost to follow- up, the investigat or or designee 
must make every  effort to regain contact with the patient (where possible, 3 telephone 
calls and, if necessary , a certified letter to the patientâ€™s last known mailing address or 
local equivalent methods). These contact attempts should be doc umented in the 
patientâ€™s medical record.
ï‚·Should the patient continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary  reason of â€œlost to follow -up.â€
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
243APPENDIX H.LIST OF ALLOWED AND PROHIBITED MEDICATIO NS
Medications that are allowed, provided that conditions outlined in the table are met, are shown in 
Table 10. Investigators are encouraged to contact the medical monitor for a ny questions 
regarding the medications listed below.  
The medical monitor must be contacted if a patient is receiving (or has to begin or stop receiving 
during the stud y) a medication that is associated with QT corrected for heart rate (QTc) 
prolongation or that is a known strong cytochrome P450 inhibitor. 
Prohibited medications that are associated with QTc prolongation are listed in Table 11.
For coronavirus disease 2019 (COVID -19) updates, refer to Appendix M.
Table 10: Allowed Medications
Generic/Drug class Condition
Stable medications allowed according to inclusion/exclusions criteria
Hormonal birth control Must be receiving stable treatment (including dose) for at least 3 months 
before screening and anticipated to remain stable (dose and frequency) 
within the study duration
Antidepressants Must be receiving stable treatment (including dose) for at least 6 weeks 
before screening and anticipated to remain stable (dose and frequency) 
within the study duration
Benzodiazepines, trihexyphenidyl, 
baclofen (oral and intrathecal), 
tizanidine, muscle relaxants, gabapentin, 
levetiracetam, carbamazepine, 
topiramate, and other anticonvulsants, 
neuroleptics (oral), typical and atypica l 
antipsychotics, and metoclopramideDosing must have been stable for at least 4 weeks before screening and 
anticipated to remain stable (dose and frequency) within the study 
duration.
Any exceptions to this period of stability for these classes of drugs s hould 
be review ed with the medical monitor, and approval for entry into the 
study will be required.
Note: PRN (as needed) use is prohibited.
Botulinum toxin May be included in the study if they have at least 2 treatments of 
botulinum neurotoxin (BoNT) at a regular interval (eg, every 3 to 
4months), in reasonably stable dosages and locations (subject to 
investigatorâ€™s judgment) to treat low er limb spasticity or dystonia, and if 
they are expected to continue this stable regimen of BoNT injections for 
the du ration of this study. The injection for spasticity or dystonia must be 
in a muscular region that is separate from the main areas affected by 
choreiform movement disorder. Pre -approval from the medical monitor is 
required for patients receiving BoNT outside of the regular interval.
Cannabis or formulations or derivatives 
of cannabis Patients may be included in this study if they are using cannabis or 
formulations or derivatives of cannabis in relatively stable amounts, for 
medical purposes, under the guidance, supervision, or prescription of a 
clinician. 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
244Table 10: Allowed Medications (Continued)
Generic/Drug class Condition
Additional medications allowed with pre- approval from m edical m onitor
Albuterol, levalbuterol Asthma
Guaifenesin Cold symptoms
Antihistamines Allergies
Melatonin Insomnia
Allowed strong CYP2D6 inhibitorsa
Bupropion Antidepressant (aminoketone)
Stable medications allowed according to inclusion/exclusions criteria
Fluoxetine Antidepressant (selective serotonin reuptake inhibitor)
Paroxetine Antidepressant (selective serotonin reuptake inhibitor)
aThe use of these medications will affect the maximum daily dose of study medication, as shown in Table 4.
Note: Changes to the allowed medications may be permitted in the context of this study if pre -approved by the 
medical monitor.
CYP=cytochrome P450; PRN=as needed.
Table 11: Prohibited QTc- Prolonging Drugs
Generic Class/Clinical use Note
Azithromycin Antibiotic/bacterial infection Patients are allow ed to 
take up to 500 mg/day of 
azithromycin
Chloroquine/Mefloquine Anti-malarial/malaria infection
ClarithromycinaAntibiotic/bacterial infection
Dom peridone Anti-nausea/nausea Not available in the USA
Droperidol Sedative; anti -nausea/anesthesia adjunct, nausea
ErythromycinaAntibiotic; GI stimulant; GI motility
Moxifloxacin Antibiotic/bacterial infection
Sevoflurane Anesthetic; general/anesthesia
Probucol Antilipemic/hypercholesterolemia Not available in the USA
Sparfloxacin Antibiotic/bacterial infection Not available in the USA
Hydroxychloroquine Hydroxychloroquine is contraindicated in this trial due to the 
risk of QT prolongation and should be considered as not 
allow ed. If there is a medical decision to initiate 
chloroquine, hydroxychloroquine, mefloquine, or other 
drugs related to chloroquine, the IMP should be suspended 
or discontinued, and an ECG should be obtained. Please 
consult with the medical monitor for further advice.
aSystemic use only. Topical use is allow ed.
QTc=QT corrected for heart rate; GI=gastrointestinal; USA=United States of America.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
245APPENDIX I.TOTAL BLOOD VOLUME
Total blood volume to be collected for each patient in this study  is approximately  40mL(at 
maximum). Blood draw volumes and ranges (in mL ) are depicted in Table 12.
Table 12: Total Blood Volumes
Test Screening Week 15/ET Week 16/EOS Unscheduled
)
Chemistry 1.25-3.5 1.25-3.5 (1.25 -3.5) (1.25 -3.5)
Hem atology 1.0-2.0 1.0-2.0 (1.0-2.0) (1.0-2.0)
CYP2D6 genotyping 3.0-5.0
Î²-HCG 1.25-3.5 1.25-3.5 (3.5)
Prothrombin/INR 4.5 4.5 (4.5) (4.5)
Total volum e (mL) per 
patient per visit 18.5 21.5
CYP2D6=cytochrome P450 2D6 ; EOS=end of study ; Î²-HCG=Beta- human chorionic gonadotropin; 
INR=International Normalized Ratio.
Notes: Values in parentheses indicate possible blood draw s. Blood draws at week 16/EOS and unscheduled visits are 
optional.
 
  

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
246APPENDIX J.PRODUCT COMPLAINTS
Clinical Product Complaints
A clinical product complaint is defined as a problem or potential problem with the phy sical 
quality  or characteristics of clinical investigational medicinal product (IMP) supplies or clinical 
device supplies used in a clinical research stud y sponsored b y Teva. Examples of a product 
complaint include, but are not limited to, the follo wing:
ï‚·suspected contamination
ï‚·questionable stability  (eg, color change, flaking, crumbling, etc)
ï‚·defective components
ï‚·missing or extra units (eg, primary  container is received at the investigational center 
with more or less than the designated number of un its inside)
ï‚·incorrect packaging or incorrect or missing labeling/labels
ï‚·unexpected or unanticipated taste or odor or both
ï‚·device not working correctly  or appears defective in some manner
Each investigational center will be responsible for reporting a possible clinical product complaint 
by completing the product complaint form provided by  Teva and emailing it to 
 within 48 hours of becoming aware of the issue.
For complaints involving a device or other retrievable item, it is required that the device (or 
item) be sent back to the sponsor for investigative testing whenever possible. For complaints 
involving an IMP, all relevant samples (eg, the remainder of the patientâ€™s IMP supply ) should be 
sent back to the sponso r for investigative testing whenever possible.
1.Product Complaint Information Needed from the Investigational Center
In the event that the product complaint form cannot be completed, the investigator will provide 
the following information, as available:
ï‚·investigational center number and principal investigator name
ï‚·name, phone number, and address of the source of the complaint
ï‚·clinical protocol number
ï‚·patient identifier (patient study  number) and corresponding visit numbers, if 
applicable
ï‚·product name and str ength for open -label studies
ï‚·patient number, bottle, and kit numbers (if applicable) for double -blind or open -label 
studies
ï‚·product available for return Yes/No
ï‚·product was taken or used according to the protocol Yes/No

Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
247ï‚·description or nature of complaint
ï‚·associated serious adverse event Yes/No
ï‚·clinical supplies unblinded (for blinded studies) Yes/No
ï‚·date and name of person receiving the complaint
Note: Reporting a product complaint must not be delay ed even if not all the required information 
can be obtained immediately . Known information must be reported immediately . The sponsor 
will collaborate with the investigator to obtain an y outstanding information.
2.Handling of Investigational Medicinal Product(s) at the Investigational Center(s)
The investigator is responsible for retaining the product in question in a location separate from 
the investigatorâ€™s clinical study  supplies. The sponsor may  request that the investigator return the 
product for further evaluation and/or anal ysis. If this is necessary , the clinic al study  monitor or 
designee will provide the information needed for returning the IMP.
If it is determined that the investigational center must return all I MP, the sponsor will provide the 
information needed to handle the return.
The integrity  of the rand omization code and corresponding blinded clinical supplies will be 
maintained whenever possible. A serious adverse event or the potential for a product quality  
problem existing bey ond the scope of the complaint may  be a reason to unblind the clinical 
suppl ies for an affected patient.
3.Adverse Events or Serious Adverse Events Associated with a Product Complaint
If there is an adverse event or a serious adverse event due to product complaint, the protocol 
should be followed for recording and reporting (Section 7.1.2).
4.Documenting a Product Complaint
The investigator will record in the source documentation a description of the product complaint 
and an y act ions taken to resolve the complaint and to preserve the safety  of the patient. Once the 
complaint has been investigated b y the sponsor and the investigator, if necessary , an event 
closure letter may  be sent to the investigational center where the complaint originated or to all 
investigational centers using the product.
Medical device incidents, including those resulting from malfunctions of the device, must be 
detected, documented, and reported b y the investigator throughout the study.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
248APPENDIX K.DATA MANAGEMENT AND RECORD KEEPING
Direct Access to Source Data and Documents
All patient data must have supportive original source documentation in the medical records, or 
equivalent, before they  are transcribed to the case report form (CRF). Data may  not be recorded 
directl y on the CRF and considered as source data, unless the sponsor provides written 
instructions specify ing which data are permitted to be recorded directl y to the CRF.
If data are processed from other institutions or by  other means (eg, clinical laboratory , central 
image center, or electronic diary  data), the results (with the exception of the cy tochrome 
P450 2D6 [CYP2D6] test results) will be sent to the investigational center, where they will be 
retained but not transcribed to the CRF, unless otherwise noted in the protocol (eg, results of 
centrall y read MD- CRS part II items will not be shared with the investigators). These data may  
also be sent electronically to the sponsor (or organization performing data management).
The medical experts, study  monitors, auditors, Independent Ethics Committee (IEC)/institutional 
review board (IRB), and inspectors from competent authority  (or their agents) will be given 
direct access to source data and documents (eg, medical charts/records, laboratory  test results, 
printouts, and videos) for source data verification, provided that patient confidentiality  is 
maintained in accordance with national and local requirements.
The investigator must maintain the original records (ie, source documents) of each patientâ€™s dat a 
at all time s.The investigator must maintain a confidential patient identification list that allows 
the unambiguous identification of each patient.
Data Collection
Data will be collected using CRFs that are specifically  designed for this study . The data collected 
on the CRFs will be captured in a clinical data management s ystem (CDMS) that meets the 
technical requirements described in 21CFR Part11 (United States) and documents of other 
concerned competent authorities. Before using the CDMS, it will be fully  validated , and all users 
will receive training on the sy stem and study -specific training. After they  are trained, users will 
be provided with individual sy stem access rights.
Data will be collected at the investigational center by  appropriatel y designated and train ed 
personnel, and CRFs must be completed for each patient who provided informed consent. Patient 
identity  should not be discernible from the data provided on the CRF.
If data are processed from other sources (eg, central laboratory, bioanal ytical laborator y, central 
image center, electronic diary  data, and electronic patient -reported outcome tablet or phone ), 
these data will be sent to the investigational center, where they  will be retained but not 
transcribed to the CRF, unless otherwise noted in the proto col. These data may  also be sent 
electronically  to the sponsor (or organization performing data management). All patient data 
must have supportive original source documentation in the medical records, or equivalent, before 
they are transcribed to the CRF. Data may  not be recorded directly  on the CRF and considered as 
source data unless the sponsor provides written instructions specify ing which data are permitted 
to be recorded directly  to the CRF.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
249For patients who enter a study  but do not meet the eligibili ty criteria, at a minimum, data for 
screening failure reason, demograph y, and an y serious adverse events from the time of informed 
consent will be entered in the CRF.
Data Quality C ontrol
Data Management is responsible for the accuracy , quality , completeness, and internal 
consistency  of the data from this study . Oversight will be carried out as described in the 
sponsorâ€™s standard operating procedures (SOPs) for clinical studies. Day -to-day data 
management tasks for this study  are delegated to a co ntract organization, and these functions 
may be carried out as described in the SOPs for clinical studies at that organization. These SOPs 
will be reviewed b y the sponsor before the start of data management activities.
Data will be verified b y the study  monitor using the data source and reviewed by  Data 
Management using both automated logical checks and manual review. Data identified as 
erroneous, or data that are missing, will be referred to the investigational center for resolution 
through data queries. A ny necessary  changes will be made in the clinical database, and data 
review and validation procedures will be repeated as needed. Data from external sources will be 
compared with the information available in the CDMS, and an y discrepancies will be queried.
Applicable terms will be coded according to the coding conventions for this study .
At the conclusion of the study , the CDMS and all other study  data will be locked to further 
additions or corrections. Locking the stud y data represents the acknowledgment t hat all data have 
been captured and confirmed as accurate. All data collected will be approved by  the investigator 
at the investigational center. This approval acknowledges the investigatorâ€™s review and 
acceptance of the data as being complete and accurate .
Archiving of Case Report Forms and Source Documents
Sponsor Responsibilities
The original CRFs will be archived by the sponsor. I nvestigational center -specific CRFs will be 
provided to the respective investigational centers for archiving.
Investigator Re sponsibilities
The investigator must maintain all written and electronic records, accounts, not es, reports, and 
data related to the study  and any  additional records required to be maintained under country , 
state/province, or national and local laws, includ ing, but not limited to, the following :
ï‚·full case histories
ï‚·signed informed consent forms
ï‚·patient identification lists
ï‚·case report forms for each patient on a per -visit basis
ï‚·data from other sources (eg, central laboratory , bioanal ytical laboratory , centra l image 
center, and electronic diary )
ï‚·safet y reports
ï‚·financial disclosure reports/forms
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
250ï‚·reports of receipt, use, and disposition of the I MPs
ï‚·copies of all correspondence with sponsor, the IEC/I RB, and an y competent authority
The investigator will retain all records related to the study  and any  additional records required, as 
indicated b y the protocol and according to applicable laws and regulations, until the contract 
research organization or sponsor notifies the institution in writing that records may be destro yed. 
If, after 25 years from study  completion, or earlier in the case of the investigational center 
closing or going out of business, the investigator reasonabl y determines that study  record 
retention has become unduly  burdensome and sponsor has not provided written notification of 
destruction, then the investigator may  submit a written request to the sponsor at least 60 days 
before an y planned disposition of study  records. After receipt of such request, the sponsor may  
make arrangements for appropri ate archival or disposition, including requiring that the 
investigator deliver such records to the sponsor. The investigator shall notify the sponsor of an y 
accidental loss or destruction of study  records.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
251APPENDIX L.PUBLICATION POLICY
All unpublished information giv en to the investigator by  the sponsor shall not be published or 
disclosed to a third part y without the prior written consent of the sponsor.
The results of this study  may  be published or presented at scientific meetings. If this is foreseen, 
the investigat or agrees to submit all manuscripts or abstracts to the sponsor before submission. 
This allows the sponsor to protect proprietary information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results: 
â€œRecommendations for the Conduct, Reporting, Editing, and Publication of Scholarly  Work in 
Medical Journalsâ€ (www.I CMJE.org). Publication of the results will occur in a timely  manner 
according to applicable regulations. In accordance with standard editorial and eth ical practice, 
the sponsor will generally support publication of multicenter studies only  in their entiret y and not 
as individual investigational center data. In this case, a coordinating investigator will be 
designated b y mutual agreement.
Authorship will be determined by  mutual agreement and in line with the following International 
Committee of Medical Journal Editors authorship requirements:
ï‚·substantial contributions to the conception or design of the work or the acquisition, 
analysis, or interpretation of data for the work
ï‚·drafting the work or revising it criticall y for important intellectual content
ï‚·final approval of the version to be published
ï‚·agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy  or integrit y of an y part of the work are appropriately 
investigated and resolved
The publications committee established b y the sponsor will oversee this process. Additional 
publications may  follow. Policies regarding the publication of the study  results are defined in the 
financial agreement.
No patent applications based on the results of the study  may  be made by  the investigator nor may  
assistance be given to any  third party  to make such an application without the written 
authorization of the sponsor.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
252APPENDIX M.MANAGEM ENT OF STUDY ACTIVITIES DURING 
COVID -19
This appendix is to address the modification in study  conduct during the coronavirus disease 
2019 (COVID -19) pandemic. 
The changes specified in this appendix will be effective for the duration of the COVID-19 
pandemic . Once the situation at specific sites/countries will allow returning to regular study  
activities, this appendix will be come void for those country /sites, except in the case of 
COVID -19 resurgence or emergence of another crisis aff ecting normal per- protocol conduct of 
the study .
The following sections are affected:  
Section 3.1. General Study Design and Study Schematic Diagram
A COVID- 19 addendum informed consent will be created to inform patients of the planned 
changes. The site w ill be allowed to conduct remote assent and consent b y phone. Site will 
obtain and document a verbal confirmation from patient and parent/ legally acceptable 
representative that they  received this information and understood it. The informed consent 
addendum will be signed by  the patient and family  as applicable at the first next in -clinic visit. 
Any updates prior to the updated consent form should be consented verbally  and documented in 
the medical sources.  
Section 3.5. Schedule of Study Procedures and Ass essments
In the event of an emergency  situation (eg, the COVID -19 pandemic), in case a patient cannot 
return to the clinic for the scheduled visits (eg, due to quarantine, isolation, patientâ€™s concern, or 
closure of the site clinic), home or remote visits are permitted for patients who are not able to go 
to the investigational site for their visit(s) or if the investigational site staff are not able to see 
patients at the investigational site.
Remote visits will allow collecting the following clinician -rated scales: 
ï‚·Columbia -Suicide Severity  Rating Scale (C -SSRS)
ï‚·Clinical Global I mpression of I mprovement (CGI -I)
ï‚·Clinical Global I mpression of Severit y (CGI -S)
ï‚·Part I  of the Extrapy ramidal Sy mptom Rating Scale (subscales I and II) [ESRS]. 
It will further allow a visual confirmation of a patientâ€™s condition using non -recording live video 
and assessment of an y new adverse events, as possible, depending on patient cooperation and the 
communication platform being in good working order. The remo te visit will not allow for fully  
completing performance outcome assessments that require ph ysical examinations, including 
those required for the Movement Disorder -Childhood Rating Scale (MD -CRS), Unified 
Huntingtonâ€™s Disease Rating Scale (UHDRS), or ESRS scales. The MD -CRS Part I  & II are 
optional at the investigatorâ€™s discretion and may  be incomplete considering patientâ€™s imbalance 
when standing and walking and prioritizing patient safet y. UHDRS -Total Motor Score (TMS) 
and ESRS should be completed as much as possible; some fields (ie, rigidity , stability ) may  be 
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
253left blank as they  cannot be assessed remotel y. The pull test should not be done due to safety 
considerations. The remote visit will not allow for measuring vital signs or obtaining an 
electrocardi ogram (ECG) or urine beta chorionic gonadotropin (Î²-HCG) test, unless a home 
nursing vendor is at the patientâ€™s home to provide that service where available.
The week 3 and week 7 visits can be completed as remote visits if safet y assessments 
(specifically vital signs, ECG, C -SSRS, and Î² -HCG test, if relevant) can be performed within a 
reasonable time from visit (approximately  2 weeks). 
The week 9 and week 12 visits can be completed as remote visits if the previous vital signs and 
ECGs were acceptable as p er protocol requirements. Any  other required safety  assessments (eg, 
C-SSRS and Î²-HCG test, if relevant) that are not completed during a remote visit should be 
completed within 2 weeks of the remote visit. 
If patient misses the week 15 visit and is approv ed by  the medical monitor to have a remote visit 
and continue on drug, and if patient cannot arrive at site within 3 weeks, a telephone call will be 
added to assess patientâ€™s condition (ie, adverse event, tolerability , sufficient investigational 
medicinal product [I MP]).
The week 16 visit can be completed as a remote visit.
The test and placebo IMP (as applicable) will continue to be administered at home. Following 
the consent of the patient or parent(s)/legall y acceptable representative, IMP will be shippe d to 
patients if they  or their parent/legall y acceptable representative cannot visit the site to collect 
IMP. All shipping arrangements will be the siteâ€™s responsibility  and will occur between site and 
patient or as a direct- to-patient shipment from the site to patient coordinated by  the sponsorâ€™s 
third party  shipping vendor, where available, and according to local practices and regulations.
Modifications to other procedures and assessments (ECG, laboratory  sample collection, etc) will 
be performed per implemented contingency measures according to sponsor instructions and the 
corresponding manual. For example, if central lab samples cannot be collected for safet y 
assessments, sites may  have patients visit a local reference laboratory , or a home service may  
visit home, to perform the assessments.
These measures will be implemented on a case- by-case basis, and onl y when and where they are 
warranted due to the emergency  situation. Preferably , the original protocol instructions will be 
followed whenever the new i nstructions are not required.
Section 4.3. Withdrawal Criteria and Procedures for the Patient
Patients who cannot complete the required safet y assessments within a reasonable time from visit 
(approximately  2 weeks for the week 3 and week 7 visits) will be early  terminated from study ; 
specificall y, these are the vital signs, ECG, C-SSRS, and Î²-HCG tests at weeks 3 and7.
Patients who cannot reach the site for a week 15 visit will be allowed to remain on drug for an 
additional 4 weeks. After 3 weeks, if the p atient has not y et completed the in -clinic week 
15visit, the investigator will perform another remote visit to check on the patientâ€™s condition. 
The contract research organization (CRO) will assess with the site if their patient can come to 
complete the w eek 15 visit in the next week. I f not, the sponsor will either allow another 
extension or the patient will be earl y terminated from the study.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
254Section 4.5. Rescreening
Patients who screen fail or terminate earl y from the study due to emergency circumstance s (such 
as coronavirus disease 2019 [COVI D-19] restrictions) may  be allowed to re -screen/re -enter 
(respectively ) the study  at a later date, depending on the circumstances. Each case should be 
referred to the medical monitor and approved in advance. Patient s re-entering the study  will be 
manually  assigned to their initial treatment group. Patients will have to redo the entire study  from 
the start, aside from the blinded CYP2D6 genot yping; these results will carried over from the 
first participation. 
Section 5.9. Randomization and Blinding
Patients re- entering the study  will be manually  assigned to their initial treatment group b y the 
RTSM unblinded vendor. Blinding will be maintained for the patient, investigator, and sponsor 
as described above; the only  information that will be available is that the patient was assigned to 
the same treatment group as previousl y. 
Section 6. Assessments of Efficacy
In the event of an emergency  situation (eg, the COVID -19 pandemic), in case a patient cannot 
return to the clinic for the scheduled visits (eg, due to quarantine, isolation, patientâ€™s concern, or 
closure of the site clinic), patients will be able to complete the efficacy  scales at home using the 
iPhone. The results of the questionnaires completed via patientâ€™s iPhon e will be transferred to the 
case report form (CRF) per the usual process. Scales collected as paper forms will be stored in 
patient source file and entered to CRF manuall y once the CRF has been adapted appropriatel y.
Section 7. Assessment of Safety
In the event of an emergency situation (eg, the COVID -19 pandemic), in case a patient cannot 
return to the clinic for the scheduled visits (eg, due to quarantine, isolation, patientâ€™s concern, or 
closure of the site clinic), patients will be allowed to obtain vi tal signs and ECGs using local 
clinics (primary  health care provider) or home nursing service, where available. 
Safety  measurements such as vital signs/ECG/Î² -HCG/C -SSRS are mandatory  for weeks 3 and 7 
(during titration) and part of the week 15/16 assessme nts.
To increase safety  assessments, and in anticipation that patients may  need to significantl y dela y 
their week 15 visit, investigators may  collect several safet y assessments at week 12 that are 
currentl y not part of the schedule of activities, but are p ossible using â€˜unscheduledâ€™ visits: 
physical examination, neurological examination, 12 -lead ECG, and 
chemistry /hematology /urinaly sis laboratory  tests. These safet y measurements are at the 
investigatorâ€™s discretion.
Section 7.5.2.1. Beta -Human Chorionic Gonadotropin Tests
If an in -clinic visit is replaced by  a remote visit, all efforts will be done to collect the Î² -HCG (eg, 
at local laboratory  or by  sending urine Î² -HCG sticks to the patient and parent/legally  acceptable 
representative, so these can be assessed at home). 
Section 7.5.2.2. Urine Drug Screen
If an in -clinic visit is replaced by  a remote visit, urine drug screen samples will not be collected, 
until a next in -clinic visit is possible.
Placebo- Controlled Study â€“Dyskinesia in Cerebral Palsy
Clinical Study  Protocol Amendment 0 5 Study  TV50717- CNS -30080
255Section 9. STATISTICS
Depending on the impact of COVID -19 on the study  assessments, additional anal yses or 
modifications of planned anal yses will be considered and detailed in a possible amendment to the 
statistical analy sis plan.
Section 10. Quality Control and Quality Assurance
Deviations from the study  conduct due to emergency  situations (eg, the COVID -19 pandemic), 
including implemented contingency  measures and their impact (eg, patient discontinuation from 
treatment with investigational product and/or study, alternative procedures used to collect critical 
safety and/or efficacy  data, etc), will be described in the appropriate sections of the clinical study  
report (CSR) as applicable.
Appendix D. Quality Control and Quality Assurance
Protocol Deviations
Deviations from the study  conduct due to emergency  situatio ns (eg, the COVID -19 pandemic), 
including implemented contingency  measures and their impact (eg, patient discontinuation from 
treatment with investigational product and/or study, alternative procedures used to collect critical 
safet y and/or efficacy data, etc), will be described in the appropriate sections of the CSR as 
applicable.
Study Monitoring
In case of an emergency  situation (eg, the COVID -19 pandemic), where study  monitors may  not 
be able to access the investigational centers for on -site visits, sit es will be monitored remotel y 
where allowed and in accordance with the local regulations. Additional details are provided in 
the monitoring plan.
Audit and Inspection
In case of an emergency  situation (eg, the COVID -19 pandemic), where auditors may  not be able 
to access the investigational centers for on -site visits, investigational centers will be audited 
remotely  where allowed and in accordance with local regulations.
Appendix E. Ethics
A COVID- 19 addendum informed consent will be created to inform patients of the planned 
changes. The site will be allowed to conduct remote assent and consent b y phone. Site will 
obtain and document a verbal confirmation from patient and parent/ legally acceptable 
representative that they  received this information and underst ood it. The informed consent 
addendum will be signed by the patient and family  as applicable at the first next in -clinic visit. 
Any updates prior to the updated consent form should be consented verbally  and documented in 
the medical sources. 
Appendix H. L ist of Allowed and Prohibited Medications
Hydroxy chloroquine is contraindicated in this trial due to the risk of QT prolongation and should 
be considered as not allowed. If there is a medical decision to initiate chloroquine, 
hydroxychloroquine, mefloquine , or other drugs related to chloroquine, the IMP should be 
suspended or discontinued and an ECG should be obtained. The medical monitor should be 
consulted for further advice.